standard_type,standard_units,count,cumulative_prop
Potency,nM,4471741,0.184
IC50,nM,3276327,0.319
GI50,nM,2617582,0.427
Inhibition,%,1589749,0.493
Percent Effect,%,1328366,0.547
k_off,s-1,826806,0.581
kon,,826159,0.616
Ki,nM,755581,0.647
Activity,,668357,0.674
MIC,ug.mL-1,633753,0.7
Activity,%,591198,0.725
EC50,nM,564874,0.748
INHIBITION,%,339133,0.762
AC50,nM,232818,0.772
Kd,nM,205107,0.78
IC50,,196043,0.788
Z score,,147592,0.794
Ratio IC50,,142161,0.8
Tissue Severity Score,,128999,0.805
Ki,,124169,0.81
MIC,nM,121102,0.815
Ratio,,118474,0.82
GI,%,103193,0.825
CC50,nM,94510,0.828
IZ,mm,91788,0.832
T1/2,hr,89387,0.836
IC50,ug.mL-1,78221,0.839
Residual Activity,%,73944,0.842
FC,,73625,0.845
Stability,%,56190,0.848
ED50,mg.kg-1,51987,0.85
% Control,%,50544,0.852
LC50,nM,48007,0.854
Bacterial Biotransformation,,47351,0.856
AC50,,45414,0.858
CL,mL.min-1.kg-1,44848,0.859
TGI,nM,43632,0.861
Ratio Ki,,43153,0.863
Growth Rate,,38334,0.865
Emax,%,38313,0.866
AUC,ng.hr.mL-1,38225,0.868
Total Cell Count,,32783,0.869
Control DMSO Fragmented Nuclei %,%,32783,0.87
Control DMSO Mitochondria Different-Phenotype Cells (%),%,32783,0.872
Population Fragmented Nuclei (%),%,32783,0.873
Population Normal (%),%,32783,0.874
Control DMSO Healthy Nuclei (%),%,32783,0.876
Control DMSO Membrane Permeable-Phenotype Cells (%),%,32783,0.877
Population Apoptotic (%),%,32783,0.879
Control DMSO Mitotic Cells (%),%,32783,0.88
Control DMSO Pyknosed Nuclei (%),%,32783,0.881
Control DMSO Tubulin Phenotype Different Cells (%),%,32783,0.883
Population Healthy Nuclei (%),%,32783,0.884
Population Hoechst High Intensity Objects (%),%,32783,0.885
Population Pyknosed Nuclei (%),%,32783,0.887
Population Mitotic Cells (%),%,32783,0.888
Population Mitochondria Different-Phenotype (%),%,32782,0.889
Population Membrane Permeable-Phenotype (%),%,32782,0.891
Population Tubulin-Different-Phenotype (%),%,32782,0.892
Solubility,nM,31800,0.893
F,%,31044,0.895
LogD,,30453,0.896
MIC90,ug.mL-1,27952,0.897
Solubility,ug.mL-1,27169,0.898
CL,mL.min-1.g-1,26600,0.899
GI,,26480,0.9
Cmax,nM,25644,0.901
MIC50,ug.mL-1,25477,0.902
Delta TM,C,24914,0.903
Selectivity Index,,22659,0.904
Control DMSO Total Cells,,22319,0.905
Selectivity ratio,,22200,0.906
Ratio EC50,,22136,0.907
Efficacy,%,21685,0.908
Ratio CC50/EC50,,21407,0.909
LogP,,20536,0.91
LUCIFERASE INFECTION ASSAY - IC50,uM,19978,0.911
HEPG2TOX ASSAY - CC90,uM,19978,0.911
LUCIFERASE EXPRESSION CONTROL - IC90,uM,19978,0.912
HEPG2TOX ASSAY - CC50,uM,19978,0.913
LUCIFERASE EXPRESSION CONTROL - IC50,uM,19978,0.914
LUCIFERASE INFECTION ASSAY - IC90,uM,19978,0.915
EC50,,19695,0.916
MIC,,19407,0.916
IFI,%,19230,0.917
WEIGHT,g,18871,0.918
Delta Tm,degrees C,17607,0.919
Drug metabolism,,17324,0.919
TIME,hr,17245,0.92
mortality,%,16427,0.921
ED50,ug ml-1,16178,0.921
Vdss,L.kg-1,15451,0.922
MIC80,ug.mL-1,15383,0.923
EC50,ug.mL-1,15166,0.923
Survival,%,15011,0.924
Control DMSO Apoptotic Cells (%),%,14544,0.924
PPB,%,14176,0.925
Tmax,hr,14107,0.926
Ratio CC50/IC50,,13826,0.926
Drug uptake,,13781,0.927
XC50,nM,13705,0.927
Fu,,13513,0.928
Cell Viability,%,13000,0.928
pKa,,12890,0.929
%Inhib (Mean),%,12829,0.93
MBC,ug ml-1,12790,0.93
Drug uptake,% ID/g,12781,0.931
ED50,uM,12690,0.931
Activity,uM,12156,0.932
T/C,%,11966,0.932
Selectivity,,11179,0.933
Control DMSO Growth Rate,%,10464,0.933
Control DMSO Total Cells,%,10464,0.933
% of control,%,10334,0.934
ED50,umol.kg-1,9766,0.934
IC90,nM,9690,0.935
Km,nM,9535,0.935
Thermal melting change,degrees C,9183,0.935
Drug metabolism,%,8829,0.936
BUN,ug.mL-1,8646,0.936
PHOS,ug.mL-1,8646,0.936
CREAT,ug.mL-1,8646,0.937
GLUC,ug.mL-1,8646,0.937
CHOL,ug.mL-1,8646,0.938
ALB,ug.mL-1,8646,0.938
RBC,cells.uL-1,8645,0.938
MCV,fL,8645,0.939
HCT,%,8645,0.939
PROT,ug.mL-1,8645,0.939
WBC,cells.uL-1,8644,0.94
MCH,pg,8642,0.94
POTASSIUM,mEq.L-1,8642,0.94
HGB,ug.mL-1,8642,0.941
SODIUM,mEq.L-1,8642,0.941
Change,%,8629,0.941
PLAT,cells.uL-1,8626,0.942
NEUTLE,%,8615,0.942
EOSLE,%,8615,0.943
BASOLE,%,8615,0.943
MONOLE,%,8615,0.943
LYMLE,%,8615,0.944
BILI,ug.mL-1,8565,0.944
CLH,uL/min,8422,0.944
Ac50,uM,8340,0.945
solubility,,7835,0.945
MIC90,nM,7470,0.945
Inhibition (mean),%,7427,0.946
Control,%,7390,0.946
Imax,%,7327,0.946
%Max (Mean),%,7141,0.946
TI,,6964,0.947
LD50,mg.kg-1,6894,0.947
DIZ,,6848,0.947
ED50,nM,6728,0.948
%max,%,6682,0.948
TGI,%,6645,0.948
Reduction,%,6318,0.948
MED,mg kg-1,6242,0.949
GI50,ug.mL-1,6221,0.949
MFC,ug ml-1,6204,0.949
Kb,nM,6076,0.949
CC50,ug.mL-1,5874,0.95
log2FC,,5791,0.95
Activity,ug ml-1,5530,0.95
FICI,,5464,0.95
Activity,g,5314,0.951
GI50,,5244,0.951
ILS,%,5227,0.951
Intrinsic activity,,5152,0.951
Kd,,5118,0.951
APTT,s,5115,0.952
ID50,uM,4911,0.952
pKb,,4875,0.952
Relative potency,,4872,0.952
PT,s,4869,0.952
MRT,hr,4852,0.953
Papp,10^-6 cm/s,4790,0.953
ALP,IU.L-1,4773,0.953
GGT,IU.L-1,4773,0.953
LDH,IU.L-1,4773,0.953
MCHC,%,4773,0.954
CALCIUM,ug.mL-1,4773,0.954
ALT,IU.L-1,4773,0.954
ALBGLOB,,4773,0.954
AST,IU.L-1,4773,0.954
PHOSLPD,ug.mL-1,4773,0.955
TERMBW,g,4773,0.955
TRIG,ug.mL-1,4773,0.955
RETIRBC,%,4773,0.955
Cl,meq/L,4773,0.955
BILDIR,ug.mL-1,4749,0.956
Vd,L.kg-1,4748,0.956
ID50,mg.kg-1,4698,0.956
FIBRINO,ug.mL-1,4637,0.956
EC90,uM,4606,0.956
LogD7.4,,4557,0.957
Papp,10'-6 cm/s,4553,0.957
AbsAC40_uM,uM,4490,0.957
TC50,uM,4289,0.957
Papp,ucm/s,4244,0.957
Retention_time,min,4218,0.957
% of inhibition,%,4072,0.958
CC50,,4049,0.958
permeability,10'-6 cm/s,4009,0.958
MST,day,3991,0.958
Selectivity index,,3971,0.958
Hepatotoxicity,,3929,0.958
MIC>99,uM,3921,0.959
-logMIC,,3898,0.959
MCHC,ug.mL-1,3876,0.959
ALP,U.L-1,3873,0.959
AST,U.L-1,3873,0.959
ALT,U.L-1,3873,0.959
CHLORIDE,mEq.L-1,3869,0.96
IZ,,3843,0.96
Emax,,3824,0.96
CK,U.L-1,3716,0.96
ID/g,%,3716,0.96
CLogP,,3694,0.96
Activity,mg/dl,3640,0.96
RBA,,3598,0.961
LD50,uM,3520,0.961
Activity,mmHg,3466,0.961
LIPASE,U.L-1,3460,0.961
URATE,ug.mL-1,3459,0.961
LDH,U.L-1,3438,0.961
INH,uM,3422,0.961
Cp,ng/ml,3419,0.962
RBA,%,3417,0.962
CO2,nM,3370,0.962
MIC99,ug ml-1,3366,0.962
MIC50,nM,3359,0.962
Drug uptake,%,3357,0.962
t1/2,,3352,0.962
CI,,3346,0.963
permeability,nm/s,3344,0.963
Ke,nM,3343,0.963
BASO,cells.uL-1,3331,0.963
MONO,cells.uL-1,3307,0.963
EOS,cells.uL-1,3307,0.963
LYM,cells.uL-1,3307,0.963
T/C,,3262,0.964
MIC100,ug ml-1,3256,0.964
MBC,uM,3246,0.964
BPR,,3237,0.964
Cp,uM,3229,0.964
permeability,10^-6 cm/s,3220,0.964
NEUTSG,cells.uL-1,3201,0.964
Intrinsic activity,%,3192,0.964
ED50,,3181,0.965
RBCNUC,/100WBC,3111,0.965
ID50,ug ml-1,3106,0.965
autophagy induction,%,3052,0.965
MIC99,uM,3051,0.965
MCC,nM,2927,0.965
% Ctrl,%,2885,0.965
LC50,ug.mL-1,2848,0.965
RatioGI50,,2823,0.966
Activity,nM,2813,0.966
Papp,nm/s,2773,0.966
AbsAC35_uM,uM,2740,0.966
Decrease,%,2725,0.966
Activity_index,,2664,0.966
Activity,mg,2643,0.966
Tm,degrees C,2625,0.966
permeability,ucm/s,2572,0.966
Activity,mm,2550,0.967
PD50,mg kg-1,2507,0.967
Drug uptake,uM,2502,0.967
Drug uptake,%ID,2501,0.967
Toxicity,,2460,0.967
TD50,mg kg-1,2414,0.967
Kcat,/s,2412,0.967
IC95,nM,2409,0.967
% Cell Death,,2400,0.967
MIC80,nM,2358,0.968
Relative activity,,2308,0.968
log(activity),,2292,0.968
Residual activity,%,2283,0.968
pD2,,2278,0.968
Log 1/C,,2270,0.968
Diet,%,2246,0.968
Protection,%,2221,0.968
MCC,ug.mL-1,2220,0.968
permeability,,2207,0.968
CLH,,2183,0.968
Activity,pg/ml,2132,0.969
DOSE,mg.kg-1,2131,0.969
pIC50,,2092,0.969
DC50,nM,2088,0.969
EC90,nM,2086,0.969
Activity,mg kg-1,2066,0.969
Drug uptake,ng/g,2049,0.969
Ratio,/M/s,2013,0.969
Activity,s,2012,0.969
MIC,10'-2 umol/ml,1986,0.969
Efficacy,,1950,0.969
Survivors,,1945,0.969
log(1/C),,1938,0.97
MIC95,uM,1932,0.97
IC90,ug.mL-1,1892,0.97
Survival,day,1883,0.97
Drug degradation,%,1872,0.97
Cp,nM,1834,0.97
pKB,,1832,0.97
Increase,%,1828,0.97
max activation,%,1787,0.97
IC50 ratio,,1786,0.97
Ratio ED50,,1760,0.97
Activity,ml,1750,0.97
CL,uL.min-1.(10^6cells)-1,1737,0.97
MEC,uM,1733,0.97
Drug recovery,%,1730,0.971
ERH,,1716,0.971
PXC50,,1705,0.971
pKD,,1700,0.971
log K,,1698,0.971
Activity,mU/ml,1694,0.971
KA,uM,1677,0.971
TGI,,1675,0.971
Hit score,,1669,0.971
Activity,pm/min/mg,1663,0.971
Kinact,nM,1607,0.971
HC50,ug ml-1,1600,0.971
Motility,%,1597,0.971
SI,,1578,0.971
Inhibition index,,1577,0.972
Drug uptake,nM,1569,0.972
MTD,mg kg-1,1568,0.972
Delta MST,day,1559,0.972
Cytotoxicity,,1555,0.972
IC50 relative,nM,1551,0.972
MIC,ug,1548,0.972
AUC,,1543,0.972
MEC,ug ml-1,1524,0.972
Ratio IC50/EC50,,1512,0.972
Papp,,1495,0.972
AbsAC35,uM,1489,0.972
log10cfu,,1482,0.972
CL,,1464,0.972
Log K,,1447,0.972
pEC50,,1440,0.972
EC,uM,1438,0.973
Concentration,ug ml-1,1431,0.973
Potency,,1414,0.973
SUV,,1404,0.973
AbsAC26_uM,uM,1390,0.973
Fold change,,1389,0.973
Dose/organ,%,1386,0.973
Activity,equiv,1377,0.973
Concentration,uM,1362,0.973
PI,,1354,0.973
Displacement,%,1345,0.973
Dose/g,%,1344,0.973
Activity,U/L,1338,0.973
Ratio TD50/ED50,,1330,0.973
Rm,,1326,0.973
Activity,ng/ml,1325,0.973
MIC=>90,ug ml-1,1301,0.973
Activity,mM,1301,0.973
deltaT,degrees C,1292,0.974
AbsAC40,uM,1268,0.974
ID/organ,%,1260,0.974
MBC,,1251,0.974
Concentration @ Maxi,um,1244,0.974
CLH,ml/min,1231,0.974
Hepatotoxicity (malignant tumour),,1215,0.974
Hepatotoxicity (severe hepatitis),,1215,0.974
Hepatotoxicity (steatosis),,1215,0.974
Hepatotoxicity (choleostasis),,1215,0.974
Hepatotoxicity (successful reintroduction),,1215,0.974
Hepatotoxicity (acute),,1215,0.974
Hepatotoxicity (moderate),%,1215,0.974
Hepatotoxicity (mechanism),,1215,0.974
Hepatotoxicity (granulomatous hepatitis),,1215,0.974
Hepatotoxicity (cirrhosis),,1215,0.974
Hepatotoxicity (cytolytic),,1215,0.974
Hepatotoxicity (comment),,1215,0.974
Hepatotoxicity (acute),%,1215,0.974
Hepatotoxicity (animal toxicity known),,1215,0.974
Hepatotoxicity (association with vascular disease),,1215,0.975
Hepatotoxicity (chronic liver disease),,1215,0.975
Hepatotoxicity (benign tumour),,1215,0.975
Hepatotoxicity (time to onset),,1215,0.975
Hepatotoxicity (moderate),,1215,0.975
Effect,,1203,0.975
K,/min,1201,0.975
Relative Growth,,1195,0.975
ID50,nM,1191,0.975
BP,mmHg,1187,0.975
LC50,,1182,0.975
Cmax,ug.mL-1,1163,0.975
LC50,ppm,1162,0.975
% inhibition,uM,1143,0.975
Response,%,1136,0.975
Ratio AUC,,1112,0.975
Max,%,1100,0.975
Inhibition,ug ml-1,1092,0.975
Survival,,1087,0.975
Activity,nm,1076,0.975
UI,,1074,0.975
mortality,,1074,0.976
Peff,10'-6 cm/s,1067,0.976
Compound recovery,%,1061,0.976
Cytotoxicity,%,1059,0.976
K obs / 1,M-1 s-1,1058,0.976
"K(p,uu,brain)",,1045,0.976
Conc @ Max Fold Incr,um,1040,0.976
C50,uM,1039,0.976
Activity,bpm,1027,0.976
Growth,%,1026,0.976
log Pe,,1014,0.976
Activity,nmol,997,0.976
DC50,uM,990,0.976
ID50,umol.kg-1,971,0.976
Cures,,970,0.976
Activity,ug,968,0.976
FIC,,968,0.976
log10CFU/ml,,967,0.976
Inhibition,uM,965,0.976
MSD,day,961,0.976
Flu intensity,,959,0.976
Activity,mm3,957,0.976
Drug uptake,ng/ml,950,0.976
Injected dose,%,942,0.976
Stimulation,%,942,0.977
Imax,,939,0.977
ED50,M,938,0.977
logPapp,,933,0.977
DILI_severity_class,,929,0.977
DILI_Concern,,929,0.977
MPE,%,909,0.977
Activity,um,908,0.977
TDI,,908,0.977
Kp,,904,0.977
Distribution,%,896,0.977
HepSE_liver disease,,888,0.977
HepSE_jaundice,,888,0.977
HepSE_hepatomegaly,,888,0.977
HepSE_hepatic failure,,888,0.977
HepSE_hepatic necrosis,,888,0.977
HepSE_elevated liver function tests,,888,0.977
HepSE_liver function tests abnormal,,888,0.977
HepSE_cholelithiasis,,888,0.977
HepSE_cirrhosis,,888,0.977
HepSE_Combined Scores,,888,0.977
HepSE_bilirubinemia,,888,0.977
HepSE_cholecystitis,,888,0.977
HepSE_liver fatty,,888,0.977
HepSE_hepatitis,,888,0.977
HC50,uM,880,0.977
ID50,M,877,0.977
deltaTm,K,872,0.978
NT,,869,0.978
OD,,857,0.978
PC50,uM,850,0.978
Therapeutic index,,850,0.978
Stability,microL/min/mg,847,0.978
Phospholipidosis,,846,0.978
Biodistribution,%,843,0.978
Dose,%,842,0.978
Rf,,840,0.978
permeability,%,838,0.978
CD,uM,838,0.978
logIC50,,834,0.978
MBC>99.9,uM,829,0.978
AD50,mg kg-1,822,0.978
Cp,ug ml-1,817,0.978
MBC99.9,ug ml-1,815,0.978
Activity,mmol/L,813,0.978
LD50,umol.kg-1,812,0.978
ER-phagy suppression,%,808,0.978
Drug uptake,ug ml-1,804,0.978
GI,uM,795,0.978
Duration,min,795,0.978
Log 1/D50,,792,0.978
MED,,789,0.978
RatioLC50,,782,0.978
Log 1/LD10,,776,0.978
RLU,,774,0.978
Activity,cm,774,0.978
Ratio pKi,,773,0.978
Ratio,%,766,0.979
ILS,,759,0.979
MFC,uM,758,0.979
MST,,757,0.979
HC10,uM,748,0.979
CL_renal,mL.min-1.kg-1,746,0.979
pKi,,745,0.979
Activation,%,737,0.979
Potency ratio,,735,0.979
LD50,ug ml-1,726,0.979
MBC,10'-2 umol/ml,722,0.979
Ka,uM,718,0.979
K,,717,0.979
% residual kinase activity,%,716,0.979
TD50,uM,712,0.979
Injected dose/g,%,711,0.979
Rmax,%,704,0.979
OD,mg kg-1,699,0.979
Reversal,%,699,0.979
Concentration,,699,0.979
pA2,,694,0.979
Kinetic_solubility,,693,0.979
,,680,0.979
deltaG,kcal/mol,679,0.979
MIC50,,679,0.979
Activity,log10CFU/ml,673,0.979
Activity,umol/L,672,0.979
ID50,,671,0.979
Compound recovery,,671,0.979
AC40,uM,669,0.979
Decrease in blood pressure,%,666,0.979
Activity,log10CFU,665,0.979
Delta Tm,,662,0.979
MTC,uM,660,0.979
CHI,,656,0.98
Activity,U/mg,651,0.98
Delta mean survival time,,649,0.98
fT>MIC,%,643,0.98
Vmax,%,642,0.98
Max_Activity,uM,640,0.98
No. of survivors,,636,0.98
Kcat/Km,/uM/s,636,0.98
Relative binding affinity,,634,0.98
k obs / 1,M-1 s-1,632,0.98
Activity,day,632,0.98
Remaining,%,632,0.98
Kinact,/min,629,0.98
IP,nM,628,0.98
MPC,ug ml-1,627,0.98
Binding,%,625,0.98
% Inhibition of Control Specific Binding (Mean n=2),%,623,0.98
MIC90,,620,0.98
log Ks,,614,0.98
Reduction,,613,0.98
ED90,mg kg-1,613,0.98
Log 1/MMIC,,612,0.98
Rate of inhibition,%,609,0.98
Animals,%,608,0.98
Delta TC,%,607,0.98
Log S,,607,0.98
MFC,,606,0.98
MFC,10'-2 umol/ml,604,0.98
Delta MST,,604,0.98
Ratio pIC50,,603,0.98
INH,nM,589,0.98
Activity,min,589,0.98
MIC100,uM,588,0.98
CL/F,mL.min-1.kg-1,583,0.98
Effect,%,581,0.98
pCC50,,580,0.98
CD50,uM,579,0.98
K,/M/s,579,0.98
Drug excretion,%,573,0.98
ILSmax,%,568,0.98
Variation,%,567,0.981
ID,%,563,0.981
Suppression,%,562,0.981
MIC=>90,uM,561,0.981
LD10,mg kg-1,554,0.981
IA,,551,0.981
Log Ki,,550,0.981
Diuretic activity,,549,0.981
Zone of inhibition,mM,549,0.981
Activity,pmol,547,0.981
Weight change,%,545,0.981
Log2 MIC,,543,0.981
Viability,%,541,0.981
deltaTm,,541,0.981
Occ,%,540,0.981
MRT(t),hr,539,0.981
T,degrees C,538,0.981
Max response,%,534,0.981
No. of cured mice,,534,0.981
Cp(f),nM,534,0.981
LD50,,532,0.981
Activity,IU/L,529,0.981
EC,nM,529,0.981
IC90,,528,0.981
ED30,mg kg-1,526,0.981
2PT,uM,517,0.981
GI,ug ml-1,515,0.981
MIC>90,ug ml-1,514,0.981
AFI,%,512,0.981
AbsAC1000_uM,uM,505,0.981
Kis,uM,504,0.981
Virus rating,,503,0.981
EDmin,mg kg-1,501,0.981
Delta IOP,mmHg,498,0.981
Kinact,uM,498,0.981
Activity,U,495,0.981
Activity,nmol/min,495,0.981
Log k',,493,0.981
MOTILITY REDUCTION/CYTOTOXICITY,%,491,0.981
SGOT Increase - Number of Reports,,490,0.981
GGT Increase - Activity Score,,490,0.981
SGPT Increase - Activity Score,,490,0.981
SGOT Increase - Activity Score,,490,0.981
LDH Increase - Number of Reports,,490,0.981
Composite Activity - Active,,490,0.981
SGPT Increase - Index Value,,490,0.981
SGPT Increase - Number of Reports,,490,0.982
GGT Increase - Number of Reports,,490,0.982
Alkaline Phosphatase Increase - Number of Reports,,490,0.982
Composite Activity - Score,,490,0.982
Alkaline Phosphatase Increase - Activity Score,,490,0.982
LDH Increase - Index Value,,490,0.982
GGT Increase - Index Value,,490,0.982
LDH Increase - Activity Score,,490,0.982
Alkaline Phosphatase Increase - Index Value,,490,0.982
Composite Activity - Marginal,,490,0.982
SGOT Increase - Index Value,,490,0.982
Activity,mV,489,0.982
Drug metabolism,uM,488,0.982
pGI50,,488,0.982
Activity,ms,487,0.982
Kcat,/min,485,0.982
Peff,ucm/s,484,0.982
Ct,ng/ml,484,0.982
Mortality,,484,0.982
Ratio Ke,,483,0.982
Ratio Ki(app),,481,0.982
K ass,l M-1,479,0.982
Activity,ug/g,476,0.982
K,/s,475,0.982
Drug uptake,nmol/g,474,0.982
-log(solubility),,474,0.982
CC10,uM,474,0.982
Concentration,%,472,0.982
log(ratio),,470,0.982
Duration,hr,469,0.982
Drugexcretion,%,467,0.982
Activity,degrees C,467,0.982
Vmax,,465,0.982
deltaCT,,464,0.982
MIC>95,uM,464,0.982
Cmax,,462,0.982
Recovery,%,462,0.982
MBC,mg/L,461,0.982
Locomotor activity,,461,0.982
MED,g/acre,459,0.982
Log 1/Ki app,,458,0.982
Ct,nM,458,0.982
% binding,%,454,0.982
IA,%,454,0.982
pED50,,450,0.982
Ki ratio,,442,0.982
k3/Ki,M-1 s-1,440,0.982
Km,,440,0.982
K app,M-1,439,0.982
CLH,%,439,0.982
TC50,ug ml-1,438,0.982
Radioactivity,%,438,0.982
MIC=>80,ug ml-1,435,0.983
deltaH,kcal/mol,434,0.983
MBEC,uM,428,0.983
Remaining (without cofactor),%,427,0.983
CL,L/hr,425,0.983
k_obs,s-1,422,0.983
Weight change,g,422,0.983
Increase,,421,0.983
MIC,ug cm**-2,420,0.983
Ct,ng/g,419,0.983
RFU,,419,0.983
Vd/F,L.kg-1,418,0.983
IC80,umol/L,418,0.983
Score,,415,0.983
EC90,,415,0.983
Activity,micromol/min,415,0.983
LCK,,414,0.983
CL,%,413,0.983
Phytotoxicity,%,411,0.983
No. of animals,,410,0.983
CD50,mg kg-1,410,0.983
In vitro activity,,409,0.983
log(1/MIC),,407,0.983
K app,uM,407,0.983
delta Tm Staurosporine positive control,,406,0.983
delta Tm,,406,0.983
IZ,nm,405,0.983
ERH,%,405,0.983
Activity,nmol/min/mg,404,0.983
QH,%,401,0.983
T1/2,,401,0.983
Permeability,nm s-1,400,0.983
Growth Inhibition,%,400,0.983
Max_Activity_Concent,uM,400,0.983
Anticonvulsant activity,,399,0.983
GI90,ug ml-1,398,0.983
Cmax,ng/g,398,0.983
Block,%,397,0.983
EC50,ppm,397,0.983
AbsAC1,uM,395,0.983
LD50,ug,395,0.983
Cp,,392,0.983
fluorescence,,390,0.983
pD'2,,390,0.983
k_on,M-1.s-1,390,0.983
MIC95,ug ml-1,388,0.983
Biodistribution,%ID/g,387,0.983
Radiolabel recovery,ngequiv/g,382,0.983
IC20,uM,380,0.983
Kcat/Km,/s/microM,380,0.983
Motility,,380,0.983
Cytotoxicity,uM,378,0.983
MIC=>50,ug ml-1,378,0.983
Heart rate,beats min-1,378,0.983
EC1.5,uM,378,0.983
MFC99.5,10'-2 umol/ml,378,0.983
TGI,ug.mL-1,376,0.983
Injected,%,376,0.983
Paw swelling,mM,375,0.983
CLH,ml/min.g,375,0.983
Vmax,pmol/min,374,0.984
log(ILSmax),,374,0.984
Solubility ratio,,373,0.984
activity,%,373,0.984
kon,Ms-1,372,0.984
IG50,uM,370,0.984
Concentration,ug g-1,369,0.984
Drug uptake,ug/g,368,0.984
MIC>90,uM,368,0.984
Optimal dose,mg kg-1,367,0.984
-Log KB,,367,0.984
MBC,uM/ml,366,0.984
2aPTT,uM,366,0.984
FPDc,,361,0.984
Cured,%,361,0.984
KE,,359,0.984
Activity,mg dl-1,359,0.984
Activity,g/dl,358,0.984
MIC80,,357,0.984
Drug excretion,,357,0.984
No. of mice cured,,355,0.984
RUmax,%,354,0.984
Hill coefficient,,354,0.984
Relative affinity,,354,0.984
Peff,10^-6 cm/s,353,0.984
ED50,ug,352,0.984
Ka,,352,0.984
ED50,mg kg-1 day-1,351,0.984
Cooperativity,,350,0.984
Relative IC50,,350,0.984
Inhibition,mm,348,0.984
CL,uL/min,348,0.984
Drug uptake(free),nM,347,0.984
SDL,%,346,0.984
Activity,RFU,345,0.984
MLC,ug ml-1,345,0.984
Kcat/Km,,344,0.984
log(%),,344,0.984
INH,ug ml-1,340,0.984
ED,nM kg-1,339,0.984
TD50,,336,0.984
MIC95,umol/L,336,0.984
Activity,microM/min,336,0.984
Relative potency,%,333,0.984
% Residual activity with Skepinone-L,%,333,0.984
Delta blood pressure,mmHg,332,0.984
Fa,,331,0.984
Therm_solubility,,331,0.984
MTC,mg kg-1,331,0.984
Distribution of radioactivity,dose g-1,330,0.984
IC30,uM,329,0.984
MPC8,ug ml-1,328,0.984
Ka,10'5/M,328,0.984
Release,%,328,0.984
Activity,V,328,0.984
MIC,10'-2umol,328,0.984
k cat,s-1,327,0.984
IC80,ug ml-1,326,0.984
-log(1/MIC),,324,0.984
Max fall in blood pressure,mmHg,324,0.984
MBIC50,ug ml-1,324,0.984
Radiolabel recovery,ugequiv,324,0.984
CL,ml/min,323,0.984
MIC99,,323,0.984
Change,,323,0.984
PFA,,323,0.984
Safety ratio,,322,0.984
Activity,mg/ml,322,0.984
k',,322,0.984
CTD50,uM,321,0.984
Viable cells,%,321,0.984
FPD measurement,,321,0.985
Activity,a.u.,321,0.985
HR,beats min-1,320,0.985
No. of revertants per plate,,320,0.985
pKa2,,318,0.985
Activity,/min,318,0.985
Cp(f),uM,318,0.985
Mean fold stimulation,,318,0.985
Affinity,,317,0.985
Schizont size,um,315,0.985
PAE,hr,315,0.985
MIC=>80,uM,314,0.985
Activity rating,,314,0.985
Radiolabel recovery,%,314,0.985
IC80,uM,314,0.985
Inhibition zone,mM,313,0.985
Vmax,nmol/min,313,0.985
Activity,mm2,312,0.985
ED,mg kg-1,311,0.985
deltaH,kJ/mol,311,0.985
Decrease in SBP,%,311,0.985
Fh,,310,0.985
Max,,310,0.985
Fg,,310,0.985
MFC99.9,uM,310,0.985
Ke,,309,0.985
F_fraction,,308,0.985
Activity,uEq/min,308,0.985
Mean injected dose/g,,307,0.985
PF50,,307,0.985
Activity,mg/L,307,0.985
-Log C,mM l-1,306,0.985
Inhibition,,304,0.985
MIC99.9,ug ml-1,303,0.985
Mean survival time,day,303,0.985
Relative activity,%,303,0.985
IZ,mM,300,0.985
Permeability,,300,0.985
MIC,ppm,299,0.985
pKa1,,299,0.985
Kii,uM,298,0.985
MBC99.9,uM,297,0.985
log(10^6/IC50),,297,0.985
C0,ng/ml,296,0.985
CD50,ug ml-1,295,0.985
Kel,/hr,294,0.985
ED50,10'-1 ug/ml,293,0.985
Kb,,292,0.985
Log 1/M,,291,0.985
dTM,K,291,0.985
fAUC,ng.hr.mL-1,290,0.985
MBEC,ug ml-1,290,0.985
Repellency,%,290,0.985
TC50,,289,0.985
VR,,289,0.985
GR80,ppm,289,0.985
Activity,umol,287,0.985
CCIC50,uM,287,0.985
Drug uptake,kBq/ml,287,0.985
IC100,uM,287,0.985
Drug uptake,nmol,286,0.985
AUC/dose,uM.hr.kg/mg,286,0.985
LTKB_BD DILI severity score,,286,0.985
-TdeltaS,kcal/mol,286,0.985
MBC,umol/ml,285,0.985
EC80,mg/L,284,0.985
Drug metabolism,pmol,284,0.985
EC50,mgAi/L,283,0.985
MBC99.5,10'-2 umol/ml,282,0.985
Radiolabel recovery,ugequiv/g,282,0.985
Drug metabolism,nmol/min/mg,282,0.985
APD95,%,280,0.985
Cell survival,%,280,0.985
% Activity remaining,%,280,0.985
pXC50,,279,0.985
IC12,ug ml-1,279,0.985
ED30,ug kg-1,279,0.985
EC25,uM,279,0.985
Drug metabolism,nmol/min,279,0.985
MNCC,uM,278,0.985
pKA,,278,0.985
Cmin,ng/ml,278,0.986
CC20,uM,278,0.986
MIC=<90,ug ml-1,277,0.986
Solubility,,277,0.986
AUC,uM.hr,277,0.986
ED50 ratio,,276,0.986
Diameter of inhibition zone,mM,275,0.986
Recovery A to B (mean),%,274,0.986
Activity,mol/mol,274,0.986
Log EC50,,273,0.986
Average IC90,uM,273,0.986
Inhibitory activity,,273,0.986
Ratio LC50/IC50,,273,0.986
TD50,ug ml-1,273,0.986
deltaG,kJ/mol,272,0.986
delta logD,,272,0.986
Oral activity,,272,0.986
Relaxation,%,272,0.986
log(1/I50),,271,0.986
ED20,mg kg-1,271,0.986
HD50,uM,271,0.986
I.D./g,%,270,0.986
Drug uptake,ng,270,0.986
Growth_index,,270,0.986
Complex formation,%,270,0.986
MBIC,uM,269,0.986
CC90,uM,269,0.986
Time,,268,0.986
MBC90,ug ml-1,268,0.986
%max,,268,0.986
EC150,uM,267,0.986
Response,,266,0.986
Fold activation,,266,0.986
D40,mg kg-1,266,0.986
MABP,mmHg,265,0.986
K,uM,265,0.986
Activity,pg,265,0.986
logKi,,264,0.986
Activity,Zone units,264,0.986
TDI,%,263,0.986
log(RBA),,261,0.986
pKa_B1,,261,0.986
DILI positive/negative,,261,0.986
Ka,M-1,260,0.986
log(1/ID50),,260,0.986
log(43000/Ki),nM,260,0.986
MTD,uM kg-1,259,0.986
T-C,day,259,0.986
Kcat/Km,/mM/s,258,0.986
Polyamine,%,258,0.986
Fold reversion,,258,0.986
EC50,mg kg-1,257,0.986
Activity,g/L,256,0.986
Activity,umolequiv/umol,256,0.986
MIC,10'-2mmol/ml,255,0.986
fAUC/MIC,,255,0.986
Activity,IU/ml,254,0.986
Activity,/hr,253,0.986
RF,,253,0.986
IOP,mmHg,253,0.986
IC50,mg kg-1,253,0.986
Concentration,ng ml-1,252,0.986
GIC50,nM,252,0.986
BBR,,252,0.986
ID50,ng ml-1,251,0.986
Emin,%,251,0.986
Amnesia reversal,%,251,0.986
MIC,ug mg-1,250,0.986
fIC50,nM,249,0.986
Blood glucose,%,249,0.986
ID50,mM,249,0.986
Fabs,%,248,0.986
Ka,10'6/M,247,0.986
RatioAUC/MIC,,247,0.986
ALD50,mg kg-1,246,0.986
LTS,,246,0.986
MBC,mg/ml,246,0.986
Log IC50,nM,246,0.986
Formation,%,246,0.986
Drug uptake,pmol,246,0.986
Relative Vmax,,245,0.986
Kcat/Km,/M/s,245,0.986
MFC,uM/ml,244,0.986
Papp A to B (mean),1E-6 cm/s,244,0.986
Activity,10'2mEq,244,0.986
fCmax,uM,244,0.986
EC30,uM,243,0.986
ED50,10'-2 ug/ml,243,0.986
Ke(app),nM,243,0.986
Activity,deltalog10CFU,242,0.986
IC50,ug,241,0.986
ED50,10'-3 ug/ml,240,0.986
ED50,mg/kg/day,240,0.986
ED50,g ml-1,240,0.986
MBC50,ug ml-1,239,0.987
No. of mice,,238,0.987
Antagonist potency,,237,0.987
Diet,,237,0.987
Activity,micromol/kg/min,237,0.987
MRC,ug ml-1,237,0.987
Ct,uM,236,0.987
Stability,nmol/min,236,0.987
Stability,ml/min.kg,235,0.987
MEC,nM,235,0.987
MBIC50,uM,235,0.987
MNTD,uM,234,0.987
MIC,p.p.m.,234,0.987
Growth inhibition,,234,0.987
MHC10,uM,234,0.987
EC2,uM,234,0.987
Activity,pmol/min,234,0.987
EC99,uM,234,0.987
Ratio LD50/ED50,,233,0.987
% of engagement,%,233,0.987
Max inhibition,%,233,0.987
Mean survival days,day,232,0.987
Body weight,g,231,0.987
K,10'5/M/s,231,0.987
Potency,%,230,0.987
ED50,nmol,230,0.987
LC99,uM,229,0.987
Solubility (mean),uM,229,0.987
Level,,229,0.987
Decrease,,228,0.987
Vmax,nmol/min/mg,228,0.987
Drug release,%,228,0.987
HC10,ug ml-1,228,0.987
deltaA,,228,0.987
Activity,milliequivalent,227,0.987
Mole fraction,,227,0.987
LC90,ppm,227,0.987
Toxicity,%,227,0.987
Drug degradation,,227,0.987
MED50,mg kg-1,226,0.987
OD,mg kg-1 day-1,226,0.987
Binding affinity,,226,0.987
R,%,226,0.987
Mortality,%,226,0.987
Toxic deaths,,225,0.987
Activity,c.p.m. 50ul-1,225,0.987
AUC,uM.hr.Kg/mg,224,0.987
AP,uM,224,0.987
MITC95,uM,223,0.987
Kinetic,ug/ml,223,0.987
INH,min,223,0.987
fCmax,nM,222,0.987
Max fall in blood pressure,%,222,0.987
MEC,p.p.m.,221,0.987
pKa_A1,,221,0.987
Weight change,,221,0.987
pTC50,,221,0.987
Decrease in blood pressure,,221,0.987
Drug metabolism,pmol/min,220,0.987
DNAUC,kg.min/L,220,0.987
Smax,%,220,0.987
Retention,%,219,0.987
Control,,219,0.987
MIC,10'-3micromol/ml,219,0.987
ED25,mg kg-1,219,0.987
K,M-1,219,0.987
Activity,CFU,219,0.987
Fall,,219,0.987
D,%,218,0.987
Biodistribution,,218,0.987
I,%,218,0.987
Log SP,,217,0.987
Saluretic activity,m equiv 5hr-1 kg-1,217,0.987
Activity rating,%,217,0.987
Activity,cpm,216,0.987
Activity,U/ml,216,0.987
EC90,ug ml-1,215,0.987
LogP app,,214,0.987
CL/F,L/hr,214,0.987
LED,uM,213,0.987
pK,,213,0.987
Kic,uM,213,0.987
Weight difference,g,213,0.987
Drug metabolism,nM,212,0.987
Antagonism,%,212,0.987
ED50,mM,211,0.987
nH,,211,0.987
Log RA,,211,0.987
log Kp,,211,0.987
DC50,,210,0.987
LD99,uM,210,0.987
Survivors,%,209,0.987
MES,,209,0.987
Alpha max,,208,0.987
Agonist potency,,208,0.987
Stability,hr,207,0.987
MBIC,ug ml-1,207,0.987
Residual_activity,%,207,0.987
NI,,207,0.987
TOP,,206,0.987
BOTTOM,,206,0.987
HILLSLOPE,,206,0.987
FPD measurement,FPDc,206,0.987
IC50,molar ratio,205,0.987
logKw,,205,0.987
Plasma level,ng ml-1,205,0.987
Retention time,s,205,0.987
KA,nM,205,0.987
Mean survival,day,204,0.987
Hypoglycemic activity,%,204,0.988
Activity,10'-2mm,204,0.988
Blood pressure,mmHg,204,0.988
Vmax,microM/s,204,0.988
CF,,203,0.988
Weight change,g mouse-1,203,0.988
Parasitaemia,%,203,0.988
Activity,mg/kg/day,203,0.988
Activity,uMequiv/uM,203,0.988
Basal uptake,%,202,0.988
Activity,pg/hr,202,0.988
Weight,mg,202,0.988
deltalog(Tau/KA),,202,0.988
MHC,ug ml-1,201,0.988
fAUC,uM.hr,201,0.988
MIC100,,201,0.988
Kinact,/s,201,0.988
Resistance index,,201,0.988
CLogD,,200,0.988
delta pIC50 wt-mutant,,200,0.988
K,/hr,200,0.988
Drug uptake,nmol/mg,200,0.988
log(RatioIC50),,200,0.988
Ks,uM,200,0.988
K0.5,nM,199,0.988
Drug uptake,ug,199,0.988
Acquisition time,s,199,0.988
EC1.5,nM,199,0.988
Log kill,,199,0.988
Log 1/K,,198,0.988
Activity,MU,198,0.988
Taste character,,198,0.988
Glucose normalisation,%,198,0.988
K inact,min-1,197,0.988
k2,M-1 s-1,196,0.988
Activity,10^-2mm,196,0.988
Dose/organ,,196,0.988
Survival time,day,196,0.988
deltalog10CFU/ml,,196,0.988
TDS,,195,0.988
AD50,,194,0.988
K,nM,194,0.988
Peff,,194,0.988
AUC,uM,194,0.988
Efficiency,%,194,0.988
Change in amplitude response,%,193,0.988
K,10'-3/s,193,0.988
Activity,nmol/g,192,0.988
Relative SEAP activity,%,192,0.988
Activity,IU/mg,192,0.988
Activity,ml/min,192,0.988
RI,,192,0.988
Saluretic activity,m equiv kg-1,192,0.988
Relative viability,%,192,0.988
IZ,%,192,0.988
% activity,%,191,0.988
MTD,uM,191,0.988
Activity,ppm,191,0.988
Drugexcretion,,191,0.988
IZ,Zone units,191,0.988
HC50,,191,0.988
MBC99.5,10'-2microM,190,0.988
Fu,nM,190,0.988
Activity,milliequivalent/kg,190,0.988
C10,uM,190,0.988
CFU/ml,,190,0.988
FDI,%,190,0.988
RA,,189,0.988
Delta A/min,,188,0.988
Activity,nmol/mg,188,0.988
Emetic episodes,,187,0.988
ILS max,,187,0.988
permeability,10'6cm/s,187,0.988
Activity,pg/microg/hr,187,0.988
Cell Viability Ratio,,186,0.988
MFC,10'-2umol,186,0.988
k,hr-1,186,0.988
ED90,gAi/ha,186,0.988
IZ,mm2,186,0.988
Bound,%,186,0.988
MFC90,ug ml-1,186,0.988
AUC/dose,nM.hr,185,0.988
Binding energy,kCal mol-1,185,0.988
MFC,umol/ml,184,0.988
AUC,ng.hr/g,184,0.988
Retention time,min,183,0.988
EMR,,183,0.988
Papp,10'6cm/s,183,0.988
Activity,RU,183,0.988
Survivals,,183,0.988
EC50 ratio,,182,0.988
HD50,uM kg-1,182,0.988
Log PNalk,,182,0.988
Max stimulation,%,182,0.988
MIC50,mmol/ml,181,0.988
MNEC,ug ml-1,181,0.988
AUC/dose,ng.hr/ml,181,0.988
pLD50,,181,0.988
AUC/dose,uM.hr,180,0.988
Drug uptake,%IDKg/g,180,0.988
PI,%,179,0.988
MNCC,ug ml-1,179,0.988
Activity,ng g-1,178,0.988
permeability,10'-7 cm/s,178,0.988
Activity,mmol,178,0.988
IC50 relative,uM,178,0.988
k cat,min-1,178,0.988
P,,178,0.988
CT,%,178,0.988
Partition coefficient,,178,0.988
max activation,,177,0.988
Log 1/T,,177,0.988
ED50,ppm,177,0.988
IC50,ppm,177,0.988
Thermal melting change,,177,0.988
CC100,ug ml-1,177,0.988
I50,,176,0.988
MIC,10'-2micromol/ml,176,0.988
logPeff,,175,0.988
log1/IC50,,175,0.988
IC25,uM,175,0.988
HR,%,174,0.988
Taq inhibition,,174,0.988
GC50,uM,174,0.988
GABA ratio,,173,0.988
Median survival time,,173,0.988
MBC,10'-2micromol/ml,173,0.988
R%,%,173,0.988
pIC25,,173,0.988
Log 1/MIC,,173,0.989
Vd,l,172,0.989
Control compound IC50,uM,172,0.989
"% Enzyme Activity (relative to DMSO controls, average n=2)",%,172,0.989
Reversion,%,172,0.989
AB50,mg kg-1,171,0.989
Tissue distribution,,171,0.989
Aggregation,%,171,0.989
Growth inhibition,%,171,0.989
Activity,dose ratio,171,0.989
GE,%,171,0.989
IC99,nM,171,0.989
Delta HR,%,171,0.989
ED50,ng/ml,171,0.989
EC20,uM,171,0.989
Cell growth,%,170,0.989
Fall,%,170,0.989
Activity,ng,170,0.989
EC,ug ml-1,170,0.989
MPR,,169,0.989
GABA shift,,169,0.989
Drugabsorption,%,169,0.989
Free,%,168,0.989
No. of cures,,168,0.989
Activity_index,%,168,0.989
MFC,umol/L,168,0.989
Geometric mean,,167,0.989
k3/ki,1/m/s,167,0.989
Drug metabolism,ng/ml,167,0.989
Change in BP,mmHg,167,0.989
Average skin reaction,,166,0.989
K,10'5/M,166,0.989
ED90,uM,166,0.989
BP,,166,0.989
Average weight change,g,166,0.989
PGI,%,166,0.989
RRT,s,165,0.989
Log LC50,,165,0.989
Protected,%,165,0.989
solubility,uL,164,0.989
FRP,%,164,0.989
AbsAC30_uM,uM,164,0.989
MBIC90,uM,164,0.989
LD50,mM,164,0.989
MTC,ug ml-1,163,0.989
Vdss,,163,0.989
log(permeability),,163,0.989
K obs / 1,,163,0.989
Normalization,%,163,0.989
Analgesia,%,162,0.989
ID x kg of body weight/g of tissue,%,162,0.989
ED1.5,mg kg-1,162,0.989
Response ratio,,162,0.989
Enhancement,%,161,0.989
Activity,g/day,161,0.989
Radial growth inhibition of fungi (Ā) (mm),mm,160,0.989
EC100,uM,160,0.989
Index,,160,0.989
Activity,MT/ha,159,0.989
CFU,,159,0.989
No. of survivals,,159,0.989
MFC50,ug ml-1,159,0.989
Resistance factor,,159,0.989
log10(%HIA +10),,159,0.989
Log IC50,,159,0.989
pMIC50,,159,0.989
RIS,%,158,0.989
Affinity,%,158,0.989
Remaining activity,,158,0.989
Vmax,microM/min,158,0.989
Log kon,,158,0.989
Relative ED50,,157,0.989
Conversion,%,157,0.989
IC50,%,157,0.989
TCS50,uM,157,0.989
Inhibition,radii mm-1,157,0.989
Uptake,%,157,0.989
Kd,/s,157,0.989
Drugexcretion,%ID,157,0.989
Incorporation,,156,0.989
absorbance,,156,0.989
MISS T/C,,156,0.989
Proliferative response,,156,0.989
Iron change,%,156,0.989
Residual insulin release,%,156,0.989
Delta blood pressure,,156,0.989
Hydrolysis,%,156,0.989
MRTlast,hr,156,0.989
PT,uM,156,0.989
FDI,,155,0.989
Log kOH-,,155,0.989
Peff,nm/s,155,0.989
Relative efficacy,,155,0.989
Mean arterial blood pressure,mmHg,154,0.989
Kd(app),,154,0.989
Average weight,%,154,0.989
Decrease in SBP,,154,0.989
MID,ug ml-1,154,0.989
Uptake ratio,,154,0.989
MFC99.5,10'-2microM,154,0.989
Plasma level,uM,154,0.989
CMC,uM,153,0.989
IC70,ug ml-1,153,0.989
solubility,%,153,0.989
Concentration,M,153,0.989
HACU improvement,%,153,0.989
Disease control,%,152,0.989
Fold selectivity,,152,0.989
NOAEL,uM,152,0.989
Reduction of live worms,%,152,0.989
MFC99.9,ug ml-1,152,0.989
Max effect,%,151,0.989
LD50,nM,151,0.989
Cures/total,,151,0.989
Zone size,mM,151,0.989
Neurotoxicity,,151,0.989
Drug uptake,%ID/cc,151,0.989
MED,uM,151,0.989
Css,uM,150,0.989
Vdss,l,150,0.989
Relative activation,%,150,0.989
Survival time,,150,0.989
pRA,,150,0.989
P50,mmHg,150,0.989
Culture,%,150,0.989
MIC>98,ug ml-1,149,0.989
Drug uptake,mg kg-1,149,0.989
Cmin,ug ml-1,149,0.989
Plasma concentration,ng ml-1,149,0.989
Parasitemia,%,149,0.989
Survivors at day 4,,149,0.989
MAP,mmHg,149,0.989
LC80,ppm,148,0.989
Inhibition,nM,148,0.989
Kcat/Km,/mM/min,148,0.989
Emax,uM,148,0.989
HF,,147,0.989
Lethality,%,147,0.989
logEC50,,147,0.989
IC5,uM,147,0.989
Potentiation,%,147,0.989
Log Kd,,147,0.989
RA,%,147,0.989
log(Kinetic_solubility),,147,0.989
Radiolabel recovery,,146,0.989
Tumors,%,146,0.989
XI50,molar excess,146,0.989
pDC50,,145,0.989
TD50,umol/Kg,145,0.989
pTGI,,145,0.989
Kb,10'5/M,145,0.989
Fmax,%,145,0.989
-Log MIC,ug ml-1,144,0.989
Activity,radii mm-1,144,0.989
Mean relative potency,,144,0.99
V1/2,mV,143,0.99
Swelling,%,143,0.99
Activity,cm2,143,0.99
Kb,10'6/M,142,0.99
Delta BG,%,142,0.99
pH,,142,0.99
AUC/dose,microM.hr/mg/kg,142,0.99
MBC,10'-2umol,142,0.99
MIC=>95,uM,142,0.99
MAD,mg kg-1,142,0.99
D10,mg kg-1,142,0.99
Relative IC50,nM,142,0.99
Ratio,/M/min,141,0.99
Incorporation,%,141,0.99
Concentration,nM g-1,141,0.99
Activity,mmolequiv/mmol,141,0.99
Kcat,,140,0.99
SUV,%,140,0.99
effect,%,140,0.99
BBC,ug ml-1,140,0.99
kHOX,M-1 min-1,140,0.99
Max_Concentration,uM,140,0.99
Activity,umol/Kg,140,0.99
Radioactivity,%ID/g,140,0.99
HCR,,140,0.99
k obs / 1,,139,0.99
pKi(uM),,139,0.99
Activity,ng/L,139,0.99
Leishmanicidal activity,,138,0.99
DC50,microg/cm2,138,0.99
CPE index,,138,0.99
Drug transport,,138,0.99
log(1/ED50),,138,0.99
P50e,mmHg,138,0.99
MAC,ug ml-1,138,0.99
HD50,mg kg-1,138,0.99
Average survival,day,138,0.99
Kinact,min-1,138,0.99
Activity,mol,137,0.99
Range,,137,0.99
C/I ratio,,137,0.99
Selectivity index,uM,137,0.99
Effective dose,nM kg-1,137,0.99
Activity,/m2,137,0.99
Activity,10^9/L,137,0.99
Activity,mg Kg-1,136,0.99
Crop_yield,tons/ha,136,0.99
Fa,%,136,0.99
LC70,ppm,136,0.99
Kcat/Km,10'6/M/s,136,0.99
Uptake value,,136,0.99
KB,,136,0.99
Normal beats,%,135,0.99
Toxic,,135,0.99
CLH,ug/min,135,0.99
No. of toxic deaths,,135,0.99
Cell Proliferation EC50,uM,135,0.99
UTC,%,135,0.99
ED40,uM kg-1,135,0.99
IC70,uM,135,0.99
Papp,cm s-1,135,0.99
Ki,mM/min,135,0.99
AUC/dose,hr.Kg/L,134,0.99
PF,,134,0.99
Ratio,uM,134,0.99
EC40,uM,134,0.99
AUC/dose,,134,0.99
kDPPH,M-1 s-1,134,0.99
Log koff,,134,0.99
Cmax/dose,nM,134,0.99
% of activity,%,134,0.99
Change in IOP,mmHg,134,0.99
Activity,tons/ha,134,0.99
Heart rate,,134,0.99
Hypersensitivity factor,,133,0.99
Vmax/Km,,133,0.99
Cleavage,%,133,0.99
No. of positive cases,,133,0.99
Tlast,hr,132,0.99
Alloste ic enhan er (AE),%,132,0.99
ED50,mg 2kg-1,132,0.99
GR50,gAi/ha,132,0.99
Concentration,ng/mL,132,0.99
Enzyme activity,%,132,0.99
Diuretic effect,,132,0.99
Specificity,,131,0.99
AbsAC200_uM,uM,131,0.99
NE,,131,0.99
EC200,uM,131,0.99
Equieffective dose,mg kg-1,131,0.99
MIC,uL/ml,131,0.99
T-C,g,131,0.99
Selectivity,uM,130,0.99
Concentration,mM,130,0.99
Log BR,,130,0.99
TT,s,130,0.99
k cat/Km,M-1 s-1,130,0.99
Kb,10^7/M,129,0.99
K,10^5/M,129,0.99
FR50,,129,0.99
MIC99,mM,129,0.99
LC30,mg/ml,129,0.99
CRC/CRC0,uM,128,0.99
MHC,uM,128,0.99
ED90,mg/kg/day,128,0.99
Fold increase,,128,0.99
MFC,10'-2mmol/ml,128,0.99
MTL,ug ml-1,128,0.99
Activity,CFU/ml,128,0.99
Activity,mEq/L,128,0.99
Activity,ng ml-1,128,0.99
Apoptosis,%,127,0.99
Toxicity ratio,,127,0.99
logFu,,127,0.99
K,10'-2/s,127,0.99
Number,,127,0.99
Relative efficacy,%,127,0.99
Decrease in activity,%,127,0.99
Stability,ug ml-1,126,0.99
MEC,%,126,0.99
Max salt tolerance,,126,0.99
MFC<=99.9,uM,126,0.99
ED50,pmol,126,0.99
MCC,,126,0.99
MFC99,ug ml-1,126,0.99
Tumor volume,mm**3,126,0.99
Kb,10'4/M,125,0.99
p[A50],,125,0.99
Bmax,fmol,125,0.99
Log IC50,uM,125,0.99
Activity,nmol/ml,125,0.99
MBP,,125,0.99
log(1/MLD),,125,0.99
Plasma concentration,uM,125,0.99
Protection,,125,0.99
Relative Potency,,125,0.99
ED80,gAi/ha,124,0.99
ILSmax,,124,0.99
Activity,mU,124,0.99
Ct,%,124,0.99
Flu intensity,a.u.,124,0.99
MBC,10'-2mmol/ml,124,0.99
Recovered,%,124,0.99
Absorption,%,124,0.99
logP(lung),,124,0.99
Vdss,mL/min/kg,124,0.99
CLH,L/min,123,0.99
MBC99.9,,123,0.99
Activity,nmol/min/ml,123,0.99
HI,,123,0.99
log10CFU/g,,123,0.99
MLD,mg kg-1,123,0.99
NS,,123,0.99
Heart rate,%,123,0.99
Ki(app),,123,0.99
Ratio,/uM/s,123,0.99
Log 1/MEC,,122,0.99
NOAEL,mg kg-1,122,0.99
Ct,ug/g,122,0.99
Distribution (dose/g),%,122,0.99
No. of tumors,,122,0.99
DIZ,%,122,0.99
Accumulation,%,122,0.99
TR,,121,0.99
Decrease in Systolic blood pressure,%,121,0.99
Level,nM (mg of protein)-1,121,0.99
Lysis,%,121,0.99
Proliferation,%,121,0.99
Weight change difference,g,121,0.99
log(1/Km),,121,0.99
Average weight,g mouse-1,121,0.99
MTD,g/acre,120,0.99
Vmax,pmol/min/mg protein,120,0.99
Ki app,,120,0.99
Relative potency,fold,120,0.99
CCh,%,119,0.99
AbsAC50_uM,uM,119,0.99
No. of mice protected,,119,0.99
Activity,/s,119,0.99
K app,,119,0.99
Proliferation,,119,0.99
ILS max,%,119,0.99
MMC,ug ml-1,119,0.99
Papp,cm/s * 10E6,119,0.99
KL,nM,118,0.99
Lipophilicity,,118,0.991
ND50,mg kg-1,118,0.991
Log (1/C),,118,0.991
Ratio Ki,nM,118,0.991
FIC50,,118,0.991
Kis,nM,118,0.991
Dose,uM kg-1,118,0.991
Kd,10'-3/s,118,0.991
IC90,ug,118,0.991
MBC,umol/L,118,0.991
No. of animals protected/animals tested,,118,0.991
TC50,nM,117,0.991
TD50,mg Kg-1,117,0.991
Inhibition rate,%,117,0.991
Log 1/Km,,117,0.991
Toxicity,uM,117,0.991
pA2(app),,117,0.991
Activity,mol/L,117,0.991
MBC,10'-3micromol/ml,117,0.991
MIC95,nM,116,0.991
Drug uptake,ngequiv/g,116,0.991
Stimulation index,,116,0.991
Log Ki,nM,116,0.991
D50,mg kg-1,116,0.991
Saluretic potency,u equiv,116,0.991
Resistance,,116,0.991
TC50,mM,116,0.991
ED20,mM kg-1,116,0.991
EC25,nM,116,0.991
Relative amplitude,%,115,0.991
Cmin,nM,115,0.991
Change in Cl- current,,115,0.991
MBC,mM,115,0.991
Excretion,%,115,0.991
BWD,g,115,0.991
IC50,10^2 uM,115,0.991
Ratio,10^3/M/min,115,0.991
C50,mM,115,0.991
K,/mM/min,115,0.991
Plasma concentration,ug ml-1,114,0.991
FIC,ug ml-1,114,0.991
Drug transport,%,114,0.991
MCD,mg kg-1,114,0.991
LC50,mgAi/L,114,0.991
Urine volume,ml,114,0.991
Rating,,114,0.991
-Log ED50,M acre-1,114,0.991
Ratio,M-1 s-1,114,0.991
Amount excreted,%,114,0.991
Delta t,degrees C,113,0.991
Cholesterol reduction,%,113,0.991
ED40,mg kg-1,113,0.991
Max response,,113,0.991
Urine volume,ml 6hr-1 100g-1,113,0.991
Activity,log10CFU/g,113,0.991
deltalog10CFU,,113,0.991
Change in heart rate,%,113,0.991
Kcat/Km,/s/M,113,0.991
MAC,uM,113,0.991
Hemolysis,%,113,0.991
FC,%,113,0.991
Activity scale,nM,113,0.991
LD99,ug ml-1,112,0.991
Uptake,%ID/g,112,0.991
Licking latency,s,112,0.991
Susceptibility,,112,0.991
AUC,hr.ng/g,112,0.991
Papp,10'-7 cm/s,112,0.991
MLD,nmol,112,0.991
Max,mmHg s-1,112,0.991
Selectivity quotient,,112,0.991
Glucose utilization,uM,112,0.991
IC100,ng ml-1,111,0.991
mechanism based inhibition,,111,0.991
Q,uM,111,0.991
"K(p,uu,CSF)",,111,0.991
Activity,umol/min/mg,110,0.991
IC80,nM,110,0.991
MIC>85,ug ml-1,110,0.991
Entry latency,s,110,0.991
Lowering,%,110,0.991
-Log C,mM kg-1,110,0.991
MIC100,umol/L,110,0.991
Effective dose,,110,0.991
pKa3,,109,0.991
TD50,uM kg-1,109,0.991
pTD50,,109,0.991
Ratio,/mM/s,109,0.991
Activity,mg/g,109,0.991
TdeltaS,kcal/mol,109,0.991
SC50,uM,109,0.991
Na+/K+,,108,0.991
SMT,s,108,0.991
Total iron output,ug kg-1,108,0.991
Na,m equiv 6hr-1 100g-1,108,0.991
Taste class,,108,0.991
CMC,mM,108,0.991
MGM,,108,0.991
Relative hydrolysis rate,,108,0.991
Activity,ug/mg/day,108,0.991
Injected dose/organ,%,108,0.991
Kinact,,108,0.991
Body weight,,107,0.991
IC10,uM,107,0.991
Conversion rate,%,107,0.991
TPE,hr,107,0.991
IVP,,107,0.991
Time constant,ms,107,0.991
Expression,%,107,0.991
Safety index,,107,0.991
Secretion,%,107,0.991
Kcat/Km,10'5/M/s,106,0.991
LAD,mg kg-1,106,0.991
Ratio,nM,106,0.991
Kcat/Km,10'4/M/s,106,0.991
Cell viability,,106,0.991
Sensitivity,,106,0.991
Activity index,,106,0.991
Total radioactivity,%,106,0.991
A50,uM,106,0.991
No. of rosettes/100 Jurkat T cells,,106,0.991
Kiuc,uM,105,0.991
INH,mg kg-1,105,0.991
kOX,M-1 min-1,105,0.991
fEC50,nM,105,0.991
Stability,min,105,0.991
Inhibitory index,,105,0.991
K,10'4/M,105,0.991
IC,uM,105,0.991
ED,ug ml-1,105,0.991
Estrogenic potency,,105,0.991
k3/Ki,1/Ms,104,0.991
LC50,microg/cm3,104,0.991
Activity,uM.hr,104,0.991
MIC95,uM/ml,104,0.991
T/C x100,,104,0.991
C50,nM,104,0.991
Activity,uEq,104,0.991
K,/M/min,104,0.991
Concentration,ng g-1,104,0.991
Antifertility potency,,104,0.991
Activity,disintegrations/minute,104,0.991
Ratio pKb,,104,0.991
Wet weight of tissue,nM g-1,104,0.991
deltalogIC50,,104,0.991
Kcat/Km,10'4/s/M,103,0.991
log(ratioKi),,103,0.991
Activity,uM/L,103,0.991
AD50,ug/kg,103,0.991
IR,%,103,0.991
Ki,ng/ml,103,0.991
BPR,%,103,0.991
ED50,ug injection-1,103,0.991
MTD,mg/kg/day,103,0.991
LC100,uM,103,0.991
K app,10e-7/M,103,0.991
Papp,cm/s,103,0.991
MBP,mmHg,103,0.991
Log I50,,103,0.991
Kapp,10^6L/mol,102,0.991
permeability,nM/s,102,0.991
Increase in blood pressure,mmHg,102,0.991
IS,,102,0.991
PBI,,102,0.991
Dose,ug ml-1,102,0.991
Tm,°C,102,0.991
Ka,10'4/M,102,0.991
Activity,hr,102,0.991
Protein-DNA complex formation,%,102,0.991
MFC,10'-3micromol/ml,102,0.991
Ct,,102,0.991
Beta2 duration,min,102,0.991
IC25,nM,102,0.991
pI50,mM,102,0.991
Serum Ca2+,mg dl-1,101,0.991
ID50 ratio,,101,0.991
LD10,M kg-1,101,0.991
HR,,101,0.991
Fluorescence intensity,,101,0.991
Accumulation,,101,0.991
P50c,mmHg,101,0.991
TPE,,101,0.991
pI50,uM pupa-1,101,0.991
ED90,,101,0.991
MEC,,100,0.991
pKi,uM,100,0.991
Estrogenic effect,%,100,0.991
Paw swelling,%,100,0.991
ED50,ng ml-1,100,0.991
Cures/no. of animals,,100,0.991
C0,ug ml-1,100,0.991
No. of sensitive,,100,0.991
No. of cells,%,100,0.991
Fm,,100,0.991
Inhibition zone,,100,0.991
Specific binding,%ID/g,100,0.991
Dose,,100,0.991
Adhesion,%,99,0.991
CL free,uL/min,99,0.991
AUC/dose,ng.hr/ml/mg/kg,99,0.991
Change in response,%,99,0.991
Relative binding affinity,%,99,0.991
K,10^4/M/s,99,0.991
Ki,%,99,0.991
permeability,cm/s,99,0.991
RE,,99,0.991
kinact,min-1,99,0.991
behavior,,99,0.991
pXC50,M,98,0.991
APDc,,98,0.991
Average dose per organ,%,98,0.991
K,min-1,98,0.991
IP,uM,98,0.991
Delta MAP,%,98,0.991
ED50,10'-4 ug/ml,98,0.991
Increase in IC50,,98,0.991
Agonism,%,98,0.991
Hydrolysis,,98,0.991
Hammett constant,,98,0.991
Amount of TNF-alpha,%,98,0.991
Antagonist activity,,98,0.991
Activity,mol%,98,0.991
MTD,,97,0.991
Activity,pmol/mg,97,0.991
MES,mg kg-1,97,0.991
Benzidine positive cells,%,97,0.991
CL,L/min,97,0.991
Urine volume,ml 4hr-1,97,0.992
IP,%,97,0.992
log(1/IC50),uM,97,0.992
Log10 cfu,,97,0.992
K,10'-3/min,97,0.992
Activity,RLU,97,0.992
PCMA antagonism,,97,0.992
SD90,mg kg-1 day-1,96,0.992
MFC100,ug ml-1,96,0.992
MBC,10^2umol/ml,96,0.992
Activity,uMequiv,96,0.992
MIC,10^2umol/ml,96,0.992
MFC,10'-2microM,96,0.992
Serosal/Mucosal Ca,,96,0.992
Stability,uM,96,0.992
MBC,10'-2microM,96,0.992
Residual insulin release,,96,0.992
Metabolite level,,96,0.992
K,10'-4/s,96,0.992
XI50,mole fraction,96,0.992
Rate constant,M-1 min-1,96,0.992
Transfection efficiency,RLU (ug of protein)-1,96,0.992
Max reversal,%,96,0.992
AUC,ug ml-1,96,0.992
TI50,,96,0.992
ED1.5,,95,0.992
logBB,,95,0.992
3 log kill,,95,0.992
ED50,mg,95,0.992
Fold induction,,95,0.992
pka,,95,0.992
Sleeping time,min,95,0.992
LD,uM,95,0.992
DA release,%,95,0.992
SVT,%,95,0.992
Body weight change,%,95,0.992
Estrogenic effect,,95,0.992
Taste,,95,0.992
K,10'6/M/s,95,0.992
kinact,hr-1,95,0.992
Activity,mA,95,0.992
Log K',,95,0.992
Inhibition,mM,94,0.992
log(1/BC),,94,0.992
LD50,ppm,94,0.992
H2O2 prot,,94,0.992
Plaque reduction,%,94,0.992
Log 1/D40,,94,0.992
CCID50,uM,94,0.992
Delta SBP,mmHg,94,0.992
Cytotoxicity,ug ml-1,94,0.992
Recovery B to A (mean),%,94,0.992
ED20,gAi/ha,94,0.992
IC20,ug ml-1,94,0.992
APTT,uM,94,0.992
Radiation prot,,93,0.992
Drug recovery,,93,0.992
Ki,nM l-1 hr-1,93,0.992
Average survival (days),,93,0.992
Lactone,%,93,0.992
MED=>50,mg kg-1,93,0.992
Drug metabolism,ug/g,93,0.992
Ratio LD50/IC50,,93,0.992
D,,93,0.992
EH,,93,0.992
LD50,g/Kg,93,0.992
Diuretic activity,m equiv kg-1,93,0.992
MGM,uM,92,0.992
Increase in ear thickness,1/100mm,92,0.992
Differentiation,%,92,0.992
Blood flow,100ml g-1 min-1,92,0.992
Delta G,,92,0.992
Toxic dose,mg kg-1,92,0.992
MIC95,,92,0.992
Ratio LD50/EC50,,92,0.992
Induction,,92,0.992
APD,-60mV,92,0.992
Mean aortic blood pressure,mmHg,92,0.992
NO release,%,92,0.992
Max_Delta_Tm,uM,92,0.992
Max fall in blood pressure,,92,0.992
AbsAC50,uM,92,0.992
Mean,,92,0.992
ED100,mg kg-1,92,0.992
Activity,Kg,91,0.992
K inact,,91,0.992
Excretion K+,m equiv,91,0.992
Excretion Na+,m equiv,91,0.992
Papp,10'-5cm/s,91,0.992
ED2,mg kg-1,91,0.992
pI50,,91,0.992
V,ml,91,0.992
C20,uM,91,0.992
Antagonism,,91,0.992
ED50,ug mouse-1,91,0.992
beta t1/2,,91,0.992
ID50,ug,91,0.992
Excretion Cl-,m equiv,91,0.992
Tmax,,91,0.992
Relative resistance,,91,0.992
INH,mM,90,0.992
Am,%,90,0.992
Increase in life-span,%,90,0.992
Kel,/min,90,0.992
Biliary excretion,%,90,0.992
Mean excretion of K+,m equiv,90,0.992
Mean excretion of Cl-,m equiv,90,0.992
Diameter of inhibition zone,,90,0.992
Mean excretion of Na+,m equiv,90,0.992
MIC,microg/cm3,90,0.992
Average consumed,g,90,0.992
A10,mg l-1,90,0.992
Drug metabolism,microL/min/mg,90,0.992
Biodistribution,% dose organ-1 ,90,0.992
Production,%,90,0.992
Excretion,m equiv,90,0.992
ISA,%,90,0.992
logKA,,90,0.992
Mean urine volume,ml,90,0.992
ED50,micromol/kg/min,90,0.992
Vmax,umol/min/mg,89,0.992
Fluorescence,nM,89,0.992
p[A]50,,89,0.992
logS0,,89,0.992
Activity,% dose (g of tissue)-1,89,0.992
REC,,89,0.992
ED25,mg kg-1 day-1,89,0.992
Kapp,uM,89,0.992
IC50,equiv,89,0.992
Cmax,ug/g,89,0.992
Temperature,degrees C,88,0.992
CCTD50,uM,88,0.992
Drug uptake,nmol/min,88,0.992
Metabolism,%,88,0.992
MFC,mM,88,0.992
fCmax,ng/ml,88,0.992
Nuclear cataract,%,88,0.992
mean log D,,88,0.992
pK1,,88,0.992
V0,microM/min,88,0.992
ED20,ug kg-1,88,0.992
PDK,,88,0.992
BWD,,88,0.992
ID50,ng min-1 rat-1,88,0.992
K inact/Ki,M-1 s-1,88,0.992
Activity,deltalog10CFU/ml,88,0.992
Kinetic constant,,88,0.992
% inhibition,nM,87,0.992
Glucose transport,%,87,0.992
Inhibition,ng ml-1,87,0.992
% of residual activity,%,87,0.992
Relative uterus weight,,87,0.992
AbsAC90,uM,87,0.992
BK,%,87,0.992
-Delta G,,87,0.992
Inhibitory zone,mM,87,0.992
Judgments,,87,0.992
Ke,uM,87,0.992
Diuretic activity,ml,87,0.992
Ovulating rats,,87,0.992
RAC,,87,0.992
MIC=>90,mg/L,87,0.992
EC200,ug ml-1,87,0.992
Kd,10'-2/s,87,0.992
Activity,10'3/mm3,87,0.992
Decrease in AP,%,87,0.992
Kr,/mM/min,87,0.992
Esc loss,%,87,0.992
Delta APD95,%,86,0.992
CLH(app),uL/min,86,0.992
Activity,ug/mg,86,0.992
Weight difference,,86,0.992
Cytotoxicity,U,86,0.992
Systolic blood pressure,mmHg,86,0.992
Ratio pA2,,86,0.992
Result,,86,0.992
Therapeutic ratio,,86,0.992
HC50,mg/L,86,0.992
Analgesic activity,,86,0.992
T-C,,86,0.992
pIC50(app),,86,0.992
Metabolism,uM min-1mg-1,86,0.992
No. of rats ovulated,,86,0.992
Mean blood pressure,mmHg,86,0.992
Revertants/plate,,86,0.992
pCC50,uM,86,0.992
Protective index,,86,0.992
CL,ug ml-1,86,0.992
Cell viability,%,86,0.992
EC50,ug,86,0.992
Metabolism,,86,0.992
Injected dose/g tissue,%,85,0.992
log KOW,,85,0.992
AD50,ug kg-1,85,0.992
CL free,,85,0.992
MEC,mg/L,85,0.992
Stability,uL/min.mg,85,0.992
Concentration,nM (10e6*cells)-1,85,0.992
Protection index,,85,0.992
Contraction,%,85,0.992
LC90,ug ml-1,85,0.992
Latency,s,85,0.992
Antibacterial activity,,85,0.992
EC100,ppm,84,0.992
Relative protection,,84,0.992
MPE50,mg kg-1,84,0.992
DRF,,84,0.992
Change in weight,%,84,0.992
Loss,%,84,0.992
Decrease in blood glucose,%,84,0.992
LDH,MU,84,0.992
ov. rat/total,,84,0.992
MD,,84,0.992
pA10,,84,0.992
Change in blood pressure,mmHg,84,0.992
IC50 relative,,84,0.992
IC100,ug ml-1,84,0.992
Stability,uL/min,84,0.992
logKb,,84,0.992
Binding affinity,nM,84,0.992
EII50,,84,0.992
CAC,uM,84,0.992
LLR score,,84,0.992
Inhibition ratio,,84,0.992
Brain content,nM ml-1,84,0.992
S,,84,0.992
Decrease in blood pressure,mmHg,84,0.992
Drugexcretion,mg,84,0.992
Plasma content,nM ml-1,84,0.992
Kb,10'7/M,83,0.992
Average weight change,%,83,0.992
2x APTT,uM,83,0.992
Relative JC-1 accumulation,,83,0.992
Rmax,,83,0.992
Drug metabolism,nmol/g,83,0.992
logKcat,,83,0.992
Concentration,nM,83,0.992
Survival days,,83,0.992
EC15,nM,83,0.992
Vmax,pmol/min/mg,83,0.992
Survival ratio,,83,0.992
k,min-1,83,0.992
Activity,total picomoles,82,0.992
Fibril formation,%,82,0.992
LTC,,82,0.992
EC15,uM,82,0.992
ki/Ki,M-1 min-1,82,0.992
EH,none,82,0.992
Vmax,micromol/min,82,0.992
RP,,82,0.992
Level,%,82,0.992
Kd,10'-1/s,82,0.992
BP decrease,mmHg,82,0.992
No. of Colony forming Units,,82,0.992
K,10'4/M/s,82,0.992
PD50,,82,0.992
Drug metabolism,umol/L,82,0.992
p(1/MIC),,82,0.992
Activity,nmol/mg/min,82,0.992
pIC100,,82,0.992
IC50,10^-7mol/L,81,0.992
Activity,pmol/hr,81,0.992
Extracted,%,81,0.992
Activity,L/mol/s,81,0.992
MTC,,81,0.992
Relative EC30,nM,81,0.992
EC50,microg/cm2,81,0.992
-log(RatioIC50),,80,0.992
ALP activity,,80,0.992
IAr,,80,0.992
Relative amount,%,80,0.992
Plasma level,ug ml-1,80,0.992
Lipid level,mg dl-1,80,0.992
Contraction,,80,0.992
Activity,log10FFU/ml,80,0.993
Mycelial growth,cm,80,0.993
Activity,milli optical density/minute,80,0.993
Log Ki,mM,80,0.993
LC50,ugAi/ml,80,0.993
K,10^5/M/s,80,0.993
MABP,,80,0.993
Biodistribution,%Dose/g,80,0.993
IP,,80,0.993
CMP,,80,0.993
Ki'',uM,80,0.993
logRA,,80,0.993
Emax,nM,80,0.993
Activity,/M/cm,80,0.993
AUC/dose,uM.hr.Kg/mg,79,0.993
LD90,uM,79,0.993
logMIC,,79,0.993
Mean weight,mg,79,0.993
ED50,umol/L,79,0.993
-TdeltaS,kJ/mol,79,0.993
ECS ratio,,79,0.993
EC30,nM,79,0.993
RU,,79,0.993
Activity,pM,79,0.993
SVT,,78,0.993
AA,,78,0.993
TCS50,nM,78,0.993
Concentration,pg ml-1,78,0.993
Baseline systolic BP,%,78,0.993
Duration of action,hr,78,0.993
log10CCID50,,78,0.993
Mutagenicity,,78,0.993
Kinact,mM,78,0.993
MBC90,mg/L,78,0.993
IF,,78,0.993
Ratio GI50/EC50,,78,0.993
MBC50,mg/L,78,0.993
Activity,fmol,78,0.993
DOM,%,78,0.993
Activity,/uL,78,0.993
LBF,%,78,0.993
LD90,ug/g,78,0.993
Ki/Km,,77,0.993
Binding intensity,,77,0.993
P,cm s-1,77,0.993
MNTD,ug ml-1,77,0.993
Peak rhGH,ng ml-1,77,0.993
RUmax,,77,0.993
Affinity constant,uM,77,0.993
Drug metabolism,pmol/min/mg,77,0.993
I50,ppm,77,0.993
Ratio,/uM/min,77,0.993
CL,ml/hr,77,0.993
Log Kmemb,,76,0.993
Decrease in CR,%,76,0.993
GS,,76,0.993
K 0.5,nM,76,0.993
Kapp,10'6/M,76,0.993
Krel,,76,0.993
IC16,uM,76,0.993
Oral diuretic activity,m equiv [Na+] 5hr-1kg-1,76,0.993
Activity,p.p.m.,76,0.993
Fold resistance,,76,0.993
Activity,10'3CFU/ml,76,0.993
Inhibitory response,%,76,0.993
DIZ,mm/mg,76,0.993
Activity,IU,76,0.993
Sleeping time,s,76,0.993
K,10'3/M/s,76,0.993
CI50,,76,0.993
pKa4,,76,0.993
Ct,% ID/g,76,0.993
TI rating,,76,0.993
TG100,uM,76,0.993
IC200,uM,76,0.993
Antibiotic activity,,76,0.993
Range,ug ml-1,76,0.993
Cytotoxicity,ng ml-1,76,0.993
Max decrease in heart rate,%,76,0.993
D50,mg kg-1 day-1,76,0.993
EC,,76,0.993
AUC,ng/g.hr,75,0.993
increase in mean survival time,day,75,0.993
K,10^-3/min,75,0.993
DeltaTC,%,75,0.993
CyD50,ug ml-1,75,0.993
HSAI,,75,0.993
2-DG uptake stimulation,,75,0.993
Relative affinity,%,75,0.993
Degradation,%,75,0.993
Slope,,75,0.993
Duration,,75,0.993
scMet,,75,0.993
Kbapp,nM,75,0.993
Log potency ratio,,75,0.993
Reversal activity,%,75,0.993
T50,min,74,0.993
Log Ki,uM,74,0.993
MGC,uM,74,0.993
Activity,nmol/hr,74,0.993
Rate,,74,0.993
MCC50,uM,74,0.993
ED50,%,74,0.993
Cured/treated,,74,0.993
IC50,10^-9mol/L,74,0.993
Growth zone,mM,74,0.993
K,10'6/M,74,0.993
dTm,K,74,0.993
%AUCextra,%,74,0.993
Cell Proliferation IC50,uM,74,0.993
Zone of inhibition,,74,0.993
ED10,ug kg-1,74,0.993
AUC/dose,nM.hr.kg/mg,74,0.993
FR,,73,0.993
Rblood_plasma,,73,0.993
Activity,pg/mg,73,0.993
TGIR,%,73,0.993
Activity,nM/s,73,0.993
Log [MrI],,73,0.993
Hill coefficient (n50),,73,0.993
Kdiss,/min,73,0.993
Bioreduction,%,73,0.993
K,10'-2/min,73,0.993
Drug discrimination effect,%,73,0.993
XI50,,73,0.993
Drug uptake,nmol/Kg,73,0.993
PB,pmol,73,0.993
Remaining activity,%,73,0.993
Bmax,pmol,73,0.993
No. of rabbits convulsed,,73,0.993
log(Tau/KA),,72,0.993
MBC>99.9,umol/L,72,0.993
Ka,10'5/M/s,72,0.993
Excretion rate,,72,0.993
Saluretic activity,m equiv 6hr-1 kg-1,72,0.993
Serum concentration,,72,0.993
log(1/MED),,72,0.993
Compound_Concentrati,uM,72,0.993
Activity,RPKM,72,0.993
Diuretic activity,ml kg-1,72,0.993
Sweetness potency,0-15 scale,72,0.993
Flu intensity,%,72,0.993
Blockage activity,,72,0.993
Activity,fL,72,0.993
Biodistribution,nM (g of tissue)-1,72,0.993
pK2,,72,0.993
Ratio,U,72,0.993
TBPS shift,,72,0.993
Plasmaconcentration,ug ml-1,71,0.993
Inflection point,nM,71,0.993
Activity,Da,71,0.993
Mouse behavior activity,,71,0.993
logPF,,71,0.993
k2,min-1,71,0.993
Inhibitor level,,71,0.993
Stabilty,min,71,0.993
Shift,,71,0.993
P-value,,71,0.993
Log CR,,71,0.993
Ka,10^5/M,71,0.993
Drug uptake(free),uM,71,0.993
AUC/dose,kg.hr/L,71,0.993
Relative uterus weight,mg,71,0.993
Lw/Bw,,71,0.993
Blood sugar lowering,%,71,0.993
pKd,,71,0.993
Death,%,71,0.993
Selectivity index,SI,71,0.993
Concentration,% kg dose g-1,71,0.993
log%Abs,,71,0.993
Cr,mg dl-1,71,0.993
UD50,mg kg-1,70,0.993
NOAEL,mg/kg/day,70,0.993
Ulcerogenic index,,70,0.993
AUC,uM.hr/ml,70,0.993
Ka',,70,0.993
Glyceamia evolution,%,70,0.993
KB app,uM,70,0.993
Binding affinity,%,70,0.993
ND,,70,0.993
Log cell kill,,70,0.993
Resistance,%,70,0.993
Methemoglobin,,70,0.993
Stability,nm,70,0.993
C20 APD95,uM,70,0.993
Affinity,nM,70,0.993
LogD6.5,,70,0.993
IC50,% conc,70,0.993
GHI,,70,0.993
Cells,%,70,0.993
ED30,uM kg-1,70,0.993
Biodistribution,% g-1,70,0.993
ED50,g/Kg,70,0.993
No. of cures,day,70,0.993
AUC/dose,min.kg/L,70,0.993
Papp,uL/hr/cm2,70,0.993
Latency,,69,0.993
Log A,,69,0.993
UN,mg dl-1,69,0.993
Mortality,day,69,0.993
LS,%,69,0.993
MFC,mg/L,69,0.993
Kapp,10^3/M,69,0.993
deltapIC50,,69,0.993
AOA,,69,0.993
Ratio,10'3/M/s,69,0.993
SS,%,69,0.993
Inhibitory potency,,69,0.993
EC30,,69,0.993
Activity,/M/s,69,0.993
Ka,/uM,69,0.993
MIC,microg,69,0.993
Change in reaction time,%,69,0.993
Survivors / animals tested,,69,0.993
I0.5,uM,69,0.993
ED50,mM l-1,69,0.993
Log BB,,69,0.993
Delta,%,69,0.993
Diuretic effects,,69,0.993
Activity,m,69,0.993
Change TC,%,68,0.993
MID,,68,0.993
Kinact,/mM/min,68,0.993
Convulsion,%,68,0.993
ID50,umol,68,0.993
AR,,68,0.993
Activity,ml/kg,68,0.993
Temperature change,degrees C,68,0.993
Activity,% ID/g,68,0.993
Potency,mg kg-1 day-1,68,0.993
Vasorelaxant effect,,68,0.993
ED200,uM,68,0.993
Activity,nmol/L,68,0.993
Drug uptake,ng/mg,68,0.993
Displacement,,68,0.993
Activity,10'6/ml,68,0.993
Delta G,kCal,68,0.993
MBC,ug,68,0.993
CT10,uM h,68,0.993
MBEC,,68,0.993
pC1,,68,0.993
-Delta G,kCal mol-1,68,0.993
Log relative k',,68,0.993
PCA,,68,0.993
% absorbed,%,68,0.993
MFC99.9,,67,0.993
No. of emetic episodes,,67,0.993
Activity,mmol/Kg,67,0.993
Hypothermic effect,,67,0.993
Activity,M,67,0.993
No. of chicks,,67,0.993
TC,mg dl-1,67,0.993
EC100,nM,67,0.993
Mean peak APTT,,67,0.993
[3H] concentration,% kg dose g-1,67,0.993
Bmax,fM mg-1,67,0.993
MHC,ug,67,0.993
Activity,uIU/ml,67,0.993
Uterine weight,mg,67,0.993
ED150,mg kg-1,67,0.993
Average change in body weight,%,67,0.993
SP,mmHg,67,0.993
Turnover,ng ml-1,67,0.993
Stability,ml/min,67,0.993
Occ,,67,0.993
EC2x,uM,66,0.993
MBC90,uM,66,0.993
CD100,uM,66,0.993
Ratio,M-1 min-1,66,0.993
Activity,mol/min,66,0.993
Ki 0.5,nM,66,0.993
Delta Vmax,%,66,0.993
Parasite_Clearance,%,66,0.993
Iron output,,66,0.993
Ct,ug ml-1,66,0.993
Kdiss,/s,66,0.993
delta Log P,,66,0.993
K obs,,66,0.993
log Pe,cm/s,66,0.993
Ratio_Papp,,66,0.993
-Log ID50,,66,0.993
EC20,nM,66,0.993
Urinary recovery,%,66,0.993
EC50,%,66,0.993
Ratio,/s/M,66,0.993
Weight loss,g,66,0.993
P50d,mmHg,66,0.993
PFC,,66,0.993
BWLmax,%,66,0.993
AUC,ug.hr/g,66,0.993
log1/Ki,,66,0.993
Drug uptake,ugequiv,66,0.993
Edema variation,%,66,0.993
% recovery,,66,0.993
Growth delay,day,66,0.993
Body weight change,g,65,0.993
Potency_Clk4_uM,uM,65,0.993
Kd,min-1,65,0.993
Biological activity,%,65,0.993
Specific binding,%,65,0.993
MDD,,65,0.993
Max reduction,%,65,0.993
K2,min-1,65,0.993
Selectivity,zone unit,65,0.993
Log kw,,65,0.993
No. of deaths,,65,0.993
Kieq,nM,65,0.993
K,10'3/M/min,65,0.993
Serum Ca2+,,65,0.993
Activity,nmol/sec,65,0.993
LD10,mg kg-1 day-1,65,0.993
CC25,ug ml-1,65,0.993
Pc,cm s-1,65,0.993
Ulcer incidence,number/group,65,0.993
C1.6,mM,65,0.993
Serum level,mg dl-1,65,0.993
logGI50,,65,0.993
ED50,mg ml-1,65,0.993
Activity,10^2 mm,64,0.993
Toxicity,uM kg-1,64,0.993
Fraction ionised,,64,0.993
Behavioral score,,64,0.993
LD20,,64,0.993
LD100,mg kg-1,64,0.993
ED100,,64,0.993
p24,pg ml-1,64,0.993
Discrimination ratio,,64,0.993
Inhibition Zone,cm,64,0.993
log(1/SD90),,64,0.993
Residual insulin secretion,%,64,0.993
Activity,/cm3,64,0.993
Rotarod toxicity,,64,0.993
CC,,64,0.993
Tracer,%,64,0.993
Tm,,64,0.993
Relative EC30,,64,0.993
Binding affinity,uM,64,0.993
Delta HDL,%,64,0.993
Systolic blood pressure,,64,0.993
Radius of inhibition zone,mM,64,0.993
Papp B to A (mean),1E-6 cm/s,64,0.993
eLog D,,64,0.994
Stability,ml/min/mg,64,0.994
Papp,10'-5 cm/s,64,0.994
K,10^-3/s,64,0.994
AC3,uM,64,0.994
Net cell kill,log10,64,0.994
deltaRm,,64,0.994
CL_renal,L/hr,64,0.994
Change in weight,,64,0.994
Log Pe,cm s-1,64,0.994
Metabolic stability,%,63,0.994
No. of cells,,63,0.994
Log activity,,63,0.994
BA,%,63,0.994
Cl - current change,,63,0.994
EC1.5,,63,0.994
K,M-1 s-1,63,0.994
K ass,l uM-1,63,0.994
Imax,mmHg,63,0.994
pLC50,,63,0.994
I ABC,,63,0.994
Ratio IC50,uM,63,0.994
Agonist activity,,63,0.994
Inhibition uptake,%,63,0.994
Relative velocity,,63,0.994
Activity,10'-3/M/s,63,0.994
ED85,g/ha,63,0.994
Papp,10^6cm/s,63,0.994
APD75,%,63,0.994
Activity,molar ratio,63,0.994
-Log KD,,63,0.994
RUmax,10'2/Da,63,0.994
Stability,pmol/min/mg,63,0.994
Bmax,fmol/mg,63,0.994
Activity ratio,,63,0.994
Activity,m equiv kg-1,62,0.994
Log RAI,,62,0.994
Activity,pmol/g,62,0.994
Concentration,mg ml-1,62,0.994
AUC,%,62,0.994
PHA,,62,0.994
cAMP accumulation,%,62,0.994
log(1/LD50),,62,0.994
ED99,ug ml-1,62,0.994
MIC=<50,uM,62,0.994
ED50,mg mouse-1,62,0.994
log(IA),,62,0.994
Activity,10'9/L,62,0.994
permeability,10'-5 cm/s,62,0.994
PI turnover,,62,0.994
GR50,kg/ha,62,0.994
Ulcerogenic activity,%,62,0.994
Activity,10^3 /uL,62,0.994
Deaths,,62,0.994
CPA,%,62,0.994
K,10^-2/s,62,0.994
K,10^5/M/min,62,0.994
K,10'5/M.s,62,0.994
Relative velocity,%,62,0.994
Uterotrophic effect,,62,0.994
Delta MAP,,62,0.994
pA50,,62,0.994
Max non-toxic dose,ug ml-1,62,0.994
TC,%,62,0.994
Hydrolysis rate,,62,0.994
Kdiss,uM,62,0.994
Delta MAP,mmHg,61,0.994
KD/Ki,nM,61,0.994
Papp,nM/s,61,0.994
Significance,,61,0.994
Drug metabolism,ug ml-1,61,0.994
Ka,10^5/M/s,61,0.994
Kin,hr-1,61,0.994
Organ distribution,%,61,0.994
ED20,,61,0.994
Ka,10^6/M,61,0.994
Cmin,mg/L,61,0.994
ISA,,61,0.994
Inactivation,%,61,0.994
Dead cells,%,61,0.994
T/C,day,61,0.994
Alpha E,,61,0.994
Effect,mg 100g-1,61,0.994
Log ED50,uM kg-1,61,0.994
Activity,10^-7/M,61,0.994
Tumor weight,g,61,0.994
Potency_Clk2_uM,uM,61,0.994
Lowering,,61,0.994
CLH,uL/mg/min,61,0.994
Stability,uL/min/kg,61,0.994
LD50,microgAi/g,61,0.994
ED95,mg kg-1,61,0.994
Absorbance,nm,60,0.994
Cytotoxicity,nM,60,0.994
HYPO,,60,0.994
Median day of death,,60,0.994
IFN,ml,60,0.994
% maximum response,%,60,0.994
% remaining,%,60,0.994
MG MID,uM,60,0.994
Activity,ugequiv/ml,60,0.994
-Log ED50,,60,0.994
ED50,nM mouse-1,60,0.994
Activity,mg/mg/day,60,0.994
DAR,,60,0.994
pID50,,60,0.994
No. of animals protected,,60,0.994
Ratio_ATPase activity,,60,0.994
Drug release,,60,0.994
Potency_Dyrk1a_uM,uM,60,0.994
A0.5,uM,60,0.994
PCA shift,,60,0.994
SF,,60,0.994
Bmax,fM (mg of protein)-1,60,0.994
Change in heart rate,beats min-1,60,0.994
[I],uM,60,0.994
CC30,uM,60,0.994
Activity,10'-3cpm,60,0.994
Vmax,nM min-1,60,0.994
Level,uM,60,0.994
Sensory evaluation,,60,0.994
T99.9%,hr,60,0.994
Activity,10'7mol/J,60,0.994
Weight,%,60,0.994
Latency time,s,60,0.994
Anticoccidial Activity,%,60,0.994
IC50,10^-8mol/L,60,0.994
Chemotherapeutic index,,60,0.994
ED30,,59,0.994
Other,,59,0.994
CI75,,59,0.994
Total cholesterol,mg dl-1,59,0.994
koff,min^-1,59,0.994
Inhibitory diameter,,59,0.994
kon,nM^-1 min^-1,59,0.994
LC90,uM,59,0.994
ED99,mg kg-1,59,0.994
Dose ratio,,59,0.994
Effective dose,mg kg-1,59,0.994
Half duration,min,59,0.994
Relative uterine weight,,59,0.994
RHT,,59,0.994
Erythroid induction,%,59,0.994
Relative hydrolysis,,59,0.994
CFU,/ml,59,0.994
CD,,59,0.994
Activity,microg/ml,59,0.994
Change of tumor area,%,59,0.994
Average weight,,59,0.994
ED50,g/ha,58,0.994
MLC,uM,58,0.994
Relative salidiuretic activity,,58,0.994
Potency_Dyrk1b_uM,uM,58,0.994
Body weight loss,%,58,0.994
Reduction factor,,58,0.994
ECmax,,58,0.994
Estrogenic effect,nM,58,0.994
AUC,uM.hr/mg.kg,58,0.994
Tp control,%,58,0.994
Log GI50,,58,0.994
MED,uM kg-1,58,0.994
EC5X,uM,58,0.994
dP/dt20,mg kg-1,58,0.994
LD50,mg/L,58,0.994
Activity,10'-7M,58,0.994
AE Score,%,58,0.994
KI_MICROM,um,58,0.994
Specific activity,uM min-1 (mg of protein)-1,58,0.994
Drug uptake,%ID/ml,58,0.994
AWC,g,58,0.994
IE50,uM/L,58,0.994
ACT,%,58,0.994
Cmax/dose,uM,58,0.994
Glycaemia evolution,%,58,0.994
Level,pM g-1,58,0.994
Stabilty,ml/min.kg,58,0.994
Cmax,nmol/g,58,0.994
Collapse time,min,58,0.994
Neuroprotection,%,58,0.994
Relative growth,,58,0.994
Inhibition ratio,%,58,0.994
UR,%,58,0.994
Activity,mmHg/s,57,0.994
Antiovulatory activity,%,57,0.994
ID90,uM,57,0.994
SI,uM,57,0.994
Vz/F,l,57,0.994
ED25,uM kg-1,57,0.994
K,10'-5/s,57,0.994
CL,L/Kg,57,0.994
Anti-pent effect,,57,0.994
Mean uterine weight,mg,57,0.994
Total radioactivity,ug equiv g-1,57,0.994
Surviving fraction,,57,0.994
Emax,dyn/mg,57,0.994
Onset,s,57,0.994
PC,,57,0.994
SUVmax,,57,0.994
Ratio,ug ml-1,57,0.994
TCID50,uM,57,0.994
Max PI,%,57,0.994
AUC cytotoxicity,,57,0.994
AUC Ratio,,57,0.994
Uterine activity,%,57,0.994
Ct,% dose/g,57,0.994
EC80,ug ml-1,57,0.994
Max increase,%,57,0.994
pKi,nM,57,0.994
Polyamine level,,57,0.994
ED50,microg/cm2,57,0.994
RPP,%,57,0.994
LD0,mg kg-1,57,0.994
EC30,ug ml-1,56,0.994
CD,nM,56,0.994
MDD50,mg kg-1,56,0.994
Lipid-soluble radioactivity,,56,0.994
ITP,%,56,0.994
Activity,umolequiv/g,56,0.994
IZ,mm/mg,56,0.994
ZImax/KZI,mm microL/micromol,56,0.994
Uterine weight,,56,0.994
T/C,min,56,0.994
MED,ug ml-1,56,0.994
Kr,/min,56,0.994
Deuterium retention,%,56,0.994
Activity,10'6CFU,56,0.994
Vmax,nM/s,56,0.994
Modification,%,56,0.994
CLz/F,L/hr/kg,56,0.994
Activity,uL,56,0.994
Relative stability,%,56,0.994
Growth of cells,,56,0.994
Stimulation,,56,0.994
Log k,,56,0.994
Therapeutic index 99,,56,0.994
pRA1,,56,0.994
% Inhibition of Control Values (Mean n=2),%,56,0.994
Kb,M-1,56,0.994
pRA2,,56,0.994
pTCD50,,56,0.994
STY seizure,mg kg-1,55,0.994
K,/uM/s,55,0.994
TAC,mmol/L,55,0.994
PO2,%,55,0.994
ID75,uM kg-1,55,0.994
Kinact,/M/min,55,0.994
Log 10 LC50,,55,0.994
AUC/dose,microg.hr/mL,55,0.994
CI90,,55,0.994
Antidiuretic activity,mg,55,0.994
Recovery,,55,0.994
Removal of microfilariae,%,55,0.994
Reactors/Test group,,55,0.994
Supression,%,55,0.994
Serum total triglycerides,mg dl-1,55,0.994
Log 1/EDMES(2.5),,55,0.994
K inact,s-1,55,0.994
Log AP,,55,0.994
K,10'3/s,55,0.994
Saluretic score,,55,0.994
ED50,ug ear-1,55,0.994
NOHA,%,55,0.994
pA2,nM,55,0.994
D50,,55,0.994
EDMES(2.5),mg kg-1,55,0.994
Drug metabolism,ng/g,55,0.994
Activity,uM kg-1,55,0.994
log(1/D40),,55,0.994
logKa,,55,0.994
Metabolism,pM min-1 mg-1,55,0.994
Activity,kcal/mol,55,0.994
Activity,pA/pF,55,0.994
NO formation,%,55,0.994
GC50,,55,0.994
permeability,10'-4 cm/s,55,0.994
-log(inh/100-inh),,55,0.994
MTD,ug ml-1,55,0.994
ED100,ug,55,0.994
Clearance,L/h/Kg,55,0.994
Clearance,ul min-1,55,0.994
pC,,55,0.994
Rotation number,,54,0.994
K,10^-4/s,54,0.994
CC25,,54,0.994
Length,mM,54,0.994
No. of lung colonies,,54,0.994
Binding energy,kCal M-1,54,0.994
Maximal effect,%,54,0.994
Papp,10^-8cm/s,54,0.994
Rel Max FI,,54,0.994
Kcat/Km,microM/s,54,0.994
Protected mice,%,54,0.994
Vmax,uM min-1mg-1,54,0.994
log(10'6/IC50),,54,0.994
log(1/ED30),,54,0.994
Total dose,mg kg-1,54,0.994
Biodistribution,dose/organ %,54,0.994
MBEC50,ug ml-1,54,0.994
Growth Inhibition,mm,54,0.994
Activity,umol/g,54,0.994
pKm,,54,0.994
Drug uptake,ppm,54,0.994
Injection dose/g,%,54,0.994
Concentration,ng (g of tissue)-1,54,0.994
AUBC,log10CFU/ml.hr,54,0.994
nHill,,54,0.994
Log D50,,54,0.994
No. of falls,,54,0.994
AUC,microM.hr/mg/kg,54,0.994
Polyamine content,nM g-1,54,0.994
Median survival day,,54,0.994
alphaKi,uM,54,0.994
Initial activity,%,54,0.994
ED300,ug kg-1,54,0.994
CD50,nM mouse-1,54,0.994
Receptor occupancy,%,54,0.994
Cmax/dose,ng/ml,54,0.994
Ka,L/mol,54,0.994
Relative ID50,,54,0.994
Drug uptake,pmol/mg,54,0.994
Relative inhibition,%,54,0.994
Activity,mmol/g,54,0.994
Binding,,53,0.994
Punch weight/MPO activity,,53,0.994
CS index,,53,0.994
MBC=>99.9,uM,53,0.994
Drug degradation,mol%,53,0.994
MED=>50,,53,0.994
EC95,ug ml-1,53,0.994
Inhibitory diameter,mM,53,0.994
DOPA accumulation,,53,0.994
MLD,ug ml-1,53,0.994
Delta HR50,beats min-1,53,0.994
Delta HR50,%,53,0.994
Vmax(app),/s,53,0.994
Ki,ug ml-1,53,0.994
k cat,,53,0.994
Turns,,53,0.994
Drug metabolism,umol,53,0.994
LD10,,53,0.994
Max increase,,53,0.994
LogFC,,53,0.994
Methemoglobin,%,53,0.994
KSV,10'4/M,53,0.994
Maximal activation,%,53,0.994
Anti-fighting behaviour,,53,0.994
ED90,gAi,53,0.994
Life span,day,53,0.994
Behavioral effect,,53,0.994
Relative agonistic activity,%,53,0.994
K,10'6/M/min,53,0.994
Ki',uM,53,0.994
Blood glucose,mg dl-1,53,0.994
Normalized abundances for DMSO,,53,0.994
Normalized abundances for compound,,53,0.994
Clined screen test,,53,0.994
Stool output,g (350g of rat weight)-1,52,0.994
Activity,degree,52,0.994
ECmax,uM,52,0.994
Saldiuretic activity,m equiv 6hr-1 kg-1,52,0.994
K,10'-5/M,52,0.994
GM-MIC,ug ml-1,52,0.994
Kb,10^4/M,52,0.994
Rhodamine-123 accumulation,arbitrary units,52,0.994
Distribution coefficient,,52,0.994
IC90,uM well-1,52,0.994
Transactivation,%,52,0.994
IC90,ppm,52,0.994
TWI,%,52,0.994
Fraction experiencing seizures,,52,0.994
EC50,nmol/cm2,52,0.994
MIC70,ug.mL-1,52,0.994
Kinetic_solubility,Ug/ml,52,0.994
CD,ug ml-1,52,0.994
Inhibition potency,,52,0.994
Protective effect,%,52,0.994
Ks,nM,52,0.994
SER,,52,0.994
IC50,uM well-1,52,0.994
-Log Kdiss,,52,0.994
Vmax,pM min-1 mg-1,52,0.994
Zone diameter,mM,52,0.994
Incorporation,c.p.m.,52,0.994
Delta p,%,52,0.994
Vmax/Km,uL/min,52,0.994
Max/average,,52,0.994
Vmax,uM,52,0.994
Activity,million/mm3,52,0.994
pKp,,52,0.994
Ratio,10'4/M/s,52,0.994
Eye toxicity,,52,0.994
Aneuploidy activty,,51,0.994
Zone of stimulation,mM,51,0.994
Vmax,mM/min,51,0.994
% of Control Agonist Response (Mean n=2),%,51,0.994
Antihypertensive score,,51,0.994
% control specific binding (Mean n=2),%,51,0.994
IC50,p.p.m.,51,0.994
IC90 mutant/IC90 WT,,51,0.994
Activity,kCounts,51,0.994
MOT,min,51,0.994
Relative inotropic potency,,51,0.994
Papp,10'-4 cm/s,51,0.994
Acceptor activity,,51,0.994
Challenge time,min,51,0.994
packed cell volume,%,51,0.994
Competition factor,,51,0.994
K2,uM,51,0.994
cAMP activity index,,51,0.994
Weight loss,%,51,0.994
Kis,,51,0.994
% Inhibition of Control Agonist Response (Mean n=2),%,51,0.994
Kcat/Km,10'7/M/s,51,0.994
Responding,%,51,0.994
Log ESA,,51,0.994
UI,mm,51,0.994
pIC90,,51,0.994
ascites volume,ml mouse-1,51,0.994
Max Achievable Bioavailability,%,51,0.994
Activity of control,%,51,0.994
Drug uptake,cpm,51,0.994
Increase in CBF,ml min-1,51,0.994
EC,mM,51,0.994
CLH,nmol/min/mg,51,0.994
MIC=>50,uM,51,0.994
ED50,pM mouse-1,51,0.994
CLH(app),,51,0.994
Virucidal,nM,50,0.994
GT fold stimulation,,50,0.995
Beta-lactamase induction,,50,0.995
Activity,ng/mg,50,0.995
Cp(f),%,50,0.995
Initial blood pressure,mmHg,50,0.995
Increase in concentration,uM,50,0.995
logCL,,50,0.995
Locomotor activity,mg kg-1,50,0.995
FT mean score,,50,0.995
GDP ED50,mg kg-1,50,0.995
Kcat/Km,10'3/M/s,50,0.995
Ka,10'3/M,50,0.995
BP,%,50,0.995
AbsAC30,uM,50,0.995
Cmin,uM,50,0.995
Efficacy ratio,,50,0.995
Activity,nmol/mg.min,50,0.995
Max T/C,,50,0.995
Max delta APD95,%,50,0.995
Total excretion,%,50,0.995
Log K1,,50,0.995
Delta pH,,50,0.995
Tissue distribution,ug g-1,50,0.995
T>MIC,hr,50,0.995
Uptake,nM (mg of protein)-1,50,0.995
Modulation factor,,50,0.995
LED,mg kg-1,50,0.995
pKi,mM,50,0.995
Papp,10^7cm/s,50,0.995
Avg IC90,uM,50,0.995
K,10'7/M,50,0.995
ED10,mg kg-1,50,0.995
LC95,mg/L,50,0.995
mequiv of Na+/kg,0-5h,50,0.995
Ka,10'-4L/mol,50,0.995
K,10'-8M,50,0.995
Days,,50,0.995
Blood pressure,%,50,0.995
K,10'4/M.s,50,0.995
Reversion activity,%,50,0.995
XI50,uM,50,0.995
S0.5,mM,50,0.995
BDW,g,50,0.995
Systemic effect,%,50,0.995
Log 1/ratio,,50,0.995
Ka,10'6/M/s,50,0.995
FBP mean score,,50,0.995
CL,uL/ml/kg,50,0.995
Rate of O2 consumption,nM min-1,50,0.995
Survival rate,number of mice,50,0.995
MPC,,50,0.995
C20,ug kg-1,50,0.995
Max,mmHg,50,0.995
Arterial pressure,mmHg,49,0.995
RT50,min,49,0.995
ID50,uM hr-1 kg-1,49,0.995
N,,49,0.995
Antiviral effect,,49,0.995
ka,min-1,49,0.995
Activity,um/hr,49,0.995
FA,%,49,0.995
MTL,uM,49,0.995
K,hr-1,49,0.995
Activity,CFU/g,49,0.995
-Log C,,49,0.995
Ks/i,uM,49,0.995
APTT,IU mg-1,49,0.995
ADI,,49,0.995
KSV,10^4L/mol,49,0.995
Control Uptake,%,49,0.995
KSV,10'4L/mol,49,0.995
Mean body weight,g mouse-1,49,0.995
Accumulated counts,,49,0.995
RIC50,,49,0.995
ED2,,49,0.995
pTI,,49,0.995
Efficacy,nM,49,0.995
Median life span,day,49,0.995
Delta TAO,,49,0.995
Ka,nM,49,0.995
Turnover,,49,0.995
BWC,g,49,0.995
Activity,/ml,49,0.995
Bmax,%,49,0.995
pEC100,,49,0.995
Activity,fmol/min,48,0.995
KSV,10'3/M,48,0.995
PWT,g,48,0.995
Increase in footpad thickness,mM,48,0.995
Behavior score,,48,0.995
Drug uptake,umol/Kg,48,0.995
RH,%,48,0.995
No. protected/tested,,48,0.995
CD50,,48,0.995
Survival range,,48,0.995
Pmax,mM,48,0.995
MABP change,mmHg,48,0.995
Cp,%,48,0.995
MID,uL/L,48,0.995
MTD50,mg kg-1,48,0.995
Efficacy index,,48,0.995
Vmax / Km,,48,0.995
MNTD,mg kg-1,48,0.995
K Bind,uM,48,0.995
Activity,ng/g,48,0.995
Reversal,,48,0.995
Optimal concentration,mM,48,0.995
Urine volume,ml min-1,48,0.995
Kic,nM,48,0.995
Concentration,uM g-1,48,0.995
Baseline,%,48,0.995
FI5,nM,48,0.995
log10FFU,,48,0.995
EC75,uM,48,0.995
Broncho selectivity,,48,0.995
GTP shift,,48,0.995
ED50,uM l-1,48,0.995
Total activity,uM min-1,48,0.995
Drug recovery,%ID,48,0.995
Tm shift,degrees C,48,0.995
Glucose rise,mg dl-1,48,0.995
AUC/dose,ng/hr/ml,48,0.995
ECI,%,48,0.995
MI0.5,nM,48,0.995
K bind,nM,48,0.995
Inhibitory concentration,ug ml-1,48,0.995
K inact,M-1 s-1,48,0.995
IA50,%,48,0.995
Ka,10'7/M/s,48,0.995
Skin tests intensity,,48,0.995
Diameter,mM,48,0.995
CLH,min/ml/kg,48,0.995
ED40,,48,0.995
Binding constant,M-1,48,0.995
Specific activity,nM min-1,48,0.995
logPm,,48,0.995
Irritation,arbitrary units,48,0.995
Potentiation,,48,0.995
Radioactivity,c.p.m.,48,0.995
Stability,mg/ml,48,0.995
fold selectivity,fold selectivity,48,0.995
LD50,M,48,0.995
ED25,,48,0.995
Drug concentration,uM,48,0.995
EC99,ug ml-1,48,0.995
P ABC,,48,0.995
Cytoprotective effect,,48,0.995
ID50,nM ml-1,47,0.995
CBF Ratio,,47,0.995
Contragestational activity,mg kg-1,47,0.995
FBF Ratio,,47,0.995
[35S] TBPS shift,,47,0.995
Activity,mmolequiv/L,47,0.995
Log Pn,,47,0.995
solubility,10^-6 cm/s,47,0.995
K0.5,uM,47,0.995
Log Ko,,47,0.995
Relative Ki,,47,0.995
Permeability,cm s-1,47,0.995
Pgp AbA/analogue ratio,,47,0.995
Stability,pmol,47,0.995
Alphax10E,,47,0.995
Positive cells,%,47,0.995
LMA,,47,0.995
Growth,,47,0.995
Survival rate,,47,0.995
Mean IC50,,47,0.995
Activity,IU mg-1,47,0.995
LD10,mg/kg/day,47,0.995
Drug metabolism,pmol/mg/hr,47,0.995
Body weight,%,47,0.995
Reactivation,%,47,0.995
cAMP,%,47,0.995
Rectal temperature,degrees C,47,0.995
Activity,/mm3,47,0.995
Response rate,,47,0.995
Vc/F,l,47,0.995
IC50,10^-5 mol/L,47,0.995
Compound remaining,%,47,0.995
CL,L/Kg.hr,47,0.995
Mean latency,s,47,0.995
Relative ET-A IC50,,46,0.995
Kinact,10^-3/s,46,0.995
Log SOSIP,,46,0.995
MI50,ug ml-1,46,0.995
Blood sugar lowering,,46,0.995
Ki,ug nM-1,46,0.995
C175,uM,46,0.995
Log M50,,46,0.995
Average lesion score,,46,0.995
Delta APD90,,46,0.995
Cell number,,46,0.995
Reaction time,s,46,0.995
Drug uptake,mM,46,0.995
Active/total cultures,%,46,0.995
Pm,,46,0.995
Log TGI,,46,0.995
Log ILS max,,46,0.995
MNCC,mM,46,0.995
LM,uL/min/mg protein,46,0.995
Activity,nM/mg,46,0.995
Activity,nM/mg*min,46,0.995
MED20,mg kg-1,46,0.995
Relative uptake,,46,0.995
KB app,,46,0.995
PFU/ml,,46,0.995
permeability,%/hr,46,0.995
Log 1/I50,1/M,46,0.995
EC20,%,46,0.995
PKa,,46,0.995
MDR ratio,,46,0.995
Vigour_index,,46,0.995
Cmax,ng/mg,46,0.995
REP,%,46,0.995
Dose excreted,%,46,0.995
Variation/Control,%,46,0.995
Activity,10'-3mg/ml,46,0.995
Activity,10'6/mm3,46,0.995
kin,hr-1,46,0.995
Duration of action,,46,0.995
Cytotoxic activity,,46,0.995
RD50,mg kg-1,46,0.995
Lethal dose,mg kg-1,46,0.995
IC15,uM,46,0.995
Fold-induction,,46,0.995
Ataxia,%,46,0.995
LV FRP,%,45,0.995
pEC170,,45,0.995
Papp,10^-7 cm/s,45,0.995
No. of animals with liver necrosis,,45,0.995
Apparent enzyme activity,,45,0.995
LC90,mg/L,45,0.995
Kcat,10'5/s,45,0.995
Relative Kd,,45,0.995
ka/Ki,uM-1 min-1,45,0.995
Weight,,45,0.995
Activity,ng dl-1,45,0.995
Alpha,,45,0.995
ED100,ug kg-1,45,0.995
RAC app,,45,0.995
Possible response,%,45,0.995
Level,mg dl-1,45,0.995
Delta G,kCal mol-1,45,0.995
Acute electroshock activity,,45,0.995
ED50,10'3nM,45,0.995
Activity,cm/s,45,0.995
rIC50,,45,0.995
Delta MABP,mmHg,45,0.995
Drug metabolism,micromol/min,45,0.995
Ka,10'-5/M,45,0.995
AUEC,A% min-1,45,0.995
OD(540nm),,45,0.995
Drug uptake,ng/ml/g,45,0.995
Tubulin binding,%,45,0.995
log(1/CON),,45,0.995
logK(lung),,45,0.995
NC,,45,0.995
Hepatic Extraction ratio,,45,0.995
Antiviral activity,mM,45,0.995
Foci/dish,,45,0.995
Change in body temperature,degrees C,45,0.995
Relative F%,,45,0.995
Blood level,ug ml-1,45,0.995
Level,U l-1,44,0.995
Virus yield,log pfu ml-1,44,0.995
Administered dose,%,44,0.995
ED50,10'-5 ug/ml,44,0.995
IC20,,44,0.995
MBEC50,uM,44,0.995
Activity,ug/L,44,0.995
Antitumor activity,%,44,0.995
CPP,mmHg,44,0.995
Alpha max,%,44,0.995
Liver weight,mg (g of body weight)-1,44,0.995
Fraction cured,,44,0.995
CL,ug/min,44,0.995
GSH-Px activity,,44,0.995
HD50,ug ml-1,44,0.995
GR,%,44,0.995
ECmax,%,44,0.995
Inhibition constant,,44,0.995
CC25,uM,44,0.995
LVP,mmHg,44,0.995
logK(blood),,44,0.995
Activity,10'-6M,44,0.995
Drug degradation,/hr,44,0.995
ED80,mg kg-1,44,0.995
Ki ss,nM,44,0.995
pA2/pKB,,44,0.995
No. of mice survived,,44,0.995
Delta TM,c,44,0.995
Change in response rate,%,44,0.995
Change in blood pressure,delta mmHg,44,0.995
Average weight change,,44,0.995
Cells killed,%,44,0.995
Mean blood pressure,%,44,0.995
-logKa,,44,0.995
Decrease in QA interval,,44,0.995
Decrease in MABP,%,44,0.995
log1/CLD50,,44,0.995
Reversal type,,44,0.995
Ka,10'7/M,44,0.995
Immobility time,s,44,0.995
Kcat/Km,10'6/s/M,44,0.995
RL,%,43,0.995
R,,43,0.995
REA,,43,0.995
Ratio,10^-3/microM/s,43,0.995
Cp,ng/g,43,0.995
RSA,%,43,0.995
TCID50,ug ml-1,43,0.995
Behavior,,43,0.995
TP,%,43,0.995
Diuretic activity,ml kg-1 6hr-1,43,0.995
Max inhibition,,43,0.995
Influx,nM mg-1,43,0.995
Potential,,43,0.995
LT50,ppm,43,0.995
EPMR,,43,0.995
EC5,nM,43,0.995
log1/CED90,,43,0.995
Drug metabolism,nmol/mg/hr,43,0.995
Activity,pg/g,43,0.995
Recovery time,min,43,0.995
Inhibition over time,%,43,0.995
GR80,gAi/ha,43,0.995
kr,min-1,43,0.995
SP,%,43,0.995
Unchanged,%,43,0.995
AUC,ng/ml,43,0.995
Median survival time,day,43,0.995
Papp,10^-5cm/s,43,0.995
Activity,10'3 /uL,43,0.995
Active dose,mg kg-1,43,0.995
AUClast,hr.ng/g,43,0.995
MNEC,uM,43,0.995
pEC90,,43,0.995
Activity,/mM/min,43,0.995
ED50,mg ear-1,43,0.995
LD5,uM,43,0.995
fCmax,ug ml-1,43,0.995
deltaS,kJ/mol,43,0.995
No. of entries,,43,0.995
KiH,nM,43,0.995
pD,M,43,0.995
DR10,mg kg-1,43,0.995
Sleeping time,,43,0.995
ILS30,,43,0.995
MED,mM kg-1,43,0.995
Activity,micromol/m2/s,43,0.995
CL_renal,ml/min,43,0.995
Net log cell kill,,43,0.995
Competition,%,43,0.995
Log Kw,,43,0.995
Deoxyribose degradation,uM of MDA mM-1,43,0.995
Uterine weight,g,42,0.995
No. of shocks,,42,0.995
Tremorolytic dose,uM kg-1,42,0.995
Radioactivity,nM equiv (mg of tissue)-1,42,0.995
P (Ei),,42,0.995
Antihypertensive activity,,42,0.995
RD500,mg kg-1,42,0.995
PCY,,42,0.995
MED,M kg-1,42,0.995
Ka,/M/s,42,0.995
EC80,ppm,42,0.995
K,/M,42,0.995
MLD50,uM,42,0.995
Inhibition,delta A min-1,42,0.995
Separation,,42,0.995
Compound recovery,10^-9M,42,0.995
Range,day,42,0.995
AUC,ng.hr/ml/mg/kg,42,0.995
Urinary volume,,42,0.995
IT50,min,42,0.995
Diuretic activity,m equiv,42,0.995
Distribution,% dose g-1,42,0.995
Cell protein,ug dish-1,42,0.995
Lethality,dead/total,42,0.995
k cat/Km,10e4 M-1 s-1,42,0.995
Daq,10'-6cm2/s,42,0.995
NBT positive cells,%,42,0.995
ED90,mg l-1,42,0.995
No. of dead mice,,42,0.995
Csat,g dl-1,42,0.995
Bmax,pmol/mg,42,0.995
MAC,,42,0.995
APD60,,42,0.995
Rise HR,,42,0.995
No. of cured,,42,0.995
Vdu,ml,42,0.995
MED>50,mg kg-1,42,0.995
ID40,mg kg-1,42,0.995
Loss of righting reflex,,42,0.995
Max change in blood pressure,mmHg,42,0.995
ED35,mg kg-1,42,0.995
Na+ excretion,,42,0.995
Co,g dl-1,42,0.995
Emax,pM,42,0.995
Capacity,,42,0.995
Clast,ng/ml,42,0.995
K+ excretion,,42,0.995
Decrease in SBP,mmHg,42,0.995
Csat/Co,,42,0.995
Vmax,nM min-1 mg-1,41,0.995
ID50,mg,41,0.995
Fmut,,41,0.995
Concentration,ug/g tissue,41,0.995
Cell death,%,41,0.995
GI,mM,41,0.995
permeability,10^-7 cm/s,41,0.995
Smax,uM min-1 kg-1,41,0.995
Log C,,41,0.995
Kr,M,41,0.995
ED125,uM kg-1,41,0.995
ED50,M l-1,41,0.995
CL,ml.min/kg,41,0.995
Relative rate of hydrolysis,%,41,0.995
pK50,,41,0.995
Pigment binding,%,41,0.995
Activity,U mg-1,41,0.995
Ka,10^6/M/s,41,0.995
CAR,,41,0.995
-Log IC25,,41,0.995
Migration index,,41,0.995
MfI,,41,0.995
Index,%,41,0.995
Relative rate,,41,0.995
WBC,%,41,0.995
Survival rate,%,41,0.995
MNTD90,uM,41,0.995
DNA crosslinking,,41,0.995
Antagonistic activity,,41,0.995
AUClast,,41,0.995
AC200,uM,41,0.995
LD50,g/ha,40,0.995
Delta ERPc,%,40,0.995
ED50,mg l-1,40,0.995
EC12,uM,40,0.995
Arthritic score,,40,0.995
Activity,uM min-1 (mg of protein)-1,40,0.995
Reactivity,,40,0.995
MP,%,40,0.995
ID50,ng/ml,40,0.995
Dose,ug,40,0.995
MIC100,microg/ml,40,0.995
ID90,mg kg-1,40,0.995
Kii,nM,40,0.995
Aspirin formed,%,40,0.995
Dose,uM,40,0.995
MES ED50,mg kg-1,40,0.995
IC50,g/ha,40,0.995
ED50,umol/cm2,40,0.995
ECmax,nM,40,0.995
AZT formation,,40,0.995
Ki/KI,M-1 s-1,40,0.995
EC25,,40,0.995
ED90,ug ml-1,40,0.995
K,mM,40,0.995
Activity,Bq,40,0.995
ED99.9,mg kg-1,40,0.995
Positive control,%,40,0.995
Zone diameter,,40,0.995
DD,uM of MDA mM-1,40,0.995
Activity,U/min,40,0.995
ASF,p.p.m.,40,0.995
K,1/s,40,0.995
LD20,mg kg-1,40,0.995
RU,pg/mm2,40,0.995
IC70,nM,40,0.995
MIC=<80,ug ml-1,40,0.995
GR,,40,0.995
RPF,pM nM-1,40,0.995
Change in BP,,40,0.995
T50,hr,40,0.995
RTV,,40,0.995
log(1/MIC>90),,40,0.995
Body weight reduction,%,40,0.995
Luciferase activity,RLU 10s-1,40,0.995
Mean no. of revertants,,40,0.995
Log 1/ID75 (uM L-1),,40,0.995
ID50,mM l-1,40,0.995
"Kpot A,B",,40,0.995
Drug uptake,nmol/mg.min,40,0.995
QH,,40,0.995
Drug uptake,pmol/min,40,0.995
Change in BP,%,40,0.995
Recovery time,%,40,0.995
Max inhibitory effect,%,40,0.995
pKa_B2,,40,0.995
EC90,pM,40,0.995
In vivo duration,Minutes,40,0.995
ID50,M l-1,40,0.995
Serum cholesterol,mg dl-1,40,0.995
CFU,10'8/ml,40,0.995
Biodistribution,ug of B g-1,40,0.995
Quantity,mg,40,0.995
Fluorescence Intensity,,40,0.995
Cytokine induction,,40,0.995
Fold activation,%,40,0.995
Tissue concentration,% injected dose g-1,40,0.995
Kp,ucm/s,39,0.995
K,10^-2/uM/min,39,0.995
Vmax,nM/mg*min,39,0.995
Max temperature decrease,,39,0.995
CLint,uL/min/1E6 cells,39,0.995
delta(V1/2),mV,39,0.995
E,,39,0.995
FI,,39,0.995
Dead,,39,0.995
TBMIC,ug ml-1,39,0.995
Decrease in CR,,39,0.995
BCM serum Ca,mg 100ml-1,39,0.995
Suppression,,39,0.995
I 90,,39,0.995
Vmax,microM/min/mg,39,0.995
Kdiss,10'-3/s,39,0.995
Flea,p.p.m.,39,0.995
Kq,10'12/M/s,39,0.995
Na,m equiv 6hr-1 kg-1 (body weight)-1,39,0.995
D150,mg kg-1,39,0.995
Activation,,39,0.995
MAP,,39,0.995
ID50,10'-4M,39,0.995
log Kp,cm/s,39,0.995
Relative susceptibility,,39,0.995
Lesion length,mm mice-1,39,0.995
Infectedmosquitoes,%,39,0.995
Mean arterial blood pressure,,39,0.995
Ratio AUC,%,39,0.995
k,s-1,39,0.995
Activity,ug (mg of protein)-1,39,0.995
Toxic level,M,39,0.995
Vd,ml,39,0.995
V,ml 6hr-1 (kg of body weight)-1,39,0.995
P24 concentration,ng ml-1,39,0.995
Activity,Hz,39,0.995
Average dose,ug kg-1,39,0.995
IS/AAR,%,39,0.995
RSA,,39,0.995
Analgesia duration,,39,0.995
Rate of phosphorylation,,39,0.995
k2,,39,0.995
Kp,10^-6 cm/s,39,0.995
Ka,10'4/M/s,39,0.995
Delta pCa50,,39,0.995
k cat/Km,mM-1 min-1,39,0.995
EC170,uM,39,0.996
BWC,%,39,0.996
Ka,10^4/M,39,0.996
MIC,10'-3uM/ml,39,0.996
Change in body weight,g mouse-1,39,0.996
Kobs,/min,39,0.996
Oral diuretic activity,u equiv of [Na+] kg-1 hr-1,39,0.996
Topical potency,,39,0.996
Activity,nM (mg of protein)-1,39,0.996
Dose,mg kg-1 day-1,38,0.996
AUC/dose,hr.kg.ng/ml/mg,38,0.996
CIC,nM,38,0.996
x fold,uM,38,0.996
D50,10'-5M,38,0.996
MLC,%,38,0.996
PL,%,38,0.996
I90,ppm,38,0.996
Relative luciferase response,,38,0.996
IC80,,38,0.996
Activity,log10PFU/ml,38,0.996
Activity,kilobase,38,0.996
Binding ratio,,38,0.996
CLH,ml/hr,38,0.996
Change in heart rate,,38,0.996
BMF,,38,0.996
Activity,nM min-1 mg-1,38,0.996
Activity,/g,38,0.996
AUCt,,38,0.996
Binding,(ng of DNA) dish-1,38,0.996
Apoptotic Activity,%,38,0.996
% NO2-,M/M,38,0.996
Acute toxicity,,38,0.996
Affinity ratio,,38,0.996
Stability,day,38,0.996
ED50,mg/day,38,0.996
No. of animals survived,,38,0.996
EC10,nM,38,0.996
Partition ratio,,38,0.996
IC,ug ml-1,38,0.996
Inhibition,ug kg-1,38,0.996
Time,nanoseconds,38,0.996
PDH active/PDH total,%,38,0.996
x fold,,38,0.996
Log PR,,38,0.996
MLS,day,38,0.996
IC50,mMequiv,38,0.996
K aps,l M-1,38,0.996
LD0,mg,38,0.996
DNA binding,degrees C,38,0.996
Ct,pmol/g,38,0.996
Dose/g of tissue,%,38,0.996
pKapp,,38,0.996
Histone_modification,,38,0.996
Cp,umol/L,38,0.996
LogPapp,,38,0.996
Lipophilicity,=,38,0.996
RIA,,38,0.996
pMIC,,38,0.996
Onset,hr,38,0.996
Vertebral blood flow,,38,0.996
DNA cleavage,ug ml-1,37,0.996
Hyperglycemic activity,,37,0.996
NSB,,37,0.996
AUC,ng.hr/Kg,37,0.996
H ABC,,37,0.996
K,10^-2/min,37,0.996
Fu,uM,37,0.996
Presynaptic antagonism,,37,0.996
FaFg,,37,0.996
deltapEC50,,37,0.996
CT10 ratio,,37,0.996
Inihibition,%,37,0.996
AD50,uM kg-1,37,0.996
Drug uptake,mg/L,37,0.996
Delta BG,,37,0.996
Delta HR,beats min-1,37,0.996
Drug uptake(free),,37,0.996
Alpha max,uM,37,0.996
Stability,% ID/g,37,0.996
Mu/kappa ratio,,37,0.996
Max delta HR,beats min-1,37,0.996
Agonist,%,37,0.996
MTD,mg kg-1 5day-1,37,0.996
MED,mg kg-1 5day-1,37,0.996
Max delta MAP,mmHg,37,0.996
MIC100,umol/ml,37,0.996
Glucose level,mg dl-1,37,0.996
Kdiss,10'-4/s,37,0.996
AUC/dose,nmol.hr/L,37,0.996
Vasoconstriction effect,,37,0.996
INH,mm,37,0.996
P50e/P50c,,37,0.996
log(10'3/IC50),,37,0.996
Kb,10^5/M,37,0.996
A1 selectivity,,37,0.996
BP change,%,37,0.996
Kcat/Km,/uM/min,37,0.996
Papp,%,37,0.996
Activity,PSL/mm2,37,0.996
BSI,,37,0.996
Hmax,,37,0.996
Delta T,degrees C,37,0.996
Kreact,s-1,37,0.996
Test/control survival,,37,0.996
No. of mouse protected,,37,0.996
GMMIC,ug ml-1,37,0.996
C20,uM l-1,37,0.996
Tension,%,37,0.996
G30,,37,0.996
Postsynaptic antagonist,,37,0.996
Vmax,deltaOD/min,37,0.996
Change in Tm,,37,0.996
Dose-modifying factor,,37,0.996
No. of animals exhibiting toxicity / Number of animals tested,,37,0.996
Delta pKi,,36,0.996
k,,36,0.996
BNa,%,36,0.996
log1/activity,,36,0.996
Plasma GH release,ng ml-1,36,0.996
Delta cpm x10e-3,,36,0.996
Maximal non-toxic dose 50,ug ml-1,36,0.996
Pc,nm s-1,36,0.996
RVR,,36,0.996
Incorporation rate,c.p.m. hr-1,36,0.996
Rate,%,36,0.996
Inhibition_index,,36,0.996
CMR,,36,0.996
Inhibition,pM of cAMP min-1 mg-1,36,0.996
Log M,,36,0.996
Survival increase,,36,0.996
AUC/dose,ug.hr/mL/mg/kg,36,0.996
C,uM,36,0.996
36Cl- uptake,,36,0.996
Exp Inhib Constant,,36,0.996
Vmax,pmol/mg/min,36,0.996
30 day survival / total,,36,0.996
logLD50,,36,0.996
RBA ratio,,36,0.996
Pressure,mmHg,36,0.996
MSD,,36,0.996
Degradation rate constant,hr-1,36,0.996
Polyamine,pM g-1,36,0.996
Delta/kappa,,36,0.996
ED95,p.p.m. in feed,36,0.996
pEC0.5,,36,0.996
-log(1/EC50),,36,0.996
Enzyme level,U l-1,36,0.996
Dose,rd mCi-1,36,0.996
Optimal dose,mg,36,0.996
EC1000,nM,36,0.996
nNOS activity,%,36,0.996
Ki,10^2 uM,36,0.996
Activity,Counts,36,0.996
Change of body weight,%,36,0.996
IG,%,36,0.996
koff,1-s,36,0.996
AUC/dose,nM.hr/mg/kg,36,0.996
fCmax,mg/L,36,0.996
Activity,10'-5/ml,36,0.996
Activity,/mmol/min,36,0.996
Activity,nmol/g tissue,36,0.996
K,mM/min,36,0.996
Relative inhibitory potency,,36,0.996
fpIC50,,36,0.996
Relative toxicity,,36,0.996
Initial rates,,36,0.996
MIC50/MIC90,,36,0.996
K2,nM,36,0.996
Reversal ability,,36,0.996
CL,nmol/mg.min,36,0.996
Amax,pmoles,36,0.996
SI,beats min-1,36,0.996
SD,min,36,0.996
SC50,ug ml-1,36,0.996
Formation of NO2-,nM,36,0.996
ID50,mg/day,36,0.996
Decrease in AP,,36,0.996
G index,,36,0.996
Log 1/LD50,,36,0.996
Uptake at C50,,36,0.996
Intrinsic Toxicity,,36,0.996
Log 1/ED50,,36,0.996
TI,uM,36,0.996
Thymidine shift,,36,0.996
Cross linking,%,36,0.996
% Inhibition of Control Values,%,36,0.996
Tubulin polymerization ratio,,36,0.996
IC25,umol/L,36,0.996
MEC,mg l-1,36,0.996
ED90,p.p.m.,36,0.996
MBIC50,,36,0.996
Drug uptake,umol/L,36,0.996
Vmax,mAU/min,36,0.996
Log k'w,,36,0.996
Sensitized animals,,36,0.996
Activity,umol/hr,36,0.996
Activity,g%,36,0.996
IT100,min,35,0.996
Cellular reversion,%,35,0.996
Activity,/nmol,35,0.996
C0,uM,35,0.996
Log 1/ED40,,35,0.996
Log TCID50,,35,0.996
Activity,mg ml-1,35,0.996
MPC4,ug ml-1,35,0.996
Log ED50,,35,0.996
LED,mgP kg-1,35,0.996
LOAEL,uM,35,0.996
MF,%,35,0.996
Protected,,35,0.996
Ka,10^4L/mol,35,0.996
Cmin,umol/L,35,0.996
Seizure score,,35,0.996
LD90,ppm,35,0.996
Vmax/Km,microL/min/mg,35,0.996
fT>MIC,hr,35,0.996
CLH,10^-6uL/min,35,0.996
CT50,uM,35,0.996
ED50,mg 4kg-1,35,0.996
pAlpha,,35,0.996
AFI,,35,0.996
ERP,%,35,0.996
FSC recovery,%,35,0.996
pKHB,,35,0.996
ED50,M kg-1,35,0.996
Weight gain,%,35,0.996
p alphaKa,,35,0.996
solubility,ml,35,0.996
Volume,l hr-1,35,0.996
2x aPTT,uM,35,0.996
ED50,umol,35,0.996
k cat/Km,mM-1 s-1,35,0.996
Exhibiting turning,%,35,0.996
Drug metabolism,nmol/mg/min,35,0.996
AbsAC0.39_uM,uM,35,0.996
Drug uptake,fmol,35,0.996
IA50,equiv,35,0.996
MD,mg kg-1,35,0.996
Cholesterol,mg 100ml-1,35,0.996
Activity,beats min-1,35,0.996
Decrease in IC50,,35,0.996
KSV,10^4/M,35,0.996
ID50,10'-5M,35,0.996
LD50,microg/cm2,35,0.996
TMP.decrease,degrees F,35,0.996
ED40,ug kg-1,35,0.996
Minimal dose,ug ml-1,35,0.996
Occ50,nM,35,0.996
TdeltaS,kJ/mol,35,0.996
IC5,nM,35,0.996
McPhail index,,35,0.996
Agonist activity,%,35,0.996
Tumor response,%,35,0.996
Activity,RFU min-1,35,0.996
Ratio,1/Ms,35,0.996
MTD50,ug ml-1,35,0.996
AUC,ng.hr.kg/mg/ml,35,0.996
Retention_index,,35,0.996
Plasma glucose,mg dl-1,35,0.996
SBP,mmHg,35,0.996
MTD,umol/Kg,35,0.996
Average turns,,35,0.996
Average tumor volume,mm**3,35,0.996
MIC,U ml-1,35,0.996
Mean survival time,,35,0.996
Change from Control (LV dp/dt),%,35,0.996
ED50,10'-6 ug/ml,35,0.996
Loss of righting reflex,%,35,0.996
Ratio,/mM/min,35,0.996
Motor activity,,35,0.996
LC50,microg/cm2,35,0.996
Ki low,nM,34,0.996
Range of survival days,,34,0.996
Rate constant,min-1,34,0.996
Phosphorylation rate,uM,34,0.996
CTS,,34,0.996
Activity,10^3/mm3,34,0.996
Loss of cells,%,34,0.996
Synergy,fold,34,0.996
Drug uptake,nmol/ml,34,0.996
TN,uM min-1,34,0.996
Duration,s,34,0.996
CL,ml/mg/kg,34,0.996
Serum level,,34,0.996
Kd,10^-1/s,34,0.996
Kb,10^6/M,34,0.996
KOX,M-1 min-1,34,0.996
Delta Gsolv,kCal mol-1,34,0.996
Activity,10'5U/mL,34,0.996
Peff,cm/s,34,0.996
RC50,uM,34,0.996
Ka,10'3/M/s,34,0.996
Bapp,,34,0.996
Delta Fmax,%,34,0.996
Activity,10'7No_unit,34,0.996
Activity A,uM kg-1,34,0.996
Cardio selectivity,,34,0.996
Cells in metaphase,%,34,0.996
Parent compound,%,34,0.996
Death,,34,0.996
K cat,1/sec,34,0.996
Ea,kJ/mol,34,0.996
MED,mg,34,0.996
IC75,uM,34,0.996
Log k' w,,34,0.996
Cytotoxic concentration,M,34,0.996
Currents,%,34,0.996
E 1/2,,34,0.996
K,10'4L/mol,34,0.996
Rolipram activity,%,34,0.996
PI metabolism,%,34,0.996
CLH,umol/min/mg,34,0.996
SH level,uM g-1,34,0.996
Jump latency time,s,34,0.996
MFC,ug,34,0.996
rf50,,34,0.996
Activity,cm3,34,0.996
OD,ug kg-1,34,0.996
Control current,%,34,0.996
TMED50,mg kg-1,34,0.996
AUCt,ng/g.hr,34,0.996
Cell cycle analysis,,34,0.996
TAR,,34,0.996
K,10'7/M/min,34,0.996
dP/dt,mmHg s-1,34,0.996
BA,,34,0.996
Caco-2 Papp,cm s-1,34,0.996
ER,,34,0.996
dP/dt max,,34,0.996
Survival median,,34,0.996
Agonistic activity,,34,0.996
Log KAT,,34,0.996
Stabilty,ml/min.Kg,34,0.996
Incidence,,34,0.996
% of selectivity,%,34,0.996
Kill at C50,%,34,0.996
No. of retches,,34,0.996
Selectivity ratio S3/1,,34,0.996
Vmax,U/mg,33,0.996
DNA cleavage,,33,0.996
Activity,uV,33,0.996
Polyamine level,nM,33,0.996
K,10^6/M/s,33,0.996
KT,,33,0.996
Plasma insulin,ml,33,0.996
Functional profile,,33,0.996
Cmax/dose,nM.kg/mg,33,0.996
Specific index,,33,0.996
MUD,mg kg-1,33,0.996
K ass,l mol-1,33,0.996
Edema,,33,0.996
SC50,,33,0.996
SRR,,33,0.996
permeability,uM,33,0.996
Activity in animals,%,33,0.996
No of monkeys,,33,0.996
tR,min,33,0.996
Tm shift,°C,33,0.996
Ratio,/uM,33,0.996
Activity,umol/mg/min,33,0.996
LC50,ug,33,0.996
CL,hr.Kg/L,33,0.996
No. positive cases/tested,,33,0.996
HVA control,%,33,0.996
Total score,,33,0.996
ED80,ug/kg,33,0.996
Cp,nmol/ml,33,0.996
AUC,nmol.hr/g,33,0.996
L/CE,%,33,0.996
TG,mg dl-1,33,0.996
Tlag,hr,33,0.996
Ks,M,33,0.996
ED30,uM,33,0.996
Phospholipidosis as % of positive control,%,33,0.996
Clearance,,33,0.996
Selectivity coefficient,,33,0.996
IW,,33,0.996
GI90,nM,33,0.996
Accumulation coefficient,,33,0.996
Change of SBP,%,33,0.996
Cytokinetic response,,33,0.996
RBF,,33,0.996
-Log 1/Kb,,33,0.996
Symptoms,,33,0.996
Relative inhibition index,,33,0.996
MI100,ug kg-1,33,0.996
Change of DBP,%,33,0.996
inhibition of control,%,33,0.996
dP/dt,max,33,0.996
Change of CO,%,33,0.996
Change of CF,%,33,0.996
Change of HR,%,33,0.996
K1,nM,33,0.996
cGMP content,pmol/mg protein,33,0.996
ED Arec,mg kg-1,33,0.996
BP decrease,%,33,0.996
Stereotypy score,,33,0.996
Inotropic effect,,33,0.996
Saluretic potency,u equiv min-1,33,0.996
PDD50,ug ml-1,33,0.996
K,/nM/min,33,0.996
Efficacy,uM,33,0.996
Ratio,1/uM*sec,33,0.996
Duration of action,min,33,0.996
Change in systolic pressure,mmHg,33,0.996
Cytotoxiciy,,33,0.996
Kapp,10^-6/M,33,0.996
IM,,33,0.996
Maximum test concentration that did not exhibit cytotoxicity,uM,33,0.996
Pm,10^-5 cm/min,33,0.996
AC50,%,33,0.996
OD,nm,32,0.996
GI90,uM,32,0.996
Kcat,10'6/s,32,0.996
Occ50,uM,32,0.996
Activity,10^-10.mol/mg/min,32,0.996
1/IC50,,32,0.996
Ka,10^7/M,32,0.996
Cell no/dish,,32,0.996
EC0.01,uM/A unit/min,32,0.996
Activity,pmol/ml,32,0.996
HDL-C,mg dl-1,32,0.996
CD50,nM,32,0.996
Licking latency,,32,0.996
Drug recovery,ngequiv/g,32,0.996
Drug degradation,uM,32,0.996
HC20,uM,32,0.996
Cytostatic activity,%,32,0.996
%,,32,0.996
No. of circlings,,32,0.996
Survivors / treated,,32,0.996
TAC,U,32,0.996
ED25,ug kg-1,32,0.996
KiL,nM,32,0.996
logKd,,32,0.996
AUC N,mM hr dose-1,32,0.996
Treated cells,,32,0.996
MRT,,32,0.996
MRF,,32,0.996
Activity,/day,32,0.996
Temperature,,32,0.996
Recovery,mg,32,0.996
Activity,pmol/L,32,0.996
Dry weight,%,32,0.996
Activity scale,,32,0.996
Cp,ng.Eq/ml,32,0.996
Permeability,cm hr-1,32,0.996
UI,%,32,0.996
Kq,10'12L/mol/s,32,0.996
K ass,M-1,32,0.996
Stability,nmol/min/mg,32,0.996
dP/dt,%,32,0.996
CIC95,,32,0.996
Kin x10e3,hr-1,32,0.996
Ratio,10'3/M/min,32,0.996
TD50,nM,32,0.996
CI,ml min-1 kg-1,32,0.996
Viscosity,,32,0.996
Vmax,/min,32,0.996
pIC50(calc),,32,0.996
pGC50,,32,0.996
Weight change at nadir,,32,0.996
pkB,,32,0.996
SRR,%,32,0.996
Activity,mAU,32,0.996
Anticonvulsant Activity,,32,0.996
Active dose range,mg kg-1,32,0.996
Organ weight,mg,32,0.996
Activation time,%,32,0.996
DA response,%,32,0.996
RLU/well,,32,0.996
Activity,nmol/umol,32,0.996
RBA1,,32,0.996
Oral diuretic activity,u equiv of [Na+]  kg-1,32,0.996
RBA2,,32,0.996
EC10x,mM,32,0.996
MEC,mM,32,0.996
MIC=>95,ug ml-1,32,0.996
RC10,uM,32,0.996
Relative rate of hydrolysis,,32,0.996
Reverse transcriptase activity,,32,0.996
Plasma lipids,mg dl-1,32,0.996
RLU,%,32,0.996
Ionotropic activity,mg,32,0.996
EC95,nM,32,0.996
Log B/F,,32,0.996
ED50,molar ratio,32,0.996
log10 TCID50,,32,0.996
DD,uM,32,0.996
No. of positive animals,,32,0.996
SPF,,32,0.996
AUC,nM,32,0.996
Repression,%,32,0.996
Max drop,%,32,0.996
CC25,umol/L,32,0.996
Cell viability,uM,32,0.996
Vdss/F,L.kg-1,32,0.996
MLD,,32,0.996
No. of platelets,%,32,0.996
Plasma GH,ng ml-1,32,0.996
IC30,nM,32,0.996
Log 1/IC50,mM,32,0.996
Activity,umol/L/min,32,0.996
EFTPC,nM,31,0.996
LC95,mgAi/L,31,0.996
Survivors at day 9,,31,0.996
NG ratio,,31,0.996
Tail flick latency,s,31,0.996
Potentiation,nM mg-1,31,0.996
FSC,,31,0.996
Max hypotension,%,31,0.996
Delta G,%,31,0.996
AUC/dose,ug.hr/ml,31,0.996
C50,,31,0.996
Max possible effect,%,31,0.996
Change from control,%,31,0.996
MIC+/MIC-,,31,0.996
Collateral index,,31,0.996
MIC100,nM,31,0.996
K,%,31,0.996
permeability,pmol/s,31,0.996
log1/S,,31,0.996
Vmax,nmol/mg.min,31,0.996
Cleavage,ug ml-1,31,0.996
Crel,,31,0.996
solubility,mg,31,0.996
Activity,uM g-1,31,0.996
Ka,min-1,31,0.996
IC50,10^3nM,31,0.996
RBF,ml min-1,31,0.996
Analgesic activity,%,31,0.996
SSC,,31,0.996
No. of nonpregnant/treated,,31,0.996
Cured animals,,31,0.996
MLC,,31,0.996
Uterine wet weight,,31,0.996
Log 1/MIC (mM L-1),,31,0.996
Vd,ml/cm3,31,0.996
SOD activity,mM,31,0.996
MLD50,ug ml-1,31,0.996
G30,%,31,0.996
DHP-I susceptibility,,31,0.996
Delta FC,%,31,0.996
Tail vein toxicity,,31,0.996
Spont activity,Counts 10min-1,31,0.996
LD90,J cm**-2,31,0.996
-Log IC50,,31,0.996
EC100,ug ml-1,31,0.996
MPE,,31,0.996
Binding stoichiometry,,31,0.996
-Log activity,,31,0.996
MTC50,ug ml-1,31,0.996
pEC15,,31,0.996
Kcat,10^5/s,31,0.996
Volume,,31,0.996
LD90,ug ml-1,31,0.996
Fluorescence activity ratio,,31,0.996
Urinary output,ml,31,0.996
LogD5.0,,31,0.996
Activity,10'3CFU,31,0.996
Treatment period,,31,0.996
Relative PT,,31,0.996
fVdss,L/Kg,31,0.996
MIC50,%,31,0.996
Binding site preference,,31,0.996
UVAPF,,31,0.996
Locomotor activity,uM kg-1,31,0.996
MFC,mg/ml,31,0.996
Delta ERP,%,31,0.996
K,m equiv 6hr-1 kg-1 (body weight)-1,31,0.996
Drug metabolism,nmol,31,0.996
EC0.25,,31,0.996
Dissociation constant,,31,0.996
Metabolic stability,,31,0.996
FL-1,,31,0.996
K1/2,uM,31,0.996
Time above IC50,hr,31,0.996
VT50,min,31,0.996
Kcat/Km,uM/hr,31,0.996
Hypothermic effect,degrees C,31,0.996
ID50,umol/L,31,0.996
Cl-,m equiv 6hr-1 kg-1 (body weight)-1,31,0.996
Max collateral index,,31,0.996
Ca2+ transport,,31,0.996
Accumulation,nM (mg of protein)-1,31,0.996
Cell cycle,nM,30,0.996
Log CFU,,30,0.996
ED30,nM,30,0.996
Efflux ratio,,30,0.996
Non-HDL-C,,30,0.996
Mean no. of shocks,,30,0.996
MIC>90,10'-4M,30,0.996
CC75,uM,30,0.996
PTZ protection,%,30,0.996
T-cell inhibition,,30,0.996
LD50,10'-3 mol/L,30,0.996
Activity,uL/ml,30,0.996
T/C 1,,30,0.996
Efflux ratio plus inhibitor,,30,0.996
T/V,,30,0.996
Drugexcretion,umol/min/kg,30,0.996
Activity,u equiv min-1,30,0.996
permeability,10'-9meter/s,30,0.996
GM,,30,0.996
TC,,30,0.996
TC25,uM,30,0.996
Electrolyte excretion,uM sample-1,30,0.996
LAD,M l-1,30,0.996
Tumor size,,30,0.996
pGI50,M,30,0.996
Assembly,%,30,0.996
Residual activity,,30,0.996
2aPTT,,30,0.996
K,10'5/Ms,30,0.996
Differential,,30,0.996
fEC50,uM,30,0.996
Immobility,%,30,0.996
Residual secretion,%,30,0.996
Ke,/min,30,0.996
K,10'3/M,30,0.996
DLS Concentration,uM,30,0.996
Dec,%,30,0.996
Kcat(app),/min,30,0.996
Relative binding,%,30,0.996
MSIC,ug ml-1,30,0.996
LC50,microg/mL2,30,0.996
No. of counts,uM kg-1,30,0.996
Recovery A to B plus inhibitor (mean),%,30,0.996
Recovery B to A plus inhibitor (mean),%,30,0.996
Recovery time,,30,0.996
Papp B to A plus inhibitor (mean),10E-6 cm/s,30,0.996
Papp B to A (mean),10E-6 cm/s,30,0.996
Papp A to B plus inhibitor (mean),10E-6 cm/s,30,0.996
Papp A to B (mean),10E-6 cm/s,30,0.996
TD50,mmol/Kg,30,0.996
Log sweet/bitter,,30,0.996
Activity,IU ml-1,30,0.996
Max decrease,%,30,0.996
-Log K,,30,0.996
Max delta FRP,%,30,0.996
KF,,30,0.996
-Log KB,%,30,0.996
Basal inhibition,%,30,0.996
HDL-C,,30,0.996
Max CF response,%,30,0.996
Activity,10'1AU.min,30,0.996
Mean day of death,,30,0.996
KSV,,30,0.996
Vmax,abs/min,30,0.996
VERP,ms,30,0.996
BP increase,mmHg,30,0.996
Max decrease,,30,0.996
Phorbol displacement,uM,30,0.996
Least dose,mg kg-1,30,0.996
Max stimulation,,30,0.996
A2 selectivity,,30,0.996
Cp,mg/L,30,0.996
Cardiac force,,30,0.996
Effect,mg dl-1,30,0.996
In/Fi,,30,0.996
Phototoxic effect,,30,0.996
FICI80,,30,0.996
Change in Tm,degrees C,30,0.996
ED85,mg kg-1,30,0.996
VAR,,30,0.996
Brain level,nM g-1,30,0.996
PD50,nM,30,0.996
K rel,,30,0.996
Activity,c.p.m. min-1 mg-1,30,0.996
Cave,nM,30,0.996
log(M50),,30,0.996
Skin reaction,,30,0.996
Ki/KI,,30,0.996
Ki50,uM,30,0.996
CC10,ug ml-1,30,0.996
Speed of induction,,30,0.996
Activity,ug/min,30,0.996
ID (per g of organ),%,30,0.996
Activity,cps,30,0.996
Ct,ng/mg,30,0.996
EC100,mg/L,30,0.996
ED30,ug,30,0.996
pIC50,uM,30,0.996
Stability,nM,30,0.996
Log KA,,30,0.996
KD',M,30,0.996
Cell growth,,29,0.996
Reversible,%,29,0.996
Activity,pmol/mg/min,29,0.996
MI,,29,0.996
T/C min,%,29,0.996
Log Ki,D4,29,0.996
pLADY,,29,0.996
ED15,ug kg-1,29,0.996
deltaH,,29,0.996
SubMIC,uM,29,0.996
Inhibition of control,%,29,0.996
Increase in concentration,pmol/mg prot.,29,0.996
pMIC,M l-1,29,0.996
Body weight gain,g day-1,29,0.996
Stability,nmol/min/kg,29,0.996
ED ratio,,29,0.996
CL,ml/kg.min,29,0.996
Rate constant,,29,0.996
Feed consumption,g day-1,29,0.996
Vmax,nmol/mg/min,29,0.996
Max dose,mg kg-1,29,0.996
Activity,mgequiv/mmol,29,0.996
Relative change,%,29,0.996
RHR,,29,0.996
RV,%,29,0.996
RM,,29,0.996
RIA,%,29,0.996
Max contraction,%,29,0.996
Maximal efficacy,%,29,0.996
-Log K0.5,,29,0.996
Concentration in serum,ug ml-1,29,0.996
Viable cells,*10e-5,29,0.996
MBP,ug kg-1,29,0.996
Activity,10'8CFU,29,0.996
CFU,10'5/ml,29,0.996
Cp,pmol/ml,29,0.996
CLIP,,29,0.996
Ka,10'3/M/min,29,0.996
Ka,10^-6/M,29,0.996
ED 50,mg kg-1,29,0.996
Feed efficiency,,29,0.996
KA,M-1,29,0.997
PGE2 Level,ng ml-1,29,0.997
No. of errors,,29,0.997
BFU,,29,0.997
Mean enhancement of binding,,29,0.997
Average peak Concn.,ug ml-1,29,0.997
Nr/N,,29,0.997
Kinact,10^-4/s,29,0.997
Activity,kDa,29,0.997
Enhancement,,29,0.997
Peff,10'-7 cm/s,29,0.997
Antibody stimulation,,29,0.997
Net log kill,,29,0.997
Delta mV,,29,0.997
NCC,%,29,0.997
Kd,10^-2/s,29,0.997
pC3,uM,29,0.997
Antimalarial activity,,29,0.997
LambdaZ,hr,29,0.997
Compound recovery,ng/g,29,0.997
BPR,ml/g,29,0.997
Mutagenicity,revertants plate-1,29,0.997
Total cholesterol,mg 100ml-1,29,0.997
EC>90,uM,29,0.997
EC200,nM,29,0.997
Contractility,%,29,0.997
Cmin,,29,0.997
Vz,l,29,0.997
K cat,s-1,29,0.997
Glucose normalisation,,29,0.997
IC50,10^-5 uM,29,0.997
Toxicity zone,mM,29,0.997
LD,mg kg-1,29,0.997
Activity,%ID,29,0.997
Top1 cleavage activity,,29,0.997
Lethality,,29,0.997
pKi ratio,,29,0.997
NT,mg kg-1,29,0.997
CLH,uM/ml,29,0.997
RFU,%,28,0.997
Active dose range,mg kg-1 day-1,28,0.997
EC50,mol%,28,0.997
Mean log concentration ratio,,28,0.997
A-selectivity,,28,0.997
k cat/Km,,28,0.997
Plasma glucose,mg 100ml-1,28,0.997
Cat score,,28,0.997
K,10^6/M/min,28,0.997
Relative inhibition,,28,0.997
CTL activity,,28,0.997
FSC,%,28,0.997
CL/F,ml/min,28,0.997
pKred,,28,0.997
Blockade,%,28,0.997
Activity,nanoampere,28,0.997
Content,ug (g of tissue)-1,28,0.997
Kel,hr-1,28,0.997
Blood level,Counts min-1 0.2ml-1,28,0.997
Activity,10^6 /uL,28,0.997
pLADM,,28,0.997
EC90,mg/L,28,0.997
Inverse relative potency,,28,0.997
Max effect,mmHg,28,0.997
Delta P50,,28,0.997
deltaG,J/mol,28,0.997
Drug metabolism,uM/L,28,0.997
MTD,mg Kg-1,28,0.997
Ki,10'3/M/min,28,0.997
Saldiuretic activity,,28,0.997
n50e,,28,0.997
Anti-uterotrophic effect,,28,0.997
CL/F,mL/min,28,0.997
deltaH,J/mol,28,0.997
deltapKi,,28,0.997
Ratio,Io/Eo,28,0.997
P50e / P50c,,28,0.997
RI,%,28,0.997
Activity,10'3/M/s,28,0.997
K2,M-1 min-1,28,0.997
Drug metabolism,mmol/L,28,0.997
FICI,nM,28,0.997
Organ weight ratio,,28,0.997
Effect,day,28,0.997
Edema ratio,,28,0.997
Optical density,,28,0.997
Kapp,/M/s,28,0.997
Lowest effective dose,mg kg-1,28,0.997
LogK-IAMex,,28,0.997
LC50,umol/dm3,28,0.997
No. of cultures active/total,,28,0.997
TN,M min-1 M-1,28,0.997
Synergy,,28,0.997
Optimal dosage,mg kg-1 dose-1 day-1,28,0.997
Adjusted Ki,nM,28,0.997
AUC N,uM hr dose-1,28,0.997
pED50,uM kg-1,28,0.997
ISC,%,28,0.997
Tumors with CR,%,28,0.997
Ae,%,28,0.997
T/C,survivors/total,28,0.997
MIC,g,28,0.997
Heart rate,min-1,28,0.997
Cure rate,%,28,0.997
Cure,,28,0.997
TDI,/min,28,0.997
MET,,28,0.997
Worm reduction,%,28,0.997
Antiviral index,,28,0.997
Actvity,mmHg,28,0.997
LC100,ppm,28,0.997
No. of rats,,28,0.997
Tumor-free,survivors/total,28,0.997
ICmax,ug ml-1,28,0.997
No. of tumours,,28,0.997
LC100,ug ml-1,28,0.997
Mydriasis,%,28,0.997
CLH,uL/ml,28,0.997
Ataxia,mg kg-1,28,0.997
VCR accumulation,,28,0.997
LC50,ng/cm2,28,0.997
Ep,mV,28,0.997
TdeltaS,J/mol,28,0.997
Aggregates,%,28,0.997
solubility,10'-3mol/dm3,28,0.997
Grip score,,28,0.997
IC30,ug ml-1,28,0.997
APD50,ms,28,0.997
IC30,,28,0.997
Cp(f),ng/ml,28,0.997
Arrhythmias times,,28,0.997
Tox50,uM,27,0.997
Weight loss,,27,0.997
ID16,M,27,0.997
Total turnings,,27,0.997
TG100,,27,0.997
AUC/dose,ng.hr/ml.mg,27,0.997
Zone of inhibition,uM,27,0.997
Saline control,%,27,0.997
T>IC50,hr,27,0.997
T-C/C,%,27,0.997
CC100,uM,27,0.997
ID (per g of tissue),%,27,0.997
Pm,nm/s,27,0.997
Weight gain,,27,0.997
IC50,uL,27,0.997
ID84,M,27,0.997
DD,,27,0.997
dp/dt,mmHg s-1,27,0.997
Plasma level,mg ml-1,27,0.997
Plasma level,nM,27,0.997
Plasma selectivity,,27,0.997
Kb,10'-4L/mol,27,0.997
AUC/dose,pmol.hr/g,27,0.997
Kact,nM,27,0.997
Ka,10^3/M,27,0.997
ED25,M,27,0.997
ODC,%,27,0.997
AUC/dose,pmol.hr/ml,27,0.997
Differentiated cells,%,27,0.997
Average survival days,,27,0.997
Vd,,27,0.997
Vmax,M s-1,27,0.997
Parasitaemia,,27,0.997
Na+ excretion,m equiv kg-1,27,0.997
No. of animals responding/animals receiving drug,,27,0.997
p nMED,,27,0.997
pCF,,27,0.997
No. of pos rxns,,27,0.997
Vmax,/s,27,0.997
CLH,microM/min,27,0.997
Kq,10'13L/mol/s,27,0.997
Survival after 10 days,,27,0.997
Ki,/M/s,27,0.997
PD2,,27,0.997
Activity,USP-U/mg,27,0.997
FRP C20,uM,27,0.997
Kinact,10'-3/s,27,0.997
2PT,,27,0.997
AUC,ug.hr/kg,27,0.997
log1/GI50,,27,0.997
AUCt,ng.hr/g,27,0.997
Specific activity,nM min-1 mg-1,27,0.997
Toxicity Survivors,,27,0.997
Delta G,kCal M-1,27,0.997
ascrit,,27,0.997
Ka,1/Ms,27,0.997
MCT,s,27,0.997
LD90,,27,0.997
Amount of cross-linked protein,(ug of cross-linked protein) (mg of protein)-1,27,0.997
Monoamine level,pg mg-1,27,0.997
LD50,umol/L,27,0.997
Activity,nmol/hr/mL,27,0.997
EC150,nM,27,0.997
Cave,uM,27,0.997
Mitotic index,,27,0.997
Activity,pM (10e6*cells)-1,27,0.997
Log K2,,27,0.997
Log Kobs,,27,0.997
MTD,uM day-1 kg-1,27,0.997
MPO release,ug ml-1,27,0.997
Max delta,%,27,0.997
NOEC,uM,27,0.997
MABP,delta mmHg,27,0.997
AdoMetDC,%,27,0.997
Change,mmHg,27,0.997
Activity,microM/min/mg,27,0.997
Activity,micrometer/day,27,0.997
solubility,ppm,27,0.997
Activity,mg%,27,0.997
Long-term survivors,,27,0.997
pNF,,27,0.997
Delta BP,%,27,0.997
Muscarinic agonist index,,27,0.997
SSAT,%,27,0.997
MED50,,27,0.997
f(Cave),nM,27,0.997
MED,ug,27,0.997
kinact,M-1 s-1,27,0.997
KSV,/M,27,0.997
Rate of hydrolysis,nM min-1 mg-1,27,0.997
VF,%,27,0.997
Ratio,10'5/M/s,27,0.997
K inact/Ki,M-1 min-1,27,0.997
K ass,10e6 l M-1,27,0.997
Volume of ascrit fluid,,27,0.997
ED50,mmol/L,27,0.997
Reversibility ratio,,27,0.997
CF C20,uM,27,0.997
Kcat,10'3/s,27,0.997
% activity remaining,%,27,0.997
Na,,27,0.997
Analgesic efficacy,%,27,0.997
Activity,um2,27,0.997
Myoblasts with parasites,%,27,0.997
Cardiotoxicity,,27,0.997
E1/2,,27,0.997
Log 1/EC50,uM,27,0.997
Activity,nM (10e6*cells)-1,27,0.997
Delta IC,%,27,0.997
pKi1-pKi2,,27,0.997
LDL cholesterol,mg 100ml-1,26,0.997
Kb,10'3/M,26,0.997
Pleural fluid,ml,26,0.997
Plaque accum,,26,0.997
Phorbol displacement,,26,0.997
Papp,10'-6/cm,26,0.997
Catalepsy,%,26,0.997
LT50,hr,26,0.997
CLH,microL/min/g,26,0.997
Kaliuretic activity,uM g-1,26,0.997
Kd,10'-4/s,26,0.997
log(PB),,26,0.997
PTD50,mg kg-1,26,0.997
Kapp,/M,26,0.997
Potency,IU mg-1,26,0.997
QH,ml/min.kg,26,0.997
Potency,uM kg-1,26,0.997
Radioactivity,,26,0.997
Fabs,,26,0.997
EC125,uM,26,0.997
KSV,10'5L/mol,26,0.997
RHA,%,26,0.997
PC100,uM,26,0.997
Ki,M-1,26,0.997
R.I,,26,0.997
Ca2+ antagonism,,26,0.997
Activity,mg/day,26,0.997
Ka,10'8/M/s,26,0.997
HDL cholesterol,mg 100ml-1,26,0.997
EC68,uM,26,0.997
Potency_Clk3_uM,uM,26,0.997
Antibiotic resistance,,26,0.997
Day of first positve reaction,,26,0.997
Lactone production,,26,0.997
KH,nM,26,0.997
log(1/ED80),,26,0.997
Heart rate,delta beats min-1,26,0.997
MBC>99.9,ug ml-1,26,0.997
MTD,mM kg-1,26,0.997
Ratio,equiv,26,0.997
Fm,%,26,0.997
Ratio,/min/microM,26,0.997
Lowest effective concentration,p.p.m.,26,0.997
Rate constant (k),Ie3 M-1 s-1,26,0.997
Rate,mg of protein,26,0.997
Radiolabel recovery,ngequiv/ml,26,0.997
Total cells,ml,26,0.997
Ventricular rate,beats min-1,26,0.997
K inact/Ki,,26,0.997
Liver weight,g,26,0.997
V,,26,0.997
AE activity,%,26,0.997
Etopic beats,%,26,0.997
AFC50,mg/ml,26,0.997
Activity,mole fraction,26,0.997
K aff,,26,0.997
Activity,g/m,26,0.997
Unaltered compound,%,26,0.997
Min lytic concentration,uM,26,0.997
Residual contractile activity,%,26,0.997
DNA relaxation,,26,0.997
Residual peptide,%,26,0.997
V,%,26,0.997
Drug metabolism,ug/kg,26,0.997
K1,min-1,26,0.997
ED50,10'-7 ug/ml,26,0.997
MNTD50,ug ml-1,26,0.997
tox/total,,26,0.997
CLH,mL.min/g,26,0.997
ED75,mg kg-1,26,0.997
DC50,mg/L,26,0.997
Bmax,pM (mg of protein)-1,26,0.997
Selectivity,Ratio,26,0.997
pAI50,,26,0.997
Kif,nM,26,0.997
Triglycerides,mg 100ml-1,26,0.997
Optimal dose,ug kg-1,26,0.997
AP50,ng ml-1,26,0.997
MA,%,26,0.997
DAP,%,26,0.997
Inhibitory activity,nM,26,0.997
HC10,ug.mL-1,26,0.997
Triglycerides,M,26,0.997
deltaS,J/mol.K,26,0.997
Serum Mg2+ level,,26,0.997
LD50,mg kg-1 i.p.,26,0.997
Sinus beats,%,26,0.997
Staining potential,,26,0.997
K,10'-7/s,26,0.997
Mitotic index,uM,26,0.997
Sp St,%,26,0.997
Body temp change,degrees C,26,0.997
Speed of performance,,26,0.997
Stability,ml/min/g,26,0.997
Stability,months,26,0.997
Transcriptional activation,,26,0.997
CCCT,uM,26,0.997
AUClast,%,26,0.997
Occupancy,%,26,0.997
Activity,um/min,26,0.997
HYPO,mg kg-1,26,0.997
MED,g,26,0.997
Improvement,,26,0.997
Antitumor activity,,26,0.997
Activity,pmol/min/mg,26,0.997
Activity,nM/min,26,0.997
cAMP production,pM min-1 well-1,26,0.997
Alpha-cholesterol,%,26,0.997
Km,/s/microM,26,0.997
Alpha-adrenolytic activity,,26,0.997
Activity,V/s,26,0.997
Diuretic activity,ml g-1,26,0.997
Activity,uM (g of spores)-1,26,0.997
ID80,mg kg-1,26,0.997
Toxic dose,uM,26,0.997
Change in cholesterol,%,26,0.997
Surviving factor,%,26,0.997
GT rate,nM min-1 (mg of protein)-1,26,0.997
ICD,,26,0.997
ID50,10'-7M,26,0.997
Natriuretic activity,uM g-1,26,0.997
Log beta3,,26,0.997
No effect dose,mg kg-1,26,0.997
Vmax,milli optical density/minute,26,0.997
Activity,ug/kg,26,0.997
TT,uM,26,0.997
Alloste ic enhan er (AE),,26,0.997
Coronary flow,,26,0.997
permeability,10^6cm/s,26,0.997
LD100,,26,0.997
Activity,/mm2,25,0.997
Activity,log10IU/ml,25,0.997
MIC75,uM,25,0.997
Velocity,%,25,0.997
Rate response,min-1,25,0.997
log1/S0,,25,0.997
k2/Ki,M-1 s-1,25,0.997
Tumor number,,25,0.997
MI0.5,uM,25,0.997
Activity,10'6PFU/ml,25,0.997
MET,umol/min/mg,25,0.997
pAFC50,,25,0.997
Activation (% of control),%,25,0.997
Relative enzyme activity,,25,0.997
Survival,months,25,0.997
Drug response,%,25,0.997
Change in WBC,%,25,0.997
Uptake/Binding ratio,,25,0.997
Ratio,mg dl-1,25,0.997
Vmax,nM/min,25,0.997
pKa_A2,,25,0.997
Protected/Tested,,25,0.997
T inh,s,25,0.997
Binding selectivity,,25,0.997
Mean life extension,,25,0.997
Relative maximum,,25,0.997
Delta blood pressure,mM,25,0.997
PTZ seizure,mg kg-1,25,0.997
Clast,ug ml-1,25,0.997
Total tumors,,25,0.997
T/C untreated,,25,0.997
solubility,g,25,0.997
Potency,nM kg-1,25,0.997
Relative tumor growth,,25,0.997
MDL50,uM,25,0.997
Papp,nm s-1,25,0.997
Mean graph mid point,,25,0.997
Peff,10'-5cm/s,25,0.997
% recovery,%,25,0.997
Count/h,,25,0.997
APTT,,25,0.997
Tumor mass,g,25,0.997
HSF,ml,25,0.997
Min oral dose,mg kg-1,25,0.997
Food intake,g mouse-1 day-1,25,0.997
Erythema,,25,0.997
Excess zone radius,mM,25,0.997
EC150,,25,0.997
Ki,min-1,25,0.997
Kcat,10^-3/s,25,0.997
Kcat,%,25,0.997
Ka,10^4/M/s,25,0.997
CMC,mmol/L,25,0.997
Binding activity,c.p.m.,25,0.997
CTE,uM,25,0.997
E2 response,%,25,0.997
ED30,ug/kg,25,0.997
Fold selective,,25,0.997
ED5,mg kg-1,25,0.997
IC,nM,25,0.997
CD50,mg/kg/day,25,0.997
IC50,10^-4microM,25,0.997
IC50,/uM,25,0.997
CD90,mg/kg/day,25,0.997
Biodistribution,ug equiv/g,25,0.997
Cardiotoxicity,nM,25,0.997
CPM,,25,0.997
Kis,mM,25,0.997
Ileal activity,uM,25,0.997
Biological evaluation,,25,0.997
Epileptogenicity,,25,0.997
K,10'7/M/s,25,0.997
Injected (dose/g),%,25,0.997
Log K-1,,25,0.997
Inhibition (% of control),%,25,0.997
ED20,uM kg-1,25,0.997
Increase in dP/dTmax,%,25,0.997
K,10'-2/hr,25,0.997
GI99,ug ml-1,25,0.997
ED99,,25,0.997
K aff,M-1,25,0.997
GSH,%,25,0.997
K ass,M-1 s-1,25,0.997
Drug uptake(free),%,25,0.997
Calcium release,,25,0.997
GR50,ppm,25,0.997
LC90,mgAi/L,25,0.997
Activity,pg/L,24,0.997
deltaG,,24,0.997
apE,,24,0.997
AUC,%ID/g/hr,24,0.997
Drug transport,pmol/cm2/hr,24,0.997
Vss/F,l,24,0.997
HC5,ug ml-1,24,0.997
pA2 - pA10,,24,0.997
Cmax/dose,uM.kg/mg,24,0.997
Activity,mol/L.sec,24,0.997
Lysis diameter,mm,24,0.997
Actvity,ngAoxigen/min/mg of RLM,24,0.997
% nucleotide present,%,24,0.997
AIDH activity,nM min-1,24,0.997
MBIC90,ug ml-1,24,0.997
MLC,umol/ml,24,0.997
FI,%,24,0.997
Formation of erythema,,24,0.997
fAUClast,hr.ng/ml,24,0.997
k obs / 1,M-1,24,0.997
Femoral blood flow,,24,0.997
kOH,M-1 min-1,24,0.997
MIC=>80,mg/L,24,0.997
Activity,pA,24,0.997
Cmax/dose,kg/L,24,0.997
MG-MID,uM,24,0.997
Mean no. colonies,10e4*cells,24,0.997
Antiinflammatory Activity,%,24,0.997
Mean score,,24,0.997
P50,%,24,0.997
Others,%,24,0.997
ERP,ms,24,0.997
% turnover,%,24,0.997
Mean % growth (n = 2) for 10.0 µM probe concentration,%,24,0.997
Edema,ml,24,0.997
VDR affinity,%,24,0.997
Ratio,/min/M,24,0.997
Time,hr/ha,24,0.997
Tissue distribution,%,24,0.997
Cmax,ng g-1,24,0.997
Transport inhibition,%,24,0.997
Tritium release,%,24,0.997
Mean % growth (n = 2) for 0.01 µM probe concentration,%,24,0.997
CC90,ug ml-1,24,0.997
IC10,mM,24,0.997
Vmax,10'-3uM/min,24,0.997
Verapamil index,,24,0.997
Mean % growth (n = 2) for 100.0 µM probe concentration,%,24,0.997
Level,pM min-1,24,0.997
Mean % growth (n = 2) for 1.0 µM probe concentration,%,24,0.997
Mean % growth (n = 2) for 0.1 µM probe concentration,%,24,0.997
pKact,,24,0.997
Urinary glucose excretion,,24,0.997
ED50,10'-8M,24,0.997
MTC,M,24,0.997
Frequency,,24,0.997
Vmax,uM s-1,24,0.997
Enzyme inhibition,%,24,0.997
Log TA98,,24,0.997
pC60,uM kg-1,24,0.997
MED,mg Kg-1,24,0.997
pED40,,24,0.997
-log(1/MKC),,24,0.997
-log(1/MED),,24,0.997
Drug uptake,pmol/L,24,0.997
Aggregation response,,24,0.997
Ratio,/min.mg,24,0.997
No. of axonal points,,24,0.997
K'a,,24,0.997
NADPH oxidation,nM min-1 (mg of protein)-1,24,0.997
Sweetness potency,,24,0.997
Suppression ratio,%,24,0.997
Substrate specificity,uM min-1mg-1,24,0.997
Substrate activity,c.p.m.,24,0.997
Activity,c.p.m.,24,0.997
LD50,M kg-1,24,0.997
Selectivity ratio S3/2,,24,0.997
Beats/min,,24,0.997
AUCt/dose,hr.ng/ml.mg,24,0.997
Schizont size,,24,0.997
No. of sensitive animals,,24,0.997
ED,uM,24,0.997
Biodistribution ratio,,24,0.997
PTD50,mg,24,0.997
LD50,ng,24,0.997
INH,ug,24,0.997
T/C 41,,24,0.997
T/C-CQ,,24,0.997
Phototoxicity,,24,0.997
TC50,M,24,0.997
AUC/dose,micromol.hr/L,24,0.997
Cardiac depression,%,24,0.997
Intrinsic activity,pmol,24,0.997
New tumors,,24,0.997
Net accumulation,,24,0.997
No. of mice receovered,,24,0.997
Astrocyte reversal,%,24,0.997
LC20,uM,24,0.997
Activity,cells ml-1,24,0.997
Rm,%,24,0.997
Ratio,l s-1 M-1,24,0.997
KSV,10'-4L/mol,24,0.997
Ae,a.u.,24,0.997
Delta C urate / delta C insulin,,24,0.997
Activity,Miller_unit,24,0.997
EC90,mM,24,0.997
Oncostatic index,,24,0.997
Kinact,10'-4/s,24,0.997
P50,Torr,24,0.997
Activity,/nl,24,0.997
Number,millions,24,0.997
Ref I oncostatic index,,24,0.997
Cumulative dose,,24,0.997
Rel max,,24,0.997
No. toxicity/tested,,24,0.997
Cage leaving,,24,0.997
Relaxation,,24,0.997
Occ90,nM,24,0.997
EC37,uM,24,0.997
Reduction in RBS,%,24,0.997
Activity,10'12/L,24,0.997
Kd,/uM,24,0.997
Activity,EU/ml,24,0.997
Activity,10^4/M/cm,24,0.997
Ka,10'8/M,24,0.997
Ca2+ current,mV,24,0.997
Precursor inhibition,%,24,0.997
Decrease in Systolic blood pressure,,24,0.997
BWL,%,24,0.997
Change systolic BP,%,24,0.997
Kapp,mM,24,0.997
BIC,ug ml-1,24,0.997
EC50 iGC,nM,24,0.997
Delyse,%,24,0.997
Kapp,10^-7/M,24,0.997
Ki,10'5/M/min,23,0.997
MIC,ug disk-1,23,0.997
Ki,Ratio,23,0.997
Distribution,,23,0.997
Activity,nmol.hr/g,23,0.997
Organ weight,g,23,0.997
MIC>99,,23,0.997
MIC>98,,23,0.997
Log EC50,nM,23,0.997
PGI,,23,0.997
Optimal dose,mg kg-1 day-1,23,0.997
Activity,uM/g,23,0.997
Fapp,%,23,0.997
MED25,mg kg-1,23,0.997
Kdiss,,23,0.997
ED90,mg kg-1 5day-1,23,0.997
ED,,23,0.997
Plasma concentration,,23,0.997
Insulin release,,23,0.997
kOH-,M-1 s-1,23,0.997
ka,/hr,23,0.997
FPT,,23,0.997
Cell survived,day,23,0.997
kon,M-1-s-1,23,0.997
Dopamine release,%,23,0.997
EC40,nM,23,0.997
Activity,nM min-1 (mg of protein)-1,23,0.997
No. of transfers,,23,0.997
Ratio Ki,uM,23,0.997
Acute toxicity,%,23,0.997
Palpha,,23,0.997
Log10ED50,,23,0.997
MCC50,,23,0.997
Papp,10e-6 cm s-1,23,0.997
Kcat/Km,/min/mM,23,0.997
Activity,ugequiv,23,0.997
Drug uptake,umol,23,0.997
Change MAP,%,23,0.997
PMA,%,23,0.997
Caspase induction,,23,0.997
Mean hemagglutination titers,,23,0.997
Antilipid peroxidation,%,23,0.997
LD50,mg/kg/day,23,0.997
Drug metabolism,%ID,23,0.997
EC,mg kg-1,23,0.997
MTD50,,23,0.997
LC50,umol/g,23,0.997
LC50,ug/g,23,0.997
Log,,23,0.997
No. of crosses,,23,0.997
Dose interval,hr,23,0.997
Intinsic activity,,23,0.997
AC10,uM,23,0.997
Hydrogen peroxide degradation,,23,0.997
Vmax,uM min-1 (mg of protein)-1,23,0.997
Delta RM,,23,0.997
INH,10'4L/mol/s,23,0.997
AUC,ug hr uM-1,23,0.997
pC2A,uM,23,0.997
Imax,uM,23,0.997
ED50 Ratio,,23,0.997
EC60,uM,23,0.997
Delta HR,,23,0.997
Change of body temperature,degrees C,23,0.997
Ka,10'9/M,23,0.997
Emax,meter/s,23,0.997
Plasma-E2 concentration,pg ml-1,23,0.997
"Emax,diss",%,23,0.997
Q50,uM,23,0.997
"pEC0.5,diss",,23,0.997
ED200,mg kg-1,23,0.997
RD500,,23,0.997
KSV,10'5/M,23,0.997
Increase in volume,ml min-1,23,0.997
ED80,uM/g,23,0.997
ED90,uM kg-1,23,0.997
Activity,10^12/L,23,0.997
Cp(f),,23,0.997
Tumor volume,,23,0.997
CLT50,uM,23,0.997
"median survival time, days",,23,0.997
K,10^4/M,23,0.997
Influx Ki,uM,23,0.997
KA,10'6/M,23,0.997
FBP,,23,0.997
2x PT,uM,23,0.997
S.I,,23,0.997
TOX,,23,0.997
Intrinsic_solubility,,23,0.997
AZT formation,%,23,0.997
Blood level,uM ml-1,23,0.997
AbsAC0.54_uM,uM,23,0.997
Bmax,,23,0.997
AUCmet/AUCp,%,23,0.997
HSF release,ug ml-1,23,0.997
ED50,mg kg-1 5day-1,23,0.997
deltaS,cal/mol.K,23,0.997
deltaH,cal/mol,23,0.997
DHP-I stability,,23,0.997
CL,min/ml/kg,23,0.997
SD90,mg kg-1,23,0.997
K,/mM/s,23,0.997
Gated current,,23,0.997
AI,,23,0.997
kon,10e3* M-1 s-1,22,0.997
CTL activity,M,22,0.997
CV dose,mg kg-1,22,0.997
logSI,,22,0.997
BEI,%,22,0.997
Decrease in QA interval,ms,22,0.997
kn,M-1 min-1,22,0.997
Ka,/M,22,0.997
Excretion,ml,22,0.997
RBA,g,22,0.997
Amount,ml,22,0.997
EC50,g/m2,22,0.997
K,10^-4/min,22,0.997
Cell number,%,22,0.997
k0,M-1,22,0.997
Kinact,10'3/s,22,0.997
Optimal dose,,22,0.997
GI80,uM,22,0.997
No. resp animals / Total,/ 7,22,0.997
CT10,uM hr-1,22,0.997
permeability,uL/hr/cm2,22,0.997
c90,uM,22,0.997
Max IOP reduction,mmHg,22,0.997
Max intensity,turns min-1,22,0.997
Solubility,%,22,0.997
Activity,M g-1,22,0.997
pEC200,,22,0.997
Rate of decomposition,(nM of drug) min-1 ml-1,22,0.997
BW loss,%,22,0.997
Mutagenicity,%,22,0.997
PR,,22,0.997
ECmax,ug ml-1,22,0.997
GI20,uM,22,0.997
pI50,M l-1,22,0.997
Ep,V,22,0.997
Log 1/conc (mM min-1 L-1),,22,0.997
MITC95,nM,22,0.997
K,uM-1,22,0.997
Ke ratio,,22,0.997
AI50,,22,0.997
Observed log APA,,22,0.997
log(1/LC50),,22,0.997
Recovery time,mg kg-1,22,0.997
MED,mg/kg/day,22,0.997
fEC50,mM,22,0.997
Log APA,,22,0.997
Activity,10'3No_unit,22,0.997
Activity,/s/microM,22,0.997
Ki,M-1 s-1,22,0.997
FA,,22,0.997
PDE inhibition,,22,0.997
Log potency,,22,0.997
ED50,uM/L,22,0.997
Ulcer score,,22,0.997
HIA,%,22,0.997
IC2x,uM,22,0.997
SD50,mg kg-1 day-1,22,0.997
X1(50),,22,0.997
AUC,AU.min,22,0.997
K,10^-6/s,22,0.997
TGI correlation coefficient,,22,0.997
Gastric toxicity,,22,0.997
DNA,ug,22,0.997
Vrel,,22,0.997
Covalent binding,,22,0.997
LC50,g/m2,22,0.997
Log 1/D125 (L1210) (mM kg-1),,22,0.997
ED75,uM kg-1,22,0.997
Vmax/Km,/min,22,0.997
E/Emax,%,22,0.997
Physical dependence capacity,,22,0.997
TC50,umol/L,22,0.997
Platelet aggregation,uM,22,0.997
No effect dose,mg,22,0.997
SI,%,22,0.997
Mean time to seizure,s,22,0.997
Anesthesia duration,min,22,0.997
DC50,pM,22,0.997
IG50,,22,0.997
LED100,mg kg-1,22,0.997
T>MIC,%,22,0.997
Absorption,,22,0.997
TFS,%,22,0.997
Remaining,,22,0.997
IC50,milliequivalent,22,0.997
bwc,g,22,0.997
Permeability coefficient,cm s-1,22,0.997
VERP,,22,0.997
ED90,nM,22,0.997
Incidence,N,22,0.997
Increase in plasma amylase,IU ml-1,22,0.997
EC10,uM,22,0.997
Toxicity,ug ml-1,22,0.997
Cytocidal activity,%,22,0.997
T decrease,degrees C,22,0.997
Mean activity counts,,22,0.997
Thymidine uptake,c.p.m. (mg of protein)-1,22,0.997
LD90,ug/kg,22,0.997
Median T/C,day,22,0.997
LD50,uM/L,22,0.997
Median T/C,,22,0.997
solubility,mg/g,22,0.997
Mean vesicle score,,22,0.997
Minimal bacteriostatic concentration,,22,0.997
Activity,kC/sec,22,0.997
Life span,,22,0.997
Intestinal toxicity,,22,0.997
c30,uM,22,0.997
Accumulation counts,,22,0.997
Rate,pM,21,0.997
EC99,,21,0.997
K,/min/microM,21,0.997
SI,ug ml-1,21,0.997
No. effective,,21,0.997
RTW,%,21,0.997
Range of death,day,21,0.997
Kapp,10'4/M,21,0.997
Picoequivalents of amine/10e6 cells,,21,0.997
Delta pEC50,,21,0.997
Paw weight increase,%,21,0.997
Platelet aggregation,%,21,0.997
Pmax,%,21,0.997
Passivity,mg kg-1,21,0.997
Kcat/Km,10'5/s/M,21,0.997
DIZ,mm3,21,0.997
K,u equiv kg-1,21,0.997
K,10'-7M,21,0.997
No. of escape failures,,21,0.997
Postjunctional antagonist potency,,21,0.997
Deaths/total,,21,0.997
K calc,M-1 s-1,21,0.997
Activity,/cm2,21,0.997
CT50,ug ml-1,21,0.997
Reflex,mg kg-1,21,0.997
TGD,day,21,0.997
Average,%,21,0.997
Bmax,nM,21,0.997
ED delta20,nM kg-1,21,0.997
ED delta5,nM kg-1,21,0.997
Ataxia,,21,0.997
K,10^3/M/s,21,0.997
Absolute turn angular/3 min,,21,0.997
Retention ratio,,21,0.997
Postjunctional agonist potency,,21,0.997
INH,Miller_unit,21,0.997
Potency index,,21,0.997
BT,,21,0.997
Symptom initiation,%,21,0.997
Serum lipoprotein cholesterol,,21,0.997
CT10,mM hr,21,0.997
Initial average tumor weight,mg,21,0.997
Solubility,g,21,0.997
ED25,ug,21,0.997
Survivor increase,,21,0.997
NEA,,21,0.997
Incidence of RBC decrease,,21,0.997
Apoptosis,,21,0.997
TG,%,21,0.997
Mean survival days,,21,0.997
Mean number of parasites,,21,0.997
Modification of hemoglobin,%,21,0.997
Ratio,10^3/M/s,21,0.997
Metabolic stability,mg ml-1,21,0.997
Metabolism,pM min-1,21,0.997
Drug degradation,nmol/min,21,0.997
Ka,10'8/M/min,21,0.997
BUN,mg 100ml-1,21,0.997
Prejunctional agonist potency,,21,0.997
Prejunctional antagonist potency,,21,0.997
Kd,10^2 uM,21,0.997
POT,nM,21,0.997
Protected/tested,,21,0.997
Ka,10'4L/mol,21,0.997
C20 FRP,uM,21,0.997
Activity,10'6dpm,21,0.997
CV,%,21,0.997
Activity,10'5/ml,21,0.997
Activity,10'4Meq,21,0.997
RTW,,21,0.997
Na,u equiv kg-1,21,0.997
Change in entry latency,s,21,0.997
Supression,,21,0.997
Decrease in MABP,mmHg,21,0.997
Change HDL -C,%,21,0.997
pC60,,21,0.997
ICmax,uM,21,0.997
logC50,,21,0.997
IC99,ug.mL-1,21,0.997
Log MBC,,21,0.997
d tox,,21,0.997
Hill slope,,21,0.997
LH level,ng ml-1,21,0.997
Final average tumor weight,mg,21,0.997
pKb,nM,21,0.997
Cmax/SS,uM,21,0.997
Log 1/D125 (mM kg-1),,21,0.997
MPE50,,21,0.997
Weight,mg dl-1,21,0.997
AUC,hr,21,0.997
Activity,turns hr-1,21,0.997
Total lysis,uM,21,0.997
CL,nmol/min/mg,21,0.997
LED,,21,0.997
Optimal dose,uM kg-1,21,0.997
Creatinine,mg 100ml-1,21,0.997
Treated,,21,0.997
pC25,,21,0.997
MIC,%,21,0.997
Ct,nmol/Kg,21,0.997
MED,mg kg-1 day-1,21,0.997
logCC50,,21,0.997
CC50,10^2 uM,21,0.997
Testes weight,mg,21,0.997
Toxicity,mg kg-1,21,0.997
AUC,ugequiv/l.hr,21,0.997
Eggs,%,21,0.997
Thrombus weight,mg,21,0.997
Total turns,,21,0.997
Gain,%,21,0.997
Log TA100,,21,0.997
ED50,mg/ml,21,0.997
V0,/s,21,0.997
MTD,mg,21,0.997
-Log KA,,21,0.997
koff,,21,0.997
Animal death,%,21,0.997
CI,uM,21,0.997
HTD,mg kg-1,21,0.997
ED99,mg Kg-1,21,0.997
Vmax,uM min-1,21,0.997
Drugabsorption,,21,0.997
Log delta (1/T2),,21,0.997
Kcat,10'-3/s,21,0.997
ID/g tissue,%,21,0.997
Relapses,,21,0.997
Distribution,pM mg-1,21,0.997
Edema inhibition,%,21,0.997
Vc,l,21,0.997
MST increase,,21,0.997
Log K' IAM,,21,0.997
Activity,umol/ml,21,0.997
-Log IC50,uM,21,0.997
LogIC50,,21,0.997
Log 1/ID50,,21,0.997
AI recovery time,min,21,0.997
GII50,,21,0.997
ID/brain,%,21,0.997
HD100,uM,21,0.997
Cell cycle,,21,0.997
IC100,,21,0.997
kOH,M-1 s-1,21,0.997
Cp(f),ug ml-1,21,0.997
Activity,um3/um2,21,0.997
Log K3,,21,0.997
CD90,mg kg-1,21,0.997
Mean LAF,ml min-1,20,0.997
Activity,10'-2/hr,20,0.997
Flow rate,ml min-1 100g-1,20,0.997
Ratio,10^4/M/s,20,0.997
Kq,10^12/M/s,20,0.997
k2',min-1,20,0.997
k2'',min-1,20,0.997
Mean HR,beats min-1,20,0.997
MAPD90,ms,20,0.997
Log II50,,20,0.997
Lipid peroxidation,%,20,0.997
Turns/first hour,,20,0.997
CL,uL/ml.millig,20,0.997
Activity,ng/hr,20,0.997
Recovered radioactivity,%,20,0.997
Log AC50,uM,20,0.997
Average No. of metastasis,%,20,0.997
Tumor weight,mg,20,0.997
Vmax,cm-1,20,0.997
increase in RFU,%,20,0.997
Hemodynamic change,%,20,0.997
I50,molar excess,20,0.997
HVA level,%,20,0.997
Selectivity,A1/A2A,20,0.997
Vc,ml,20,0.997
Vmax,pmol/hr,20,0.997
Selectivity,nM,20,0.997
AUC,mg hr-1 kg-1,20,0.997
Ip,,20,0.997
AFC50,ug ml-1,20,0.997
Activity,mmol/ml,20,0.997
CI,l hr-1 kg-1,20,0.997
Vmax(app),pmol/min,20,0.997
Serum cholesterol,%,20,0.997
Kr,,20,0.997
Activity,nM ml-1,20,0.997
Average onset,min,20,0.997
Km,ug ml-1,20,0.997
Drug metabolism,% ID/g,20,0.997
MLD,umol,20,0.997
ED15,mg kg-1,20,0.997
Distribution,fM mg-1,20,0.997
Drug uptake,pmol/g,20,0.997
CS50,uM,20,0.997
Delta latency time,s,20,0.997
CTF,%,20,0.997
Cp(T),uM,20,0.997
DP,%,20,0.997
ED15,ug,20,0.997
ED3,mg kg-1,20,0.998
ED10,mM,20,0.998
Complex formation,,20,0.998
Concentration ratio,,20,0.998
Complex_formation,deltaA.10^4nmol-1,20,0.998
ED25,mM,20,0.998
Activity,g/m2,20,0.998
Diameter,nm,20,0.998
Change in cAMP,%,20,0.998
Dead/total,,20,0.998
MMC,uM,20,0.998
APD90,ms,20,0.998
Kp,10'-6 cm/s,20,0.998
Analgesic effect,%,20,0.998
dTagg,K,20,0.998
Serum concentration,hr,20,0.998
I/C,,20,0.998
Urinary Na+,m equiv,20,0.998
Average,,20,0.998
K50,M,20,0.998
Change non HDL-C,%,20,0.998
Control,ug kg-1,20,0.998
Cardiac frequency,beats min-1,20,0.998
ED (1mV),ug kg-1,20,0.998
Drug metabolism,pmol/mg.hr,20,0.998
CQ,uM,20,0.998
Ca2+ transport S/M,,20,0.998
Degree of resistance,,20,0.998
AUCt/dose,ng/mL.hr,20,0.998
K,10^6/M,20,0.998
Intrinsic efficacy,,20,0.998
pLADm,,20,0.998
Brain concentration,ng g-1,20,0.998
Min effective dose,,20,0.998
Activity,pg ml-1,20,0.998
Activity,K/uL,20,0.998
Survivors at day 8,%,20,0.998
NSR,,20,0.998
Pw,,20,0.998
Log Y,,20,0.998
Kb,ug kg-1,20,0.998
Photo-cross-linking of DNA,,20,0.998
Actual duraction,min,20,0.998
Kb,10^22/M,20,0.998
MBC90,,20,0.998
p[BH+50],,20,0.998
Kb,10'4L/mol,20,0.998
Kcat/Km,/s/mM,20,0.998
Activity,umolequiv/L,20,0.998
Stabilty,microL/min/mg,20,0.998
CLH,ml/mg/kg,20,0.998
RCI,,20,0.998
Epidermal thickness,,20,0.998
Activity,pmol/mg/hr,20,0.998
2DG uptake,uM,20,0.998
Ka,10'7/M/min,20,0.998
Rate of formation,pM min-1 (mg of protein)-1,20,0.998
Ki,/M/min,20,0.998
QTc interval,ms,20,0.998
Mortality inhibition,%,20,0.998
Toxic level,mg kg-1,20,0.998
RC50,ug ml-1,20,0.998
Log K delta,,20,0.998
Survivors alive/total,,20,0.998
Activity,nmol/ml.min,20,0.998
MIC=>90,,20,0.998
PI hydrolysis,%,20,0.998
Ki,10'4/M/min,20,0.998
Ka,/hr,20,0.998
ID99,ug ml-1,20,0.998
FPG correction,%,20,0.998
-Log EC20,,20,0.998
CL,/uM/min,20,0.998
Activity,nM mg-1,20,0.998
Highest active dose,mg kg-1,20,0.998
Activity,day of onset,20,0.998
MTD,uM/g,20,0.998
K,10'6L/mol,20,0.998
No. of mice effected/No. of treated,,20,0.998
Respiratory frequency,r.p.m.,20,0.998
Serum HDL-cholesterol,%,20,0.998
Ratio,1/sM,20,0.998
Urine volume,ml kg-1,20,0.998
Residual binding,%,20,0.998
Removal,%,20,0.998
Serum LDL-cholesterol,%,20,0.998
S50,mM,20,0.998
HD50,,20,0.998
BHIA50,,20,0.998
Mean RBF,ml min-1,20,0.998
Water consumption,ml,20,0.998
CLH,uL/ml.millig,20,0.998
-ln K,,20,0.998
TBPS IC50,uM,20,0.998
Kapp,10'5/M,20,0.998
Time constant T1,ms,20,0.998
Total counts,,20,0.998
IC50,ug/g,20,0.998
-TdeltaS,,20,0.998
Effective molarity,M l-1,20,0.998
Time constant T2,ms,20,0.998
CLH,ug/min/mg,20,0.998
MDL50,,20,0.998
Papp,10'-8cm/s,20,0.998
Increased life span,%,20,0.998
LD50,p.p.m.,20,0.998
IC50,kJ m**-2,20,0.998
T max,nM,20,0.998
CMC,ug ml-1,19,0.998
Max,(fM of GTP-gammaS bound) (mg of protein)-1,19,0.998
TT,,19,0.998
Disease control,,19,0.998
MNTC,uM,19,0.998
TVI,%,19,0.998
Ki high,nM,19,0.998
Decrease,degrees C,19,0.998
PT,,19,0.998
Decrease in RFU,%,19,0.998
log KOA,,19,0.998
K+ Ion content,,19,0.998
Activity,U/g,19,0.998
Activity,ml min-1,19,0.998
permeability,10'-6/cm,19,0.998
Incidence,%,19,0.998
MTD,ug/kg,19,0.998
Analgesic efficacy,,19,0.998
Na+ ion content,,19,0.998
Smax,ul min-1 kg-1,19,0.998
Kinact,10^5nM,19,0.998
Number,%,19,0.998
Improvement,%,19,0.998
permeability,10'-8cm/s,19,0.998
Activity,min-1,19,0.998
Kinetic,,19,0.998
K+/Na+ ratio,,19,0.998
Change in body weight,%,19,0.998
Selectivity factor,,19,0.998
log Pe,10^-3cm/min,19,0.998
IC12,nM,19,0.998
Combination_index,,19,0.998
permeability,10'-5cm/s,19,0.998
Binding competition,mean counts,19,0.998
AUC,mmHg hr-1,19,0.998
ClT,ml min-1,19,0.998
ED0,gAi/ha,19,0.998
Occ50,mg kg-1,19,0.998
Cation influx,,19,0.998
Catalase rate,uM of O2 min-1,19,0.998
Vdss,L/hr/kg,19,0.998
Max aggregation response,,19,0.998
Ct,mg kg-1,19,0.998
Activity,mU/mg,19,0.998
Tested/Control,,19,0.998
PKC,uM,19,0.998
Change in systolic BP,%,19,0.998
Skin uptake,uM,19,0.998
pLADy,,19,0.998
CT1,,19,0.998
Kapp,10'7/M,19,0.998
Ratio,10'6/M/s,19,0.998
ERP1,,19,0.998
ERP3,,19,0.998
Activity,g/cm2,19,0.998
pKinc,,19,0.998
CT2,uM,19,0.998
Viability,,19,0.998
CFU,10^4/ml,19,0.998
Prolongation,%,19,0.998
Relative protection,%,19,0.998
Kr,uM,19,0.998
Drug uptake,microM,19,0.998
Approx. lethal dose,,19,0.998
Drug metabolism,pmol/hr,19,0.998
Level,ng ml-1,19,0.998
Time,%,19,0.998
RFU,a.u.,19,0.998
Activity,10^-9No_unit,19,0.998
Inhibition activity,uM,19,0.998
Corr,%,19,0.998
PG,%,19,0.998
ke,hr-1,19,0.998
LD50,10'-3M,19,0.998
LED100,,19,0.998
AUMC,hr.hr.ng/ml,19,0.998
EC50,mol/g,19,0.998
fCmax/MIC,,19,0.998
Relative stability,,19,0.998
Survivors at day 15,%,19,0.998
IC50/IC50,,19,0.998
ED25,microg/cm3,19,0.998
LC99.9,mg/L,19,0.998
GTP-gammaS index,,19,0.998
Average inhibition,,19,0.998
increase in mean survival time,,19,0.998
ED50,nM min-1 kg-1,19,0.998
Change in weight,g,19,0.998
Cytotoxic endpoint,uM,19,0.998
Activity,millimeter/min,19,0.998
Activity,log10ng/ml,19,0.998
Max effect,,19,0.998
Tumor uptake,uM,19,0.998
HI,%,19,0.998
Log CDGH,,19,0.998
AUC,mg/dl,19,0.998
[EOP']infinity/[EOH]infinity,,19,0.998
1/kobsd-ka,min,19,0.998
Urine osmolality,mOsmol kg-1,19,0.998
Antagonist effect,,19,0.998
ILSmax,mg kg-1,19,0.998
No. of metastases,,19,0.998
Max hemorrhage,,19,0.998
Cmax_[GH],ng ml-1,19,0.998
ILS30,mg kg-1,19,0.998
CFC20,uM,19,0.998
ActiveConcentrationI,uM,19,0.998
MID,ug,19,0.998
Cmax/dose,nM/mg/kg,19,0.998
Log CDQR,,19,0.998
Concentration,ug (g of wet tissue)-1,19,0.998
Average seizure score,,19,0.998
Horizontal activity,Counts min-1,19,0.998
C100,uM,19,0.998
Treated cells,%,19,0.998
FOC,,19,0.998
Basal,(fM of GTP-gammaS bound) (mg of protein)-1,19,0.998
PFU,,19,0.998
Log ED50,mM kg-1,19,0.998
Activity,N,19,0.998
MIC,ug/disk,19,0.998
Ratio,Ratio,18,0.998
AUC,nM hr ml,18,0.998
Vd/F,L,18,0.998
Decrease in MAP,%,18,0.998
Ratio,[Na+]/[K+],18,0.998
Dmax,,18,0.998
Rate,nM,18,0.998
MTS,day,18,0.998
Ratio Cmax,,18,0.998
Change in conflict,%,18,0.998
permeability,ng/cm2/min,18,0.998
Kq,10^12L/mol/s,18,0.998
K app,1/min,18,0.998
Macrophage cytotoxicity,%,18,0.998
permeability,mN/meter,18,0.998
Glucose correction,%,18,0.998
pMED,,18,0.998
Uterine activity,mg,18,0.998
Imbalance,,18,0.998
Activity,/millimeter,18,0.998
Rate of decrease,%,18,0.998
Activity,U (mg of protein)-1,18,0.998
V0,RFU/s,18,0.998
Vmax,10^-8mol/s,18,0.998
Brain level,pM g-1,18,0.998
K eff,M-1 min-1,18,0.998
Anticonvulsant dose,mg kg-1,18,0.998
pED50,ug,18,0.998
AUC,min.g.nM/mg,18,0.998
ED25,uM,18,0.998
permeability,10^-5 cm/min,18,0.998
Drug metabolism,pmol/min/ug,18,0.998
Relative molar potency,,18,0.998
Kd,l M-1,18,0.998
1/IC50,/uM,18,0.998
EC80,%,18,0.998
ED50,2mg kg-1,18,0.998
Acc. counts,,18,0.998
2*APTT,uM,18,0.998
MIC,%v/v,18,0.998
Max lowering,%,18,0.998
Kp,s-1,18,0.998
Vmax,(nM of H202) min-1 (ug of protein)-1,18,0.998
MBC90,mg/ml,18,0.998
Optimal dose,mg uM kg-1,18,0.998
Efficacy,pM,18,0.998
MBC50,mg/ml,18,0.998
Kinact,/hr,18,0.998
Efficacy,mg kg-1,18,0.998
Affinity constant,,18,0.998
ERP observations,,18,0.998
Initial rate ratio,,18,0.998
permeability,um/s,18,0.998
Rate of oxidation,,18,0.998
Colony formation,%,18,0.998
Q1/2,mM,18,0.998
Cp,ug/L,18,0.998
Inactivation,,18,0.998
Intrinsic activity,nM,18,0.998
Kobs,/hr,18,0.998
Activity,10'6CFU/g,18,0.998
K,M,18,0.998
Activity,pM of drug (10e6*cells)-1,18,0.998
max Delta Vmax,,18,0.998
Response,mmHg,18,0.998
Cholesterol,mM l-1,18,0.998
MI20,nmol/L,18,0.998
Bmax,pM mg-1,18,0.998
Ka,10'5L/mol,18,0.998
IE,%,18,0.998
P,M l-1,18,0.998
Binding activity,,18,0.998
Kon,s-1,18,0.998
K,10^7/M/min,18,0.998
Chemotactic index,,18,0.998
EC50,uM kg-1,18,0.998
GOF,,18,0.998
Initial_rate,deltaA.10^4nmol-1.min-1,18,0.998
Activity,delta mmHg,18,0.998
Activity B,uM kg-1,18,0.998
Iron excretion,mg kg-1,18,0.998
EC100,,18,0.998
EC5,ug ml-1,18,0.998
GI50 ratio,uM,18,0.998
Transport rate,M hr-1,18,0.998
A/B ratio,,18,0.998
Antiemetic activity,%,18,0.998
Activity,pixel,18,0.998
GR50,g/ha,18,0.998
MBC99.99,ug ml-1,18,0.998
Drug uptake,pmol/min/mg,18,0.998
Ex-vivo screening,,18,0.998
SD90,mg/kg/day,18,0.998
Hemolytic activity,%,18,0.998
Insulin secretion,,18,0.998
No. of lung metastasis,,18,0.998
GID75,mg m**-2,18,0.998
Selective toxicity,,18,0.998
Iron excretion,%,18,0.998
Mean day appearance of lesions,,18,0.998
Log Pc18,,18,0.998
Intact,%,18,0.998
Cpss,ng/ml,18,0.998
Vmax,V s-1,18,0.998
C24,ug ml-1,18,0.998
Mean no. of lung colonies,,18,0.998
Triglycerides,mM l-1,18,0.998
Activity,delta mV,18,0.998
Kn,M-1 min-1,18,0.998
Binding,pM 30min-1 (mg of DNA)-1,18,0.998
Drug metabolism,ng,18,0.998
Relative ODN uptake,,18,0.998
Tt,k,18,0.998
Onset of action,min,18,0.998
TT,ug ml-1,18,0.998
Mean survival in days,,18,0.998
Min effective dose,mg kg-1,18,0.998
Thymolysis,,18,0.998
LC50 ratio,uM,18,0.998
Stability,nmol/mg/min,18,0.998
Log 1/LD50 (mM kg-1),,18,0.998
fAUC/dose,uM.min,18,0.998
EC20,,18,0.998
ED50,microg/cm3,18,0.998
CT5,uM,18,0.998
CE logK',,18,0.998
LD10,mg m**-2,18,0.998
Conversion dose,mg kg-1,18,0.998
Cured/Infected,,18,0.998
Activity,nm/s,18,0.998
Blockade,,18,0.998
Nature,,18,0.998
TCID50,/ml,18,0.998
ALD50,g/Kg,18,0.998
AUC/dose,hr.ng/ml,18,0.998
Partial remission,%,18,0.998
Controls,%,18,0.998
LD100,%,18,0.998
LD50,J/cm2,18,0.998
Na+ excretion,ml kg-1,18,0.998
GHmax,ng ml-1,18,0.998
No. of counts,,18,0.998
Extremes treated,,18,0.998
Slow binding,,18,0.998
Kdiss,10^5/M/s,18,0.998
Histamine level,,18,0.998
MED,ug kg-1,18,0.998
Stability,ml/min.Kg,18,0.998
CT3,,18,0.998
Min antiviral concentration,ug ml-1,18,0.998
FIC50,nM,18,0.998
Cell size,,18,0.998
C50,umol/L,18,0.998
CL,nl/min,18,0.998
Med tumor weight,mg,18,0.998
Locomotor activity,Counts,18,0.998
krel,,18,0.998
FBF,,18,0.998
AUC,ug.hr/mL/mg/kg,18,0.998
Tm,K,18,0.998
IC85,uM,18,0.998
Duration of block,min,18,0.998
MEC2,uM,18,0.998
Antimalarial activity,%,18,0.998
Stability,cpm,18,0.998
Polyamine pools,%,18,0.998
Cell no,,18,0.998
ED100,microg/cm3,18,0.998
TD90,ug ml-1,18,0.998
Metabolic turnover,%,18,0.998
TGI ratio,uM,18,0.998
Survival treated,,18,0.998
Activity,ng/uL,18,0.998
Differential affinity,,18,0.998
KD app,uM,18,0.998
fIC50,uM,18,0.998
IC50,10'-5g/L,18,0.998
Mydriasis,,18,0.998
AUC,ugequiv.hr/g,18,0.998
fCmin,mg/L,18,0.998
CE37,uM,18,0.998
Prodrug reduction,%,18,0.998
Dissociation ratio,,18,0.998
Log LD50,,18,0.998
pK1d,,18,0.998
GSH level (mg),%,18,0.998
Uncut DNA,%,18,0.998
Vmax,mM s-1,18,0.998
pK1a,,18,0.998
pK1b,,18,0.998
Urinary excretion,ml kg-1,18,0.998
MRP,,18,0.998
Drug metabolism,uM/min.mg,18,0.998
DT,hr,18,0.998
CLH(app),uL/min/mL,18,0.998
INH,ppm,18,0.998
dP/dt,nM,18,0.998
Muscarinic receptor affinity,,18,0.998
Aggregation,mg kg-1,18,0.998
Serum corticosterone,ug ml-1,18,0.998
CC,ug ml-1,18,0.998
Control response,%,18,0.998
Activity,fold,18,0.998
LD50,10'-5M,18,0.998
Fold_activity,,18,0.998
ED10,gAi/ha,18,0.998
AUC metabolite/AUC radiolabel,%,18,0.998
Net dry weight,mg,18,0.998
Kiuc,,18,0.998
IC50,10^-6 mol/L,18,0.998
Stability,pmol/mg/hr,18,0.998
k1,s-1,18,0.998
G2/M,%,18,0.998
MFED,mg kg-1,18,0.998
Time constant,s,18,0.998
Stomach,%,18,0.998
[GSH],nM (10e6*cells)-1,18,0.998
Delta Vmax,,18,0.998
AUC,ug/hr.kg,18,0.998
Mortality,day of death,18,0.998
Phagocytosis,,18,0.998
Drug level,ug ml-1,18,0.998
AUClast,ng.hr/g,18,0.998
Stability,weeks,18,0.998
Activity,HAU/ml,18,0.998
Delta F75,M l-1,17,0.998
DNA,%,17,0.998
Effective concentration,uM,17,0.998
pCD,,17,0.998
Drug responding,%,17,0.998
MEC,ug/g,17,0.998
Relative daunomycin accumulation,,17,0.998
TC lowering,%,17,0.998
Survival,min,17,0.998
KDs,uM,17,0.998
Activity,mg/cm3,17,0.998
ED50,(mg/kg)/day,17,0.998
ED90,mg kg-1 day-1,17,0.998
TC25,,17,0.998
Intrinsic activity,uM,17,0.998
Activity,um3,17,0.998
CLH,ug/ml/min,17,0.998
Concentration,g dl-1,17,0.998
Mean response/min,,17,0.998
Drug uptake(free),ug ml-1,17,0.998
EC50,umol/Kg,17,0.998
Ccellular,ug of B (g of cells)-1,17,0.998
MABP,%,17,0.998
EC50,ug/kg,17,0.998
"Log Pe,max",,17,0.998
Relative lipophilicity,,17,0.998
Ki,10'6/M/min,17,0.998
Drug metabolism,mg kg-1,17,0.998
MDR,,17,0.998
KmH,uM,17,0.998
Log Po,,17,0.998
Activity,nM/min/mg,17,0.998
Efficiency,,17,0.998
Clearance,ml hr-1,17,0.998
Synergy,nM,17,0.998
IC100,nM,17,0.998
Pigment induction,,17,0.998
ID50,ug min-1 kg-1,17,0.998
Rats blocked,%,17,0.998
Kiuc,mM,17,0.998
K,10'2/min,17,0.998
influx_CL,ml/min.Kg,17,0.998
Swimming activity,,17,0.998
Synergy EC50,nM,17,0.998
permeability,10^-5 cm/s,17,0.998
Permeability,nM hr-1 cm**-2,17,0.998
Activity remaining,%,17,0.998
Emax,mg kg-1,17,0.998
KD50,ug/g,17,0.998
Km,/s,17,0.998
Mean log GI50,M,17,0.998
Deaths/total,%,17,0.998
Cytotoxicity,mM l-1,17,0.998
Increase in dP/dt max,%,17,0.998
Ratio,10^5/M/s,17,0.998
deltaS,cal/mol/deg,17,0.998
IC10,ug ml-1,17,0.998
Ratio,uL/min,17,0.998
Parasites,%,17,0.998
DNA cleavage activity,,17,0.998
TFS,,17,0.998
K,10'9/M/s,17,0.998
Drug uptake,umol/g,17,0.998
NR,,17,0.998
ED50,10'-12 ug/ml,17,0.998
Decrease in Bmax,,17,0.998
Agonism,IU mg-1,17,0.998
efflux_CL,ml/min.Kg,17,0.998
Ka,/s/microM,17,0.998
Mean IC70,ug ml-1,17,0.998
Max T/C,%,17,0.998
FS-SIF,mg ml-1,17,0.998
APD95,ms,17,0.998
Activity,g/Kg,17,0.998
Thromboxane B2 (TxB2),pg 0.1ml-1 500x10^3,17,0.998
ED50,mg/kg.day,17,0.998
Hydrophobicity index,,17,0.998
Antipapilloma activity,%,17,0.998
CPE50,uM,17,0.998
Vmax,nmol/sec,17,0.998
Time,microsec,17,0.998
Toxicity day survivors,,17,0.998
Antiovulatory activity,,17,0.998
LDL oxidation,%,17,0.998
Time constant T3,ms,17,0.998
GABA current,%,17,0.998
Hypnosis duration,min,17,0.998
GI50/EC50,,17,0.998
Optimal dose,mg kg-1 injection-1,17,0.998
GSH level,,17,0.998
Vmax / Kmax100,,17,0.998
PD50,ug ml-1,17,0.998
CL_renal,mL/min,17,0.998
KA,10'6L/mol,17,0.998
AUC,ug hr-1 g-1,17,0.998
LTS,%,17,0.998
ToxD/Surv,,17,0.998
Toxicity,hr,17,0.998
No. of deaths/mice injected,,17,0.998
Uptake,nM g-1,17,0.998
Liver cholesterol,mg g-1,17,0.998
Kcat/Km,10'8/M/s,17,0.998
Kinact,10'6nM,17,0.998
Fraction of accumulated 86Rb remaining.,,17,0.998
GR20,ppm,17,0.998
Cp max,ng ml-1,17,0.998
Tlag,min,17,0.998
Load,%,17,0.998
GDP ED50,,17,0.998
KR,uM,17,0.998
MLC50,uM,17,0.998
Activity,(fM of O6-MeG removed) (mg of protein)-1,17,0.998
C,nM g-1,17,0.998
ID50,mg/ml,17,0.998
LC50,mg kg-1,17,0.998
Day 22-T/C,%,17,0.998
Remains,%,17,0.998
Activity,ug/dl,17,0.998
ED50,uL,17,0.998
CMC,,17,0.998
30 days survivors,,17,0.998
Day 9-RTV,%,17,0.998
Cmax/dose,ug/mL/mg/kg,17,0.998
Gastric emptying,%,17,0.998
Drug uptake,%ID/cm3,17,0.998
kOX,,17,0.998
kHOX,,17,0.998
G-protein activation,,17,0.998
EA,,17,0.998
Sterilized,%,17,0.998
ED50,10'-8 ug/ml,17,0.998
Worm movement inhibition,%,17,0.998
MHC,,17,0.998
Dose,nM,17,0.998
Drug uptake,mg/ml,17,0.998
No. of animals protected / no animals tested,,17,0.998
AQ,,17,0.998
Cr release,%,17,0.998
P2 uptake,,17,0.998
LD99,,17,0.998
Cp,% ID/g,17,0.998
Vmax,nM s-1,16,0.998
Kcat,10'-3/min,16,0.998
LED,mM,16,0.998
Drug metabolism,uM/Gy,16,0.998
Activity,nanoseconds,16,0.998
Vmax,optical density/minute,16,0.998
Vmax,pM min-1,16,0.998
EC90/MIC,,16,0.998
CL,ug/min/mg,16,0.998
BUN,mg dl-1,16,0.998
AD,mM l-1,16,0.998
FC50,uM,16,0.998
Control value,g dl-1,16,0.998
EC95,mg/L,16,0.998
Max cAMP,%,16,0.998
Activity,mmHg/min,16,0.998
NM,,16,0.998
CTS increase,,16,0.998
ER max,mM,16,0.998
ACT,,16,0.998
CLH,mg/min/mL,16,0.998
K2,,16,0.998
LC10,ug ml-1,16,0.998
CLH,l/min/mg,16,0.998
No. of canine,,16,0.998
pK3,,16,0.998
Serum triglyceride,mg dl-1,16,0.998
LC50,uL/L,16,0.998
Effect on polyamine pools,,16,0.998
Ca2+ reduction,,16,0.998
CFU,10^3/ml,16,0.998
Cave,ng/ml,16,0.998
Total binding,%,16,0.998
Log KH,,16,0.998
Pressor activity,mg,16,0.998
Toxic dose,,16,0.998
Activity,pmol/ug,16,0.998
Delta Gm,,16,0.998
Toxic level,,16,0.998
Probability,,16,0.998
ED300,uM kg-1,16,0.998
Serum metabolite,mg dl-1,16,0.998
Tp,min,16,0.998
AUC,uM h kg/mg,16,0.998
MIC,ng,16,0.998
C24,ng ml-1,16,0.998
Apoptotic activity,,16,0.998
Potentiation,uM kg-1,16,0.998
Activity,ng (g of tissue)-1,16,0.998
Activity,mMequiv/mg,16,0.998
K obs / 1,uM-1 s-1,16,0.998
Drug metabolism,uL/min,16,0.998
Maximal relaxation,%,16,0.998
Activity,log10/ml,16,0.998
Kobs,/s,16,0.998
MTT reduction,%,16,0.998
EDmin,,16,0.998
Virus rating,VR,16,0.998
Change in IC50,fold,16,0.998
MIC>99,ug ml-1,16,0.998
Drug metabolism,%/min/pmol,16,0.998
fAUC,,16,0.998
Cmax,μg/mL,16,0.998
ED90,mg Kg-1,16,0.998
KB,uM kg-1,16,0.998
k,se-1,16,0.998
Drug metabolism,umol/ml,16,0.998
Colony_count,,16,0.998
Kinact,10^-5/s,16,0.998
Fluorescence,nm,16,0.998
k1,M-1 s-1,16,0.998
Non-HDL-C,%,16,0.998
MIC>80,ug ml-1,16,0.998
LC60,mgAi/L,16,0.998
EC50rel,uM,16,0.998
LC95,uL/L,16,0.998
Fluorescence intensity,a.u.,16,0.998
Apoptosis index,,16,0.998
Viability,mM,16,0.998
Specific Displacement,%,16,0.998
No. total,,16,0.998
ED90,(mg/kg)/day,16,0.998
Activity,log10PFU,16,0.998
LC90,,16,0.998
Carbohydrate,ug,16,0.998
MNTD,umol/L,16,0.998
A,ug (g of abscess)-1,16,0.998
No. deaths/treated,,16,0.998
[Ca2+] variation,,16,0.998
Dose/ml,%,16,0.998
Efficacy,ug ml-1,16,0.998
A0,,16,0.998
Fu,ng/ml,16,0.998
Ka,1/M.sec,16,0.998
Concentration,mg kg-1,16,0.998
Cell protein in untreated control,%,16,0.998
A50,nmol,16,0.998
Activity,mU/L,16,0.998
Vmax/Km,ml/min,16,0.998
AB50,,16,0.998
MNCC,nM,16,0.998
pEC99,,16,0.998
ED80,,16,0.998
Median survival,day,16,0.998
Activity,equiv/uM,16,0.998
Kr,10^-3/min,16,0.998
k',min-1,16,0.998
Log KL,,16,0.998
Increase in dP/dtmax,%,16,0.998
Selectivity,%,16,0.998
Decrease in the QA interval,ms,16,0.998
CT-luci TAR,T/C,16,0.998
Average score,,16,0.998
MAT,hr,16,0.998
IZ,U,16,0.998
RTP,%,16,0.998
AUC,nmol/g.hr,16,0.998
K,s/counts.M,16,0.998
Ulcerative index,,16,0.998
Unbound,%,16,0.998
AUC,nmol.min.g-1,16,0.998
Relative intrinsic activity,,16,0.998
Reduction in virus titer,%,16,0.998
Plasma cholesterol,mg dl-1,16,0.998
Uptake,,16,0.998
Acute tolerability,,16,0.998
Relative esterase susceptibility,,16,0.998
Radioactive constituents,%,16,0.998
Inhibition of damage,%,16,0.998
HR,mmHg,16,0.998
Response,min,16,0.998
Ionization,%,16,0.998
Original amplitude,%,16,0.998
Amount delivered,pg ml-1,16,0.998
Activity,ug/100mg of tissue,16,0.998
Ratio,10^6/M/s,16,0.998
ED20,nM kg-1,16,0.998
Kin,/s,16,0.998
Activity,10'-4/min,16,0.998
ILB,,16,0.998
HF ratio,,16,0.998
Kd,10^3nM,16,0.998
Cholesterol Concentration,mg dl-1,16,0.998
Log t1/2,,16,0.998
Remaining ratio,%,16,0.998
Activity,10'6 /uL,16,0.998
Organ weight,,16,0.998
Relative value,,16,0.998
Resistance reversal,,16,0.998
MDD50,,16,0.998
E/Eref,,16,0.998
MBC,umol,16,0.998
Ke,/M,16,0.998
Rate constant,k hr-1,16,0.998
HC10,,16,0.998
Rate of hydrolysis,,16,0.998
Activity,/mmol,16,0.998
Binding inhibition,%,16,0.998
Inactivation time,min,16,0.998
Incidence_count,,16,0.998
Inflamed,mmHg,16,0.998
Infarct,%,16,0.998
Suppressive dose,mg kg-1,16,0.998
Remaining rate,%,16,0.998
Amount of Acotine used,,16,0.998
Heart weight,g,16,0.998
Peak deltaMAP,mmHg,16,0.998
MET,%,16,0.998
Analgesic,%,16,0.998
Survivors at day 30,,16,0.998
K,1/Ms,16,0.998
Specific activity,Ci mM-1,16,0.998
MBEC90,uM,16,0.998
Activity (mg),%,16,0.998
Transport rate,nM min-1 mg-1,16,0.998
EC50,10'8pM,16,0.998
Cleavage rate,nM min-1 mg-1,16,0.998
B,ug (g of abscess)-1,16,0.998
K,10'5L/mol,16,0.998
ED50,10'-7M,16,0.998
SC200,,16,0.998
Rs,uM min-1 kg-1,16,0.998
Hematotoxicity,%,16,0.998
ID50,nmol/ml,16,0.998
Insulin release,ng/islet/h,16,0.998
ED2sec,mg kg-1,16,0.998
HT50,%,16,0.998
Tumor growth,10e3mm,16,0.998
Retention_time,,16,0.998
Stretches,,16,0.998
Peak deltaHR,beats min-1,16,0.998
KiAH,nM,16,0.998
Activity,FU/min,16,0.998
Survival median,day,16,0.998
Normal,mmHg,16,0.998
Amount excreted,,16,0.998
Time to max. inhibition,hr,16,0.998
Stability,pmol/min,16,0.998
K,10'-4/nM/min,16,0.998
Tissue/Blood ratio,,16,0.998
IC50,pmol/L,16,0.998
Cell kill,%,16,0.998
MED,%,16,0.998
Kd,1/s,16,0.998
Spreading,%,16,0.998
IC50/[E],,16,0.998
K,10'8/M,16,0.998
Survivors / total,,16,0.998
CC50/EC50,,16,0.998
Tensile strength,g cm**-2,16,0.998
Dependency,,16,0.998
Difference,%,16,0.998
E max,%,16,0.998
Cmax,min,16,0.998
Papp,10'-6nanometer/s,16,0.998
TI,%,16,0.998
E,mV,16,0.998
Log2,,15,0.998
INH,10'-3M,15,0.998
Vm/Km,,15,0.998
Kcat/Km,10'2/M/s,15,0.998
CL,ml/kg.hr,15,0.998
LD95,mg kg-1,15,0.998
P50d/P50c,,15,0.998
Antidiuretic activity,,15,0.998
GTP-gamma35S bound,%,15,0.998
Reduction in movement,%,15,0.998
No. of cells,ml,15,0.998
ED85,ng ml-1,15,0.998
Vd/F,l,15,0.998
EC40,mM,15,0.998
Ae,%ID,15,0.998
Kq,10^13L/mol.s,15,0.998
Co,uM,15,0.998
MAC,mg/kg/day,15,0.998
CLogD7.4,,15,0.998
Efficacy,picometer,15,0.998
K app,nM,15,0.998
Inhibitory effect,,15,0.998
Decrease in fighting,%,15,0.998
Animals cured,%,15,0.998
Activity,mmolequiv,15,0.998
Ratio CC50/IC50,10'4No_unit,15,0.998
pEC50 diss,,15,0.998
Activity,RLU/mg,15,0.998
-Log I50,,15,0.998
Drug recovery,umol,15,0.998
Cp,mg/ml,15,0.998
Optimal dose,mg uM kg day-1,15,0.998
ED70,mg kg-1,15,0.998
Body weight change,BWC,15,0.998
RMP,mV,15,0.998
Total number of entries,,15,0.998
Tumor volume,cm*3,15,0.998
-Log concentration,M l-1,15,0.998
Relative differentiating activity,,15,0.998
RVR ED15,ug kg-1,15,0.998
Drug uptake,ug/L,15,0.998
B50,M,15,0.998
Effectiveness,%,15,0.998
Decrease RVR,%,15,0.998
GI,nM,15,0.998
ED80,uM kg-1,15,0.998
Kapp,10'-5/M,15,0.998
RBI,,15,0.998
Remaining compound,%,15,0.998
CHI,%,15,0.998
Vz,,15,0.998
E50,uM,15,0.998
Triglyceride correction,%,15,0.998
CGI,nM,15,0.998
Cholesterol,ug,15,0.998
MPE,mmHg,15,0.998
p alpha,,15,0.998
Hemispheres reduction,,15,0.998
PD50,mg Kg-1,15,0.998
Cell proliferation,%,15,0.998
pD2,M,15,0.998
Average survival time,day,15,0.998
No. of entries,%,15,0.998
Crop_yield,kg/ha,15,0.998
Accumulated counts/30 min,,15,0.998
cpm,,15,0.998
pAD,,15,0.998
WLC PRA,,15,0.998
GI25,nM,15,0.998
Communicating cells,,15,0.998
Max agonist response,%,15,0.998
VCT,,15,0.998
MTX equivalent,mg kg-1,15,0.998
No. of suncus vomited,,15,0.998
Dose,mg ml-1,15,0.998
CL_renal,ml/hr,15,0.998
HC30,mg/ml,15,0.998
Kact,uM,15,0.998
Vmax,RFU/min,15,0.998
pAH50,,15,0.998
Gastric concentration,ug g-1,15,0.998
Rate constant,M-1 s-1,15,0.998
Activity,/10'2cm3,15,0.998
Activity,M-1 s-1,15,0.998
Insulin-sensitizing activity,%,15,0.998
No. of living cells,,15,0.998
Kinact,10'4/M/s,15,0.998
2x APTT,,15,0.998
IC50,M ml-1,15,0.998
T/C (ratio of treated to control),%,15,0.998
MEC1.5,nM,15,0.998
Log 1/Th+200,,15,0.998
S,Dilution factor,15,0.998
3H-TdR incorpolation,c.p.m.,15,0.998
Ka,10'2/M,15,0.998
Log concentration,,15,0.998
Scavenging activity,%,15,0.998
Hx shift,,15,0.998
Cytotoxicity,mM,15,0.998
Blood glucose level,,15,0.998
Average tumor volume,,15,0.998
ID50,umol/cm2,15,0.998
Log 1/B+1,,15,0.998
ID50,umol/kg/hr,15,0.998
Tonic seizures,%,15,0.998
Change in rat blood sugar,%,15,0.998
Analgesia duration,min,15,0.998
NBT positivity,%,15,0.998
CLH,mg/min/microL,15,0.998
deltaOD,/min,15,0.998
k obs / 1,1/M 1/s,15,0.998
Rmax,RU,15,0.998
AUMCt,hr.hr.ng/ml,15,0.998
TI,Ratio,15,0.998
Cmax,ng.hr/ml,15,0.998
Food intake,g,15,0.998
Weight changes,g,15,0.998
MOT,,15,0.998
Drug metabolism,ml/min.kg,15,0.998
Survival,weeks,15,0.998
Activity,ug disk-1,15,0.998
fIC50,,15,0.998
Root_galling_index,%,15,0.998
ED40,nM kg-1,15,0.998
Activity,FU,15,0.998
C10,mM hr,15,0.998
CF,%,15,0.998
AUC/dose,ng/mL.hr/(mg/kg),15,0.998
Hypoglycemic activity,mg kg-1,15,0.998
Log 1/B+100,,15,0.998
Survival,hr,15,0.998
CMC,umol/L,15,0.998
Alkylation,%,15,0.998
Clp,ml.min-1,15,0.998
Weight change,g mouse-1 on day 8,15,0.998
Log 1/B.5,,15,0.998
Activity,g/ml,15,0.998
Log K'W,,15,0.998
EC25,ug ml-1,15,0.998
Preventive_index,,15,0.998
Activity,mS/cm,15,0.998
Extent of skin lesions,cm**2,15,0.998
Kcat/Km,L/mmol/s,15,0.998
Delta HDL-C,%,15,0.998
AERP,,15,0.998
Activity,Angstrom,15,0.998
T/C survival days,,15,0.998
Kcat,10'-4/s,15,0.998
I50,ppb,15,0.998
AUClast,min.ng/g,15,0.998
AUCt,ng.min/g,15,0.998
Activity,uA.cm^-2,15,0.998
Activity,mMequiv,15,0.998
T50,nM,15,0.998
Plasma concentration,nM,15,0.998
Cures,survivors/total,15,0.998
Activity,mJ/m2,15,0.998
T/C 1.2,,15,0.998
C8h,uM,15,0.998
Fresh weight,ng g-1,15,0.998
Metabolite levels,ug,15,0.998
Spent time,hr,15,0.998
Average change in weight,%,15,0.998
K,1/Maa,15,0.998
AP,,15,0.998
Kcat/Km,10^6/M/s,15,0.998
FE,,15,0.998
Succeeded/tested,s,15,0.998
Metabolite levels,,15,0.998
Amount bound,M g-1,15,0.998
Stability,%/hr,15,0.998
Stability,yr,15,0.998
deltaS,kcal/mol,15,0.998
Mineral apposition rate,mm day-1,15,0.998
CL free,%,15,0.998
EC95,uM,15,0.998
CR,,15,0.998
Activity,uM of MDA (mM of deoxyribose)-1,15,0.998
CL free,10^3uL/min/mg,15,0.998
Dissociation rate constant,1/S,14,0.998
Activity,uM/day,14,0.998
K,10^5/Ms,14,0.998
PD50,mg/kg/day,14,0.998
Hypotensive activity,mmHg,14,0.998
MIC,ug m/L,14,0.998
Net grain counts,,14,0.998
K,10^-5/s,14,0.998
Therapeutic effect,%,14,0.998
Ct,hr.fmol,14,0.998
Free complex,%,14,0.998
POT vigilance,,14,0.998
Ouabain,ug kg-1,14,0.998
Tumor growth delay,day,14,0.998
Tumor weight,%,14,0.998
GOT Level,U l-1,14,0.998
Increase over control,%,14,0.998
K obs,uM,14,0.998
GPT Level,U l-1,14,0.998
Vmax,uM min-1 mg-1,14,0.998
No. of males fertile,,14,0.998
EC10,ug ml-1,14,0.998
AUC,mg kg-1,14,0.998
No. of males mated,,14,0.998
Lethal dose,p.p.m.,14,0.998
Vmax,nmol/min/mg protein,14,0.998
LD50,10'-6M,14,0.998
GSTCP activity,,14,0.998
No. of writhings,,14,0.998
PEI,%,14,0.998
AUC c,,14,0.998
Myoblast with parasites,%,14,0.998
UD,mg kg-1,14,0.998
G0/G1,%,14,0.998
HC20,ug ml-1,14,0.998
Activity,IU/dl,14,0.998
Of control,%,14,0.998
No. of scratches,,14,0.998
LD50,mg/ml,14,0.998
K,10^3/M/min,14,0.998
Drug uptake,ml/min/mg,14,0.998
Antimicrobial activity,,14,0.998
K NBP,s-1,14,0.998
Kidney weight,,14,0.998
K H,s-1,14,0.998
TPO,%,14,0.998
Tonic-clonic seizure,,14,0.998
Net turns/min,,14,0.998
Hypocotyl length,cm,14,0.998
LD50,ug/mg,14,0.998
Therapeutic index,ug ml-1,14,0.998
I75,gAi/ha,14,0.998
K app,min-1,14,0.998
APA,mV,14,0.998
deltaA,nm,14,0.998
Control relaxation,%,14,0.998
Activity,uM min-1,14,0.998
VM,pM min-1,14,0.998
No. of mice dead/day died,,14,0.998
Blood glucose,mM (l of whole blood)-1,14,0.998
Change in blood flow,,14,0.998
AUC,nM.hr.kg/mg,14,0.998
NLCK,,14,0.998
Activity,uS,14,0.998
Bilurubin Level,mg %,14,0.998
T/C corr,%,14,0.998
AI50,nM,14,0.998
Cmax,hr.fmol,14,0.998
TC50,umol,14,0.998
Activity,10^6/mm3,14,0.998
Peak time,min,14,0.998
Growth delay (T-C/C),%,14,0.998
Fungicidal,ug ml-1,14,0.998
Cmax,mg kg-1,14,0.998
IC20,nM,14,0.998
TC90,umol,14,0.998
TCID50,ml-1,14,0.998
Pcaco2,cm s-1,14,0.998
dose BP/BP,,14,0.998
deltaTm,hr,14,0.998
IC,mM,14,0.998
LWI,%,14,0.998
AUC p,,14,0.998
fCmax,,14,0.998
ALP Level,U l-1,14,0.998
NADH oxidation,uM min-1mg-1,14,0.998
Parasites no. per 100 Myoblasts,,14,0.998
Vdss,ml,14,0.998
No. protected/ No.dosed,,14,0.998
Average body weight change,%,14,0.998
LD10,mM,14,0.998
Vmax,nM hr-1 mg-1,14,0.998
MFC,mg l-1,14,0.998
MIC,umol/uL,14,0.998
Kid,uM,14,0.998
No. of dogs reverted,,14,0.998
MI50,uM,14,0.998
GI,square millimeter,14,0.998
Toxicity related death,,14,0.998
Activity,L/s,14,0.998
No. of dogs used,,14,0.998
No. of plaques,,14,0.998
Liver TG,mg g-1,14,0.998
PB,pmolequiv,14,0.998
Kcat/Km,10'-3/microM/s,14,0.998
EC100,mg ml-1,14,0.998
Activity,pmol/min.mg,14,0.998
ED50,10'-7mol/cm2,14,0.998
Activity,pmol/min/ug,14,0.998
Vmax(app),pmol/mg.min,14,0.998
ECLT,min,14,0.998
Vmax / Km,nM min-1 mg-1 mM-1,14,0.998
Lipid peroxidation,,14,0.998
HVA level,ug g-1,14,0.998
Tumor burden,mg,14,0.998
No. of males cohabited,,14,0.998
CCh,,14,0.998
Vmax,nM hr-1 (10e6*cells)-1,14,0.998
fAUC/MIC,hr,14,0.998
K,10'3/uM/s,14,0.998
Dose range,mg kg-1,14,0.998
Histopathology,,14,0.998
Time,10'3s,14,0.998
Photosensitization,,14,0.998
k,M-1 min-1,14,0.998
Maximum response,%,14,0.998
Plasma ALT at 24 h,mU ml-1,14,0.998
LD0,,14,0.998
30 day survivors,,14,0.998
Increase in DPM,(mg of protein)-1,14,0.998
Activity,nM g-1,14,0.998
Cl,mg ml-1 kg-1,14,0.998
KDMPC,M-1,14,0.998
MCCD,mg kg-1,14,0.998
Change,uM,14,0.998
C1.3,uM,14,0.998
Kdiss,10'-2/s,14,0.998
Infectious virus,ffu ml-1,14,0.998
Duration of reversal,min,14,0.998
Kr,10'-3/min,14,0.998
Pigmentation capacity,,14,0.998
Activity,10'-10mol/min,14,0.998
Kdapp,nM,14,0.998
Log change,,14,0.998
Plasma histamine,ng ml-1,14,0.998
Rate max,beats min-1,14,0.998
Adjuvant effect,,14,0.998
Reduction,hr,14,0.998
Inhibitory activity,uM,14,0.998
Sp Max,%,14,0.998
Radiation equivalent,,14,0.998
Abdominal fat,g,14,0.998
K,10'-6/M,14,0.998
Ko,min-1,14,0.998
gammaCMC,mN/meter,14,0.998
Increase in blood pressure (P/R),%,14,0.998
k-2,10e-3 1/s,14,0.998
Activity,10'-5OD/s,14,0.998
EDmin,uM kg-1,14,0.998
MID log LC50,M,14,0.998
ID50,nmol,14,0.998
Drug uptake(free),ng/g,14,0.998
Thermodynamic solubility,ugA/ml,14,0.998
ID50,ng,14,0.998
EI,,14,0.998
Reactivity,%,14,0.998
ED15,uM kg-1,14,0.998
KI',uM,14,0.998
Max tolerated dose,mg kg-1,14,0.998
Rate of inhibition,s-1,14,0.998
Max MBP,mmHg,14,0.998
k2,10e-3 1/s,14,0.998
Increase in plasma lipase,IU ml-1,14,0.998
Survivors at 24 h,,14,0.998
Activity,ml/min.Kg,14,0.998
Kd1,nM,14,0.998
pXI50,,14,0.998
DNA cleavage,%,14,0.998
Stability,nmol,14,0.998
Delta TC,,14,0.998
B(DPB),%,14,0.998
Subcut score,,14,0.998
IC60,nM,14,0.998
Stain index,,14,0.998
Ki,10'6/M,14,0.998
Emax,mV,14,0.998
k3,s-1,14,0.998
Bullatacin index,,14,0.998
Lysis area,mm.mm,14,0.998
CAR,MPK,14,0.998
Complete remission,%,14,0.998
log10PFU/ml,,14,0.998
C20 APD95,,14,0.998
ED33,mg kg-1,14,0.998
Agonistic activity,%,14,0.998
Activity,%mol/mol,14,0.998
Log rate constant,M-1 s-1,14,0.998
Positive,%,14,0.998
Kt,uM,14,0.998
Activity,ul min-1,14,0.998
K,10'-1/min,14,0.998
Max decrease in blood pressure,mmHg,14,0.998
Blood urea nitrogen,mg 100ml-1,14,0.998
Amount,nM (mg of protein)-1,14,0.998
Mean decrease,%,14,0.998
Edema density,,14,0.998
Body weight change,g (100g of body weight)-1,14,0.998
Emax,mM,14,0.998
C/P,,14,0.998
-Log Sw,,14,0.998
Decrease in Bmax,%,14,0.998
Nitric oxide,%,14,0.998
Max relaxation,%,14,0.998
5-HT syndrome,,14,0.998
Erythema induction,,14,0.998
Reduction,mg kg-1,14,0.998
Log Pmic,,14,0.998
Potentation,,14,0.998
Reduction,mg,14,0.998
MBC=>99,ug ml-1,14,0.998
ED6,mg kg-1,14,0.998
AUCt,nM/ml.hr,14,0.998
RT,min,14,0.998
Relative level,,14,0.998
ED50,uM site-1,14,0.998
Activity,10'7/ml,14,0.998
Activity,millimeter/hr,14,0.998
Concentration,M l-1,14,0.998
Ka,10'-6/M,14,0.998
Inhibition potency T/II,,14,0.998
Serum triglyceride,%,14,0.998
Max increase in coronary flow,%,14,0.998
Serum stability,,14,0.998
kc,10e-3 1/s,14,0.998
Equilibrium OD340,,14,0.998
Relative t1/2,,14,0.998
CT10,mM-hr,14,0.998
Drug uptake,ug base equiv/g,14,0.998
Relaxed DNA,%,14,0.998
Experimental DPM,,14,0.998
K,10'-4/min,14,0.998
Prolactin control,ng ml-1,14,0.998
Prolactin treatment,ng ml-1,14,0.998
Shutdown time,min,13,0.998
Increase in HR,%,13,0.998
MTX ratio,,13,0.998
Protective Index,,13,0.998
ED90,mg/kg.day,13,0.998
Ki int,uM,13,0.998
ED50,mpk/d,13,0.998
kR,uM,13,0.998
Ratio,mg/L,13,0.998
VOLSYN,,13,0.998
MIC,U/ml,13,0.998
Spontaneous motor activity,,13,0.998
I50,gAi/ha,13,0.998
K bind,,13,0.998
Induction,fM,13,0.998
deltaA,%,13,0.998
Vagal response,,13,0.998
TO,min,13,0.998
NOAEL,ng/ml,13,0.998
Activity,10'9CFU/g,13,0.998
Cell permeation,nm s-1,13,0.998
Activity,10^6No_unit,13,0.998
Kd,10^-3/s,13,0.998
Drug deaths,,13,0.998
EC99.9,uM,13,0.998
Kd,10^-12M,13,0.998
Ct,%ID/cc,13,0.998
Excreted,%,13,0.998
Amine formed,ug,13,0.998
Ka,/mM,13,0.998
ln Kp,,13,0.998
ln Kt,,13,0.998
Ratio,/min,13,0.998
Necrosis response,%,13,0.998
IC>80,,13,0.998
MEC,%w/v,13,0.998
Km/Kcat,,13,0.998
Exploratory activity,,13,0.998
Negation,%,13,0.998
Parasitemia,,13,0.998
Serum level,ug ml-1,13,0.998
Alpha Ki,M,13,0.998
ED100,nM,13,0.998
Activity,10^6/ml,13,0.998
Ki',mM,13,0.998
BMD,mg/cm3,13,0.998
E100,M,13,0.998
EC50,Ke nM-1,13,0.998
K,10'-4/M/s,13,0.998
Kr,mmol/min,13,0.998
AUCt/dose,nM.hr,13,0.998
TPI,%,13,0.998
CMI,mg l-1,13,0.998
Kcat/Km,/min/microM,13,0.998
Caco-2 permeability,,13,0.998
Ki,s-1,13,0.998
C120/ED50,,13,0.998
Urine/bile,,13,0.998
ED50,gAi/ha,13,0.998
S,%,13,0.998
Change in cholesterol,,13,0.998
ED50,kg/ha,13,0.998
LD50,mg,13,0.998
ID50,uM ml-1,13,0.998
Average tumor volume,T/C,13,0.998
Chlorine uptake,,13,0.998
Migration,%,13,0.998
Activity,mg l-1,13,0.998
ST,s,13,0.998
LD50,mg kg-1 day-1,13,0.998
Wet weight,mg,13,0.998
MNTD,mg/kg/day,13,0.998
Fmax,,13,0.998
Ki/(Km/Kcat),,13,0.998
Kq,10'11/M/s,13,0.998
Activity,(ng of PGE2) (mg of protein)-1,13,0.998
AUC,nM/ml,13,0.998
Root_galling_index,,13,0.998
MBIC=>90,ug ml-1,13,0.998
SB,%,13,0.998
Behavioral response,,13,0.998
Activity,mg.min/dL,13,0.998
TT,min,13,0.998
Cp,ng/mg,13,0.998
Log 1/IC90,,13,0.998
K,/min/nM,13,0.998
Ka,10'-4/M,13,0.998
LC50,ugAi/L,13,0.998
Hill coefficient,nH,13,0.998
Enhancement ratio,,13,0.998
Hormonal activity,,13,0.998
Occ50,ng/ml,13,0.998
Equilibrium,ug/ml,13,0.998
ED50,m equiv [H+] l-1,13,0.998
Differentiation activity ratio,,13,0.998
log10LT50,,13,0.998
Log cfu/g,,13,0.998
LD50,mg/m2,13,0.998
Ip score,,13,0.998
Tissue levels,ug ml-1,13,0.998
Average weight change,mg kg-1,13,0.998
PDI,%,13,0.998
QT interval,ms,13,0.998
Length,mm rat-1,13,0.998
AD50,nmol,13,0.998
Vmax,pmol,13,0.998
D,10'-10m2/s,13,0.998
Inotropic potency,nM kg-1,13,0.998
logPc,,13,0.998
AUC,SUV.min,13,0.998
IC20,10'-5M,13,0.998
Rate constant,hr-1,13,0.998
Weight change on day 5,%,13,0.998
BEI,kDa-1,13,0.998
Activity,pmolequiv/mg,13,0.998
B/P,,13,0.998
Kdiss,10^-2/s,13,0.998
Activity,10^3/ml,13,0.998
LBF,ml/min,13,0.998
MBC>99.9,,13,0.998
ID95,nM,13,0.998
Activity,mg/g DW,13,0.998
Hepatic necrosis in survivors,,13,0.998
MAP,%,13,0.998
Relativity,,13,0.998
Emax,ms,13,0.998
Vz,ml,13,0.998
DNA fragmentation,,13,0.998
Activity,degreeC.hr,13,0.998
Relative stimulatory activity,%,13,0.998
MTD,mg/m2,13,0.998
Change in temparature,degrees C,13,0.998
K HOX,,13,0.998
Tumor inhibition ratio,%,13,0.998
Basal,%,13,0.998
ED2,ug kg-1,13,0.998
Ks,mM,13,0.998
Kcat/Km,10'2/s/M,13,0.998
LVEDP,mmHg,13,0.998
Cmax,ug g-1,13,0.998
Vmax,c.p.m.,13,0.998
MED10,mg kg-1,13,0.998
ED50,M mouse-1,13,0.998
CL,ml/min.g,13,0.998
ILS (T/C),%,13,0.998
Blockade duration,min,13,0.998
Transcriptional activity,%,13,0.998
Cures,%,13,0.998
K,10^8/M,13,0.998
Agonism,,13,0.998
p10 MIC,nM,13,0.998
K OX,M-1 min-1,13,0.998
LBF,L/min,13,0.998
RBP,%,13,0.998
Absorbance,,13,0.998
Max SBP,mmHg,13,0.998
k'',s-1,13,0.998
Delta ED50,mg kg-1,13,0.998
Relative florescence,,13,0.998
IC25,,13,0.998
Body weight loss at nadir,%,13,0.998
EC5,uM,13,0.998
LC90,ugAi/L,13,0.998
Ki,10^5/M,13,0.998
Rate,nM min-1 (10e6*cells)-1,13,0.998
MRD,V s-1,13,0.998
Vm,10'-4m3/mol,13,0.998
Log tumor cell kill,,13,0.998
RHA,,13,0.998
AUC,hr/mL,13,0.998
P value,,13,0.998
Cmax,uM-1 kg-1,13,0.998
KDNB,,13,0.998
Kt,,13,0.998
Max enhancement,,13,0.998
Reduction in virus yield,pfu/ml,13,0.998
Peff,10'-4 cm/s,13,0.998
Effectiveness,,13,0.998
AERP,ms,13,0.998
Regression response,%,13,0.998
RSA tR,min,13,0.998
Ratio,10^4/M/min,13,0.998
Kup,ml/min/g,13,0.998
EC40,,13,0.998
MST,%,13,0.998
Kdiss,10^-3/s,13,0.998
Effective dose,uM kg-1,13,0.998
Ka,10^3/M/s,13,0.998
Cell Proliferation AC50,nM,13,0.998
MED98,mg kg-1,13,0.998
Effective concentration,,13,0.998
increase in response,%,13,0.998
CL,ml.Kg/min,13,0.998
Max delta BP,mM,13,0.998
MIC,umol/cm3,13,0.998
Relative bioavailability,,13,0.998
Photolysis,,13,0.998
Radioactivity level,ml,13,0.998
Logit_p(conc),,13,0.998
T,min,13,0.998
Radioligand bound,%,13,0.998
fAUC/dose,nM.hr/mg/kg,13,0.998
Optimal dose,mg uM kg-1 day-1,13,0.998
Lesion_Clearance,%,13,0.998
MED50,mg,13,0.998
Duration time,hr,13,0.998
Peroxidase rate,uM of ABTS min-1,13,0.998
Kd,s-1,13,0.998
Rate,delta OD340 min-1,13,0.998
KB app,nM,13,0.998
Survivals,%,13,0.998
logt1/2,,12,0.998
FIC index,,12,0.998
CLH,/hr,12,0.998
kinact/Ki,M-1 s-1,12,0.998
lesions,,12,0.998
EC30,M,12,0.998
Extraction,%,12,0.998
log S,M/m3,12,0.998
AC,,12,0.998
Excretion,% of dose,12,0.998
Excretion,mg kg-1,12,0.998
mBP(delta),%,12,0.998
Excretion,m equiv 4hr-1,12,0.998
CLH,microM/min/mg,12,0.998
Cmax/dose,kg.ng/ml/mg,12,0.998
LC50,mg/cm2,12,0.998
log10PFU,g,12,0.998
Cmax_unbound,nM,12,0.998
logK-IAMex,,12,0.998
LC30,ug ml-1,12,0.998
LC90,ug,12,0.998
Effect,mmHg,12,0.998
CLp,L.h-1.m-2,12,0.998
-log(1/AD50),,12,0.998
k,10e-3 min-1,12,0.998
LC50,ng,12,0.998
k cat/Kuncat,,12,0.998
LAD,,12,0.998
EC30,mgAi/L,12,0.998
L-T3,%,12,0.998
Concentration,% dose g-1,12,0.998
Conc_plasma,uM,12,0.998
Effect,pM (10e6*cells)-1,12,0.998
CL_renal,,12,0.998
Concentration,nM min-1 (mg of protein)-1,12,0.998
ED70,,12,0.998
pKabz,,12,0.998
pKapy,,12,0.998
Complete spontaneous reversal,,12,0.998
ERP (delta),%,12,0.998
%R,%,12,0.998
pSI,,12,0.998
Emesis,,12,0.998
Log PI,,12,0.998
Anticoagulant activity,uM,12,0.998
Viscosity,%,12,0.998
CC10,mg/L,12,0.998
DAP,,12,0.998
Serum TG,mg dl-1,12,0.998
Ki,10'-4/M,12,0.998
Log Ka,,12,0.998
IC90,ug well-1,12,0.998
C5a max,%,12,0.998
D50,uM,12,0.998
Amount of Ouabain used,,12,0.998
Slope of Schild plot,,12,0.998
Clp,,12,0.998
IC50H,nM,12,0.998
Specific activity,dpm,12,0.998
Spermatogenic index,,12,0.998
IC50,ug well-1,12,0.998
Stability,%ID,12,0.998
Stability,ng/ml,12,0.998
Static tumors,%,12,0.998
Vmax/Km,uL/mg/min,12,0.998
CQ,,12,0.998
Log 1/E100,,12,0.998
IC10,umol/L,12,0.998
TAC,%,12,0.998
CL,mg/ml/kg,12,0.998
Cmax,hr,12,0.998
T bound,ns,12,0.998
T free,ns,12,0.998
T/A,,12,0.998
T/C,mg kg-1 injection-1,12,0.998
IC35,nM,12,0.998
T1/2 increase,%,12,0.998
Ki,M-1 min-1,12,0.998
TVR,mmHg ml-1 min-1 g-1,12,0.998
AUC/dose,hr.microg/ml,12,0.998
TDI,uM,12,0.998
AUC normalised,((ug.h.ml-1)/(mg/kg),12,0.998
TI,TD50/MIC50,12,0.998
TLm,ug ml-1,12,0.998
Ct,pmol/ml,12,0.998
TOC ED50,M,12,0.998
TOX/TEST,,12,0.998
Vmax,10'-4deltaA/s,12,0.998
ED25,mM kg-1,12,0.999
LD50,uM/ml,12,0.999
AUC,g.hr,12,0.999
Brain penetration index,%,12,0.999
Activity,10'-2k/min,12,0.999
Ibuprofen,%,12,0.999
Ratio CC50/IC50,10'5No_unit,12,0.999
Bronchoalveolar lavages,,12,0.999
Logit bioavailability,,12,0.999
DNA single strand breaks,rad equiv,12,0.999
M50,%,12,0.999
Log [-7],,12,0.999
Log [-8],,12,0.999
C0,mg/L,12,0.999
Rise HR,%,12,0.999
Log [-6],,12,0.999
Ct,nmol/g,12,0.999
Relative Bioavailability,,12,0.999
Age,d,12,0.999
Activity,(ng of TXB2) (mg of protein)-1,12,0.999
Regiospecificity,,12,0.999
Relative growth,%,12,0.999
Acid output,u equiv of [H+] 2hr-1,12,0.999
INH,%/min,12,0.999
Relative intensity,,12,0.999
Log Pmw,,12,0.999
Log [-5],,12,0.999
DNA photo-crosslinking,,12,0.999
Residual contractile activity,,12,0.999
Relative binding potency,,12,0.999
Response,RU,12,0.999
Absorption,ng ml-1,12,0.999
Relative effect,,12,0.999
Kel,L/hr,12,0.999
Relativity,c.p.m. mg-1,12,0.999
INCC50,uM,12,0.999
SC,mg dl-1,12,0.999
Acetaldehyde,nM (mg of protein)-1,12,0.999
Reducing activity,%,12,0.999
MAC,mM,12,0.999
Relative inhibitor potency,,12,0.999
Ae,umol,12,0.999
Ratio IC50/EC50,uM,12,0.999
SBP decrease,%,12,0.999
DIZ,cm2,12,0.999
BsI,%,12,0.999
ED25,10'-5M,12,0.999
Vmax / Km,10^-9 L min-1,12,0.999
ASAT levels,IU/l,12,0.999
Weight gain or loss,%,12,0.999
LH concentration,mU ml-1,12,0.999
GT rate,,12,0.999
Vmax,pM hr-1,12,0.999
GPI,nM,12,0.999
GPGB tension,g,12,0.999
AUC,h·fmol/million cells,12,0.999
Vmax(app),%,12,0.999
Average activity,,12,0.999
[3H] TdR uptake,c.p.m.,12,0.999
Vmax/Km,pl/min,12,0.999
Vmax/Km,uL/min.mg,12,0.999
LD90,ng/ml,12,0.999
Volume,ml,12,0.999
Counts/30 min,,12,0.999
LD80,ug/mg,12,0.999
AUC,hr.sec,12,0.999
hSlo current,%,12,0.999
Falling,%,12,0.999
Log k'o,,12,0.999
deltaS,J/mol/K,12,0.999
MTD,(mg of CPT) kg-1,12,0.999
Log Phep,,12,0.999
av,,12,0.999
cAMP content,pmol/mg protein,12,0.999
Formaldehyde,nM (mg of protein)-1,12,0.999
Control growth,,12,0.999
Average colony count,,12,0.999
LD20,mg/ml,12,0.999
ALAT levels,IU/l,12,0.999
Fe removed,%,12,0.999
alphaKi,nM,12,0.999
EC20,ng ml-1,12,0.999
Cmax normalised,(ug/ml)/(mg/kg),12,0.999
AH interval,ms,12,0.999
AH interval,,12,0.999
Average No. of metastasis,,12,0.999
Cmax(app),uM,12,0.999
Fecal recovery,%,12,0.999
Log K,M-1,12,0.999
EC50,10^3nM,12,0.999
Analgesic response,,12,0.999
Activity,no. of living cells (10E3) /mL,12,0.999
Activity,ucat/L,12,0.999
Peff,10^-7 cm/s,12,0.999
Activity,log CFU,12,0.999
Myristoylpeptide,%,12,0.999
Phosphorolysis,,12,0.999
Potency vs EKC,,12,0.999
Protonated,%,12,0.999
Activity,10e-4 K s-1,12,0.999
Change in MST,,12,0.999
Protective activity,%,12,0.999
Iron excretion,ug kg-1,12,0.999
Mean relative surviving fraction,,12,0.999
MDL,day,12,0.999
ME increase,nM min-1 mg-1,12,0.999
Neostigmine reversal,,12,0.999
Bmax,fM assay-1,12,0.999
Progressed tumors,%,12,0.999
Baseline,,12,0.999
MIC98,uM,12,0.999
MES/TEST,,12,0.999
Peak current,%,12,0.999
Peak concentration,ug ml-1,12,0.999
Kcat,10'-1/s,12,0.999
Ka,10^-6M,12,0.999
K+ excretion,m equiv 5hr-1 kg-1,12,0.999
PC50,,12,0.999
Adduct formation,,12,0.999
Activity,nM stent-1,12,0.999
Mean duration,min,12,0.999
NRD,mg/kg/day,12,0.999
Metabolic rate,pM min-1 (mg of protein)-1,12,0.999
Min concentration,ug ml-1,12,0.999
N/T,,12,0.999
Drug uptake,PSL/mm2,12,0.999
Platelet aggregation,,12,0.999
Plasma lipid level,mg dl-1,12,0.999
Drug metabolism,%molar,12,0.999
Activity,uU/ml,12,0.999
Plasma levels,ug ml-1,12,0.999
Plasma corticosterone,ng ml-1,12,0.999
Mortality range,day,12,0.999
PL-017 shift,,12,0.999
KSV,L/mol,12,0.999
Activity remaning,%,12,0.999
Na+ excretion,m equiv 5hr-1 kg-1,12,0.999
Diuretic activity,m equiv [Na+] 5hr-1kg-1,12,0.999
No. of mice protected/tested,,12,0.999
K 0.5,uM,12,0.999
O2 production,%,12,0.999
MAO deamination,%,12,0.999
Rate of decomposition,,12,0.999
No. of pits,,12,0.999
Change in cell number,%,12,0.999
Activity,Torr,12,0.999
Infarct volume,mm**3,12,0.999
Kapp,,12,0.999
Drug metabolism,ug/L,12,0.999
K app x10e-7,M-1,12,0.999
Activity,cm/min,12,0.999
Ratio,/s/microM,12,0.999
Adjuvant activity,,12,0.999
K L,,12,0.999
OD,/hr,12,0.999
Kq,10'5/M,12,0.999
Macrophage activation,,12,0.999
Kd2,nM,12,0.999
Optimal dose,%,12,0.999
Rate,beats min-1,12,0.999
Cell cycle fraction,%,12,0.999
KSV,10^5/M,12,0.999
Mean value,,12,0.999
Activity,AUC units,12,0.999
Potencymean,ng g-1,12,0.999
Kb app,uM,12,0.999
Activity,uM min-1 mg-1,12,0.999
Kcat/Km,10^4/M/s,12,0.999
MIC>90,,12,0.999
Dopamine level,ng mg-1,12,0.999
Kapp,10'-7/M,12,0.999
Activity,cm s-1,12,0.999
OSAV,%,12,0.999
Activity,10'-8M,12,0.999
Rate,ka/Ks,12,0.999
K diss,s-1,12,0.999
ED,ug/kg,12,0.999
Cholestrol levels,g l-1,12,0.999
Max intensity,,12,0.999
Observed at,ug ml-1,12,0.999
Activity,micrometer,12,0.999
AUDPC,,12,0.999
AUC,pM ml-1,12,0.999
Thyroid status,nM l-1,12,0.999
Time in flight,%,12,0.999
Tissue concentration,uM,12,0.999
Tmin,hr,12,0.999
Total,%,12,0.999
Total acid output,%,12,0.999
CFU,10^8/ml,12,0.999
CFU,10^9/ml,12,0.999
Crop_yield,%,12,0.999
Transacylation rate,,12,0.999
HbS solubilized,%,12,0.999
Tubulin polymerization,%,12,0.999
HV interval,,12,0.999
Tumor cure,%,12,0.999
HR(delta),%,12,0.999
Kic,,12,0.999
Tumor/blood ratio,,12,0.999
CITH,,12,0.999
UR,,12,0.999
Unchanged tracer,%,12,0.999
VI30,%,12,0.999
V0,microM/s,12,0.999
Activity,M min-1 (M of enzyme)-1,12,0.999
Lesion length,mm rat-1,12,0.999
Urinary level,mg,12,0.999
Urinary volume,ml kg-1 5hr-1,12,0.999
Urine,ml,12,0.999
Urine K+,m equiv,12,0.999
Urine Na+,m equiv,12,0.999
Urine volume,,12,0.999
Cmax,ngequiv/g,12,0.999
EC,uM 15min-1 mg-1,12,0.999
Cp,ug base equiv/g,12,0.999
Vaginal activity,,12,0.999
Latency,min,12,0.999
Catalyptic action,,12,0.999
LambdaZ,/hr,12,0.999
Cmax,pmol/g,12,0.999
LV dP/dTmax(delta),%,12,0.999
Cp,nmol/L,12,0.999
UB,,12,0.999
Threshold active dose,mg kg-1,12,0.999
Tumor/liver ratio,,12,0.999
QT,ms,12,0.999
Drug metabolism,pM,12,0.999
QH,L/hr/kg,12,0.999
Max. activation,%,12,0.999
Max release,%,12,0.999
Activity,10'-9PFU/ml,12,0.999
RVmax,,12,0.999
Osmolality,mOsmol kg-1,12,0.999
Activity,10'3/cm2,12,0.999
Drug metabolism,pmol/ml,12,0.999
RPP,mmHg beats min-1,12,0.999
Activity,pmol/s,12,0.999
K obs / 1 1/Ms,,12,0.999
Kb,10'3L/mol,12,0.999
Degranulating activity,,12,0.999
Activity,10'5/cm'3,12,0.999
Dose (urinary recovery),%,12,0.999
RH/RL,,12,0.999
Mean tumor volume,cm*3,12,0.999
Activity,micromol/s,12,0.999
Mean day of death for total dead,,12,0.999
Ka,10^4/Ms,12,0.999
MHC,mg/ml,12,0.999
No. of animals with damage,,12,0.999
K,10^4/Ms,12,0.999
PDC,,12,0.999
K-1 decrease,%,12,0.999
Mean,pM mg-1,12,0.999
Ka,10'4/Ms,12,0.999
MFI,,12,0.999
MIC80,%v/v,12,0.999
MNTD70,uM,12,0.999
Change,hr,12,0.999
No. of animals protected/number of animals tested,,12,0.999
Activity,fmol/g,12,0.999
Intensity of erythemia,,12,0.999
Activity,KA,12,0.999
No. of animals alive,,12,0.999
Activity,mg m-1,12,0.999
Quantity,pM mg-1,12,0.999
QTc delta,%,12,0.999
RAP,,12,0.999
ID50,nM (mg SR protein)-1,11,0.999
T-cell binding,%,11,0.999
Kel,,11,0.999
AUC/dose,ng/mL.hr,11,0.999
Rotorod,,11,0.999
Rating,beats min-1,11,0.999
Kq,10^13L/mol/s,11,0.999
AUC/dose,ng.hr/ml/mg,11,0.999
Log 1/delta/Ca,,11,0.999
T1/29,min,11,0.999
pFe3,,11,0.999
SBP change,%,11,0.999
Ca2+ flux,,11,0.999
AUClast/dose,nM.hr,11,0.999
MED99,MKP,11,0.999
Activity,millimeter/sec,11,0.999
MED90,MKP,11,0.999
Cells arrested,%,11,0.999
10E2 k1,min-1,11,0.999
Phosphor,%,11,0.999
Phosphorolysis,%,11,0.999
S/T,,11,0.999
AUCED90,ug.hr/ml/day,11,0.999
Delta mmHg,,11,0.999
Activity,10'-6mg/kg,11,0.999
Change of predose,%,11,0.999
AUMC,ug/ml.hr^2,11,0.999
ICL50,uM,11,0.999
Serum level,ug dl-1,11,0.999
rK,,11,0.999
"pKa,1",,11,0.999
"pKa,2",,11,0.999
General activity,,11,0.999
MAC,mg/L,11,0.999
Vmax,deltaA/min,11,0.999
Drug period,hr,11,0.999
Apoptotic index,,11,0.999
Vmax,AU/min,11,0.999
No. of rats with 5-HT syndrome,,11,0.999
Kcat(app),/s,11,0.999
EC50,ng/g,11,0.999
CL,microM/min/mg,11,0.999
K,10'-5/M/s,11,0.999
Brain/Plasma,,11,0.999
AUC,microM/L.hr,11,0.999
No. of mice alive,,11,0.999
Vmax,pmol/uM/min,11,0.999
Vmax / Km,mM-1 min-1,11,0.999
AHV,%,11,0.999
Vmax,10^4M,11,0.999
7-day weight change,%,11,0.999
Log Pion,,11,0.999
ED50,ug min-1 kg-1,11,0.999
Clp,ml min-1,11,0.999
pI50,M,11,0.999
Ratio Ki,10^-4No_unit,11,0.999
Activity,10'-3M,11,0.999
Drug metabolism,ppm,11,0.999
Substrate specificity,,11,0.999
EC50,ug.cm'-2,11,0.999
ED60,mg kg-1,11,0.999
Max delta BP,mmHg,11,0.999
Plasma level,pg ml-1,11,0.999
SC200,nM,11,0.999
Stability,uL/mg/min,11,0.999
Platelet count,ul,11,0.999
Protein interaction energy,kCal M-1,11,0.999
% of effect,%,11,0.999
Prolonged ARP,%,11,0.999
Log 1/ISA,,11,0.999
TI50,uM,11,0.999
Log geometric mean,pfu mg-1,11,0.999
TD100,uM,11,0.999
Max.stimulation,%,11,0.999
2aPTT,nM,11,0.999
2x TT,uM,11,0.999
IC10,ng ml-1,11,0.999
AUCt,ug/g.min,11,0.999
IC10,nM,11,0.999
CD90,,11,0.999
K,10^-4/M,11,0.999
Kdiss,10'-5/s,11,0.999
Activity,uM/micrometer/s,11,0.999
Ca2+,mM l-1,11,0.999
CLH,nmol/min,11,0.999
Arthritis scores,,11,0.999
Cells,,11,0.999
K,10^-5/M,11,0.999
Papp,10'-2 cm/s,11,0.999
Pe,10e-6 cm s-1,11,0.999
Papp,10-6 cm/s,11,0.999
Average weight gain,g,11,0.999
log10cfu,/ml,11,0.999
Max suppression,%,11,0.999
Log 1/Kd,,11,0.999
CLu/F,L/hr/kg,11,0.999
Aberrant cells,%,11,0.999
Delta Ca,mM,11,0.999
TG,,11,0.999
Maximum Tmax,h,11,0.999
Kcat,10^6/s,11,0.999
Ca2+ binding protein,ug (100mg of duodenum)-1,11,0.999
Enhancement,uM,11,0.999
Papp,10'-6cm/min,11,0.999
IC50,umol/Kg,11,0.999
Log P',,11,0.999
Ratio,M/s,11,0.999
Activity,mm3/day,11,0.999
ED30,nmol/Kg,11,0.999
Alkylating activity,,11,0.999
Drugexcretion,ug,11,0.999
MTD,mg/L,11,0.999
Selective index,,11,0.999
Activity,10'7log10CFU/ml,11,0.999
Bmax,cpm,11,0.999
Psychotropic Effect,,11,0.999
AUCt,ng/ml,11,0.999
SF50,uM,11,0.999
IC50,ug/mol,11,0.999
%hepatic blood flow,%,11,0.999
Inflammation units,,11,0.999
%T>MIC,%,11,0.999
Change of size,%,11,0.999
Max CF response,,11,0.999
D/P,,11,0.999
Collapse time,s,11,0.999
K,1/M.sec,11,0.999
Ks,,11,0.999
Ca2+ elevation,nM,11,0.999
ED100,mg/kg/day,11,0.999
ED80,mg,11,0.999
Atttacks,%,11,0.999
CT10 ratio,air/N2,11,0.999
Blood AcH,uM,11,0.999
Active dose range,mg uM  kg-1 day-1,11,0.999
TI,hr-1,11,0.999
Relative cytotoxicity,,11,0.999
Ileal activity,,11,0.999
KiA,uM,11,0.999
Translation,,11,0.999
AUC,uM h/mpk,11,0.999
AUC,uM hr l-1,11,0.999
Release,,11,0.999
Exclusion parameter,,11,0.999
ABBC,log10CFU/ml/hr,11,0.999
Tubulin polymerization,,11,0.999
ClC95,nM,11,0.999
Activity,KgAi/ha,11,0.999
Kn,M-1,11,0.999
Relative rate metabolism,,11,0.999
KmL,uM,11,0.999
Binding site fraction,,11,0.999
Hind-paw lick latency time,s,11,0.999
Mean rate constant,,11,0.999
CGI,,11,0.999
K,10^6/Ms,11,0.999
Tumor cure,,11,0.999
Tox50,ug ml-1,11,0.999
Ca2+,%,11,0.999
Resorbing implants,%,11,0.999
Tolerance,,11,0.999
Kb,L/mol,11,0.999
Tmax,uM,11,0.999
K,M/s,11,0.999
LC50,ppb,11,0.999
Extent,,11,0.999
Hgb levels,g dl-1,11,0.999
Others,,11,0.999
KiL,uM,11,0.999
Tlast,min,11,0.999
E2,%,11,0.999
Diuresis,ml kg-1,11,0.999
AD50,nM mouse-1,11,0.999
Mean volume of hind paws,,11,0.999
K',abs/time,11,0.999
Activity,uA.cm'-2,11,0.999
Ulceration,%,11,0.999
Med tumor area,mm**2,11,0.999
AbsAC0.47_uM,uM,11,0.999
Activity,IU/g,11,0.999
AUC,ngequiv.hr/g,11,0.999
A2,nM,11,0.999
Untreated control,%,11,0.999
CLH,ml/(min.mg),11,0.999
Log,%,11,0.999
Response,min-1,11,0.999
Distribution ratio,,11,0.999
Agonist effect,%,11,0.999
ED20,nM,11,0.999
Ki',,11,0.999
MI50,,11,0.999
log1/CMC,,11,0.999
Mean tumor volume,,11,0.999
KPCB,M-1,11,0.999
Ratio_EC50,,11,0.999
CT,,11,0.999
HAR,,11,0.999
Kii,mM,11,0.999
AUC,ng.hr/ml/mg,11,0.999
Degradation ratio,,11,0.999
Drug metabolism,10'-5/s,11,0.999
kHO,M-1 s-1,11,0.999
INH,/M/s,11,0.999
BGL,%,11,0.999
CPE50,ug ml-1,11,0.999
Lesion frequency,%,11,0.999
K,microM/min,11,0.999
K1,10e-3 min-1,11,0.999
Relative inhibitory activity,,11,0.999
MIC,pug ml-1,11,0.999
No. of vomiting episodes,,11,0.999
K''IAM,,11,0.999
No. of implants/pregnancy,,11,0.999
fAUC/dose,microg.hr/mL,11,0.999
IPA,,11,0.999
KA,,11,0.999
Relative agonist activity,,11,0.999
[A],uM,11,0.999
G Index,,11,0.999
[EA],uM,11,0.999
KA,10'7/M,11,0.999
Control period,,11,0.999
Km,10^4M,11,0.999
K cat,1/S,11,0.999
FR10 treated,,11,0.999
Ki slope,uM,11,0.999
FR10 control,,11,0.999
Minimum Tmax,h,11,0.999
Kcat/Km,/min/M,11,0.999
KIs,M,11,0.999
Vbeta,l,11,0.999
Vasodilatory rate,%,11,0.999
Relative phosphorylation,,11,0.999
Vascular relaxation,%,11,0.999
Ke,/hr,11,0.999
EC25,mM,11,0.999
LC90,mg/ml,11,0.999
Cell Proliferation EC70,uM,11,0.999
Glucose,%,11,0.999
Change in No. of trophozoites x 10E-5,,11,0.999
AUC,mmHg.hr,11,0.999
Fu,ng/g,11,0.999
CT10,,11,0.999
VFT,mA,11,0.999
dP/dt,,11,0.999
Counts,min-1,11,0.999
Relative agonistic activity,,11,0.999
ND,mg kg-1,11,0.999
K-1,min-1,11,0.999
Count,,11,0.999
Fluoroscence,%,11,0.999
No. of dead animals,,11,0.999
Fluorescence intensity,%,11,0.999
Low,%,11,0.999
Mice with lesions,,11,0.999
f(Cave),uM,11,0.999
Vss,,11,0.999
Kd,um2/s,11,0.999
Vp/F,l,11,0.999
NOEL,mg kg-1,11,0.999
amount in urine,%,11,0.999
cAMP production,pM min-1 mg-1,11,0.999
LD90,g/ha,11,0.999
Inhibition activity,,11,0.999
cAMP,pM well-1,11,0.999
Free,,11,0.999
Binding affinity,spec bound mg-1,11,0.999
ED20,gAi,11,0.999
Activity,pM of citrulline min-1 (mg of protein)-1,11,0.999
EC15,,11,0.999
Decrease in heart rate,beats min-1,11,0.999
Relative concentration,,11,0.999
LD90,mg/L,11,0.999
Cytotoxicity index,,10,0.999
CC50,10^1 uM,10,0.999
K,10'-9M,10,0.999
Pka,,10,0.999
Amount of metabolite,nM ml-1,10,0.999
Phosphorylating activity,pM min-1 assay-1,10,0.999
Survivors / total,%,10,0.999
R%,,10,0.999
Cytoplasmic vacuolization,,10,0.999
K,10'3/mol,10,0.999
Post drug blood pressure,mmHg,10,0.999
Delta RBF,%,10,0.999
Post Antibiotic Effe,hr,10,0.999
Serum cholesterol,mg %,10,0.999
Jss,nM hr-1 cm**-2,10,0.999
ED100,mg kg-1 day-1,10,0.999
ST,min,10,0.999
Clonazepam,%,10,0.999
Iron mobilization,%,10,0.999
Log P16,,10,0.999
B,%,10,0.999
D,10^-7cm2/sec,10,0.999
Suppression of parasitemia,%,10,0.999
Substrate metabolized at 1hr,%,10,0.999
O2 consumption,%,10,0.999
Log TCID50/mg,,10,0.999
PB,pmolequiv/mg,10,0.999
Log,k,10,0.999
Transactivation,fold,10,0.999
Amount,pM (10e6*cells)-1,10,0.999
AUClast/dose,ng.hr/ml/mg/kg,10,0.999
AUClast/dose,hr.ng/ml,10,0.999
Stability,mmol/min,10,0.999
Stability,nM/min,10,0.999
Drug uptake,pmol/mg/min,10,0.999
Stability,ppm,10,0.999
IC50,mmol/Kg,10,0.999
Ki,10^3nM,10,0.999
Substrate,uM,10,0.999
ED37,uM,10,0.999
MED,umol/Kg,10,0.999
Delta coronary flow,,10,0.999
Delta heart rate,,10,0.999
Alpha-lipoprotein cholesterol,mg dl-1,10,0.999
Analgesic efficacy compared to morphine,%,10,0.999
Bmax,disintegrations/minute,10,0.999
Serum total cholesterol,mg dl-1,10,0.999
C10 N2,uM,10,0.999
MFC99.5,,10,0.999
DNA alkylation,%,10,0.999
Log 1/E50,,10,0.999
TTO,min,10,0.999
MFC>99,ug ml-1,10,0.999
Activity,Counts 30min-1,10,0.999
PKa2,,10,0.999
PKa1,,10,0.999
Log k GSH (s-1),,10,0.999
AUC,umol/L,10,0.999
Response unit,umol/L,10,0.999
Time constant T4,,10,0.999
Horizontal screen,number passed,10,0.999
K21,hr-1,10,0.999
AUC,ug.ml-1,10,0.999
Activity,KA Units,10,0.999
Tissue/Plasma Ratio,,10,0.999
Decrease in mean arterial pressure,%,10,0.999
Intensity,%,10,0.999
Activity,ug mouse-1,10,0.999
K,10^7/M/s,10,0.999
CA activity,%,10,0.999
Ki,10'1/M,10,0.999
Si,,10,0.999
C20,,10,0.999
Activity,pmol/uL,10,0.999
Sigmap,,10,0.999
Activity,um2/s,10,0.999
D50,quanta*10e-18,10,0.999
CA,%,10,0.999
Amount,%,10,0.999
MEC,mg/ml,10,0.999
Intrinsic actvity,,10,0.999
Specific binding,fM mg-1,10,0.999
Spleen weight,g,10,0.999
Spleen weight,mg,10,0.999
Delta LV,,10,0.999
Drug uptake,nmol/hr,10,0.999
Delta MABP,%,10,0.999
MED,nM,10,0.999
GMS activity,,10,0.999
K Bapp,uM,10,0.999
Vmax,uM min-1 g-1,10,0.999
Tumor weight,,10,0.999
Occ50,ng/g,10,0.999
Inhibitory potential,,10,0.999
Tumor half growth,,10,0.999
Onset,min,10,0.999
INH,10'-4 mol/L,10,0.999
ED50,U ml-1,10,0.999
Relative seminal vesicle weight,,10,0.999
DNA unwinding concentration,uM,10,0.999
INH,10'-5 mol/L,10,0.999
Oxygen uptake,nM min-1,10,0.999
MBC99.5,,10,0.999
Level,ug of tissue,10,0.999
Uptake selectivity,,10,0.999
Brain concentration,nM kg-1,10,0.999
K ass,,10,0.999
Body weight In. / Fi.,g,10,0.999
Vss,L.m-2,10,0.999
CL,ml/min/m2,10,0.999
Radioactivity level,%,10,0.999
ED 50,uM,10,0.999
Distribution percent,,10,0.999
Vmax,pmol.min.mg-1,10,0.999
HD50,umol/L,10,0.999
ED25,nM,10,0.999
HV interval,ms,10,0.999
Triglyceride level,mg dl-1,10,0.999
Initial mean arterial pressure,mmHg,10,0.999
P50d/P50c,mmHg,10,0.999
VRT,hr2,10,0.999
HA release,,10,0.999
V0,pmol/min,10,0.999
Acid output,u equiv hr-1,10,0.999
Growth rate,%,10,0.999
CI,mg/kg uM h,10,0.999
Residual activity,c.p.m.,10,0.999
RD1000,mg kg-1,10,0.999
Cp(T),ng/ml,10,0.999
Uterotropic activity,,10,0.999
Kd,10^6/M,10,0.999
Accumulation,ug ml-1,10,0.999
HMGR activity,,10,0.999
Log sensitivity,,10,0.999
Kcat,10^-4/s,10,0.999
Inhibition effect,,10,0.999
Kdiss,10^3/M/s,10,0.999
Average latency,%,10,0.999
Drugabsorption,nM,10,0.999
BK,,10,0.999
Relative ionotropic activity,,10,0.999
Cp,ngequiv/ml,10,0.999
Change in body weight,g,10,0.999
Heart weight,mg 10g-1,10,0.999
Vmax,10'5mmol/min/mg,10,0.999
No. of untreated cells,%,10,0.999
No. of tumors/mouse,,10,0.999
Gellar cook activity,,10,0.999
Vmax,IU mg-1,10,0.999
Gastric lesion score,mM,10,0.999
Relative influx,,10,0.999
Vmax,U/ms,10,0.999
GTPase Activity,,10,0.999
MIC,ug m1 l-1,10,0.999
Inhibition type,,10,0.999
Vmax,nmol/mg,10,0.999
CMpH,,10,0.999
Catalepsy score,,10,0.999
CT10,uM,10,0.999
INH,mole fraction,10,0.999
K13+K23,hr-1,10,0.999
Activity,fM ml-1,10,0.999
Writhes,,10,0.999
Z,%,10,0.999
Vmax/Km,10'6/min,10,0.999
CL,nmol/mg/min,10,0.999
Activity,pM of cGMP (min)-1 (mg of protein)-1,10,0.999
Dose/g tissue,%,10,0.999
K12,hr-1,10,0.999
Function,,10,0.999
INH,ng/ml,10,0.999
[I] for Km',uM,10,0.999
ED50,mg/m2,10,0.999
EC>90,nM,10,0.999
C/I,,10,0.999
Relative activity,c.p.m.,10,0.999
APTT,ug ml-1,10,0.999
Dose per organ,%,10,0.999
LD99,mg/ml,10,0.999
Liver weight,mg 10g-1,10,0.999
Parasitemia clearance after immunosuppression,%,10,0.999
AUC,uM min l-1,10,0.999
Mice,%,10,0.999
k3,min-1,10,0.999
lnK,,10,0.999
Cellular uptake,uCi ml-1,10,0.999
EC50,M 50ul-1,10,0.999
% bound,none,10,0.999
Arterial pressure,% mmHg min,10,0.999
rb,,10,0.999
NOAEL,,10,0.999
Fold activation,uM,10,0.999
Cellular uptake,pCi cell-1,10,0.999
rIC50,nM,10,0.999
Mean graft survival,day,10,0.999
Antiviral activity,nM,10,0.999
Kapp,10^5/M,10,0.999
Activity,nM.min,10,0.999
MTT,s,10,0.999
Inflection point,,10,0.999
A50,nM,10,0.999
Concentration,uCi ml-1,10,0.999
Mice,,10,0.999
pC25,uM kg-1,10,0.999
Km',uM,10,0.999
k2c,min-1,10,0.999
Kp,cm hr-1,10,0.999
ACT,uM,10,0.999
Emax,fmol/mg,10,0.999
Average,uM,10,0.999
Max reduction in mean arterial pressure,mmHg,10,0.999
KD1,uM,10,0.999
Concentration,nM min ml-1,10,0.999
k3/k1,M-1 s-1,10,0.999
Rating,hr,10,0.999
M-agonist index,,10,0.999
Efflux Ki,min-1,10,0.999
Kp,10^-3cm/min,10,0.999
Max tolerated dose,mg kg-1 day-1,10,0.999
pC30,,10,0.999
Aqueous solubility,,10,0.999
kA-,M-1 s-1,10,0.999
Kd2,uM,10,0.999
Recovery,min,10,0.999
Mice In. / Fi.,,10,0.999
Mean increased life span,%,10,0.999
Fold shift,,10,0.999
permeability,ng/uL,10,0.999
Drug uptake,a.u.,10,0.999
Rel potency,,10,0.999
MAC reduction,%,10,0.999
CL_Ratio,%,10,0.999
% of growth rate,%,10,0.999
Activity,nM min-1 ml-1,10,0.999
Activity,millipolarization,10,0.999
Drug metabolism,nmol/ml,10,0.999
Induced convulsion,number convulsed,10,0.999
Drug metabolism,ml/min/g,10,0.999
Emesis_Cmax,uM,10,0.999
permeability,10'-6cm/min,10,0.999
Mean inhibition,%,10,0.999
ED99,mg/kg/day,10,0.999
cAMP increase,%,10,0.999
Ka,10'5/s/M,10,0.999
permeability,day,10,0.999
CLblood,mL/min/kg,10,0.999
A50,mg kg-1,10,0.999
Liver weight,g 100g-1,10,0.999
CL/F,,10,0.999
A50,,10,0.999
MyristoylCoA,%,10,0.999
60-day survivors,,10,0.999
EC50,ug/g,10,0.999
MTD,mM,10,0.999
cKi,nM,10,0.999
clogP-logP,,10,0.999
log2(ratio),,10,0.999
Kq,10'4/M,10,0.999
A/Ad,,10,0.999
LD50,10'-4M,10,0.999
Active/total,,10,0.999
BAT weight,g,10,0.999
CTP,mg/L.hr,10,0.999
Mean effect,mg,10,0.999
logCMC,,10,0.999
NTD,mg kg-1,10,0.999
Relative ability,,10,0.999
Kcat,10'-2/s,10,0.999
permeability,ml/min,10,0.999
Concentration_Plasma,nM ml-1,10,0.999
kinact,s-1,10,0.999
CLH,ng/ml,10,0.999
Concentration,nM ml-1,10,0.999
Concentration,pmol/10E6 cells,10,0.999
Parasitemia clearance after treatment,%,10,0.999
CPM x1000,,10,0.999
Parasite suppression,%,10,0.999
Ctt2,uM,10,0.999
Rice stem length,cm,10,0.999
K,10'8/M/s,10,0.999
Log 1/GI50,,10,0.999
IAR,,10,0.999
TGI50,mg kg-1,10,0.999
Analgesic efficacy compared to epibatidine,%,10,0.999
K,10^-1/min,10,0.999
Activity,10'6No_unit,10,0.999
I50,ug,10,0.999
Activity,AU.min,10,0.999
Frel,,10,0.999
Binding activity,uM,10,0.999
Max fall in IOP,mmHg,10,0.999
Cell toxicity,uM,10,0.999
pI,,10,0.999
DeltaTC,,10,0.999
R50,uM,10,0.999
TCID50,,10,0.999
DNA alkylation,,10,0.999
Km x10e3,hr-1,10,0.999
PCR cure rate,%,10,0.999
Kcat/Km,10'3/s/M,10,0.999
Tp,,10,0.999
Transacetylation rate,nM/mg*min,10,0.999
TOC ED50,,10,0.999
PTZ,,10,0.999
TMSW,%,10,0.999
ED5,ug,10,0.999
TC50,10'4nM,10,0.999
K,10'4No_unit,10,0.999
R/S ratio,,10,0.999
METD,%,10,0.999
T>MIC90,hr,10,0.999
ID50,quanta,10,0.999
AUC/dose,nM.hr/mg,10,0.999
TC25,ug ml-1,10,0.999
BBC50,uM,10,0.999
pH1/2,,10,0.999
TD50,ng/ml,10,0.999
Kbapp,mM,10,0.999
Drug uptake,10^-2microM,10,0.999
Induction number,,10,0.999
Kd1,uM,10,0.999
Activity,10'-2/min,10,0.999
k cat/Km,uM-1 s-1,10,0.999
-Log alpha,,10,0.999
Activity,mg/dl/g,10,0.999
Maximal decrease in IOP,,10,0.999
EC80,nM,10,0.999
MNTD,ug,10,0.999
CLH,ug/(min.mg),10,0.999
LC50,ug/sq.cm,10,0.999
Max protection,%,10,0.999
FC,10'5No_unit,10,0.999
Carboxylase activity,dpm,10,0.999
MNCC,,10,0.999
Emax,log10CFU/ml,10,0.999
Ae,,10,0.999
k'/k'+1,,10,0.999
kAH,M-1 s-1,10,0.999
FT50,hr,10,0.999
Kb,/M,10,0.999
k2 / Ki,M-1 s-1,10,0.999
M.A.D,ug kg-1,10,0.999
k'o,M-1 s-1,10,0.999
CL/F,L/min,10,0.999
k/K,M-1 s-1,10,0.999
Infected erythrocytes,%,10,0.999
Min lethal dose,mg kg-1,10,0.999
LC80,,10,0.999
Activity,mU m l-1,10,0.999
k2',M-1 min-1,10,0.999
Max vasoconstriction,,10,0.999
ED50,ug day-1 kg-1,10,0.999
Max delta HR,%,10,0.999
Km,10'5mM,10,0.999
Induction,%,10,0.999
A50,ug,10,0.999
Rate max,,10,0.999
KD2,uM,10,0.999
MA,,10,0.999
FaFg,%,10,0.999
Control tumor volume,,9,0.999
Fold_reduction,,9,0.999
APD70,ms,9,0.999
Formation,,9,0.999
dP/dt max,mmHg s-1,9,0.999
Creatinine_CL,ml min-1 kg-1,9,0.999
[LDH]max,UI l-1,9,0.999
[ALP]max,UI l-1,9,0.999
AP,mV,9,0.999
AT1 affinity,nM l-1,9,0.999
deltaG,cal/mol,9,0.999
Toxic/total,,9,0.999
Control death day,,9,0.999
Fold reduction,,9,0.999
Gastriculcer index,,9,0.999
CL,ul.min.nmol-1,9,0.999
Geometric mean,M,9,0.999
Vehicle control,%,9,0.999
Cmax,ng/kg,9,0.999
Hemolysis,,9,0.999
Total peripheral resistance,mmHg ml-1 min-1,9,0.999
Weight change at nadir,%,9,0.999
Corpora lutea,,9,0.999
Onset seizure,,9,0.999
Vz/F,ml,9,0.999
Volume of urine,ml,9,0.999
ODC activity,(nM of CO2) hr-1 (mg of protein)-1,9,0.999
ED50,10'-8mol/cm2,9,0.999
Occ50,mg Kg-1,9,0.999
Onset time,min,9,0.999
K A,M-1,9,0.999
Distribution,l kg-1,9,0.999
Oral duration,hr,9,0.999
K,L/mol/s,9,0.999
Activity,M kg-1,9,0.999
K,10^7/M,9,0.999
Periosteal mineralizing surface,%,9,0.999
Binding competition,%,9,0.999
ED30,mM,9,0.999
Activity,10'5log10CFU/ml,9,0.999
AUC,micromol.hr/L/mg/kg,9,0.999
Vmax,uM hr-1 mg-1,9,0.999
Vmax,uM/min,9,0.999
Vmax,umol/mg/min,9,0.999
Vmax(app),M/min,9,0.999
Vmax(app),mM/min,9,0.999
VmaxH,pmol/min,9,0.999
AUC,uM L,9,0.999
deltaS,cal/mol,9,0.999
ED50,10'-9 ug/ml,9,0.999
Tumor free survivors,,9,0.999
logPi,,9,0.999
Emax,ug,9,0.999
pA2,%,9,0.999
Emax,hr,9,0.999
Eicosanoid production,pM 2hr-1,9,0.999
ED6,,9,0.999
pKa5,,9,0.999
ERH,min,9,0.999
pMLD,,9,0.999
ED97,mg kg-1,9,0.999
permeability,mole fraction,9,0.999
ED80,umol/Kg,9,0.999
selectivity,,9,0.999
solubility,mg kg-1,9,0.999
t1/2lambda,hr,9,0.999
tz,hr,9,0.999
Concentration,ug ml-1 ml-1,9,0.999
CLH,ml/kg,9,0.999
ABC,mmHg hr-1,9,0.999
Flaking score,,9,0.999
NonRGS-EC50 (uM),uM,9,0.999
2x aPPT,uM,9,0.999
logMEC,,9,0.999
Cmax/dose,ng/mL/(mg/kg),9,0.999
Vasodilation,,9,0.999
Cp/dose,nM,9,0.999
HR,delta beats min-1,9,0.999
HHP,mg,9,0.999
Unwinding,,9,0.999
Urine output,ml kg-1,9,0.999
HC30,ug ml-1,9,0.999
ED50,fmol,9,0.999
Vascular accumulation ratio,,9,0.999
CL,mL/min,9,0.999
Vd,kg-1,9,0.999
Endosteal eroded surface,%,9,0.999
AUC,nM.hr/L,9,0.999
COF,c.p.m. (mg of protein)-1,9,0.999
Vdss/dose,L/Kg,9,0.999
Glucuronidation,nmol/min/mg,9,0.999
Total activity,,9,0.999
CL free,10^3uL/min,9,0.999
Cmax,ugequiv/g,9,0.999
logI50,,9,0.999
Endosteal mineralizing surface,%,9,0.999
OD max,mg,9,0.999
Production,ng 2hr-1,9,0.999
No. pregnant/mated,,9,0.999
Marrow area,mM,9,0.999
Min ED,mg kg-1,9,0.999
KL,uM,9,0.999
Minimum single dose,mg kg-1,9,0.999
Mortality number,,9,0.999
Motor activity,Counts,9,0.999
Mu/delta ratio,,9,0.999
Mutation frequency,,9,0.999
Median,day,9,0.999
NADH oxidation,nM min-1,9,0.999
KA,10^3/M,9,0.999
Na,uM,9,0.999
Na+ inactivation,,9,0.999
Na+ output,uM kg-1,9,0.999
Na+ restoration,%,9,0.999
K2,1/M*s,9,0.999
ECAUC0.2,,9,0.999
No. of animals,%,9,0.999
Activity,gAi/ha,9,0.999
K+ output,uM kg-1,9,0.999
KT4,M-1,9,0.999
Change TC,,9,0.999
KSV,10'3L/mol,9,0.999
Peak effect,,9,0.999
Kq,10^12/M,9,0.999
Chelator,%,9,0.999
Activity,10^2CFU,9,0.999
K,10'3L/mol,9,0.999
Potency,MU,9,0.999
K,/nM/s,9,0.999
Primary response,,9,0.999
Pregnant,%,9,0.999
Activity,10^-6No_unit,9,0.999
AHA,delta mmHg,9,0.999
Postdrug,ug kg-1,9,0.999
K,1/M,9,0.999
Pt,cm s-1,9,0.999
Propioaldehyde generated,uM,9,0.999
K,10'2/M/s,9,0.999
RBA,h/min,9,0.999
Ionotropic activity,,9,0.999
Predrug,ug kg-1,9,0.999
K,10'-1/s,9,0.999
K,/ms,9,0.999
Permeated,%,9,0.999
Permeability coefficient,,9,0.999
MTS50,ug ml-1,9,0.999
Max binding,%,9,0.999
No. partial,,9,0.999
Max blood pressure fall,%,9,0.999
Activity,Amax nM-1,9,0.999
Bleeding time,min,9,0.999
PD50,mg kg-1 day-1,9,0.999
PT extension,nM,9,0.999
Activity,A570 min-1,9,0.999
Papp,10'-6cm/s,9,0.999
Derived trabecular thickness,uM,9,0.999
K,10'8/M/min,9,0.999
K,10'6/uM/s,9,0.999
DeltaTm,,9,0.999
Pc,,9,0.999
K,10'5/s,9,0.999
Pa,,9,0.999
K,10^5/M.s,9,0.999
PD50,mM kg-1,9,0.999
CT50,mM,9,0.999
K obs,M-1 s-1,9,0.999
Binding activity,%,9,0.999
No. of mice surviving >6 months,,9,0.999
No. of strains,,9,0.999
Dose,mg,9,0.999
PRL,ng ml-1,9,0.999
K,10^-6/M/s,9,0.999
PKB,,9,0.999
EC80,uM,9,0.999
Max change,%,9,0.999
Ka,10^8/M,9,0.999
Max delta,uM,9,0.999
Activity,millimeter/mg/ml,9,0.999
Mean survival,time day-1,9,0.999
Activity,microg/cm2/h,9,0.999
Activity,microM/s,9,0.999
Maxi-K current,,9,0.999
Maximal binding,,9,0.999
Activity,mg.equiv,9,0.999
PDR,,9,0.999
Ka,10'3/M.s,9,0.999
Mean change,mM,9,0.999
Ka,10'10/M,9,0.999
Activity,microg/cm2,9,0.999
No. of ferrets,,9,0.999
K x10e-5,M-1,9,0.999
Binding Decrease,%,9,0.999
PDD50,,9,0.999
Directly measured thickness,uM,9,0.999
First adverse effect,,9,0.999
ED50,ug/Kg/min,9,0.999
fIC20,nM,9,0.999
Social interaction,,9,0.999
CAC,,9,0.999
IC50,uM tube-1,9,0.999
IC50,mol,9,0.999
IC50,min,9,0.999
ED300,nM,9,0.999
Kapp,10^-3/hr,9,0.999
Inhibition,(nM of H202) min-1 (ug of protein)-1,9,0.999
MPR,%,9,0.999
Duration time,,9,0.999
Ca2+ serum,,9,0.999
Ki,10e2 M-1 s-1,9,0.999
MED100,mg kg-1,9,0.999
LC100,ng/ml,9,0.999
Kbb,,9,0.999
Kcat/Km,10^-6 microM/s,9,0.999
MIC,10^3nM,9,0.999
MED,ug/kg,9,0.999
Lung weight,g,9,0.999
Cells sickled,%,9,0.999
Activity,uL/min,9,0.999
Average weekly weight change,%,9,0.999
AUCt,hr/ng.ml,9,0.999
Smax,nM min-1 kg-1,9,0.999
Therapeutic efficacy,,9,0.999
Clonic seizures,,9,0.999
Hypotension,%,9,0.999
Summation MABP,,9,0.999
ED40,10^-5 mol/L,9,0.999
SubG0,%,9,0.999
CC10,,9,0.999
DD,uM mM-1,9,0.999
ID50,10'-6 mol/L,9,0.999
ST/CB ratio,,9,0.999
STY seizure,,9,0.999
AUG,ng ml-1 hr-1,9,0.999
SUV,g/ml,9,0.999
Scavenging Activity,%,9,0.999
Secondary response,,9,0.999
ID25,mg kg-1,9,0.999
DC,,9,0.999
Sensitisation,,9,0.999
Delta,,9,0.999
DA utilization,,9,0.999
IC>80,uM,9,0.999
C50,ug ml-1,9,0.999
Simulation,%,9,0.999
MBIC,mg/ml,9,0.999
EC1000,uM,9,0.999
MST,hr,9,0.999
Kbapp,,9,0.999
Kinase activity,pM min-1*ml-1,9,0.999
Activity,nmol/mg/hr,9,0.999
Drug uptake,pg,9,0.999
Activity,pM min-1 (mg of protein)-1,9,0.999
MTC50,uM,9,0.999
Acute toxicity,M dm-3,9,0.999
Kq,10^4/M,9,0.999
Animals dead,,9,0.999
LD50,10'-1 ug/ml,9,0.999
Keq,,9,0.999
MIC90,%v/v,9,0.999
Log ratio,,9,0.999
EC50,M kg-1,9,0.999
MDH Reactivation,%,9,0.999
Kcat,10'-5/s,9,0.999
LD50,ug fly-1,9,0.999
Log GTI,,9,0.999
MTC50,mg kg-1,9,0.999
MNTD,,9,0.999
Drug uptake,micromol/min,9,0.999
fIC30,nM,9,0.999
MDD,mean day of death,9,0.999
EC37,ug ml-1,9,0.999
Ae,% ID/g,9,0.999
Amplitude,mV,9,0.999
LD10,mg/m2,9,0.999
Anticonflict activity,,9,0.999
Amylase stimulation,max,9,0.999
Activity,nM min-1 (10e-6*cells)-1,9,0.999
EC25,%,9,0.999
Antiamnesic activity,,9,0.999
Approx. pKa,,9,0.999
MPC/MIC,,9,0.999
Activity,pmol/mg.min,9,0.999
E,-V,9,0.999
Activity,ng/dl,9,0.999
E,%,9,0.999
Drug uptake(free),nmol/L,9,0.999
EC30,M kg-1,9,0.999
LogD5.5,,9,0.999
Drug uptake,mg/g,9,0.999
Latency time,%,9,0.999
Ki,app,9,0.999
Acute TI,,9,0.999
Area,mm**2,9,0.999
Therapeutic index,%,9,0.999
Lag time,min,9,0.999
Tetramer,%,9,0.999
Rs,nM min-1 kg-1,9,0.999
Recovered in urine,%,9,0.999
Clast,ng/g,9,0.999
Reduction of heart rate,%,9,0.999
Relative adrenal weight,mg 100g-1,9,0.999
Active dose range,,9,0.999
C0,nM,9,0.999
DSB,,9,0.999
Clast,uM,9,0.999
INH,IU/mg,9,0.999
INH,10'5L/mol/s,9,0.999
INH,10'-8M,9,0.999
Acid secretion,,9,0.999
INH,10'-4/min,9,0.999
Acetylcholine level,uM,9,0.999
Relative thymus weight,mg 100g-1,9,0.999
DOM,,9,0.999
Responders,,9,0.999
DNA damage,10e7 exchanged dCps (ng of DNA),9,0.999
Resting potential,mV,9,0.999
Abrasion score,,9,0.999
C10 air,uM,9,0.999
Immobility time,%,9,0.999
Implants,,9,0.999
Threshold concentration,uM,9,0.999
k2,10e3 s-1,9,0.999
fT>MIC,,9,0.999
I / E100,,9,0.999
Cmax normalised,nM.kg/mg,9,0.999
AFC50,ppm,9,0.999
k cat/Ki,M-1 min-1,9,0.999
Contractility,mmHg s-1,9,0.999
FRE,,9,0.999
k0,s-1,9,0.999
CLz/F,ml/min.kg,9,0.999
Contractility,,9,0.999
Tissue area,mM,9,0.999
k2/KI,nM-1 min-1,9,0.999
Content of cell cycle,%,9,0.999
AD50,nmol/kg,9,0.999
Connectivity density,mm**-3,9,0.999
khydr,min-1,9,0.999
kobs,/min,9,0.999
F/dose,%,9,0.999
AC30,uM,9,0.999
A50,mM kg-1,9,0.999
Reaction time,hr,9,0.999
Time constant T4,ms,9,0.999
Reaction,%,9,0.999
Cutaneous toxicology score,,9,0.999
Decay-time constant,ms,9,0.999
Rs,ul min-1 kg-1,9,0.999
SC50,mM,9,0.999
SEC50,M,9,0.999
CC50,%,9,0.999
IC50,10^-2microM,9,0.999
IC50,10^-10mol/L,9,0.999
Cytotoxicity,M dm-3,9,0.999
IC50,10'-4nM,9,0.999
T,,9,0.999
T1/2,%,9,0.999
ED200,nM,9,0.999
AUC/dose,ng.hr/g/mg/kg,9,0.999
TAI,,9,0.999
TC50,uM/ml,9,0.999
TD50,micromol/kg,9,0.999
AUC(app),uM.hr,9,0.999
TDI,10'-4/min,9,0.999
TE50,,9,0.999
Increase in CBF,,9,0.999
I50,10'6mol/L,9,0.999
TW,,9,0.999
Increase in concentration,,9,0.999
Cytotoxic concentration,,9,0.999
Ratio,L/min/umol,9,0.999
Body weight gain,mg,9,0.999
RF,delta beats min-1,9,0.999
Degree of activation,fold,9,0.999
Ratio,10'-4No_unit,9,0.999
RD500,ug rat-1,9,0.999
Inhibitory rate,%,9,0.999
Activity,10'4log10CFU/ml,9,0.999
Decrease in pressure,mmHg,9,0.999
Inhibition (at concentration M),%,9,0.999
Range of deaths,day,9,0.999
Range of survival,,9,0.999
Body temperature,%,9,0.999
Rate,nM min-1 (nM of cytochrome P450)-1,9,0.999
Rate of death,%,9,0.999
Ratio,/min/mM,9,0.999
Rate of rotation,,9,0.999
Chronic TI,,9,0.999
Infection score,,9,0.999
Inhibition,c.p.m./Abs,9,0.999
Activity,10'-8mol/L,9,0.999
ED50,ug ear-1 dose-1,8,0.999
Tidal volume,ul,8,0.999
Effective dose,mg,8,0.999
IC50/[E],nM milliunit-1,8,0.999
Jmax,pmol/min,8,0.999
Free C,nM,8,0.999
MAC,mg/ml,8,0.999
Activity MABP,%,8,0.999
Oligo modified,%,8,0.999
Therapeutic index,mg kg-1,8,0.999
Of non-HDL-C,%,8,0.999
Ka,10^3/M.s,8,0.999
Tidal volume,%,8,0.999
Normal weight gain,%,8,0.999
Of HDL-C,%,8,0.999
Tissue level,ug ml-1,8,0.999
Onset of block,min,8,0.999
AUC,ug.min/g,8,0.999
Total cholesterol,mg kg-1,8,0.999
M/T,,8,0.999
Dobs,,8,0.999
Delta APD90,%,8,0.999
Receptor occupied,%,8,0.999
Triglyceride level,,8,0.999
BW,%,8,0.999
Delta I/I,mV,8,0.999
Lipoprotein level,%,8,0.999
Eudismic ratio,,8,0.999
CFU,10^2/ml,8,0.999
Km,/uM,8,0.999
CAC,mM,8,0.999
Ke naloxone,nM,8,0.999
Ka,10'2/M/s,8,0.999
Activity,OD/mm2,8,0.999
Kel,h-1,8,0.999
CFU,10^6/ml,8,0.999
CL(app),uL/min,8,0.999
Ka,10'-5/M/s,8,0.999
Basal control,%,8,0.999
Ka,10'-2/M,8,0.999
Fg,%,8,0.999
K,min,8,0.999
HDL cholesterol,mg kg-1,8,0.999
CL,uL/min/pmol,8,0.999
HSA shift,,8,0.999
C0,ug/L,8,0.999
HDL-C change,%,8,0.999
Kd,10^5/s,8,0.999
Brain level,pM forebrain-1,8,0.999
K,10^4No_unit,8,0.999
HPB,,8,0.999
ED50,mg/kg/hr,8,0.999
Frequency,beats min-1,8,0.999
Ca2+ elevation,,8,0.999
Kdiss,1/s,8,0.999
Inhibitory concentration,mM,8,0.999
Frequency,%,8,0.999
Activity,pmol/million cells,8,0.999
AUC,pmol.min,8,0.999
TC90,uM,8,0.999
Tumor uptake,uM kg-1,8,0.999
LT50,min,8,0.999
LSD,%,8,0.999
Vmax,M min-1 mg-1,8,0.999
Dose normalized clearance,ml/min.kg,8,0.999
V0,,8,0.999
Latency to step through,s,8,0.999
V/K,,8,0.999
Tumor response,,8,0.999
Level,ug ml-1,8,0.999
No. of protected/tested,,8,0.999
No. of pits/slice,,8,0.999
Level,mequiv/L,8,0.999
Activity,/uM,8,0.999
Permeability,*10e6,8,0.999
Turnover,%,8,0.999
AUC,pM kg-1,8,0.999
Ratio of depolarizing activity,,8,0.999
Urinary excretion,ug,8,0.999
Activity,10'-3dpm,8,0.999
Uterotonic activity,IU mg-1,8,0.999
Uterotrophic activity,,8,0.999
Ratio I/P,,8,0.999
Activity,pg/ml/hr,8,0.999
Damage score,,8,0.999
Vmax,M-1 s-1,8,0.999
Km/Ki,,8,0.999
Drug uptake,nmolequiv/g,8,0.999
Cp,nmol,8,0.999
Oxidation rate,,8,0.999
Ct,ng,8,0.999
Cumulative amount,ug,8,0.999
Affinity,M-1,8,0.999
E/Emax,,8,0.999
Reduction in TG,%,8,0.999
Delta K,,8,0.999
AUC normalised,(umol.h/L)/(mg/kg),8,0.999
AUC normalised,((ng/mL).hours)/(mg/kg/day),8,0.999
Activity,RU^2,8,0.999
Ct,ug,8,0.999
Ct,pmol,8,0.999
Reduced BP,%,8,0.999
Tc,uM,8,0.999
TGI50,ug kg-1,8,0.999
No. of axonal branch points/cell,,8,0.999
Tt,,8,0.999
Tumor area,mm**2,8,0.999
Level,units/mL,8,0.999
No. of killed or paralyzed,,8,0.999
Ratio CIC95/IC50,,8,0.999
Vd,L,8,0.999
Ratio,uL/min/pmol,8,0.999
LZ,/min,8,0.999
AUC,nM.hr/mg/kg,8,0.999
Dose elevation,mg kg-1,8,0.999
Latency time,,8,0.999
Dose modification,,8,0.999
Ka,10'9/M/min,8,0.999
Binding,dpm mg-1,8,0.999
ED25,mg/kg/day,8,0.999
CC30,nM,8,0.999
Jss,ug/cm2.hr,8,0.999
CLH,L/hr,8,0.999
IC27,uM,8,0.999
K m,uM,8,0.999
K1,M-1 min-1,8,0.999
K,/day,8,0.999
IC05,ug ml-1,8,0.999
KA,M,8,0.999
Hypermotility,,8,0.999
ITP,,8,0.999
ED50,10'-3mmol/kg,8,0.999
Brain level,ug weight-1,8,0.999
ED50,nmol/mouse,8,0.999
Boron concentration,ug g-1,8,0.999
Hypocalcemic activity,IU mg-1,8,0.999
K alkyl,s-1,8,0.999
KDss,M,8,0.999
I/E,,8,0.999
I/IC50,,8,0.999
ED50,pg/ml,8,0.999
K app ratio,,8,0.999
Ka,/mM.s,8,0.999
Ki,mg/ml,8,0.999
Binding,M of drug (M of BSA)-1,8,0.999
FICI90,,8,0.999
FICI50,,8,0.999
K-2,min-1,8,0.999
IC40,nM,8,0.999
ED70,uM,8,0.999
KSV,10^3/M,8,0.999
Activity,%Idose,8,0.999
Kii,,8,0.999
CFU,10'4/ml,8,0.999
EDmax,uM kg-1,8,0.999
Fever response,degrees C,8,0.999
Human potency,MU,8,0.999
ED50,10'-5M,8,0.999
ED50,ng,8,0.999
Highest nontoxic dose,mg kg-1 (day in diet)-1,8,0.999
Koff,M-1,8,0.999
Extension,%,8,0.999
K DMPG,M-1,8,0.999
Khydrol,s-1,8,0.999
ED25,10'-8M,8,0.999
K DMPC,M-1,8,0.999
Kinact,10'5/M/s,8,0.999
ITI activity,,8,0.999
K6,1/min,8,0.999
Ki(1.8x10e-11),M,8,0.999
K5,1/min,8,0.999
Ki.c,,8,0.999
IC12,ug,8,0.999
K2,10e-3 min-1,8,0.999
CC50%,ug ml-1,8,0.999
K6,s-1,8,0.999
CLH,g/ml/min,8,0.999
IC0,ug ml-1,8,0.999
Hyperactivity,%,8,0.999
Ki,kcat/Km,8,0.999
Kinact,10^3/min,8,0.999
GR10,gAi/ha,8,0.999
C10,nM,8,0.999
Kcat/Km,10'-2/microM/s,8,0.999
Emesis,vomiting/tested,8,0.999
GTP-gammaS Index,,8,0.999
GI80,nM,8,0.999
Increase in LD50,%,8,0.999
Kcat,pmol/min,8,0.999
GID75,mg/m2,8,0.999
ED30,MPK,8,0.999
Kd,1/ks,8,0.999
Blood clearance,ug ml-1,8,0.999
Enantiomeric composition,%,8,0.999
Average proportion,,8,0.999
CMT,uM,8,0.999
EC50,pmol/L,8,0.999
ED50,mg kg-1 (day in diet)-1,8,0.999
K,s-1,8,0.999
CT,ms,8,0.999
CL,nmol/min,8,0.999
CGI,uM,8,0.999
Edema,ul,8,0.999
ED50,mpk day-1,8,0.999
CAT activity,,8,0.999
Km(unbound),uM,8,0.999
K,10'-5/nM/min,8,0.999
ID50,ng/kg,8,0.999
ID50,uL/L,8,0.999
GR50,nM,8,0.999
Emax,pg/ml,8,0.999
K,pM,8,0.999
Kinact,10^6nM,8,0.999
KiH,uM,8,0.999
Increase in blood pressure,%,8,0.999
Blood glucose,mM l-1,8,0.999
ID40,,8,0.999
Increase (Emax),%,8,0.999
Interferon response,ml,8,0.999
ID95,uL/L,8,0.999
EC50,ucm,8,0.999
ID50,10'-6M,8,0.999
Kd,10^-5/s,8,0.999
BPR,10'-3/hr,8,0.999
Kd,10^-6/s,8,0.999
Kd,10^1 uM,8,0.999
K,10^-6M,8,0.999
HCMV yield,pfu/ml,8,0.999
HD10,uM,8,0.999
HD10,ug ml-1,8,0.999
CL,ng/ml,8,0.999
Kina,min-1,8,0.999
Bmax1,%,8,0.999
GDPactivity,nM min-1 mg-1,8,0.999
EC50,ppb,8,0.999
Glucuronidation rate,nM min-1 mg-1,8,0.999
TAD,%,8,0.999
MIC,10^-3mM,8,0.999
Papp e-6,cm s-1,8,0.999
Max delta MABP,mmHg,8,0.999
max inhibition,%,8,0.999
molecular ellipticity,deg.cm2/dmol,8,0.999
Mean time to seizure,,8,0.999
2TT,ug ml-1,8,0.999
Max delta FRP,,8,0.999
pA2,mg,8,0.999
pBBB,10'-6 cm/s,8,0.999
Max delta FC,%,8,0.999
pD2,uM,8,0.999
Cmax_metabolite,ng/ml,8,0.999
pEMR,,8,0.999
-ln (MIC),,8,0.999
Activity,nM/ml,8,0.999
2x APTT,nM,8,0.999
Cmax/dose,,8,0.999
LC99,ug ml-1,8,0.999
WBC x10e-3,ul-1,8,0.999
Antilipid peroxidation,,8,0.999
Weight at term,g,8,0.999
Change in MABP,%,8,0.999
Property,,8,0.999
Wet weight,g,8,0.999
XL50,uM,8,0.999
NSR survival rate,,8,0.999
AUC,0-24hr,8,0.999
Drug uptake,RFU,8,0.999
Max fall,mmHg,8,0.999
Max fall in MAP,mmHg,8,0.999
[Ca2+] increase,,8,0.999
Cocaine,%,8,0.999
MPD,ug kg-1,8,0.999
R+V,90 min,8,0.999
Max lowering MABP,mmHg,8,0.999
Drug metabolism,ug,8,0.999
permeability,10'-7nmol/cm2/min,8,0.999
Krelative,,8,0.999
permeability,10^-5cm/s,8,0.999
permeability,a.u.,8,0.999
permeability,microg/cm2/h,8,0.999
Activity,10'6/M,8,0.999
MBEC90,ug ml-1,8,0.999
permeability,pmol/min/cm2,8,0.999
rT3 Production,pM tube-1,8,0.999
MBIC80,uM,8,0.999
Deiodination,%,8,0.999
Cellular uptake,pM ul-1,8,0.999
RBC x 10e 3,ul-1,8,0.999
RBI,%,8,0.999
tRNA peak exclusion,%,8,0.999
Activity,mmHg.hr,8,0.999
Atherogenic index,,8,0.999
Calculated Ratio,,8,0.999
Activity,10'5No_unit,8,0.999
MBC99,uM,8,0.999
Activity,mutants (10e4*survivors)-1,8,0.999
Cholesterol,%,8,0.999
Change in LV dp/dt,%,8,0.999
NADH oxidized,nM min-1,8,0.999
Drug metabolism,mol,8,0.999
MDA content,uM (g of tissue)-1,8,0.999
dp/dt(max),%,8,0.999
Microsomal stability,pg min-1 (mg of protein)-1,8,0.999
fAUC,nM.hr.kg/mg,8,0.999
fAUC/dose,microM.hr/mg/kg,8,0.999
Cmax normalised,(ng/mL)/(mg/kg/day),8,0.999
Median retension latency,,8,0.999
Activity,mM-1,8,0.999
fCmin,nM,8,0.999
Cmax normalised,(umol/L)/(mg/kg),8,0.999
LD app,mM kg-1,8,0.999
Cholesterol level,mg dl-1,8,0.999
Mean total resorption,um2,8,0.999
LD40,uM,8,0.999
MBBC,ug ml-1,8,0.999
Restoration,%,8,0.999
Protection,nM,8,0.999
Rate of reduction,uM min-1mg-1,8,0.999
Drug degradation,pmol/min,8,0.999
Proportion of survivors,,8,0.999
delta logP,,8,0.999
LD50,%,8,0.999
Antitumour activity,,8,0.999
Control of P-450 marker,%,8,0.999
MID,mg kg-1,8,0.999
Activity,ng/mL.hr,8,0.999
AUEC,%,8,0.999
Rate,nM min-1,8,0.999
LD100,uM,8,0.999
aPTT,uM,8,0.999
Drug uptake,cpm/uL,8,0.999
LC95,ug ml-1,8,0.999
alkaline phosphatase activity,U l-1,8,0.999
AUBC,log10CFU/ml,8,0.999
LD50,umol,8,0.999
LD50,umol/ml,8,0.999
Vz/F,(mg/kg)/(ug/ml),8,0.999
Vmax,nmol,8,0.999
Vmax,nmol/hr/microg,8,0.999
Ratio,10^3/uM/s,8,0.999
LDL-C,%,8,0.999
LDL cholesterol,mg kg-1,8,0.999
Progesterone production,ng 2hr-1 (10e5*cells)-1,8,0.999
Prolonged VRP,%,8,0.999
cholesterol level,mg dl-1,8,0.999
Vmax(app),pmol/min.mg,8,0.999
Cmax,ug,8,0.999
NSVT,mg kg-1,8,0.999
LD90,p.p.m.,8,0.999
Vocalization time,s,8,0.999
Volume of air,ml,8,0.999
Activity,nmol/mg.hr,8,0.999
Counts/30,min,8,0.999
Vss,l hr-1 kg-1,8,0.999
APTT,nM,8,0.999
cAMP production,N,8,0.999
LD50,mg kg-1 (day in diet)-1,8,0.999
k3/ki,M-1 s-1,8,0.999
Morphology,,8,0.999
Drug metabolism,mmol/L/hr,8,0.999
MHC,umol/L,8,0.999
Cavg,pg/mL,8,0.999
MTD,%,8,0.999
AUMC,%,8,0.999
Log TCI,,8,0.999
Cleavage,M,8,0.999
Diazepam antagonism,,8,0.999
Severity,,8,0.999
Plasma concentration,uM l-1,8,0.999
DT50,day,8,0.999
Active culture,%,8,0.999
Supressive effect,ug ml-1,8,0.999
Survival extension,,8,0.999
Survival ratio,%,8,0.999
DFMBMD,mg/Ecm,8,0.999
Drug uptake,nmol.hr/g,8,0.999
Cytotoxity,%,8,0.999
Survivors,N/total,8,0.999
Activity,L/min,8,0.999
PC95,ug,8,0.999
T,uM,8,0.999
Cysteine reaction,min-1,8,0.999
PC50,ug,8,0.999
T/C max,%,8,0.999
DW,,8,0.999
Relative Potency Ratio,,8,0.999
Amount incorporated,M (M of tubulin)-1,8,0.999
AUMC,hr2.ng/ml,8,0.999
AUMC,ng.hr/ml,8,0.999
Stabilty,hr,8,0.999
AUCt,ngequiv.hr/g,8,0.999
k2,min-1 M-1,8,0.999
Scavenging Activity,,8,0.999
Relative to DA,%,8,0.999
Log PTA,,8,0.999
Papp,cm min-1,8,0.999
Papp,10'-6cm/s2,8,0.999
Ac,uM,8,0.999
Selectivity,uM s-1,8,0.999
Log P/(100-P),,8,0.999
Activity,10^3No_unit,8,0.999
Drugexcretion,ug/g,8,0.999
Activity,uM ml-1,8,0.999
Delta mean blood pressure,,8,0.999
Drug uptake,ng/kg,8,0.999
Selectivity rating,,8,0.999
Delta logS,,8,0.999
Density,mg/cm3,8,0.999
DC50,ug ml-1,8,0.999
Reversion,,8,0.999
Log effect,,8,0.999
Revertant colonies per plate,,8,0.999
Rotations/10 h,,8,0.999
DeltaCp,kcal/mol/K,8,0.999
Activity,10^5/ml,8,0.999
Log cfu/g of tissue,,8,0.999
Reserpine hypothermia,,8,0.999
Activity,Kcal/kg/day,8,0.999
Serum concentration,nM l-1 hr-1,8,0.999
Du,,8,0.999
Delta FFA,,8,0.999
AAL,,8,0.999
ROR,%,8,0.999
Concentration,ug/10e6 cells,8,0.999
Arrhythmia score,,8,0.999
Max weight loss,%,8,0.999
Carbonyl group,,8,0.999
Max uterine weight,mg,8,0.999
log10CFU/ml/day,,8,0.999
Drug uptake,uL,8,0.999
Activity,microL/min/kg,8,0.999
Delta F,%,8,0.999
Activity,10'1/mm2,8,0.999
Vmax,cpm,8,0.999
ABC,,8,0.999
QT interval,,8,0.999
Contractility (LV dP/dt),,8,0.999
Apparent binding constant,M-1,8,0.999
Mean response,,8,0.999
ADD,s,8,0.999
Activity,nM/hr,8,0.999
k x10e-3,min-1,8,0.999
k-1,s-1,8,0.999
Mean reaction,,8,0.999
Antiuterotrophic activity,,8,0.999
Mean pit size,um2,8,0.999
Quenching,%,8,0.999
ABBC,log10CFU/ml.hr,8,0.999
k obs / concentration,,8,0.999
RP,mV,8,0.999
AUClast/dose,uM.hr,8,0.999
Skin scaling,,8,0.999
Log K'w,,8,0.999
log Pe,cm2/sec,8,0.999
Skin response,,8,0.999
Plasma half life,min,8,0.999
Smax,,8,0.999
PT,nM,8,0.999
Plasma level,,8,0.999
Specific activity,ukat kg-1,8,0.999
Platelets x10e-3,ul-1,8,0.999
D-2,%,8,0.999
Stability,%Idose,8,0.999
Relative metabolic rate,,8,0.999
Pm,10'-5 cm/min,8,0.999
Vm,%,8,0.999
Change,beats min-1,8,0.999
RRI,,8,0.999
Activity,10'4 /uL,8,0.999
Ratio,10^5/s/M,8,0.999
ka,L/hr,8,0.999
LH,,8,0.999
AUC/dose,ng.hr.kg/ml.mg,8,0.999
Diffusion analysis,,8,0.999
Diffusion,%,8,0.999
Drug metabolism,nmol.min,8,0.999
Max Uosm,mOsmol kg-1,7,0.999
Kapp,10'-2/s,7,0.999
Ka(T4),%,7,0.999
Ka1,,7,0.999
K,10^4L/mol,7,0.999
K,10^4/M/min,7,0.999
Kapp,/hr,7,0.999
AUCt,nmol.hr/g,7,0.999
Kapp,/s,7,0.999
ED50,10'-9M,7,0.999
Ulcer index,,7,0.999
EC50,umol/g,7,0.999
Kb,10'8/M,7,0.999
Vmax,1/min,7,0.999
Depression,%,7,0.999
ID30,uM,7,0.999
Vagus,delta %,7,0.999
SF50,nM,7,0.999
Vm,uM min-1 (mg of protein)-1,7,0.999
AUC,s,7,0.999
AUMC,ug/ml.hr'2,7,0.999
CIC90,,7,0.999
MPC,uM,7,0.999
CIC IC50,nM,7,0.999
HR,delta %,7,0.999
Selectivity ratio,%,7,0.999
HCMV yield reduction,pfu/ml,7,0.999
Papps,cm s-1,7,0.999
AUC,ng.min/g,7,0.999
Change in respiratory frequency,%,7,0.999
HC50,10'-5M,7,0.999
Change in respiratory frequency,beats min-1,7,0.999
BPI,%,7,0.999
Drug responding,,7,0.999
Kb,10'4No_unit,7,0.999
MPE,mg kg-1,7,0.999
AUCt/dose,nM.hr/mg,7,0.999
Uterotropic effect,,7,0.999
Activity,mmol/min/mg,7,0.999
Unreacted drug,%,7,0.999
PFC/spleen,,7,0.999
K,10^3/M,7,0.999
Ka,10^6/Ms,7,0.999
Max delta BP,,7,0.999
Ka,M,7,0.999
Max contractile force,,7,0.999
S50,umol/L,7,0.999
Vd/F,,7,0.999
S50,uM,7,0.999
Max intensity,rotations min-1,7,0.999
Activity,nmol/hr/L,7,0.999
Cell saturation,pM (10e5*cells)-1,7,0.999
Papp,10^-5 cm/s,7,0.999
Activity,omegacm2,7,0.999
CL,mg/min/kg,7,0.999
Glucose uptake,nM hr-1 (mg of worm),7,0.999
Saq,,7,0.999
Vmax,pM s-1 mg-1,7,0.999
Max efficacy,%,7,0.999
AUC/dose,uM.min.kg/mg,7,0.999
MITC95,,7,0.999
Cmax,%,7,0.999
I50,%,7,0.999
ED,mg,7,0.999
Drug degradation,nmol/J,7,0.999
K app,M-1 s-1,7,0.999
Mutation frequency,10e6 F,7,0.999
ODC Activity,(nM of CO2) 30min-1 (mg of protein)-1,7,0.999
Drug recovery,g,7,0.999
NO2- (mol/mol),%,7,0.999
Activity,ng/kg/day,7,0.999
Group toxicity,,7,0.999
Virus yield reduction,,7,0.999
CO,mM,7,0.999
Vmax,U/min,7,0.999
AUC,min,7,0.999
Block time,ms,7,0.999
AUC,microM/hr/mg,7,0.999
K,10'6/s/M,7,0.999
Kcat/Km,10'-5/M/s,7,0.999
Vmax,nM min-1 (mg of protein)-1,7,0.999
Rn,,7,0.999
CNS activity,,7,0.999
AUC,ml/min.kg,7,0.999
Cp,pmol,7,0.999
Viral titer,PFU.mL-1,7,0.999
Kb,10^6L/mol,7,0.999
K,10^-5/M/s,7,0.999
EC50,uL/L,7,0.999
Saftey margin,,7,0.999
PTZ seizure,,7,0.999
Vbeta,L/hr,7,0.999
Change in stroke volume,%,7,0.999
CL,mg min-1 kg-1,7,0.999
Cp(f),mg/ml,7,0.999
Concentration of max response,,7,0.999
DBP-20,ug kg-1,7,0.999
Lambda-ex,nm,7,0.999
ED25,10'-7M,7,0.999
pCB50,,7,0.999
Infarct volume,mM,7,0.999
LLR msad,mg kg-1,7,0.999
Activity,10'5AU/sec,7,0.999
Concentration,ug of B g-1,7,0.999
Kii,uM kg-1,7,0.999
A50,umol/Kg,7,0.999
Incidence of occlusion,,7,0.999
pA2-pA10,,7,0.999
Anti-infectious effect,,7,0.999
rel ko,,7,0.999
Cmedia,ug of B/ml,7,0.999
Boron incorporation,ug/10e6,7,0.999
Kin,10^-4ml/g/s,7,0.999
2aPTT,10'-3M,7,0.999
Intrinsic vasorelaxation,M,7,0.999
permeability,umol/cm2/hr,7,0.999
Emax,uM kg-1,7,0.999
Pyrogenic effect,,7,0.999
Activity,10'3log10CFU/ml,7,0.999
Level,ug g-1,7,0.999
Kinact,1/min,7,0.999
Decrease in No. of avoidence responses,%,7,0.999
Antidiuretic,mg,7,0.999
Mitogenic effect,,7,0.999
LDH release,%,7,0.999
Lethality,mg kg-1,7,0.999
CL_renal,ml min-1,7,0.999
Ratio,10^-3/min/uM,7,0.999
AD50,MPK,7,0.999
LD,uM kg-1,7,0.999
Ratio,10'6/M,7,0.999
Irreversible binding,,7,0.999
Iron mobilized,%,7,0.999
CLint,uL min-1 mg-1,7,0.999
Antagonist activity,ug min-1 kg-1,7,0.999
Clast,nM,7,0.999
LD10,mg/me2,7,0.999
Increased life span,,7,0.999
CL_renal,ml s-1,7,0.999
LAL test,,7,0.999
CLb,%,7,0.999
Dead/treated,,7,0.999
pEC20,,7,0.999
Radiolabel recovery,ng/g,7,0.999
Lambda-em,nm,7,0.999
MTD,mpk,7,0.999
LC50,umol/dm'2,7,0.999
logD IAM,,7,0.999
LD84,mg kg-1,7,0.999
Catalepsy,,7,0.999
Activity,10'4/M/s,7,0.999
Activity,10'5/mm3,7,0.999
LD95,microg/cm2,7,0.999
ClM,ml min-1,7,0.999
sigmaL,%,7,0.999
Lesion index,mM,7,0.999
Radiolabel recovery,ug ml-1,7,0.999
sigmaH,%,7,0.999
CLH,micromol/min,7,0.999
Activity,10'7CFU/g,7,0.999
LD90,mg/ml,7,0.999
ED50,ug embryo-1,7,0.999
pM,,7,0.999
LC20,ug ml-1,7,0.999
Induced frequency,,7,0.999
K',,7,0.999
Vdss,L/hr,7,0.999
K,10^-8M,7,0.999
EC30,10'-7M,7,0.999
pIC30,,7,0.999
Activity,10'-3 mol/L,7,0.999
ED50 mg/kg,,7,0.999
Rate of reduction,nM min-1 mg-1,7,0.999
Ratio CC50/EC50,10'3No_unit,7,0.999
Pupil size,mM,7,0.999
Ratio,10'2/s.M,7,0.999
-Log KD50,,7,0.999
Km(app),,7,0.999
Lactate produced,nM hr-1 (mg of worm),7,0.999
CLtotal,ml s-1,7,0.999
Decrease,mM,7,0.999
Kun,s-1,7,0.999
Antiuterotropic effect,,7,0.999
Apparent_pKa,,7,0.999
Iron clearence,ug kg-1,7,0.999
Concentration,ug rat-1 hr-1,7,0.999
ED20,ng,7,0.999
Lethal toxicity,,7,0.999
Efficacy,number ul-1,7,0.999
Receptor binding,,7,0.999
ClB,ml min-1,7,0.999
Erythema intensity,,7,0.999
AUClast,hr.nmol/ml,7,0.999
Kcat,10'4/s,7,0.999
KH,uM,7,0.999
Average survived,day,7,0.999
Absolute ratio,,7,0.999
"Kd,app",nM,7,0.999
Duration of immobility,,7,0.999
MAP,delta %,7,0.999
Log Dmax,,7,0.999
Plasma glucose level,mg dl-1,7,0.999
Amount formed,pM,7,0.999
k act,M-1 s-1,7,0.999
[Ca2+] variation,nM,7,0.999
Delta heart rate,beats min-1,7,0.999
Relative potency,M,7,0.999
Damaged area,%,7,0.999
G1,%,7,0.999
GABA agonism,,7,0.999
ATP content,pM (mg of protein)-1,7,0.999
k cat,-1/min,7,0.999
Change in tidal volume,%,7,0.999
MEC,mg ml-1,7,0.999
ED25,ug/kg,7,0.999
"kC,U",hr-1,7,0.999
Drugabsorption,ug/g,7,0.999
EC50,10^-4nM,7,0.999
INH,10'-6 mol/L,7,0.999
Free radical scavenging,%,7,0.999
Delta HR,min-1 hr-1,7,0.999
MCD,mg/kg/day,7,0.999
Log 1/ED30,uM kg-1,7,0.999
Resowing,%,7,0.999
WBC,10e3 ul-1,7,0.999
Change in tidal volume,ul,7,0.999
IE1,eV,7,0.999
Phospholipidosis_MEC,,7,0.999
Relative liver weight,%,7,0.999
Zone of stimulation,,7,0.999
ILS40,mg kg-1 day-1,7,0.999
Kcat/Km,10^-5/nM/s,7,0.999
Relative substrate velocity,%,7,0.999
Log IC50,%,7,0.999
Relative rate of decomposition,(nM of drug) min-1 ml-1,7,0.999
Delta I,%,7,0.999
cAMP,,7,0.999
cell kill activity,,7,0.999
K,/uM/min,7,0.999
KdL,uM,7,0.999
KdH,uM,7,0.999
CMV yield,pfu/ml,7,0.999
kH,s-1,7,0.999
E0,,7,0.999
ED250,,7,0.999
Drug uptake,nmol/mg/min,7,0.999
Perturbations,,7,0.999
Log rate,,7,0.999
Volume,ml 4hr-1,7,0.999
k2,m M-1 hr-1,7,0.999
Log net cell kill,,7,0.999
Volume,ml 2hr-1,7,0.999
Kel,10^-3/min,7,0.999
Agonist,,7,0.999
Vmax/Km,uL/min/U,7,0.999
AE activity,,7,0.999
fAUC,ng.hr/g,7,0.999
C0,,7,0.999
Production,,7,0.999
Proconvulsant action,,7,0.999
MED,mpk,7,0.999
Vmax/Km,uL,7,0.999
Permeability coefficient,nm s-1,7,0.999
Drug uptake,nmol/L,7,0.999
ED50,uM g kg-1,7,0.999
Hypnosis potentiation,%,7,0.999
Vss,L,7,0.999
MED,(mg of base) 20g-1,7,0.999
MED,uM.kg/diet,7,0.999
Vmax,uM min-1 unit-1,7,0.999
Brain/Blood concentration,,7,0.999
C/T,,7,0.999
GID75,mg/me2,7,0.999
fIC90,uM,7,0.999
Kd,1/Ms,7,0.999
Profile,,7,0.999
AUC,mM.min,7,0.999
DTT inhibition,,7,0.999
Vmax,ug/min.kg,7,0.999
K,10'4/M/min,7,0.999
Activity,%.min,7,0.999
Fh,%,7,0.999
Kcat/Km,10^7/M/s,7,0.999
ID50 mg/kg,,7,0.999
DNA binding,M-1,7,0.999
Light transmission,%,7,0.999
Vmax,rel,7,0.999
Activity,10'8CFU/ml,7,0.999
Vmax,pmol/s,7,0.999
Retention,,7,0.999
Activity,10^-3/min/uM,7,0.999
Vomiting frequency,,7,0.999
DNA peak exclusion,%,7,0.999
D2 duration,min,7,0.999
AUC/dose,hr.nM,7,0.999
NTD50,mg kg-1,7,0.999
TD50/ED50,,7,0.999
TDI,/min/M,7,0.999
CPI,mN/meter,7,0.999
IC60,uM,7,0.999
Hydrolysis,nM min-1 mg-1,7,0.999
ED50,10'-4M,7,0.999
CBF-ID75,ug kg-1,7,0.999
Drug metabolism,nmol/J,7,0.999
Stability,microM/min,7,0.999
Change,mg kg-1,7,0.999
IC50,ppm g dm**-3,7,0.999
Oxygen consumed,nM min-1,7,0.999
AUC,uM hr-1 ml-1,7,0.999
Spread,%,7,0.999
CFU,10^7/ml,7,0.999
Spontaneous activity,,7,0.999
Ba,%,7,0.999
Activity,mgequiv/g,7,0.999
IC50 reduction,%,7,0.999
IC100,umol/L,7,0.999
K3,min-1,7,0.999
Nephrotoxicity,mg dl-1,7,0.999
AUC/dose,uM.hr.mg/kg,7,0.999
Drug metabolism,/min,7,0.999
AUC,cm2,7,0.999
KII,M,7,0.999
Change in dP/dt,%,7,0.999
Activity,m/3h,7,0.999
IC50,10^3 uM,7,0.999
Modification of adsorbed drug,%,7,0.999
AUC ratio,,7,0.999
NOAEL,ug/L,7,0.999
IC30,10'-6M,7,0.999
Nephrotoxicity,ng ml-1,7,0.999
T/C (survival),%,7,0.999
T>EC99,hr,7,0.999
Activity,fg,7,0.999
T.I.,,7,0.999
ECAUC0.2,uM,7,0.999
Cure,%,7,0.999
AUC/dose,min.ug/ml/(mg/kg),7,0.999
T max,,7,0.999
AUC/dose,min.uM,7,0.999
Max rev,%,7,0.999
ED5,ug ml-1,7,0.999
Change in mean aortic flow,%,7,0.999
Platelet,10e6 ul-1,7,0.999
Stroke volume,ul,7,0.999
Drug uptake,mmol/Kg,7,0.999
Kq,10'5L/mol,7,0.999
Cmax normalised,microM/mg/kg,7,0.999
Acceleration,,7,0.999
k',s-1,7,0.999
Drug uptake(free),ug/g,7,0.999
Writhing number,,7,0.999
Repellency,,7,0.999
MBEC99.9,ug ml-1,7,0.999
IC50,nM/unit,7,0.999
Delta MA,hr,7,0.999
Avoidance time,s,7,0.999
Repolarization time,,7,0.999
FLT,%,7,0.999
MBIC80,ug ml-1,7,0.999
Ki 0.5,,7,0.999
Ka,10^1/Ms,7,0.999
Activity,%/mmol,7,0.999
Log Ki,%,7,0.999
CFU,10^7/g,7,0.999
k1,min-1,7,0.999
Activity,meter/s,7,0.999
Time to onset,min,7,0.999
Mean aortic flow,ml min-1,7,0.999
CFU,10^5/ml,7,0.999
Max lowering,,7,0.999
Drug metabolism,nanomol/min,7,0.999
Drug metabolism,mol%,7,0.999
Melanotropic potency,,7,0.999
Melanotropic activity,,7,0.999
Median life span,,7,0.999
Time to offset,min,7,0.999
Offset time,min,7,0.999
Ka,/s,7,0.999
CFU,10'3/ml,7,0.999
Ka,1/M*1/S,7,0.999
Binding intensity,%,7,0.999
Ka,/mM/s,7,0.999
EC90,ng/ml,7,0.999
Creatinine_CL,ml/min,7,0.999
K Bind,nM,7,0.999
Tissue swelling,ul g-1,7,0.999
AUClast,ng.min/g,7,0.999
Change in TPR,%,6,0.999
TD50,mg,6,0.999
Cmax,ug/kg,6,0.999
Activity,W,6,0.999
Aggregation,,6,0.999
Immunosupressive activity,%,6,0.999
Log beta,,6,0.999
Relative analgesic potency,,6,0.999
Relative dissociation rate,,6,0.999
fKi,nM,6,0.999
Amount,pM,6,0.999
K2,s-1,6,0.999
Ratio_[3H]:tubulin,,6,0.999
Binding,fM uterus-1,6,0.999
Boron in media at 0h,ug of B/ml,6,0.999
Na+ ratio,,6,0.999
Protein content,%,6,0.999
Ke,10'6/M,6,0.999
Non-HDL-C,mg dl-1,6,0.999
CL/F,ml/hr,6,0.999
Activity,U l-1,6,0.999
Relative metabolic stability,,6,0.999
Change in TC,%,6,0.999
k2,M-1,6,0.999
E max,,6,0.999
CLH,microL/ml/min,6,0.999
Rat turning,%,6,0.999
NED,mg kg-1,6,0.999
K bind,uM,6,0.999
Ke,10'7/M,6,0.999
deltaS,cal/mol/K,6,0.999
Kq,10^13/M/sec,6,0.999
Activity,kU,6,0.999
Control cell number,%,6,0.999
Avoidance response,,6,0.999
IC20,10'-7M,6,0.999
Latency,ms,6,0.999
graft survival,day,6,0.999
Relative Selectivity,,6,0.999
Agonistic effect,%,6,0.999
Druguptake/dose,nM/mg/kg,6,0.999
Average ratio,,6,0.999
CC90,,6,0.999
Relative Km,,6,0.999
Death dose,mg kg-1,6,0.999
Culture negative,%,6,0.999
Cytochrome loss,,6,0.999
Active dose range,mg uM kg-1 day-1,6,0.999
Log MrI,,6,0.999
ED50,nM day-1 kg-1,6,0.999
Rate,pM min-1 (g dry weight)-1,6,0.999
Rate of hydride transfer,s-1,6,0.999
k x10e3,min-1,6,0.999
ED50,10'-10M,6,0.999
"KCS, APP",uM,6,0.999
fAUClast,hr.nM,6,0.999
ks,min-1,6,0.999
Fallen/treated,,6,0.999
Anti-fXa activity,%,6,0.999
Net Swelling,,6,0.999
Neurite bearing cells/total cells,%,6,0.999
K inact,10e-3 s-1,6,0.999
Reaction rate,,6,0.999
No. of shocks accepted/5 min,,6,0.999
AE,%,6,0.999
TCT,s,6,0.999
Flu intensity,RU,6,0.999
No. of relapses,,6,0.999
IogP,,6,0.999
K,10'-1/hr,6,0.999
k cat,M-1,6,0.999
Relative Fluorescent Unit,,6,0.999
scMet,mg kg-1,6,0.999
Kq,10'11L/mol/s,6,0.999
C,ug ml-1,6,0.999
Rate of turbidity change,,6,0.999
Cminss,nmol/g,6,0.999
Cmax,mg Kg-1,6,0.999
CL free,uL/min/nmol,6,0.999
Ratio,10'3/M.s,6,0.999
Cardiac output,ml min-1,6,0.999
Ep2/2,mV,6,0.999
ED50,mg kg-1 4day-1,6,0.999
Activity,10'2/M,6,0.999
CL free,L/hr,6,0.999
Log k,hr-1,6,0.999
Susceptibility,nmol/mg protein/h,6,0.999
Clp,ug hr ml-1,6,0.999
Blood loss,mg kg-1,6,0.999
FPTase activity,fM ug-1 min-1,6,0.999
IC50,10'-4g/L,6,0.999
k+2,s-1,6,0.999
Change of hemoconcentration,,6,0.999
Agonist activity,IU mg-1,6,0.999
NO release,,6,0.999
Ka,10^2/Ms,6,0.999
Kcat,10'-2/min,6,0.999
RRT,,6,0.999
Drug uptake,cpm/mm2,6,0.999
Nitrate,uM,6,0.999
SR,,6,0.999
C24,,6,0.999
Approximate colony formation unit,(g kidney)-1,6,0.999
D2 selectivity,,6,0.999
IC50(app),,6,0.999
Antiproliferative effect,uM,6,0.999
Max platelet response,,6,0.999
Transport rate,uM min-1 g-1,6,0.999
Km,mg/ml,6,0.999
pKH,,6,0.999
RRT,mean,6,0.999
SMT,,6,0.999
SNA,%,6,0.999
Cr secretion,%,6,0.999
log(1/C50),,6,0.999
k+2/k,M-1 s-1,6,0.999
Rat fertility,%,6,0.999
Blood pressure,,6,0.999
No. of writhes,,6,0.999
Relative binding,,6,0.999
Drug degradation,10'-8mol/min,6,0.999
deltaT,,6,0.999
Relative permiability,,6,0.999
APD75,ms,6,0.999
Activity,U/uM,6,0.999
TPO(max),%,6,0.999
Binding constant,,6,0.999
Average turns/first 15 min,,6,0.999
Control of growth,%,6,0.999
Nephrotoxicity,,6,0.999
Loss of inactivation,%,6,0.999
K app,uM-1,6,0.999
deltaG,degrees C,6,0.999
Amount of [3H]thymidine,c.p.m.,6,0.999
Fluorescence,a.u,6,0.999
CCID50,mM,6,0.999
Log d50,nM,6,0.999
k-1 app,hr-1,6,0.999
Agonist index,,6,0.999
Reduction of IOP,mmHg,6,0.999
K1,M-1 s-1,6,0.999
Cmax,umol/Kg,6,0.999
Caverage,uM,6,0.999
Activity,cmH2O/ms,6,0.999
Kq,10'13/M/sec,6,0.999
KA,nm,6,0.999
Activity,units/assay,6,0.999
Exploration motility,,6,0.999
TC50,10'5nM,6,0.999
T-C,days (optimal dose)-1,6,0.999
Log 10 cell kill,,6,0.999
No. cured/total,,6,0.999
fAUC/dose,nM.hr,6,0.999
Radioactivity,nM equiv (ml of blood)-1,6,0.999
AUC units,,6,0.999
M2/M1 index,,6,0.999
MBIC,,6,0.999
I,M,6,0.999
Latency to exit,,6,0.999
AUC 1/T1,s-1 min-1,6,0.999
Temperature decrease,degrees F,6,0.999
Cdyn,%,6,0.999
Bmax,MFU,6,0.999
K app,1/M,6,0.999
Residual RR activity,%,6,0.999
Cmax,ug/hr,6,0.999
Concentration,ul,6,0.999
Kq,,6,0.999
d50,nM,6,0.999
CLH,10'-6uL/min,6,0.999
k3,min-1 M-1,6,0.999
cpm/million cells,,6,0.999
Irritation of eyes,arbitrary units,6,0.999
Threshold current,nA,6,0.999
Drug metabolism,10'-2/hr,6,0.999
MBEC2,uM,6,0.999
Midpoint dose,mg kg-1,6,0.999
IC50,10^2pM,6,0.999
Prolongation effect,,6,0.999
GFR,ml min-1 kg-1,6,0.999
ILC,%,6,0.999
Min effective dose,ug kg-1,6,0.999
Average,c.p.m.,6,0.999
Hypochromic shift,%,6,0.999
Inhibition,uM kg-1,6,0.999
Kw,min-1,6,0.999
ED100,ppm,6,0.999
EAUC50,hr.ng/ml,6,0.999
Thr uptake,,6,0.999
No. of foci per dish,,6,0.999
Kd,10^2/s,6,0.999
FACO Activity,%,6,0.999
CLz/F,ml/hr/kg,6,0.999
k2,s-1,6,0.999
Testosterone,,6,0.999
AD50,pM,6,0.999
Bmax,fM g-1,6,0.999
Activity,eggs/g,6,0.999
Antibody titer,,6,0.999
Survival,number,6,0.999
Anticonulsant activity,%,6,0.999
I,uM,6,0.999
Kdiss,10'-1/s,6,0.999
ODC activity,(nM of CO2) 30min-1 (mg of protein)-1,6,0.999
CL/F,uM.hr,6,0.999
Kin,uL/g.min,6,0.999
Binding constant,l M-1,6,0.999
permeability,umol cm2/hr,6,0.999
Conversion rate,,6,0.999
Antitumor activity,g,6,0.999
MABP change,,6,0.999
t,ns,6,0.999
Mortality,number of descendants/number of tested,6,0.999
T>EC50,hr,6,0.999
CC50,ppm,6,0.999
Relative threshold dose,,6,0.999
Change in FVR,%,6,0.999
Relative response,%,6,0.999
Antagonism effects,,6,0.999
A50,M,6,0.999
CL,uL/mg/min,6,0.999
OMNI med,mg kg-1,6,0.999
T>fEC50,hr,6,0.999
MAP,beats min-1,6,0.999
Free fraction,%,6,0.999
CL,uL/ml,6,0.999
Plasma insulin,pM l-1,6,0.999
t1/2,%,6,0.999
Intrinsic efficacy,%,6,0.999
No. of infected cells,%,6,0.999
Plasma,ug ml-1,6,0.999
AD99,mg kg-1,6,0.999
No. of mice dead,,6,0.999
rate constant app,min-1,6,0.999
Blood/Plasma ratio,,6,0.999
Ext AUC,%,6,0.999
Iron binding,m equiv kg-1,6,0.999
rapp,,6,0.999
Formation,pM/10e9,6,0.999
Excretion,mg dl-1,6,0.999
Modification of hemoglobin,,6,0.999
ED50,ug mg-1 kg-1,6,0.999
Relative uterotrophic activity,,6,0.999
Accumulation counts,Counts,6,0.999
Activity,m equiv l-1,6,0.999
K aff,nM,6,0.999
Zone size,,6,0.999
GABA enhancement,,6,0.999
Therm_solubility,g,6,0.999
AUC/dose,Kg.mg.hr/L.mg,6,0.999
Nitrite,uM,6,0.999
Change in MAP,%,6,0.999
K1,uM,6,0.999
Relative amplitude,,6,0.999
Lag time,s,6,0.999
Duration of plateau,min,6,0.999
ED90,mg/kg,6,0.999
Ctau,ng/ml,6,0.999
Final plasma concentration,nM,6,0.999
CLm,l hr-1,6,0.999
k obs / concentration,M-1 s-1,6,0.999
Fibers/preparations,,6,0.999
Alpha 50,molar fraction,6,0.999
ED50,(ug of misoprostol) kg-1,6,0.999
No. of spikes,,6,0.999
Log Palk,,6,0.999
Khydrol,,6,0.999
Synergy with methicillin,,6,0.999
Mitotic index,nM,6,0.999
Convulsion threshold,mg kg-1,6,0.999
Activity_index,mg/g,6,0.999
[I],mM,6,0.999
E1/2,mV,6,0.999
log(activity),/ml,6,0.999
K,10'-7/hr,6,0.999
Remaining at 40 min,%,6,0.999
Xi50,,6,0.999
Radioactivity,nM equiv (ml of urine)-1,6,0.999
Activity regained,%,6,0.999
Activity,/cm,6,0.999
Occ80,mg kg-1,6,0.999
K obs x10e2,min-1,6,0.999
k_elim,hr-1,6,0.999
KNBP,min-1,6,0.999
Activity (umol/g.of liver 75.min),%,6,0.999
Cell aggregates,,6,0.999
Recovery rate,%,6,0.999
Acetylation,%,6,0.999
K alkyl,,6,0.999
K inact/Ki,uM-1 min-1,6,0.999
K,10'-6M,6,0.999
Relaxivity,mM-1 s-1,6,0.999
Ratio Ki,10^-5No_unit,6,0.999
Radioactivity,nM equiv mg-1,6,0.999
QT,,6,0.999
Activity,/10'3mm'-3,6,0.999
Incorporated,%,6,0.999
Fungicidal concentration,uM,6,0.999
Cell,%,6,0.999
K,10'-6/s,6,0.999
Level,ng g-1,6,0.999
Molar primaquine Index,,6,0.999
Adduct formation,%,6,0.999
Kd,ug ml-1,6,0.999
Reduction,beats min-1,6,0.999
Occ50,,6,0.999
Transcriptional activation,%,6,0.999
Testosterone,ng ml-1,6,0.999
Activity,nm s-1,6,0.999
Basis motility,,6,0.999
MED,(mg of base) kg-1,6,0.999
Ratio IC50,10'4No_unit,6,0.999
EMax,,6,0.999
Time over 100ng/ml,hr,6,0.999
Static remission,%,6,0.999
Time of licking,s,6,0.999
LDH release,MU,6,0.999
Concentration,uM 100ml-1,6,0.999
Vmax,ug/ml/min,6,0.999
EC90,mg kg-1,6,0.999
Vmax/Km,U/mg/uM,6,0.999
Abortion,%,6,0.999
CL,ml/hr/mg,6,0.999
Mean log GI50,,6,0.999
Kinact,/ms,6,0.999
Activity,mV/ms,6,0.999
logD,pH7.4,6,0.999
permeability,10'-4 cm/min,6,0.999
Time to peak tension,min,6,0.999
GI25,uM,6,0.999
Kcat/Km,10^5/M/s,6,0.999
Resting potential,-mV,6,0.999
Bathochromic shift,nm,6,0.999
AUClast,nmol/hr/L,6,0.999
3D PSA,,6,0.999
Increase contractility,%,6,0.999
Hexobarb ST,min,6,0.999
IC50,nA,6,0.999
Onset for sleep,min,6,0.999
Antigen p24 content,ng ml-1,6,0.999
VmaxH,pmol/min/g,6,0.999
% of inhibition or stimulation,%,6,0.999
Volume,uM,6,0.999
Volume,ml min-1,6,0.999
Response,mg kg-1,6,0.999
CLup,ml/min,6,0.999
ED250,umol/Kg,6,0.999
-log(1/HC50),,6,0.999
Stability,pmol/ml,6,0.999
Inhibition tumor index,%,6,0.999
Periosteal mineral apposition rate,mm day-1,6,0.999
Cell no./dish x10E3,,6,0.999
Median tumoral volume,cm*3,6,0.999
Cell no./dish x10E5,,6,0.999
Topoisomerase-I activity,,6,0.999
Ka,/uM/s,6,0.999
MIC,10'-6mmol/L,6,0.999
Retraction time,s,6,0.999
Papp,ucm,6,0.999
Ka,10'5/Ms,6,0.999
Score,%,6,0.999
VLDL,ug mg-1,6,0.999
Tumor volume,%,6,0.999
Cp,ug,6,0.999
pC20,,6,0.999
Respiratory system resistance,,6,0.999
Css,ng/ml,6,0.999
Vz,uL/g,6,0.999
%PFU,%,6,0.999
Aberrant cells,,6,0.999
Total binding,pCi mg-1,6,0.999
Body temp drop,degrees C,6,0.999
Ratio CC50/IC50,10'3No_unit,6,0.999
Reverse potential,,6,0.999
pKinact,,6,0.999
Activity,RFU/min,6,0.999
Ka,10'-6/M/s,6,0.999
Total DPM,,6,0.999
MED90,mg monkey-1 day-1,6,0.999
Permeability,Papp* 10E6 cm/s,6,0.999
Vmax rel,,6,0.999
Vmax/Km,10'3ml/min,6,0.999
Distribution of excreted Fe,%,6,0.999
MED,ug/L,6,0.999
High,%,6,0.999
LDL,ug mg-1,6,0.999
Body temperature drop,degrees C,6,0.999
Weight,(mg of prostate) (100g of body weight)-1,6,0.999
Drug uptake,pg/mg,6,0.999
Peak radioactivity in blood,% injected dose cm**-3,6,0.999
Peak inhibition,%,6,0.999
EC1000,umol/L,6,0.999
Distribution,% dpm,6,0.999
Mean arterial blood pressure,%,6,0.999
mequiv of HCl,,6,0.999
Thyroid status,ng ml-1,6,0.999
K H,,6,0.999
Absorbance,%,6,0.999
GST activity,nM min-1 (mg of protein)-1,6,0.999
CBF increasing activity,%,6,0.999
Vmax,nM min-1 g-1,6,0.999
Kinact,10^-2/min,6,0.999
Hepatocyte stability,uL/min/10e6 cells,6,0.999
Drug metabolism,nmol/L,6,0.999
Cmin,fmol,6,0.999
Activity,um3/um2/day,6,0.999
C10 air/C10 N2,,6,0.999
Total radioactivity,,6,0.999
PC95,ug ml-1,6,0.999
IFN,,6,0.999
Vmax,pM,6,0.999
WBC_CHANGE,%,6,0.999
Hydrolysis,nM min-1,6,0.999
Change in hematology,,6,0.999
GH peak,ug l-1,6,0.999
Membrane integrity,%,6,0.999
IC50,nmol/mg,6,0.999
Distribution,% dose organ-1 ,6,0.999
MFC>99,,6,0.999
LC50,mg,6,0.999
Vmax,pmol/min/pmol,6,0.999
Reversibility,,6,0.999
Ratio,10'-5/M,6,0.999
RT activity,%,6,0.999
Vmax,mmol/min/mg,6,0.999
DMF,,6,0.999
GH AUC 0-180,ug min l-1,6,0.999
Activity,10'6/100microL,6,0.999
EC50,mh/kg,6,0.999
Rmax,mM,6,0.999
Crop_yield,Kg,6,0.999
MHPG_SO4,ug g-1,6,0.999
Thymidylate shift,,6,0.999
GSH,uM g-1,6,0.999
Decrease in tone,,6,0.999
GI50,%,6,0.999
Stability,nmol/g,6,0.999
logED50,,6,0.999
50% naproxen formed,%,6,0.999
Activity,Ratio,6,0.999
Cell growth,number of cells ml-1,6,0.999
IC50,microg/cm3,6,0.999
CFU,10^8/g,6,0.999
Cz,ng/ml,6,0.999
Ka,10'4/M.s,6,0.999
Crop_yield,g,6,0.999
Kcat/Km,10'-4/uM/s,6,0.999
Drug uptake,microL/min/mg,6,0.999
AUClast/dose,mg.hr/ml,6,0.999
Concentration,pM (10e6*cells)-1,6,0.999
Occlusions,,6,0.999
Activity,umol/mol,6,0.999
Denaturation rate constant,min-1,6,0.999
AUC,uM.h. kg/mg,6,0.999
Cmax,ng/mL.hr,6,0.999
Ear thickness,uM,6,0.999
Vmax,nmol/min/U,6,0.999
GRI,,6,0.999
K,10'6/M.s,6,0.999
Decrease of SBP,mmHg,6,0.999
Change in tumor area,%,6,0.999
ROI,,6,0.999
Mean ED50,mg kg-1,6,0.999
COI,%,6,0.999
RD100,mg kg-1,6,0.999
Trabecular thickness,nm,6,0.999
Kcat,10^-2/s,6,0.999
Virus yield,ffu ml-1,6,0.999
Virus titer,pfu/ml,6,0.999
pKL,,6,0.999
RCI,%,6,0.999
Specificity,%,6,0.999
Max respose,,6,0.999
AUC,ng.hr.kg/ml/mg,6,0.999
Drug uptake,mg,6,0.999
SC50,%,6,0.999
Antinociception,%,6,0.999
Plaque inhibition result,,6,0.999
Vmax,mM min-1,6,0.999
Parasite_Clearance_time,hr,6,0.999
Vmax,delta A/min,6,0.999
Tumor growth delay,,6,0.999
MIC70,uM,6,0.999
ID50,fmol,6,0.999
RC50,umol/ml,6,0.999
ID/g femur,%,6,0.999
LD,g/Kg,6,0.999
LD,ppm,6,0.999
Kapp,/min,6,0.999
Tumor growth inhibition,%,6,0.999
Cellular uptake of boron at 16h,ug of B (g of cells)-1,6,0.999
LD50,pmol/g,6,0.999
pA1,,6,0.999
SD50,mg kg-1,6,0.999
p24,ng ml-1,6,0.999
Spermidine concentration,nM (10e6*cells)-1,6,0.999
Drug uptake,kBq/cm3,6,0.999
P ratio,,6,0.999
Trabecular no.,mM-1,6,0.999
Km,nmol/mg,6,0.999
"S20,w",Svedberg,6,0.999
Vmax,amol/cell.min,6,0.999
MIC,mg,6,0.999
Developed tension,%,6,0.999
Block,,6,0.999
CLH,uM/min.mg,6,0.999
AUC,u-1 hr-1 ml-1,6,0.999
Kinact,M/s,6,0.999
ED300,ug ml-1,6,0.999
Slope,mutants ug-1,6,0.999
Pancreatic response,,6,0.999
AUC,nM.hr/g,6,0.999
ka,/min,6,0.999
Slope,g dl-1M-1,6,0.999
Vd,%,6,0.999
PC50,ug ml-1,6,0.999
Activity,AU/mm,6,0.999
Effect,pM g-1,6,0.999
PRCF,,6,0.999
Triglycerides,mg dl-1,6,0.999
BP,mM,6,0.999
IC50,ucm,6,0.999
SSAT,pM min-1 mg-1,6,0.999
Ratio,ng/mg,6,0.999
Toxic level,mg ml-1,6,0.999
Depletion,%,6,0.999
Kcat/Km,/M/min,6,0.999
CAI activity,,6,0.999
Gastric score,,6,0.999
RC50,,6,0.999
CFU/g,,6,0.999
Area,AU mm-1,6,0.999
Derived trabecular number,mM,6,0.999
ID50,mg ml-1,6,0.999
Papp,umol/L/s,6,0.999
Activity,pM (2*10e6*cells)-1,6,0.999
Trans,%,6,0.999
Activity,Momega,6,0.999
AUCt/dose,microM.hr/mg/kg,6,0.999
Glycine antagonism,,6,0.999
K,10^-5/nM/s,6,0.999
Max delta APD95,,6,0.999
Average for skin reaction,,6,0.999
PCP activity,cysts g-1,6,0.999
Inhibitory activity ratio,,6,0.999
CI95,,6,0.999
Cleavage rate,uM min-1 g-1,6,0.999
-TdeltaS,cal/mol,6,0.999
CL,mL/min/m2,6,0.999
Ka,10^9/M,6,0.999
BPI,,6,0.999
PCoct,,6,0.999
CR,%,6,0.999
Cell survival,,6,0.999
K,10^-4/M/s,6,0.999
Max dV/dt,V s-1,6,0.999
Bmax,uM,6,0.999
EC50,uM.hr,6,0.999
MLD,pmol,6,0.999
BUN_CHANGE_BY,%,6,0.999
LD50,10'-2 ug/ml,6,0.999
Tumor size,mM,6,0.999
V0,10^-8M/s,6,0.999
Egg reduction,%,6,0.999
Change in sensitivity,,6,0.999
Growth Index,,6,0.999
Cmax,pmol.hr/g,6,0.999
Activity,million,6,0.999
Kb,10'5L/mol,6,0.999
PPB,pmolequiv/mg,6,0.999
Secretion,uM hr-1 kg-1,6,0.999
Kb,10'4mol/L,6,0.999
AUC,ng.eq.h.ml-1,6,0.999
LD,Gy,6,0.999
Growth rate,uM,6,0.999
VRT(t),hr2,6,0.999
VT50,,6,0.999
AUC,pmol.hr/g,6,0.999
Serum glucose,mg dl-1,6,0.999
AUCt/dose,min.kg/L,6,0.999
Cp(T),nM,6,0.999
K,10^2/M/s,6,0.999
Activity,Kb M-1,6,0.999
HDT,mg kg-1,6,0.999
Kb,10'-5L/mol,6,0.999
1/krel,,6,0.999
Ratio,10^2/M/s,6,0.999
ID/organ,,6,0.999
Cells positive,%,6,0.999
Kiuc,nM,6,0.999
Bitter taste intensity,0-15 scale,6,0.999
C50,M,6,0.999
Kb,10'-4/M,6,0.999
MRTlast,min,6,0.999
U osm,mOsmol kg-1,6,0.999
AUC,pM hr-1 g-1,6,0.999
MSC,ug ml-1,6,0.999
Activity,J,6,0.999
MRT(t),min,6,0.999
Drug mol/base pair,,6,0.999
Cellular growth,%,6,0.999
K,10^-7M,6,0.999
Efflux,uM,6,0.999
Bmax2,%,6,0.999
PIC seizure,mg kg-1,6,0.999
Cellular content,pM (10e6*cells)-1,6,0.999
Selectivity ratio,nM,6,0.999
pD2 app,,6,0.999
1/MIC,L/mg,6,0.999
AUC,nmol.hr,6,0.999
Kapp,10'6/M/s,6,0.999
Concentration,mg dl-1,6,0.999
LD0,uM kg-1,6,0.999
Ulcer index,mM,6,0.999
Activity,KA/dl,6,0.999
Epoxide formation,nM,5,0.999
[I] 0.5,uM,5,0.999
Blood level,,5,0.999
MBC100,,5,0.999
MBC50,uM,5,0.999
CL,ml/min.mg,5,0.999
Epinephrine level,,5,0.999
IL-1 production,pg ml-1,5,0.999
Responding,,5,0.999
AOC,mmHg.hr,5,0.999
BAV,%,5,0.999
INH,pM,5,0.999
Phospholipidosis_index,,5,0.999
A2,10'-8M,5,0.999
QH,L/hr.Kg,5,0.999
aPTT,,5,0.999
Drug uptake,ug/kg,5,0.999
Adrenal uptake,,5,0.999
AAC,deltalog10CFU/ml.hr,5,0.999
Lysis time,min,5,0.999
INCC50,nM,5,0.999
Relative rate,%,5,0.999
Drug uptake(free),ng/ml,5,0.999
INH,10'-5M,5,0.999
K,10'-6/M/s,5,0.999
LOAEL,mg kg-1,5,0.999
Concentration,ug kg-1,5,0.999
Actual duraction,,5,0.999
Absolute,%,5,0.999
damage reduction,%,5,0.999
Vr,ml,5,0.999
ED50,mg/L,5,0.999
CL,ml/mm/kg,5,0.999
Platelet count/ul,,5,0.999
Rescued neurons,%,5,0.999
CL,nL/pmol/min,5,0.999
Food intake,,5,0.999
Food intake,%,5,0.999
DR20,ug kg-1,5,0.999
AUC,hr.kg.ng/ml/mg,5,0.999
Kd,10^-4/s,5,0.999
MD,%,5,0.999
K,10'10/M/s,5,0.999
Loss of affinity,,5,0.999
IG50,ug ml-1,5,0.999
Residual amine (ee),%,5,0.999
C0,ng/L,5,0.999
Correlation coefficient,,5,0.999
deltaH,10^4cal/mol,5,0.999
CLu/F,ml/min.kg,5,0.999
LDH,,5,0.999
VmaxL,pmol/min/g,5,0.999
GI50,10^4M,5,0.999
Covalent binding,%,5,0.999
Antifungal activity,%,5,0.999
CS50,ug ml-1,5,0.999
AOC,,5,0.999
MEC,ug,5,0.999
Delta weight,,5,0.999
Accumulation,nM g-1,5,0.999
BC,uM,5,0.999
Weight difference,T-C,5,0.999
Log Pe,,5,0.999
C10APD90,uM,5,0.999
AUMCt,ng.hr/ml,5,0.999
Kh,min-1,5,0.999
fEC50,ng/ml,5,0.999
Ratio AUC,ml/g,5,0.999
C2,ug g-1,5,0.999
ED100,ug ml-1,5,0.999
Cp,microM,5,0.999
MIC,ug l-1,5,0.999
p value,,5,0.999
Increase in [Ca+2],nM,5,0.999
Gated current,%,5,0.999
Vmax,M min-1,5,0.999
Activity,pmol/(s.cm2),5,0.999
Activity,pmol/Kg,5,0.999
C 8 h,uM,5,0.999
MFED,,5,0.999
MIC,mg kg-1,5,0.999
Change of weight,%,5,0.999
Log Ko/w,,5,0.999
fNOAEL,uM,5,0.999
Ki,1/M.s,5,0.999
Ki,/nM,5,0.999
MIC,10'-4/M,5,0.999
Blood urea nitrogen,,5,0.999
Phosphorylation,%,5,0.999
S-phase,%,5,0.999
Khd,,5,0.999
Log Pcyc,,5,0.999
Plasmaconcentration,nM,5,0.999
LambdaZ,min,5,0.999
Drug uptake,uM.hr,5,0.999
log(1/MEC),,5,0.999
Ratio IC50/EC50,10'5No_unit,5,0.999
88Y-serum,%,5,0.999
Relative loss of potency,,5,0.999
Kd,10'-8/s,5,0.999
MBEC80,ug ml-1,5,0.999
Plasma MIC,ug ml-1,5,0.999
Remission,%,5,0.999
ILS,day,5,0.999
X,min,5,0.999
Plasma total cholesterol,mg dl-1,5,0.999
AUC,/hr,5,0.999
INH,10'-7M,5,0.999
LMA,%,5,0.999
Acquisition time,,5,0.999
Ke,10'5/M,5,0.999
INH,umol/Kg,5,0.999
ABD50,mg kg-1,5,0.999
EC50,10^2 uM,5,0.999
2X PT,uM,5,0.999
Partition coefficient,min,5,0.999
IPol,nM,5,0.999
IP3-sensitive Ca2+ stores,%,5,0.999
MI0.5,,5,0.999
Activity,10^5No_unit,5,0.999
MHC10,,5,0.999
ME,%,5,0.999
Animals affected,,5,0.999
Vz/F,(mg/kg)/(uM),5,0.999
AUC,min.sec,5,0.999
Virus inactivation,%,5,0.999
1/Vmax,deltaA/s,5,0.999
Activity,pM hr-1 mg-1,5,0.999
Animals affected,%,5,0.999
Activity,pM 10min-1,5,0.999
Vm rel,%,5,0.999
ISC,,5,0.999
Virucidal,,5,0.999
ID50,mg ear-1,5,0.999
CL/F,L/Kg,5,0.999
Decrease,mmHg,5,0.999
Cp,pg/mg,5,0.999
SDL,,5,0.999
Ratio,min-1,5,0.999
SGPT activity,units/mL,5,0.999
2PT,10'-3M,5,0.999
Uptake,fM cell-1,5,0.999
lambda-z,L.h-1,5,0.999
C20 FRP,,5,0.999
MTD,mg/day,5,0.999
Initial heart rate,bts min-1,5,0.999
Kb,10'9/M,5,1.0
Vdss,Not_given,5,1.0
Ki1,uM,5,1.0
Activity,nanometer2/sec,5,1.0
LD100,ug ml-1,5,1.0
Drug uptake,%Idose/kg,5,1.0
SGOT activity,units/mL,5,1.0
Vm,uM min-1mg-1,5,1.0
Kic,mM,5,1.0
AUCt,pmol.hr,5,1.0
Ambulation score,,5,1.0
DFM,mg/cm2,5,1.0
AUMC,microM.hr^2,5,1.0
Activity,10^-10No_unit,5,1.0
Exudate volume,ml,5,1.0
MIC99.9,,5,1.0
Concentration,ng day-1,5,1.0
Log IC50,log(1/M),5,1.0
Kapp,10'8/M,5,1.0
MIC=<90,,5,1.0
k cat/Km,uM-1 min-1,5,1.0
Kcat,10'-3/hr,5,1.0
PI turnover,%,5,1.0
Papp,um/s,5,1.0
Progressed remission,%,5,1.0
Amount Recovered in urine,mg,5,1.0
Extent of DNA binding,,5,1.0
HD100,ug ml-1,5,1.0
FRS50,uM,5,1.0
EC50,10'11PFU,5,1.0
Isometric contraction,%,5,1.0
Ki2,uM,5,1.0
Liver CH levels,,5,1.0
Liver TG,,5,1.0
Ratio,ml/g,5,1.0
Uptake rate,nM min-1 cm**-2,5,1.0
Animals with palpable tumor,,5,1.0
kinact,,5,1.0
ED30,mg/kg/day,5,1.0
Kcat/Km,/M/hr,5,1.0
Log DSF,,5,1.0
Lesion score,,5,1.0
Cp,ug.hr/ml,5,1.0
Log AC50,,5,1.0
kn,,5,1.0
DBP/UP ratio,,5,1.0
Vd,ml/min.kg,5,1.0
Ki_app,nM,5,1.0
Liver weight,g (100g of body weight)-1,5,1.0
EC50,10^-2nM,5,1.0
Anesthetic effect,%,5,1.0
ED200,,5,1.0
MLC,mg kg-1,5,1.0
SWo,,5,1.0
Ratio,10^6/M/min,5,1.0
Reduction in AUC,,5,1.0
Impaired,%,5,1.0
Cp,pmol/g,5,1.0
ED10,M,5,1.0
1/n,,5,1.0
Prodrug remains,%,5,1.0
Concentration,ml,5,1.0
LD50,10'-3 ug/ml,5,1.0
AUCt/dose,ug.hr/mL/mg/kg,5,1.0
LD100,ppm,5,1.0
Pressor response,%,5,1.0
Excreted,,5,1.0
mortality,day,5,1.0
CL/F,mg kg-1,5,1.0
Liver cholesterol,mg (g of tissue)-1,5,1.0
ED100,nM kg-1,5,1.0
Vdss,ml/min.kg,5,1.0
Log 1/KL,,5,1.0
Cmax/dose,umol/L,5,1.0
Protection,day,5,1.0
Cp,uM.hr,5,1.0
Kb,mg kg-1,5,1.0
EC50,uL/ml,5,1.0
BP decrease,,5,1.0
Ratio,10^3/s/M,5,1.0
Reduction in respiratory volume,ml,5,1.0
Kinetic_solubility,10'-4mg/ml,5,1.0
Log 1/I50,,5,1.0
Inhibitory ratio,%,5,1.0
Delta H-V,ms,5,1.0
Kb,10^4L/mol,5,1.0
Bmax,disintegrations/min,5,1.0
Uterus effect,,5,1.0
PPM,,5,1.0
CL/F,ug/ml.hr,5,1.0
2 x APTT,uM,5,1.0
MNTD>75,uM,5,1.0
Drug uptake,%ID.m^-2,5,1.0
Kinetic_solubility,10'-5mg/ml,5,1.0
EC20,M,5,1.0
C,mg ml-1,5,1.0
ED50,Ug/ml,5,1.0
MRTV,,5,1.0
ID50,10'-8M,5,1.0
Vmax,area/min/mg,5,1.0
Fraction Recovered in urine,%,5,1.0
CL/F,(mg)/(ug/ml)/hr,5,1.0
Decrease in CVR,%,5,1.0
Bicarbonate level,,5,1.0
Kobs,/ms,5,1.0
Total binding inhibited,%,5,1.0
Activity,Pmol,5,1.0
Drug degradation,pmol/min/mg,5,1.0
Carbamoylating activity,,5,1.0
Cross reaction,%,5,1.0
Decrease in heart norepinephrine,%,5,1.0
Mean blood pressure,mM,5,1.0
Kobs,,5,1.0
Ratio,10'-7No_unit,5,1.0
Activity,10'3/ml,5,1.0
AUClast,pmol.hr/g,5,1.0
I,mM,5,1.0
KH,s-1,5,1.0
% release of nitric oxide,uM uM-1,5,1.0
Morbidity,%,5,1.0
Ratio,1/M.sec,5,1.0
CFU,10'6/ml,5,1.0
Activity,log10RLU,5,1.0
K,nmol/min,5,1.0
Stability,pmolequiv/mg,5,1.0
Behavioral syndrome,,5,1.0
Mean no. of days post-infection to death,,5,1.0
Drug metabolism,microM/min/mg,5,1.0
AUC,ug h/g,5,1.0
Observed relaxivity,mM-1 s-1,5,1.0
LC50,%,5,1.0
Observed [pt],mM (mg of protein)-1,5,1.0
Surface involvement,%,5,1.0
AUC ED50,mg kg-1,5,1.0
AUC 100,mg kg-1,5,1.0
EC90,ppb,5,1.0
Infected,%,5,1.0
CFR rating,,5,1.0
Brain concentration,nM,5,1.0
AUC,umol.hr/kg,5,1.0
% of activity remaining,%,5,1.0
Hypoglycemic activity,,5,1.0
Sterility,%,5,1.0
Efficiency,uM-1 s-1,5,1.0
EC95,ppm,5,1.0
Substrate efficiency,%,5,1.0
Activity,mAU ml-1,5,1.0
KNBP,s-1,5,1.0
Inhibition of increase in weight,%,5,1.0
Decrease in hypothalamus norepinephrine,%,5,1.0
Time constant T3,,5,1.0
CC100,,5,1.0
Brain concentration,,5,1.0
Of dose excreted,%,5,1.0
Activity,mJ,5,1.0
CLint,,5,1.0
IC50,liposomes ml-1,5,1.0
Average 14-day MGR,mm**3 day-1 ,5,1.0
Thy-1 expression,,5,1.0
Molar potency,,5,1.0
ED,ug,5,1.0
I,,5,1.0
Mean log LC50,,5,1.0
Negative ionotropic activity,%,5,1.0
s-GPT level,Karmen units,5,1.0
TC,uM,5,1.0
t1/2,ml/min.kg,5,1.0
Max activation,%,5,1.0
PD200,umol/Kg,5,1.0
Serum T4,ug dl-1,5,1.0
BUI,,5,1.0
K+2,min-1,5,1.0
pEC5,,5,1.0
Kix,mM,5,1.0
LD/ED80,,5,1.0
No. of invaded cells,,5,1.0
No. of avoidance,,5,1.0
Sleep ratio,,5,1.0
Inhibitory activity,%,5,1.0
No. of mice without tumors,,5,1.0
HTS data,,5,1.0
Change in TC,,5,1.0
T inh,,5,1.0
Ulcer index,mm,5,1.0
Activity,ml/cm3/min,5,1.0
Inhibition,mg kg-1,5,1.0
Activity,ml/cm3,5,1.0
Concentration,dpm,5,1.0
AUC/dose,nM/hr,5,1.0
T3,%,5,1.0
No. of guinea pigs protected,,5,1.0
AV block,,5,1.0
Kapp,10'3/M/s,5,1.0
K+2/Ki,uM min-1,5,1.0
Ka,l mol-1,5,1.0
TG 2X lag,uM,5,1.0
TC50/IC50,,5,1.0
K0.5,10'-5M,5,1.0
AUC/dose,ng.hr.kg/mg/ml,5,1.0
Cl,ml mg-1 kg-1,5,1.0
Ratio,10'5/M/min,5,1.0
No. of openarm entries,,5,1.0
T1/2 h,,5,1.0
K inact/Km,M-1 s-1,5,1.0
ICA,,5,1.0
solubility,mg/uL,5,1.0
No. of escape failure,,5,1.0
Max Achievable Bioavailability,,5,1.0
Change in blood flow,%,5,1.0
AUC,nmol/g.min,5,1.0
Cp(f),umol/L,5,1.0
No. of rats displaying DA syndrome,,5,1.0
No. of new tumors,,5,1.0
AUC,nmol/g/min,5,1.0
Rate,nM-1 min-1 (mg of protein)-1,5,1.0
K+ excretion,ml 6hr-1 100g-1,5,1.0
Max APD90 (delta),%,5,1.0
pIC35,,5,1.0
Activity,dyn/cm,5,1.0
Activity,deltalog10pfu/g,5,1.0
T2,hr,5,1.0
PD50,umol/Kg,5,1.0
UD50,,5,1.0
Max agonist activity,%,5,1.0
Therm_solubility,%,5,1.0
C8h,,5,1.0
Activity,mM hr-1,5,1.0
Km/Kcat,uM s-1,5,1.0
DTH,mM,5,1.0
max Delta Vmax,%,5,1.0
IOP lowering,mmHg,5,1.0
Activity,10^-7No_unit,5,1.0
Peff,10^-6nanometer/s,5,1.0
Concentration,pmol/10E9 cells,5,1.0
Activity,10^-8No_unit,5,1.0
Concentration,pmol/E109 cells,5,1.0
Lambda-z,L.h-1,5,1.0
Phospholipidosis,uM,5,1.0
ka,/uM/min,5,1.0
Dilation,,5,1.0
Ks,10'5/M,5,1.0
Oxytocic activity,U mg-1,5,1.0
KA,uM kg-1,5,1.0
Hepatic cholesterol,mg g-1,5,1.0
Maximal change,%,5,1.0
Carbonyl group,nM mg-1,5,1.0
Ratio,10'2/M/s,5,1.0
No. of virus free mice,,5,1.0
AUC,uM hr ml-1,5,1.0
Ca2+ antagonistic activity,%,5,1.0
Max. potentiation,%,5,1.0
CI,%,5,1.0
ED delta,mg kg-1,5,1.0
Activity,N/mm,5,1.0
Maximal activation,,5,1.0
Max tolerated dose,uM kg-1,5,1.0
K,10'4/Ms,5,1.0
Positive paws,%,5,1.0
fCmax,nmol/g,5,1.0
Vmax,pmol/min/ug,5,1.0
MED99.9,mg kg-1,5,1.0
Brain concentration,mM,5,1.0
CLH,mg/min/g,5,1.0
Agonist response,,5,1.0
No. of lung lesions,,5,1.0
Emin,,5,1.0
fAUC,nmol/g/min,5,1.0
Relative antitumor activity,,5,1.0
ED50,uM.hr,5,1.0
B-A/A-B,,5,1.0
Vmax(app),microM/s,5,1.0
ED50,mg kg-1 dose-1,5,1.0
Peripheral restriction index,,5,1.0
Retention time,,5,1.0
Enantioselectivity coefficient,,5,1.0
Vmax/Km,ml/min/mg,5,1.0
Delta S-H,ms,5,1.0
Vmax / K,,5,1.0
Flu intensity,10^9/s/cm2,5,1.0
Vmax,umol,5,1.0
Delta CPP,mmHg,5,1.0
MFC90,mg/L,5,1.0
Keq,uM,5,1.0
RBC,10e6 ul-1,5,1.0
Peff,10'-3cm/min,5,1.0
K,10'4/s,5,1.0
IP+SC score,,5,1.0
Toxic effect,,5,1.0
Ratio EC50,microM,5,1.0
AUClast/dose,hr.kg.ng/ml/mg,5,1.0
Max fall in IOP,,5,1.0
pK4,,5,1.0
AUC/dose,uM.hr/mg,5,1.0
Kr,s-1,5,1.0
Ka,10^10/M,5,1.0
Binding affinity,M-1,5,1.0
No. of survivors/total,,5,1.0
pKR+,,5,1.0
Activity,g/mm,5,1.0
Rate of formation,pM min-1,5,1.0
Rate of formation,nM (mg of protein)-1,5,1.0
AUC/dose,hr.kg.ug/ml/mg,5,1.0
Specific radioactivity,Ci/M,5,1.0
Transport,pM min-1 (mg of protein)-1,5,1.0
Max protective effect,%,5,1.0
Max protection,,5,1.0
Max potentiation,%,5,1.0
Helicity,%,5,1.0
Na+ excretion,ml 6hr-1 100g-1,5,1.0
AUC/dose,M.hr.kg/mg,5,1.0
I40,uM,5,1.0
TPE,toxicity,5,1.0
AUCED90,uM.hr/day,5,1.0
ED50,10'-4umol/ml,5,1.0
Ratio,/s/mM,5,1.0
K beta,nM,5,1.0
Kpol,s-1,5,1.0
Mitotic figures,,5,1.0
Negative chronotropic activity,%,5,1.0
Oligo shifted,%,5,1.0
Tubulin,,5,1.0
AUC/dose,umol/l.hr,5,1.0
K,10^8/M/min,5,1.0
Drug degradation,a.u.,5,1.0
Ka,10'5/uL,5,1.0
Inhibition at 5nM,%,5,1.0
Compound recovery,hr,5,1.0
AUC,uM min uM-1,5,1.0
No. survived,,5,1.0
I50 M,,5,1.0
Hepatic triglyceride,mg g-1,5,1.0
MeAIB uptake,,5,1.0
Drug metabolism,nmol/min/nmol,5,1.0
Cmax,%ID,5,1.0
Ka,10'5/M.s,5,1.0
TED,nM kg-1,5,1.0
EC80,,5,1.0
Ts,degrees C,5,1.0
s-GOT level,Karmen units,5,1.0
Max score,,5,1.0
LC90,mg,5,1.0
Challenge dose,,5,1.0
Necrosis,,5,1.0
Ka,10^2/M/s,5,1.0
Clonic seizures,%,5,1.0
AUCt,hr.ng/g,5,1.0
TD,uM,5,1.0
I80,mM,5,1.0
Consumption,%,4,1.0
AD50,%,4,1.0
MBIC50,mM,4,1.0
MFC50,,4,1.0
AUC,mg/L,4,1.0
CL,min.kg/L,4,1.0
Vmax,nM hr-1 (mg of protein)-1,4,1.0
Level of cGMP,pM,4,1.0
AUC,10^4nM.min,4,1.0
ka/kr,,4,1.0
k eff (rel),,4,1.0
Vmax,nmol/ mL h,4,1.0
Drug uptake,microg/g,4,1.0
BG reduction,%,4,1.0
Cooperative effect,,4,1.0
Activity in animals,,4,1.0
Activity Score,,4,1.0
BG,mM,4,1.0
Kcat/Km,10'4/Ms,4,1.0
Vmax,nM/min/mg,4,1.0
AD50,mM kg-1,4,1.0
KiH,fM,4,1.0
Tumor size,mg,4,1.0
2aPTT,ug ml-1,4,1.0
Lipid peroxidation,nM MDA (mg LDL)-1,4,1.0
kb,M-1 min-1,4,1.0
k eff,M-1 min-1,4,1.0
Kcat,uM,4,1.0
Convulsions,%,4,1.0
ko,min-1 s-1,4,1.0
F1/2,,4,1.0
Activity,l kg-1,4,1.0
k cat/Km,%,4,1.0
Kcat,mM,4,1.0
Vmax,/RU/s,4,1.0
Cmax,uM.hr,4,1.0
kirr,s-1,4,1.0
EBD20,mg kg-1,4,1.0
Cp,ng.hr/ml,4,1.0
MIC,ug/mg,4,1.0
F3/4,,4,1.0
Drug uptake,ml/g,4,1.0
ED50,uM mouse-1,4,1.0
Vmax,10'-5 uM/s,4,1.0
kaKr/kr,M,4,1.0
MI50,umol/L,4,1.0
GDP activity,nM min-1 mg-1,4,1.0
Drug uptake,ml/min,4,1.0
Vmax,nmol/min/ug,4,1.0
Activity Factor,,4,1.0
Vmax,pM U-1 min-1,4,1.0
Activity,uL/L,4,1.0
Limiting t1/2,min,4,1.0
Vmax,pMl hr-1,4,1.0
CL/F,L.h-1,4,1.0
NADH oxidation,uM min-1,4,1.0
NAD+ level,%,4,1.0
AMPA effect,%,4,1.0
Kp,nM,4,1.0
ED90,umol/Kg,4,1.0
Drug degradation,ug ml-1,4,1.0
Log10CCID50/g,,4,1.0
pKa6,,4,1.0
KD hydro,mM,4,1.0
Thermogenesis,%,4,1.0
fIC90,nM,4,1.0
Cmin,ng,4,1.0
Cmin,mg/dl,4,1.0
-Log IC50/IC50,,4,1.0
Ct,%ID,4,1.0
Thylpositive cells,%,4,1.0
KOH,M-1 s-1,4,1.0
Thylpositive cells/spleen,%,4,1.0
KSV,/uM,4,1.0
Thymidine reversal,,4,1.0
Fold stimulation,,4,1.0
Hydroxyproline release,ug ml-1,4,1.0
Activity,mIU/L,4,1.0
Activity,mIU/ml,4,1.0
Thermogenesis,,4,1.0
Glucose,mg day-1,4,1.0
pKx,,4,1.0
LC50,10'-3ppm,4,1.0
ALT,U l-1,4,1.0
NB,,4,1.0
L/CE,,4,1.0
EC30,10'-6M,4,1.0
CLd,L/hr,4,1.0
Ke,10'8/M,4,1.0
Ke,10'4/M,4,1.0
N20 formed,nM,4,1.0
KB,s-1,4,1.0
% of NO release,,4,1.0
TRIG_CHANGE,,4,1.0
Log10 reduction,,4,1.0
Drug degradation,nmol/min/mg,4,1.0
partition_ratio,,4,1.0
EOS inhibition,%,4,1.0
I/M ratio,,4,1.0
Cmax,nM l-1 hr-1,4,1.0
deltaTCID50,,4,1.0
ALT.,U l-1,4,1.0
AUC glu,mM min,4,1.0
Fmax,pg/ml,4,1.0
Kq,/M/s,4,1.0
deltalog10CFU,/ml,4,1.0
Activity,kcps,4,1.0
KA effect,%,4,1.0
ED50,10'-14 ug/ml,4,1.0
TMED,mg kg-1,4,1.0
% change,%,4,1.0
Vmax,10'4OD/sec,4,1.0
MED50,ug ml-1,4,1.0
Cell Survival,%,4,1.0
FD,%,4,1.0
Analogue level,pM (10e6*cells)-1,4,1.0
EC50,mg,4,1.0
Drug uptake,ngequiv/ml,4,1.0
Ki'',nM,4,1.0
MED,nmol,4,1.0
AUC,fmol,4,1.0
Kd,10'-5/s,4,1.0
k2/Ki,nM-1 min-1,4,1.0
Ki',nM,4,1.0
MED,mg/L,4,1.0
Vmax(app),pmol/min.ml,4,1.0
MED100,,4,1.0
Drug uptake,uL/cm2,4,1.0
Drug uptake,ng.hr/ml,4,1.0
CL,ng.hr/ml,4,1.0
Activity,uM/hr,4,1.0
Activity,uM/kg,4,1.0
Cp,cps,4,1.0
FC,log10RLU,4,1.0
Vmax,uM min-1 ml-1,4,1.0
Vmax,uM/hr,4,1.0
Ki/K'i,,4,1.0
CL,ml min-1,4,1.0
CL,ml.min-1,4,1.0
FC,uM,4,1.0
Ki(app),mole fraction,4,1.0
GI90,M,4,1.0
Vmax/Km,%,4,1.0
AUC,ng/mL.kg,4,1.0
MTA,,4,1.0
AG80,%,4,1.0
HC90,ug ml-1,4,1.0
Activity,ml/kg/hr,4,1.0
Activity,mmHg hr-1,4,1.0
Unmetabolized,%,4,1.0
Antidiuretic activity,IU uM-1,4,1.0
Activity,ml/s/g,4,1.0
CL,%ID/cc,4,1.0
AUC,nmol.hr/kg,4,1.0
5-HTP accumulation,ug g-1,4,1.0
Urine,%,4,1.0
ED50,mg kg-1 hr-1,4,1.0
Urea Nitrogen Concentration,mg dl-1,4,1.0
Kapp,10^-5/M,4,1.0
Urinary recovery,,4,1.0
LDH release,,4,1.0
Activity,mmHg/L.min,4,1.0
Average lung weight,mg,4,1.0
Kd,10^5/M/s,4,1.0
Activity_index,mg kg-1,4,1.0
Duration,day,4,1.0
AD50,ug ml-1,4,1.0
k3',L (M min)-1,4,1.0
Vmax / Km,ml min-1 kg-1,4,1.0
Drug uptake,nmol.min,4,1.0
FBA,((mmol/day)/100g),4,1.0
AUC,hr/L.kg,4,1.0
MEC,M,4,1.0
Kd,10'6/M,4,1.0
k2,10e-3 s-1,4,1.0
Vss,kg-1,4,1.0
Vss,l,4,1.0
CL,ml/min/hr,4,1.0
CL/F,ml.min-1,4,1.0
Liver concentration,nM kg-1,4,1.0
Vmax,pmol/min/g,4,1.0
Vmax,pmol/min/10^6cells,4,1.0
ADP formation,%,4,1.0
Concentration_urine,ug ml-1,4,1.0
Antagonist activity,pA2,4,1.0
Gastric damage,%,4,1.0
Antagonist,,4,1.0
Cmax,uM.kg/mg,4,1.0
Kcat/Km,/nM/s,4,1.0
kinact,1/min,4,1.0
ki/Ki,M-1 s-1,4,1.0
k cat/Km,m M-1 min-1,4,1.0
Vmax,mAU/min/uM,4,1.0
Vmax,microM/microg/sec,4,1.0
AUC,microg.hr/mL.g,4,1.0
Drug uptake,mgequiv/ml,4,1.0
Ki,10'7/M/min,4,1.0
MEC,ng/ml,4,1.0
Vomits,,4,1.0
Activity,um/s,4,1.0
Duration of seizure,min,4,1.0
Drug uptake,mBq,4,1.0
VmaxL,pmol/min,4,1.0
Vz/F,(mg/kg)/(ng/ml),4,1.0
Vz/F,g,4,1.0
CL,ml/min/nmol,4,1.0
MDS,,4,1.0
AUC,hr.nmol/ml,4,1.0
Drug uptake,pmol/mm3,4,1.0
Water intake,ml 20min-1,4,1.0
Ki,10e3* M-1 s-1,4,1.0
Log A50,,4,1.0
Amount of TXB2 formation,ng ml-1,4,1.0
Kd,10'3/s,4,1.0
Ki,10^4/M,4,1.0
Activity,umol/min/kg,4,1.0
AUC,hr.%ID/ml,4,1.0
Drug uptake,pmol/ml,4,1.0
ED50,pM,4,1.0
CL/F,mg/(ng/ml)/min,4,1.0
CL,nM/min,4,1.0
Activity,units ml-1,4,1.0
k2,mM-1 min-1,4,1.0
MEC50,uM,4,1.0
Volume change,%,4,1.0
Competitive protection,,4,1.0
pAh,,4,1.0
Drug dissolution,%,4,1.0
pH dependence,,4,1.0
Ka,10^3(1/Ms),4,1.0
Formation of NO3-,nM,4,1.0
Kinact,10^3/s,4,1.0
Lysis time,,4,1.0
Formation of compound,nM,4,1.0
2PT,ug ml-1,4,1.0
Haptoglobin,g l-1,4,1.0
2TT,uM,4,1.0
Tubulin content,pM mg-1,4,1.0
CI25,,4,1.0
LD50,mmol/L,4,1.0
Max effect,Counts 10min-1,4,1.0
Concentration,ng mg-1,4,1.0
M/NTT,,4,1.0
Km app,,4,1.0
Drug metabolism,pg/ml/min,4,1.0
Mean paw diameter,mM,4,1.0
LC99,mgAi/L,4,1.0
LC95,ppm,4,1.0
KSV,10^5L/mol/s,4,1.0
Tm,hr,4,1.0
Conc_plasma,ng ml-1,4,1.0
Cmax,ng/hr,4,1.0
Tm(app),degrees C,4,1.0
Kkmax,/hr,4,1.0
Fraction,,4,1.0
dP/dt,1/Pmax,4,1.0
Carotid Flow Decrease,%,4,1.0
Tumor free/total,,4,1.0
AUC,uM h/(mg/kg),4,1.0
pBBB,10'-3cm/min,4,1.0
increase in temperature,,4,1.0
pBBB,,4,1.0
Activity,mg/uM,4,1.0
Challenge time,,4,1.0
Kinact,10^3nM,4,1.0
Tremorolytic dose,,4,1.0
pA2,IU mg-1,4,1.0
Emax,ng ml-1,4,1.0
Max dose,mM kg-1,4,1.0
Kinact,10^-2/s,4,1.0
Fraction change,%,4,1.0
Kinact,10^-1/s,4,1.0
Ka,10^5L/mol,4,1.0
Ka,10^6/M.s,4,1.0
Control vomits,,4,1.0
M2/M1 Index,,4,1.0
Kdiss,10'-5M,4,1.0
Cpss,nM,4,1.0
2aPTT,mM,4,1.0
Ka,L/hr,4,1.0
EC5x,uM,4,1.0
CL,uL/min.ml,4,1.0
CFU,%,4,1.0
ED50,10'-5umol/ml,4,1.0
Activity,mg/mm3,4,1.0
Activity,mU ml-1,4,1.0
Mean activity,uM,4,1.0
Total uptake,,4,1.0
Total urine activity,%,4,1.0
Basal GH,ng ml-1,4,1.0
Total tritium,%,4,1.0
Drug metabolism,nmol/hr,4,1.0
Mean,nM hr-1 mg-1,4,1.0
Mean,%,4,1.0
Food intake,g kg-1,4,1.0
Concentration,nM (g of tissue)-1,4,1.0
Ka,10'6/M.s,4,1.0
ED50 mg/animal/day,,4,1.0
Affinity constant,M-1,4,1.0
Total release,%,4,1.0
1/kmax,min,4,1.0
Total rate,g-1 min-1 ml-1,4,1.0
Total rate,1/min,4,1.0
Antiviral selectivity,,4,1.0
Total protein,mg 100g-1 24hr-1,4,1.0
AUC,ug .h/g,4,1.0
delta Log P50,,4,1.0
Average body weight,g,4,1.0
Mean body weight,%,4,1.0
Total infarct volume,mm,4,1.0
LH,ng ml-1,4,1.0
Mean axonal area,,4,1.0
ED50 / ED50 (taxol),,4,1.0
Apoptosis induction,%,4,1.0
Time constant T1,,4,1.0
CLH,ug ml-1,4,1.0
Activity,mU.nmol/h,4,1.0
LD16,mg kg-1,4,1.0
ft1/2,,4,1.0
AUC,ug/g.hr,4,1.0
Ka,1/M,4,1.0
fc max/MIC,,4,1.0
Feces,%,4,1.0
Fecal weight,g,4,1.0
Food,g rat-1 day-1,4,1.0
Behavior response,,4,1.0
Time constant T2,,4,1.0
Ka,10'3L/M,4,1.0
Cmax_tumor,uM,4,1.0
KSV,10'6/M,4,1.0
Effective concentration,nM,4,1.0
Median day of survival,,4,1.0
Time of half inactivation,min,4,1.0
Drug metabolism,L/mol/min,4,1.0
KSV,10'5L/M,4,1.0
CV,,4,1.0
pEC50,nM,4,1.0
Cortex_Clearance,ml s-1 (10e4*g)-1,4,1.0
Basal binding,%,4,1.0
Max uterotonic response,%,4,1.0
CL/F,(mg/kg)/(ng/ml)/hr,4,1.0
LC30,,4,1.0
KA,mM-1,4,1.0
Axonal regeneration rate,,4,1.0
AUC/dose,min.ug/ml,4,1.0
fEC50,,4,1.0
K0.5,,4,1.0
solubility,/mM,4,1.0
Agonistic potency,%,4,1.0
T1,,4,1.0
K'i,uM,4,1.0
Binding,ug g-1,4,1.0
Dose converted,%,4,1.0
%,%,4,1.0
Alkylating activity,10e3*k,4,1.0
Drugexcretion,uM,4,1.0
Log [-10],,4,1.0
T2,,4,1.0
T3/4,,4,1.0
fCmax,ug/g,4,1.0
Cmin(84hr),pg/mL,4,1.0
fAUC/dose,nM.hr.kg/mg,4,1.0
Cmin_PBMC,pmol/10^6cells,4,1.0
ECAR,%,4,1.0
Kr/kmax,M-min,4,1.0
Log [-9],,4,1.0
Log inhibition,,4,1.0
IC0.2,uM,4,1.0
Caco-2 permeability,% hr-1,4,1.0
TC50,mg/m3,4,1.0
TC50,10^3uM,4,1.0
NMDA effect,%,4,1.0
EPS,,4,1.0
Tail flick,%,4,1.0
EPS MED,mg kg-1,4,1.0
KDs,,4,1.0
fIC50,ug ml-1,4,1.0
Test,,4,1.0
Aggregation ratio,,4,1.0
Monocation species,%,4,1.0
LC50,10'-1ppm,4,1.0
Hypokinesia,Counts,4,1.0
Molar content,Molecules (LDL particle)-1,4,1.0
TGI50,,4,1.0
Augmentation,%,4,1.0
ALB_CHANGE,,4,1.0
Ksolv,hr-1,4,1.0
Binding,nM,4,1.0
IC20,10'-6M,4,1.0
No. of animals protected / no animals tested,300mg kg-1,4,1.0
No. of animals protected / no animals tested,100mg kg-1,4,1.0
IC20,10'-4M,4,1.0
K1,mM,4,1.0
Activity,fmol/mg,4,1.0
No. of WDS/60 min,,4,1.0
AUC/dose,mmol.L/hr,4,1.0
Ks,10^4/M,4,1.0
Ks,10^5/M,4,1.0
Critical concentration,ug ml-1,4,1.0
TEWL,,4,1.0
fIC90,ug ml-1,4,1.0
-Log Ki,,4,1.0
Ka,10'6/M/min,4,1.0
Control retches,,4,1.0
LD50,10'-4M/ml,4,1.0
Average latency,,4,1.0
Transport,%,4,1.0
LD50,10'-7M,4,1.0
ED50,umol/kg.min,4,1.0
Emax,bpm,4,1.0
Challenge dose,cells mouse-1,4,1.0
Lung weight,mg,4,1.0
Creatinine_CL,mL/min,4,1.0
Cmax/Tmax,,4,1.0
Emax,deltalog10CFU/ml,4,1.0
dP/dt,1/Pmax s,4,1.0
Heart weight absolute,g,4,1.0
Activity,microg.hr/mL,4,1.0
Drug uptake(free),nmol/g,4,1.0
ED50,10'-6M,4,1.0
Kinact,min,4,1.0
CHOL_CHANGE,,4,1.0
Antiviral activity,,4,1.0
Maximal decrease in IOP,mmHg,4,1.0
CFU-GEMM,%,4,1.0
Max contractility,%,4,1.0
KA,10'5/M,4,1.0
Ferret emesis,,4,1.0
rel T,,4,1.0
Activity,hr-1,4,1.0
Ct,umol/L,4,1.0
NRD,,4,1.0
NOAEL,mgAi/L,4,1.0
CL free,uL/hr/10^6cells,4,1.0
Activity,inches,4,1.0
Kq,10'-12/M/s,4,1.0
Kq,/kM/s,4,1.0
Ks app,uM,4,1.0
KA,mM,4,1.0
qKD,uM,4,1.0
f %t > MIC,,4,1.0
Drug Conc (serum),ug ml-1,4,1.0
CL(app),L/hr,4,1.0
TCI,%,4,1.0
IC12,,4,1.0
Atrial MAPD90,ms,4,1.0
Ks,/hr,4,1.0
Fluid,ml rat-1 day-1,4,1.0
AUC/dose,mg.hr/ml,4,1.0
AUC/dose,hr.kg.L,4,1.0
Naproxen produced,uM,4,1.0
Ks,10'6/M,4,1.0
Drug Conc (LDL),ug ml-1,4,1.0
Drug transport,nmol/hr.cm2,4,1.0
Occ90,mg kg-1,4,1.0
HC5,,4,1.0
Selectivity index,%,4,1.0
AUMClast,hr.hr.ng/ml,4,1.0
Oxygen consumption rate,nM min-1,4,1.0
DL50,mg kg-1,4,1.0
Activity,10^6CFU,4,1.0
Paraparetic mice,%,4,1.0
Depolarisation,mV,4,1.0
IC50,umol/dm3,4,1.0
SA,uM,4,1.0
Ratio,ml/min/uL,4,1.0
Ratio,10'2No_unit,4,1.0
Activity,10'3kdyun/cm3,4,1.0
P,uM,4,1.0
Papp,nM s-1,4,1.0
SDS,mg/kg,4,1.0
K,L/mol,4,1.0
AUMC,ug.hr/g,4,1.0
Papp,cm'-6/s,4,1.0
Desensitisation,%,4,1.0
Displacement of DP,,4,1.0
RD50,uM,4,1.0
Cleavage rate,nM U-1 hr-1,4,1.0
Skin thickness,,4,1.0
C70,uM,4,1.0
S/Cereb Ratio,,4,1.0
Ratio,10'7/M/s,4,1.0
RC10,,4,1.0
CT50,day,4,1.0
Activity,M/uL,4,1.0
IC75,nM,4,1.0
Papp,10'-8m/s,4,1.0
CT10,uM hr,4,1.0
PAE,day,4,1.0
K,10^-1/M/s,4,1.0
Solubility,mg kg-1,4,1.0
AUMC,hr.hr.ug/ml,4,1.0
SPAV3,nM,4,1.0
AUCt,min.ng/L,4,1.0
ST elevation,delta mV,4,1.0
IC70,,4,1.0
Activity,AU/L,4,1.0
ID50,%,4,1.0
SHR,,4,1.0
K,10^8/M/s,4,1.0
C24h,uM,4,1.0
Brain lesion,mm,4,1.0
Papp,10'-3cm/min,4,1.0
K,10^-3/M/s,4,1.0
PB,uM,4,1.0
Brain content,nM g-1,4,1.0
Activity,AU.min/L,4,1.0
ID30,ug,4,1.0
Specific activity,pM hr-1 (mg of protein)-1,4,1.0
Papp,10^-6/cm,4,1.0
AUCt/dose,mg.hr/ml,4,1.0
ED30 DBP,,4,1.0
Activity,10^9(p/s)(uW/cm^2),4,1.0
DA stim,%,4,1.0
Change in spermatogenesis,,4,1.0
Saluretic activity,,4,1.0
Severity mean,,4,1.0
IC95,,4,1.0
AUCt/dose,uM.hr.Kg/mg,4,1.0
Activity,10'-6 cm/s,4,1.0
AUCt/dose,uM.hr,4,1.0
Serum prolactin level,mg ml-1,4,1.0
Inhibitory binding,%,4,1.0
ICmax,%,4,1.0
DC50,nmol/L,4,1.0
Increase in life-span,,4,1.0
ED300,,4,1.0
AUCt/dose,ng.hr/ml/mg/kg,4,1.0
AUCt/dose,ng.hr/g/mg/kg,4,1.0
Biological activity,,4,1.0
Serum creatinine conc,mg dl-1,4,1.0
ID100,ug/kg,4,1.0
Serum creatinine,,4,1.0
Ratio,nmol/g/uM,4,1.0
S/CX Ratio,,4,1.0
Plasma integral,uCi min ml-1,4,1.0
K,10'2/mol/s,4,1.0
DNA on filter,,4,1.0
Residue fraction,%,4,1.0
C50k,mg/L,4,1.0
Bleeding time,s,4,1.0
C5a affinity,%,4,1.0
DA/NE ratio,,4,1.0
Ratio,10^-4/uM/min,4,1.0
Serum conc,uM,4,1.0
AUCt/dose,hr.kg.ng/ml/mg,4,1.0
AUCt/dose,hr.Kg/L,4,1.0
AUCt,nmol/g.hr,4,1.0
K,10^-7/s,4,1.0
Ratio,10'6/M/min,4,1.0
CREAT_CHANGE_BY,%,4,1.0
PVCs,number min-1,4,1.0
Selectivity ratio,Ratio,4,1.0
Activity,Karmen,4,1.0
Activity,10'4CFU/ml,4,1.0
Sign free dose,mg kg-1,4,1.0
DBP change,%,4,1.0
ID/g,,4,1.0
PHOSLPD_CHANGE,,4,1.0
AUCt,ug.hr/g,4,1.0
AUCt,pmol.hr/g,4,1.0
PFC/splleen,,4,1.0
K,10^3(1/Ms),4,1.0
Activity,10'5/M/s,4,1.0
PD50,uM kg-1,4,1.0
PP2A Selectivity,,4,1.0
DC50,mM,4,1.0
Initial concentration,%,4,1.0
Activity,10e-6*s cm-1,4,1.0
Ratio IC50,10^2No_unit,4,1.0
Activity,10'9uL,4,1.0
Prodrug reconversion,%,4,1.0
Infertility activity,,4,1.0
IC50,10^-1microM,4,1.0
T/C min,,4,1.0
T/C (d),%,4,1.0
Cytochrome loss,%,4,1.0
Primary tumor weight,mg,4,1.0
K inact,1/min,4,1.0
Activity,10'7CFU,4,1.0
Rats turning,%,4,1.0
Synaptic site,,4,1.0
Punishment test msad,mg kg-1,4,1.0
Rate change,%,4,1.0
Potentiation inflection point,nM,4,1.0
No. of survivors,%,4,1.0
Swimming activity,T/C,4,1.0
Dose,nM kg-1,4,1.0
Changes in airway resistance,RL,4,1.0
Relative activity of AChE,,4,1.0
IUP,,4,1.0
Changes in dynamic compliance,Cdyn,4,1.0
Pressor activity,,4,1.0
Dose,nM min-1 kg-1,4,1.0
IC50,10'-10 uM,4,1.0
Relative,g %,4,1.0
Activity,U/dl,4,1.0
Activity,10'-7 ug/ml,4,1.0
K,/M/hr,4,1.0
Recovery,dpm ml-1,4,1.0
Plasma levels,nM,4,1.0
Brain uptake,%,4,1.0
Activity,10'9/s/cm2,4,1.0
K app x10e6,M-1,4,1.0
Change of area,%,4,1.0
Activity,U/g.Hb,4,1.0
AUCED90,uM.hr,4,1.0
Acid output,u equiv 2hr-1,4,1.0
Relative initial rate,,4,1.0
ED5,nM kg-1,4,1.0
Fu,ug ml-1,4,1.0
Activity,10'-7mol/L,4,1.0
AUClast,hr.nmol/g,4,1.0
Irreversibility,%,4,1.0
Plasma triglyceride,mM,4,1.0
Acid titer,m equiv l-1,4,1.0
Relative phosphorylation rate,,4,1.0
Plasma magnesium_CHANGE_BY,%,4,1.0
K inact/Ki,mM-1 min-1,4,1.0
No. of mice infected /total,,4,1.0
Rate,nM min-1 (unit XOD)-1,4,1.0
Relative initial slope,,4,1.0
Cholesterol level,mg g-1,4,1.0
Prodrug remains,,4,1.0
AUC/dose,nmol.hr,4,1.0
CC50,10'3ug/ml,4,1.0
Ratio of stimulation,,4,1.0
Activity,10^-2No_unit,4,1.0
Relative efficiency,,4,1.0
Activity,10'-8mol/kg,4,1.0
IC37,uM,4,1.0
Activation,fold,4,1.0
DTH,,4,1.0
K cat,1/min,4,1.0
Dose,M kg-1,4,1.0
K,10'-3M,4,1.0
Cholesterol content,,4,1.0
Binding activity,fM mg-1,4,1.0
No. of uptake sites,,4,1.0
Cyclase stimulation,%,4,1.0
IVR,beats min-1,4,1.0
CTE,,4,1.0
Polyamine,nM (mg of protein)-1,4,1.0
Activity,10'1/M,4,1.0
T-cell,nM,4,1.0
Rate of oxidation,nM min-1 ml-1,4,1.0
Activity,10^1pg/ml,4,1.0
Polyamine,,4,1.0
IC50,10'-8mg/ml,4,1.0
Active,,4,1.0
Po/w,,4,1.0
Pressor response,IU mg-1,4,1.0
PG,,4,1.0
Reduction in EOS count,,4,1.0
Reduction in prostate weight,%,4,1.0
Receptor state,,4,1.0
No. of rats with lesions,,4,1.0
C,ng/mL,4,1.0
Activity,%/hr,4,1.0
Dose,mg mouse-1,4,1.0
Activity,10^-11No_unit,4,1.0
Activity,(nM of CO2) hr-1 mg-1,4,1.0
IR,,4,1.0
Activity,(nM of vector) (ug of DNA)-1,4,1.0
Relative TS,%,4,1.0
Post anitbiotic effect,,4,1.0
Inhibition,M,4,1.0
Relative Bioavailability,%,4,1.0
K inact,hr-1,4,1.0
K bind,M,4,1.0
Reflex,,4,1.0
K diss,uM,4,1.0
ED,U mg-1,4,1.0
Binding affinity,1/M,4,1.0
Pressor response,mmHg,4,1.0
INH,ugequiv,4,1.0
IC50,10'5mM,4,1.0
Change in blood pressure,,4,1.0
Activity,1/s,4,1.0
Pm,10e-5*cm/min,4,1.0
T.P.L,ng ml-1,4,1.0
Subcutaneous score,,4,1.0
Survival range,day,4,1.0
Inhibition period,hr,4,1.0
Kimut/Kiwt,,4,1.0
CMC,10'-3 mol/L,4,1.0
Kd,10^7/M,4,1.0
Glucose uptake,uM mg-1,4,1.0
EC50,10'-7mol,4,1.0
CL,mg/ml/g,4,1.0
Virucidal,uM,4,1.0
Actual clearance,ml min-1 kg-1,4,1.0
Cmax/dose,kg.mg/L.mL,4,1.0
Lesion,%,4,1.0
Activity,pM/mg,4,1.0
Amnesia reversal,,4,1.0
Zone reduction,%,4,1.0
Activity,pS,4,1.0
External nucleoside,nM g-1,4,1.0
Velocity relative to ATP,,4,1.0
Velocity,uM min-1mg-1,4,1.0
Lactose production,uM mg-1,4,1.0
Drug uptake,IU/ml,4,1.0
Activity,ngequiv,4,1.0
AB,%,4,1.0
Ca2+ flux,nM mg-1,4,1.0
ATP content,pM mg-1,4,1.0
Activity,nmol of MDA/mg of LDL,4,1.0
Kcat,1/s,4,1.0
k cat,ms-1,4,1.0
Ventricular MAPD90,ms,4,1.0
Venom,%,4,1.0
Antibody response,,4,1.0
Erosions,,4,1.0
Gross morphology,,4,1.0
Kin,uL/sec/g,4,1.0
LV,dP/dtmax,4,1.0
MBC100,ug ml-1,4,1.0
Anticonvulsant,,4,1.0
Vasopressor activity,U mg-1,4,1.0
Vasodilatory rate,,4,1.0
Growth response,%,4,1.0
CL,L/hr/1.73 m2,4,1.0
Acute lethal toxicity,,4,1.0
A,%,4,1.0
Cmax/dose,microM/mg/kg,4,1.0
Activity,pfu/ml,4,1.0
Cmax,pmol/10^6cells,4,1.0
Vacuole response,ng ml-1,4,1.0
Vasodilation,%,4,1.0
Kb,10^5L/mol,4,1.0
Erythema formation,,4,1.0
Functional selectivity,,4,1.0
MND,14-21 day,4,1.0
Kd,kcal/mol,4,1.0
Drug uptake,%Idose,4,1.0
Vdss,L/m2,4,1.0
LV dP/dtmax,%,4,1.0
CL,mg/kg/min,4,1.0
Cp,nmol/g,4,1.0
CLH,min/mL,4,1.0
log Kp,ucm/s,4,1.0
Fraction of Liver Blood Flow,%,4,1.0
Cp(f)max,nM,4,1.0
2x TG,uM,4,1.0
c.v,,4,1.0
UI,mm2,4,1.0
UC50,uM,4,1.0
UD50,%,4,1.0
UD50,uM kg-1,4,1.0
UD50,umol/Kg,4,1.0
Mass index,mg/10g body weight,4,1.0
Mass index,%,4,1.0
EC50,10'-2ppm,4,1.0
MTD,ug/kg/day,4,1.0
Antidiuretic activity,U mg-1,4,1.0
Drug recovery,ug ml-1,4,1.0
Drug recovery,uM,4,1.0
Adrenochrome formation,nM min-1 (mg of protein)-1,4,1.0
log10cfu,mg,4,1.0
Catalase,mg of protein,4,1.0
Activity,mmol/m2/s,4,1.0
MRTinf,hr,4,1.0
Average max,%,4,1.0
AUC,ng.hr,4,1.0
ARP,m/M,4,1.0
Change in volume,%,4,1.0
Kinact,10'3/M/s,4,1.0
Activity,milliosmole,4,1.0
CL/F,g/min,4,1.0
Cmax,ng/ml/mg,4,1.0
AC50,ug ml-1,4,1.0
Kcat,10'-4/min,4,1.0
AUC,ng ml-1,4,1.0
MBC,mmol/L,4,1.0
Drug transport,ug/g,4,1.0
ED50,dp/dt,4,1.0
Antihypertensive activity,mmHg hr-1,4,1.0
Kapp,10'-3/s,4,1.0
Ulcer Index,,4,1.0
MTT,min,4,1.0
LD90,ug,4,1.0
Cmax,ug/10^6 cells,4,1.0
CLH,uL,4,1.0
ED50,ugAi/ml,4,1.0
AUC,nmol/L.min,4,1.0
ED50,ug rat-1,4,1.0
MTD/ TGI50,,4,1.0
CL,pmol/min/mg,4,1.0
MTD ratio,,4,1.0
Drug mobility,,4,1.0
Kd',M,4,1.0
Drug metabolism,ug/ml.hr,4,1.0
Ki,10'3/M/s,4,1.0
Cartilage space,,4,1.0
LT99.9,hr,4,1.0
Adrenochrome formation,,4,1.0
Drug uptake,10'-8mol,4,1.0
Ratio CC50/EC50,10^2No_unit,4,1.0
IMPDH activity,(nM of XMP formed) hr-1 (mg of protein)-1,4,1.0
Occ ED50,mg kg-1,4,1.0
Plasma glucose,mM,4,1.0
Plasma concentration,pg ml-1,4,1.0
Delta latency time,,4,1.0
ILS days,%,4,1.0
ILS (mg/kg),%,4,1.0
Plasma cholesterol,mM,4,1.0
ED15,,4,1.0
CTC50,M,4,1.0
Remains,,4,1.0
Renal clearance,ml min-1,4,1.0
Renal clearance,ml min-1 kg-1,4,1.0
Ratio IC50,10^6No_unit,4,1.0
IC50,10^2 nM,4,1.0
Occ90,nmol/g,4,1.0
Inhibition rate,,4,1.0
DNA damage,,4,1.0
Ratio (Ci/Ce),,4,1.0
Ring immobility,%,4,1.0
Ratio CC50/EC50,10^4No_unit,4,1.0
Ratio CC50/EC50,10^3No_unit,4,1.0
Oral duration,,4,1.0
Stability,ng/ml/hr,4,1.0
Peff,%,4,1.0
Plasma half-life,hr,4,1.0
Cytotoxicity IC50,uM,4,1.0
Relative to control,%,4,1.0
ID95,uM,4,1.0
Ratio IC50,10^-4No_unit,4,1.0
[3H]-uptake,,4,1.0
Of rats turning,%,4,1.0
AUClast,ng.hr,4,1.0
DNA fraction,,4,1.0
K,10'2/s,4,1.0
Delta ERP,ms,4,1.0
Responder,%,4,1.0
Activity,10'6uL,4,1.0
Cz,ug/L,4,1.0
Clones,%,4,1.0
IC50,mg.min/m3,4,1.0
Ratio of dose,,4,1.0
Intima area,10e3 um2,4,1.0
ED15,mg kg-1 i.d.,4,1.0
Internalisation,%,4,1.0
Permeability rate,nm s-1,4,1.0
C10,air/N2,4,1.0
Intraperitonal score,,4,1.0
Ratio IC50,10^3No_unit,4,1.0
Absorption,u equiv min-1,4,1.0
IH50,uM,4,1.0
Plasma insulin,uUnits ml-1,4,1.0
Activity,10'7/M/s,4,1.0
Peak striatal uptake,,4,1.0
Ratio,/min/nM,4,1.0
Peak effect time,min,4,1.0
Decrease in mean arterial pressure,,4,1.0
Body temperature,degrees C,4,1.0
Insulin release,ng/islet/1h,4,1.0
Activity,10'6CFU/ml,4,1.0
Insulin release,%,4,1.0
Optimal dose,mg.kg/inj,4,1.0
Change in foot-licking latency,%,4,1.0
Activity,10'6/M/s,4,1.0
Percent remaining,%,4,1.0
ID80,micromol/kg/min,4,1.0
Penetration,,4,1.0
Activity,10'-4AU/sec,4,1.0
Retention_time,hr,4,1.0
Increase in HR,,4,1.0
Ratio,10'-3umol/min,4,1.0
Activity,10'-5AU/sec,4,1.0
Max response,uV,4,1.0
Albumin,mg 100g-1 24hr-1,4,1.0
Concentration in Brain,nM,4,1.0
Vbeta,,4,1.0
MLD,g/Kg,4,1.0
Vc,kg-1,4,1.0
Vc/F,,4,1.0
Kbapp,10'-8M,4,1.0
AUC,nM.min/ml,4,1.0
AUPAP,%,4,1.0
Decrease in MAP,,4,1.0
MLC50,%,4,1.0
Permeability,10e4*cm min-1,4,1.0
RT50,,4,1.0
Permeability,AB cm/s,4,1.0
ED10 HR,,4,1.0
Response value,uM kg-1,4,1.0
CT50,,4,1.0
AUMCt,hr2.ng/ml,4,1.0
K,l mol-1,4,1.0
AUClast,ug.hr/g,4,1.0
K,10'6/Ms,4,1.0
Rmax,uM,4,1.0
Passivity,,4,1.0
Rotorod index,ROI,4,1.0
K,10'5No_unit,4,1.0
C12h,ng g-1,4,1.0
Binding potency,,4,1.0
Ratio,1/M 1/s,4,1.0
Oxidation,uM min-1,4,1.0
K,10'3No_unit,4,1.0
Retches,,4,1.0
K,10'5/M/min,4,1.0
Ratio CC50/EC50,10^5No_unit,4,1.0
Stability,um,4,1.0
Activity,RFU/ug/min,4,1.0
IC50,nM kg-1,4,1.0
Stability,pmol/mg,4,1.0
Max T/C,mg kg-1,3,1.0
ED1/3,,3,1.0
B/P ratio,,3,1.0
Max aggregation,,3,1.0
K,10^3/min,3,1.0
MTD/4,mg kg-1,3,1.0
MTD/2,mg kg-1,3,1.0
Activity,10^3CFU/mg,3,1.0
Plasma_[5-FU],nmol/mL,3,1.0
K,10^4/M.s,3,1.0
ED15,nM day-1 kg-1,3,1.0
Aggregate,%,3,1.0
Ka,M/M,3,1.0
Activity,10^3CFU/ml,3,1.0
Ke,10^-6M,3,1.0
Kd,10^5/M,3,1.0
EC60,nM,3,1.0
Plasma clearance,ml min-1,3,1.0
Ke,L/hr,3,1.0
MBC50,,3,1.0
K,10^8No_unit,3,1.0
Dioxygen uptake rate,uM min-1,3,1.0
EC50,mM kg-1,3,1.0
Max displacement,%,3,1.0
Delta TG,,3,1.0
MED,ng,3,1.0
Drug uptake,pg/ml,3,1.0
Periosteal mineral apposition rate,%,3,1.0
Oligo shifted,,3,1.0
Activity,10^4CFU/ml,3,1.0
Iron clearence,,3,1.0
Level,mg ml-1,3,1.0
Protection ratio,,3,1.0
Activity,mN/meter,3,1.0
Activity,nM (nM of NOS),3,1.0
ED100,uM,3,1.0
Activity,10'7CFU/ml,3,1.0
Protective ratio,,3,1.0
Mean total plasma concentration,nM,3,1.0
Protein,mg ml-1,3,1.0
Lesion coverage,%,3,1.0
Ion enhancement,,3,1.0
Lesion coverage,,3,1.0
Permeability,cm (10e3*hr)-1,3,1.0
PPB,nM,3,1.0
ED85,,3,1.0
Onset of block,,3,1.0
Mean ulcer index,mM,3,1.0
Learning time,s,3,1.0
Average sample intake,mg kg-1 day-1,3,1.0
Activity,10'7/g,3,1.0
Pleural volume,ml,3,1.0
Delta TG,%,3,1.0
EC70,nM,3,1.0
Druguptake/dose,nM,3,1.0
K,/s/microM,3,1.0
EC80,ng/ml,3,1.0
Activity,10^-4/hr,3,1.0
Activity EC50,uM,3,1.0
Max response,delta mmHg,3,1.0
Post anitbiotic effect,hr,3,1.0
Activity (umol/mg.of protein. min),%,3,1.0
Druguptake(free)/dose,ng/ml,3,1.0
Ka,10E3*1/M,3,1.0
Ka,10'9/M/s,3,1.0
P/D,,3,1.0
K,10'-13/s,3,1.0
Affinity state 2,%,3,1.0
Potency,mg,3,1.0
Kel,1/min,3,1.0
Activity (nmol/mg.of protein. min),%,3,1.0
K,10^-8/s,3,1.0
Kd,10^-6 mol/L,3,1.0
Activity,umol/min/ml,3,1.0
Ki,10'4/M/s,3,1.0
Activity,10^-10M,3,1.0
Drug uptake,pmol/OD,3,1.0
Mechanistic reference,,3,1.0
Bacterial growth,,3,1.0
B incorporation,ug,3,1.0
Max effect,s,3,1.0
Kact,,3,1.0
Loss,,3,1.0
Affinity state 1,%,3,1.0
Kdiss,10^4/M/s,3,1.0
Kd,uL/OD/min,3,1.0
MAD,,3,1.0
MAC,uM/L,3,1.0
K,10'-5M,3,1.0
PD100,mg/kg/day,3,1.0
MUD,,3,1.0
BAT,g,3,1.0
Margin before onset of hypokalemia,,3,1.0
Margin before onset of tachycardia,,3,1.0
Affected animals,%,3,1.0
K,10^5L/mol,3,1.0
Kdiss,10'-6M,3,1.0
Plasma half life,hr,3,1.0
Lysozyme release,%,3,1.0
Kdiss,10^-4/s,3,1.0
Activity,ml/hr,3,1.0
Lowering activity,%,3,1.0
Kd Error,uM,3,1.0
MTD/8,mg kg-1,3,1.0
Kact,/min,3,1.0
Activity,Kg/hr.m2,3,1.0
K SH,,3,1.0
Production,pM (mg of protein)-1,3,1.0
LPS,min,3,1.0
Mean increase in survival,day,3,1.0
Ka,10'3L/mol,3,1.0
KiH,,3,1.0
MEC,nmol,3,1.0
Mean free plasma concentration,nM,3,1.0
Activity,Counts/minute,3,1.0
E2:E1,,3,1.0
Kd,10'5/s,3,1.0
Locomotion,cm,3,1.0
Drug metabolism,ml/min/mg,3,1.0
Prolactin release rate,ng mg-1 hr-1,3,1.0
K,mol/L/min,3,1.0
Phospholipidosis_MEC,uM,3,1.0
LRR,min,3,1.0
Mean index,,3,1.0
K,10'3/M.s,3,1.0
Delta plasma cholesterol,%,3,1.0
Prolonged VRP,,3,1.0
KiH,pM,3,1.0
Distribution,l,3,1.0
Prostaglandin E2 level,%,3,1.0
Delta t,,3,1.0
Animals protected,,3,1.0
Activity,10'8CFU/g,3,1.0
Protected mice,,3,1.0
Ratio,g/cm,3,1.0
Bone mineral density,mg/cm3,3,1.0
ID50,mg/kg/day,3,1.0
ID50,mg kg-1 hr-1,3,1.0
Maximum inhibition,%,3,1.0
ID50,pg,3,1.0
Rotational behavior,turns hr-1,3,1.0
GSH reactivity,,3,1.0
Vmax,nM/mgM,3,1.0
Vmax,FU uM-1,3,1.0
Vmax,10'-5deltaA/s,3,1.0
SHR delta blood pressure,dec,3,1.0
Vm,uM,3,1.0
Ventricular relative refractory period,ms,3,1.0
AUC,mmol/L,3,1.0
AUMC,microg.min/mL,3,1.0
AUMC,ng/mL.hr'2,3,1.0
CL,mg/ng/ml/hr,3,1.0
Vm,,3,1.0
Glucose level,ml d-1,3,1.0
Glucose level,m equiv l-1,3,1.0
Vmax,10'-4umol/min/U,3,1.0
Glucose level,g dl-1,3,1.0
Glucose level,g day-1,3,1.0
SD50,mg/kg/day,3,1.0
Cleavage,,3,1.0
Vmax,10'-3OD/min,3,1.0
Drug metabolism,mg.equiv,3,1.0
Activity,ms/s1/2,3,1.0
Kd,10'7/M,3,1.0
Perturbations,%,3,1.0
LUI,%,3,1.0
Lactone,,3,1.0
MED10,,3,1.0
QH,ml/min.Kg,3,1.0
PPB,uM,3,1.0
Activity,nM min-1 unit-1,3,1.0
PD'2,,3,1.0
K Tm,M-1,3,1.0
Peff,10'-8cm/s,3,1.0
Activity,mM kg-1,3,1.0
Caco-2 A-B,cm s-1,3,1.0
QTc Interval,ms s-1,3,1.0
Activity,ug kg-1,3,1.0
Blood lactate,mM,3,1.0
LT99.9,min,3,1.0
Kd,/M/s,3,1.0
Qmax,%,3,1.0
Drug metabolism,10^-3L/mol/min,3,1.0
Occlusions,ug min-1 kg-1,3,1.0
PSA,%,3,1.0
EC50,mg kg-1 day-1,3,1.0
Activity,mEq/dL,3,1.0
LS,min,3,1.0
Mean AUC,,3,1.0
Ka,/min/nM,3,1.0
K,kcal/mol,3,1.0
EC50,10'7pM,3,1.0
Activity,EU/mg,3,1.0
Difference in retention time,min,3,1.0
Pregnancy index,,3,1.0
Duration of increase in SLA,min,3,1.0
MEC,10'-5M,3,1.0
EC90,(mg/kg)/day,3,1.0
Oxygen consumption rate,,3,1.0
Log A,s-1,3,1.0
Activity,mg.min/L,3,1.0
Basal activity,%,3,1.0
Oxidation rate,uM min-1,3,1.0
Oxidation rate,nM min-1,3,1.0
Amount of unreacted substrate,,3,1.0
Presumed drug-related deaths,,3,1.0
MEC,10'-6M,3,1.0
Ki,TS,3,1.0
Analgesia,,3,1.0
MST,months,3,1.0
PL,,3,1.0
Ki app (inact),nM,3,1.0
Log 1/EC50,,3,1.0
Overt behavoiur,,3,1.0
Ouabain dose,ug kg-1,3,1.0
Duration of anesthesia,min,3,1.0
Binding,pCi mg-1,3,1.0
Activity,um3/um2/yr,3,1.0
Kinact,10'5nM,3,1.0
Ks,10^3/M,3,1.0
Drug uptake,SUV.min,3,1.0
EC50,nmol/Kg,3,1.0
Kq,10'-5L/mol,3,1.0
Kreact,min-1,3,1.0
KB,10'4/M,3,1.0
Average IOP,mmHg,3,1.0
MFC50,mg/L,3,1.0
Drug uptake,10'-7M,3,1.0
Drug uptake,nM/g,3,1.0
Paw weight,mg,3,1.0
Cholesterol,mg dl-1,3,1.0
Activity,10^-4No_unit,3,1.0
RC50,10'-1mg/ml,3,1.0
Binding constant,1E4/M,3,1.0
Drug uptake,10'-2microM,3,1.0
Carnitine acetyl transferase,mg of protein,3,1.0
ECmax,pM,3,1.0
Activity,uM J-1,3,1.0
LD90,Gy,3,1.0
Mortality threshold,mg kg-1,3,1.0
Paw edema,%,3,1.0
Kinact,10^4/M/min,3,1.0
Activity,uL/g/min,3,1.0
Activity,nmol of acetaldehyde(AcH) oxide per minute per mg of protein,3,1.0
EC300,uM,3,1.0
Drug uptake,mg Kg-1,3,1.0
Kq,10'-4L/mol,3,1.0
No. of dead mice,mg kg-1,3,1.0
No. of depolarizations,,3,1.0
Activity,pIC50,3,1.0
Papp,10^-5 cm/min,3,1.0
Activity,10'-9M,3,1.0
Drug uptake,g,3,1.0
Kreact,,3,1.0
K,10^-1/s,3,1.0
K5,,3,1.0
Activity,ng/min,3,1.0
Negation,,3,1.0
No. of protected animals/total,,3,1.0
Net log change in tumor burden,,3,1.0
K inact,uM,3,1.0
Neutrophils,%,3,1.0
Papp,nmol/sec,3,1.0
MIC,ug/sq.cm,3,1.0
No. of occlusions,,3,1.0
Activity,10'10CFU,3,1.0
Kcat,nmol/min,3,1.0
MIC50,%v/v,3,1.0
No. cured,,3,1.0
K1,pM,3,1.0
Palmitoyl-CoA oxid,uM min-1mg-1,3,1.0
MLC,ppm,3,1.0
RD1000,,3,1.0
Average food intake,g mouse-1 day-1,3,1.0
Kiso,,3,1.0
LD,ug/kg,3,1.0
Kinetic_solubility,uL,3,1.0
NAD content,M (M of enzyme)-1,3,1.0
NAD+ content,,3,1.0
LD100,microg/cm2,3,1.0
LD20,uM,3,1.0
MGDH GI50,,3,1.0
K,10^-3/M/min,3,1.0
Nucleic acids,mg mg-1,3,1.0
Activity,10'5CFU,3,1.0
NAD,%,3,1.0
EC50,(mg/kg)/day,3,1.0
KD,,3,1.0
Kis,uM/L,3,1.0
Motor activity,accumulated counts 30min-1,3,1.0
NADH content,,3,1.0
NAD+ content,%,3,1.0
Degrees Centigrade,degrees C,3,1.0
EC200,ng/ml,3,1.0
LD,,3,1.0
Kcat/Km,10^-2/mM/s,3,1.0
Dosage,ug,3,1.0
MTX equivalent,,3,1.0
K amine,M-1 s-1,3,1.0
Motor activity,Counts hr-1,3,1.0
Drug uptake,%Idose/L,3,1.0
Kinact/Ki,mM-1 min-1,3,1.0
Kcat/Km,10^3/M/s,3,1.0
Injected dose,,3,1.0
K ass,10E3*1/M*1/s,3,1.0
K,10^-4 uM/s,3,1.0
EC50,10'-3mol%,3,1.0
EC10,M,3,1.0
Kinact,/M/s,3,1.0
LED,ng/ml,3,1.0
Inotropic potency,,3,1.0
RBA data,,3,1.0
Behavioral observation,,3,1.0
ED15,nmol/kg/day,3,1.0
LDL,%,3,1.0
Min plague Inhibitory,%,3,1.0
Mobilization,%,3,1.0
KI50,M l-1,3,1.0
Mineralizing apposition rate,mm day-1,3,1.0
Bmax,nmol,3,1.0
KHOX,M-1 min-1,3,1.0
LD90,umol/L,3,1.0
Activity,uM/min/uL,3,1.0
Kcat/Km,10^6/s/M,3,1.0
Inhibition,units ml-1,3,1.0
Kq,10^11/M/s,3,1.0
Activity,pD2,3,1.0
Ka,10^-6/M/s,3,1.0
K Tm,,3,1.0
KSV,10'-4/M,3,1.0
Kc,nM,3,1.0
NOAEL,nM,3,1.0
Activity,10'3cm,3,1.0
Kobs,/M/s,3,1.0
Activity,bpm.hr,3,1.0
Kcat/Km,/s,3,1.0
GST activity,mU mg-1,3,1.0
Derived trabecular number,mM-1,3,1.0
K,10^-2/M/s,3,1.0
Activity,pmol adducts/mg DNA,3,1.0
Binding,dpm,3,1.0
Activity,10'3/min,3,1.0
BMD,mg cm**-2,3,1.0
Activity,10'3/M,3,1.0
Drug degradation,%molar,3,1.0
Activity,pgequiv/ml,3,1.0
LC5,ng/ml,3,1.0
KA,10'4/M,3,1.0
KA,10'3/M,3,1.0
RW,min,3,1.0
Na+ excretion,mg kg-1,3,1.0
EC50,10'-4 ug/cm2,3,1.0
Plasma Insulin,pM l-1,3,1.0
K6,,3,1.0
Ki,10'-16M,3,1.0
Blood lactate,mg dl-1,3,1.0
Kapp,10^4/M,3,1.0
Alpha c,,3,1.0
PAR,mg kg-1,3,1.0
PEI,,3,1.0
EC50,10^3 uM,3,1.0
Kel,min-1,3,1.0
Keq,M-1,3,1.0
MBC<=99.9,mM,3,1.0
MTD,mmol/Kg,3,1.0
Log Poct C,,3,1.0
PAO activity,pM min-1,3,1.0
Cellular concentration,nmol,3,1.0
Activity in animals,mg kg-1,3,1.0
Kf,s-1,3,1.0
Activity,microm2/micrometer/d,3,1.0
P7.4,,3,1.0
Plasma TG,mg dl-1,3,1.0
Change in myocardial conduction,,3,1.0
Plasma TC,mg dl-1,3,1.0
MTD,g/Kg,3,1.0
Max jumping rate,%,3,1.0
Activity,Mequiv,3,1.0
Activity,10'2log10CFU/ml,3,1.0
LC25,ng/ml,3,1.0
Activity,10^7No_unit,3,1.0
Paralysis,min,3,1.0
RNA fraction,,3,1.0
Ko,/M,3,1.0
MIC,(ug of base) ml-1,3,1.0
Cell plating efficiency,%,3,1.0
Activity,cmH2O,3,1.0
K,10'6/s,3,1.0
NaCl concentration,M,3,1.0
Kq,10'11L/mol,3,1.0
Activity,nmol/mg LDL,3,1.0
Activity,10^9CFU/ml,3,1.0
Papp,10-6 cm s-1,3,1.0
EC5,,3,1.0
Kq,10^4L/mol,3,1.0
Activity,cps/nM,3,1.0
EC50,p.p.m.,3,1.0
EC50,pH,3,1.0
K-1,hr-1,3,1.0
Kq,10'13L/mol,3,1.0
Decrease in exit latency,%,3,1.0
Kq,10^12L/mol.s,3,1.0
Kq,10^12L/mol,3,1.0
Activity,dB,3,1.0
Activity,pKi,3,1.0
K diss,10E-2*1/s,3,1.0
Activity,kN/m2,3,1.0
LC20,,3,1.0
K cat/Kinact,,3,1.0
Radioactivity,nCi g-1,3,1.0
Dose,mg uM (kg of body weight)-1,3,1.0
Activity,pmol/min.ug,3,1.0
RPE,,3,1.0
MIC,10'-1nmol,3,1.0
Kbapp,10'-9M,3,1.0
ED10,uM kg-1,3,1.0
Activity,ng.hr/ml,3,1.0
NADH oxidn,uM min-1,3,1.0
Drug uptake,min,3,1.0
Kkin,M-1,3,1.0
Apoptotic cell,%,3,1.0
EC99,nM,3,1.0
MI50,nM,3,1.0
Activity,a.u.L/mol.cm,3,1.0
EC50,%molar,3,1.0
Kcat/Km,10'1/s/M,3,1.0
Km,10^3/M,3,1.0
Dose,mM kg-1,3,1.0
Drug degradation,hr,3,1.0
Km,pmol/uL,3,1.0
Activity,kg/ha,3,1.0
Decreased_triglyceride,,3,1.0
AUC,microM.hr.kg/umol,3,1.0
Cp/dose,nM/mg/kg,3,1.0
C120,uM,3,1.0
Transfection activity,RLU (mg of protein)-1,3,1.0
Helicity,,3,1.0
Stability,degrees C,3,1.0
Hepatic extraction,,3,1.0
Toxicity (deaths),%,3,1.0
Spleen weight,,3,1.0
AUC,uM h/dose,3,1.0
Trabecular no.,,3,1.0
Trabecular thickness,,3,1.0
Traction test,score,3,1.0
Inhibition,nmol,3,1.0
CI,l kg-1,3,1.0
Specific incorporation,c.p.m. (mg of melanin)-1,3,1.0
Time in light,%,3,1.0
ED50,10'-6umol/ml,3,1.0
Specific activity,uM min-1 (ug of protein)-1,3,1.0
Hematocrit,g,3,1.0
AUCt,g/hr,3,1.0
Clp,kg-1 hr-1,3,1.0
Stability,mg/g,3,1.0
Toxic index,,3,1.0
Stability,mmol/min/mg,3,1.0
Topical irritation score(0-21),,3,1.0
Hind-paw lick latency time,,3,1.0
AUClast,ng/g.hr,3,1.0
fAUClast,nM.hr,3,1.0
Cp,g,3,1.0
Ratio IC50,10^4No_unit,3,1.0
Brain level,uM,3,1.0
CLH,uL/min/pmol,3,1.0
mean % of control,%,3,1.0
max activation,ug ml-1,3,1.0
Emax,s,3,1.0
2x TG,,3,1.0
Emin,nM,3,1.0
Ratio EC50,nM,3,1.0
Activity,10'-4/s,3,1.0
Empty,%,3,1.0
Eosinophils,%,3,1.0
log10cfu/day,,3,1.0
kred,M-1 s-1,3,1.0
C ss,ng/mL,3,1.0
Ratio IC50,10^5No_unit,3,1.0
88Y-serum,,3,1.0
Ratio IC50/EC50,10'4No_unit,3,1.0
A,,3,1.0
ED200,ug,3,1.0
ED50,ug hr-1 kg-1,3,1.0
Activity,10'-2nmol,3,1.0
CLH,ml.min/kg,3,1.0
Ratio plasma concentration/IC50,,3,1.0
log(1/IC50),,3,1.0
Stability,uL/ml,3,1.0
Tmax,%,3,1.0
IC50,ml,3,1.0
CR2,block/treat,3,1.0
Serum TSH,ug 100ml-1,3,1.0
AUC,nmol/g,3,1.0
Ulceration,mg kg-1,3,1.0
Tumor incidence,%,3,1.0
HSF activity x10e2,ml,3,1.0
Skin Graft Survival,,3,1.0
Cpss,ug ml-1,3,1.0
Solubility,mg,3,1.0
AUC,uA.cm'-2,3,1.0
Heart weight,,3,1.0
Heart beat,beats min-1,3,1.0
Smax,uM min-1 g-1,3,1.0
AUCt,nM.hr.kg/mg,3,1.0
Cmax,ng/mg prot.,3,1.0
Tumor,number,3,1.0
Tumor growth,%,3,1.0
AUCt,nM/ml.min,3,1.0
C90,nM,3,1.0
AUCt,ng.hr2/ml,3,1.0
Tumor burden,,3,1.0
IC80,ng/ml,3,1.0
HVA,,3,1.0
Tumor free survival,,3,1.0
AUC,nmol/hr,3,1.0
CL,% ID/g,3,1.0
Tmax,mg/L,3,1.0
Cp(f)/dose,ng/ml,3,1.0
Tmin,,3,1.0
Css,nM,3,1.0
Stability,mol%,3,1.0
Total cells,number ul-1,3,1.0
Css,mcg/mL,3,1.0
Total coenzyme,%,3,1.0
D,10'-6cm2/s,3,1.0
Total liver weight,g,3,1.0
Total no. of turns,,3,1.0
IC50,nmol/Kg,3,1.0
Specific activity,nM Pi min-1 (mg of protein)-1,3,1.0
IC50L,nM,3,1.0
IC50,mg Kg-1,3,1.0
AUCt,hr.nmol/g,3,1.0
Tumor latency,day,3,1.0
ICL5,uM,3,1.0
HR/chol,,3,1.0
Cp(f)ss,uM,3,1.0
Tumor weight reduction,%,3,1.0
Cp(f)max,ng/ml,3,1.0
CIT,ml min-1 kg-1,3,1.0
Tumour_[5-FU],nmol/g,3,1.0
AUC,pmol,3,1.0
Ratio CC50/EC50,10'4No_unit,3,1.0
Activity,10'-4nmol,3,1.0
Ratio IC50,10'3No_unit,3,1.0
Ratio,10'5/s/M,3,1.0
pD10,,3,1.0
Ratio,10^1/M/s,3,1.0
Cmax_PTH,pM,3,1.0
2*APTT,,3,1.0
Ratio,10^4/s/M,3,1.0
Ratio,10^7/M/s,3,1.0
Elevation of threshold,%,3,1.0
Activity,10'-5M,3,1.0
Kq,10'6/M,3,1.0
Ratio,hr,3,1.0
pA2,uM,3,1.0
Ratio,mM-1s-1,3,1.0
CLtot,ml hr-1,3,1.0
2PT,mM,3,1.0
p24 synthesis,ng ml-1,3,1.0
([I]/[S]0.5),,3,1.0
CL_Ratio,,3,1.0
Competition,,3,1.0
Inflection point,nm/s,3,1.0
Bone mineral density,mg/cubic cm,3,1.0
Cmin ss,nmol/L,3,1.0
t1/2ss,hr,3,1.0
% Inhibition,"%,%",3,1.0
Efflux,%,3,1.0
Conc_brain,uM,3,1.0
% Inhibition of Control Specific Binding,%,3,1.0
pIC50(mM),,3,1.0
CL,microL/ml/min,3,1.0
CL/F,(mg/kg)/(ug/ml).hr,3,1.0
Activity,(mM of AZT) (mg k-carrageenan)-1,3,1.0
Activity,%/min,3,1.0
k cat,M-1 s-1,3,1.0
AE,,3,1.0
CMC,10'-4M,3,1.0
Fana,,3,1.0
ED50,nmol/kg/day,3,1.0
CMC,10'-4 mol/L,3,1.0
ft1/2,hr,3,1.0
Femur weight,%,3,1.0
AUC/dose,ng/(hr.mL.mg.kg),3,1.0
CMC,10'-2 mol/L,3,1.0
Emax,mg/kg/day,3,1.0
pKic,,3,1.0
Cmax_unbound,ug ml-1,3,1.0
ED70,ug/kg,3,1.0
pKa value,,3,1.0
pKa app,,3,1.0
ED60,uM,3,1.0
Cmax_unbound,mg/L,3,1.0
Eff,%,3,1.0
solubility,min,3,1.0
sigmaSH,%,3,1.0
kr,min1 M1,3,1.0
Concentration_plasma,microM,3,1.0
AC_50,uM,3,1.0
ki/Ki,,3,1.0
kel,hr-1,3,1.0
Imax,nM,3,1.0
Day of vaginal opening,,3,1.0
Conduction,mm/m/s,3,1.0
ka,,3,1.0
Day of death,,3,1.0
k_2,s-1,3,1.0
Activity,/M,3,1.0
Reduced_parasitemia,,3,1.0
kR,min,3,1.0
kONOO-,M-1 s-1,3,1.0
Consumption,g day-1,3,1.0
FC,10'6No_unit,3,1.0
Brain uptake,nM g-1,3,1.0
Consumption,ml d-1,3,1.0
Reduction in AUC,%,3,1.0
k2,d se-1,3,1.0
k0,min-1,3,1.0
ED50,pmg kg-1,3,1.0
Ratio_tumour/plasma,,3,1.0
Ratio_liver/blood,ng/ml,3,1.0
Improved,,3,1.0
Reaction rate,nM hr-1,3,1.0
CLp,L.h-1,3,1.0
koff,*10e6/s,3,1.0
Choline uptake,pM (4 min)-1 (mg of protein)-1,3,1.0
rate constant app,M-1 s-1,3,1.0
Infusion rate,ug min-1 kg-1,3,1.0
Cl,,3,1.0
proof of principle,,3,1.0
Activity,10'-6 ug/ml,3,1.0
pkb,,3,1.0
Activity,10'-7No_unit,3,1.0
Activity,10'-6microL,3,1.0
ED80,nM,3,1.0
ED80,mg/ml,3,1.0
CLd/F,L/hr,3,1.0
permeability,nanometer/sec,3,1.0
permeability,min,3,1.0
permeability,10^6m/s,3,1.0
EF200,,3,1.0
permeability,10'-5cm/hr,3,1.0
Emax,mg/dl,3,1.0
nKa,M/M,3,1.0
FPGS activity,nM hr-1 mg-1,3,1.0
n,,3,1.0
ACT,s,3,1.0
Brain levels,,3,1.0
Histamine release,%,3,1.0
permeability,ug,3,1.0
Flu intensity,10^3No_unit,3,1.0
Coronary flow,%,3,1.0
deltaH1,cal/mol,3,1.0
deltalog10CCID50,,3,1.0
CL(%Q),%,3,1.0
Flu intensity,10^4No_unit,3,1.0
Active dose,,3,1.0
dP/dt20,,3,1.0
DR2,,3,1.0
Control survivals/total,,3,1.0
DOPA level,ug g-1,3,1.0
GFR,ml min-1,3,1.0
Weight reduction,%,3,1.0
GD200 [d],%,3,1.0
CL,ml kg-1,3,1.0
GAG,%,3,1.0
Zinc finger reactivity,RFU min-1,3,1.0
C0,umol/L,3,1.0
Relativity,%,3,1.0
Fraction cleared renally,%,3,1.0
DOPAC,,3,1.0
DOPAC concentration,nM g-1,3,1.0
Fu,nmol/g,3,1.0
APTT,min,3,1.0
Conversion,,3,1.0
Relative substrate velocity,,3,1.0
Activation Factor,,3,1.0
deltaH,10^5cal/mol,3,1.0
INH,mg/L,3,1.0
Fold stimulation,%,3,1.0
Vmax,pmol/h,3,1.0
Vmax,pmol/mg.min,3,1.0
Cp,g/ml,3,1.0
Abolition,,3,1.0
GR50,KgAi/ha,3,1.0
T/C x100,mg kg-1,3,1.0
GR activity,mU mg-1,3,1.0
Vmax / Km,FU min-1 uM-1,3,1.0
GIC50,uM,3,1.0
Ability,%,3,1.0
CL,ml/kg,3,1.0
C0/dose,umol/L,3,1.0
Residual activity,nM,3,1.0
Unbound plasma,%,3,1.0
Weight difference,%,3,1.0
dPT,nM,3,1.0
APD90,%,3,1.0
Food intake,g day-1,3,1.0
APD50,%,3,1.0
APD30,%,3,1.0
DR2,ug min-1 kg-1,3,1.0
delta pKa,,3,1.0
Fold_increase,,3,1.0
Acetylcholine release,%,3,1.0
GR50,uM,3,1.0
GSH,,3,1.0
AUC,ng/g,3,1.0
CL,10'-6uL/min,3,1.0
HC50,mM,3,1.0
CL,L/hr/m2,3,1.0
Selectivity Index,10^4No_unit,3,1.0
HC50,10'-4M,3,1.0
Uterine weight,mg cm-1,3,1.0
ID/thyroid,%,3,1.0
Uterine weight effect,,3,1.0
Uterotrophic effect,%,3,1.0
ID25,mg kg-1 p.o.,3,1.0
Glutathione levels,umol/g tissue,3,1.0
Glutathione,nM mg-1,3,1.0
SI,ml beat-1 kg-1,3,1.0
Vmax,min uM-1,3,1.0
Cp,ng,3,1.0
Vmax,RFU/s,3,1.0
Cp,microg/ml,3,1.0
S/N,,3,1.0
Vmax,deltaA/s,3,1.0
DLBT,mg kg-1,3,1.0
AUC,microM/mg/kg,3,1.0
Vmax,min-1,3,1.0
IC50,10'5pM,3,1.0
Selectivity index,ug ml-1,3,1.0
CPCC,,3,1.0
CO,%,3,1.0
HDL,,3,1.0
AUC,mg/dl.hr,3,1.0
Varea,,3,1.0
AUC,ng,3,1.0
CL,mL/mg/kg,3,1.0
Vasopressor responses,,3,1.0
AUC,nM.hr/ml,3,1.0
Vd,ml/hr.kg,3,1.0
Vd,ml/min.Kg,3,1.0
AUEC,%.hr,3,1.0
Grip strength,g,3,1.0
Graft survival,day,3,1.0
Vdss,g/Kg,3,1.0
AUIC,%.hr,3,1.0
Vdss,mL,3,1.0
Vdss,mg/ng/ml,3,1.0
Vdss,ml/hr.kg,3,1.0
Vdss,ng/ml,3,1.0
ID30,mg kg-1,3,1.0
VDR affinity,M,3,1.0
CL,g/hr/kg,3,1.0
AUC,ng/10^6 cells × hr,3,1.0
HDL,ug mg-1,3,1.0
HDL,%,3,1.0
Vmax,pmol/OD/min,3,1.0
DDT msad,mg kg-1,3,1.0
AUC,mg.hr/kg,3,1.0
Survivals / total,,3,1.0
ED5,mg Kg-1,3,1.0
T>MIC,min,3,1.0
TC90,ug ml-1,3,1.0
CC50,U/mg,3,1.0
IC20,10'-8M,3,1.0
TC50,10'3nM,3,1.0
Cyotoxicity,,3,1.0
T max,uM,3,1.0
CC50/IC50,,3,1.0
Cumulative urine volume,,3,1.0
TMED50,,3,1.0
Homovanillic acid concentration,nM g-1,3,1.0
Time,pS,3,1.0
I50,(ug of base) ml-1,3,1.0
IC50,10^-6 uM,3,1.0
Therapeutic indices,TI,3,1.0
AUC,uh ml-1,3,1.0
Superoxide anion,mM,3,1.0
Threshold value,mg kg-1,3,1.0
Succeeded/tested,,3,1.0
Thrombin time,s,3,1.0
Thromboxane B2 level,%,3,1.0
Thymus weight change,g,3,1.0
ED37,,3,1.0
T50,,3,1.0
T4,ng ml-1,3,1.0
T1/2 regen,s,3,1.0
IC2x,,3,1.0
TCS50,,3,1.0
AURC,hr,3,1.0
IC5,ug ml-1,3,1.0
TD50,microM/Kg,3,1.0
Cmax,microg.hr/mL,3,1.0
IC10,,3,1.0
TDS ratio,,3,1.0
TED,microg/cm2/h,3,1.0
IC50,10'-3g/L,3,1.0
Susceptibilty Ratio (Liver/Intestine),,3,1.0
AUC total,,3,1.0
AUC/dose,uM.hr/mg.kg,3,1.0
AUC second treatment,,3,1.0
Cytotoxic effect,%,3,1.0
IC,,3,1.0
TGIR,,3,1.0
I90,g/ha,3,1.0
I80,uM,3,1.0
ED5,,3,1.0
IC12,uM,3,1.0
CC50,10^4 uM,3,1.0
T1/2,min-1,3,1.0
IC30,10'-7M,3,1.0
ED35,uM kg-1,3,1.0
AUC/dose,microg.min/mL,3,1.0
Stoichiometry,,3,1.0
Vz,mg/ng/ml,3,1.0
ED30,nmol/kg/day,3,1.0
AUC,g/hr,3,1.0
C10,mM,3,1.0
Vmax/Km,nmol/min.uM,3,1.0
Vmax/Km,uL/OD/min,3,1.0
ID90,ug ml-1,3,1.0
ID95,mg/ml,3,1.0
Vss,L.kg-1,3,1.0
Vss,L/hr,3,1.0
Counts of rotation,turns hr-1,3,1.0
Vz,mg kg-1,3,1.0
Vz/F,,3,1.0
ED50,L/ha,3,1.0
C1.6,,3,1.0
AUC,hr.ng/L,3,1.0
C1,ml min-1 kg-1,3,1.0
AUC,hr.fmol,3,1.0
Cortical infarct volume,%,3,1.0
Vmax/Km,U/min/nM,3,1.0
Clearance,mg kg-1 uM-1 hr-1,3,1.0
GI90,,3,1.0
Time constant,,3,1.0
Reversing activity,,3,1.0
C100,,3,1.0
AUC,nmol/100.000 cells x h,3,1.0
Walking behaviour,%,3,1.0
AUC Npo,uM x h/dose,3,1.0
TPR,%,3,1.0
Hours above EC90,,3,1.0
AUClast,nM.hr/L,3,1.0
TWI,,3,1.0
Stimulations,%,3,1.0
CD90,uM,3,1.0
Ct,nM/g,3,1.0
I.D./g tissue,%,3,1.0
AUC first treatment,,3,1.0
Survival time,hr,3,1.0
AUCED90,,3,1.0
AUCED90,microg.hr/mL,3,1.0
AUC glu reduction,%,3,1.0
AUCED90,ug.hr/ml,3,1.0
Survival,10'5CFU/ml,3,1.0
IC50,10^-4nM,3,1.0
ED50,10'-15 ug/ml,3,1.0
Survival extension,%,3,1.0
TSH/chol,,3,1.0
TTO,,3,1.0
TPR,mmHg ml-1 min-1 kg-1,3,1.0
TRAP staining,,3,1.0
SF50,,2,1.0
Rs,uM min-1 g-1,2,1.0
SNGFR,nl min-1,2,1.0
K,10^-3/nM/min,2,1.0
ID50,fM,2,1.0
AUMC,ug.hr/ml,2,1.0
K,10'7/s/microM,2,1.0
AUMClast,hr.hr.ug/ml,2,1.0
SBP,,2,1.0
Parent remaining at time,%,2,1.0
K,10'6Lmol,2,1.0
SA,%,2,1.0
ED10,nmol/Kg,2,1.0
"S20,w",,2,1.0
Activity,A% min-1,2,1.0
Block of activity,%,2,1.0
DI50,ppm,2,1.0
Papp,10'-6cm,2,1.0
Activity,10^8No_unit,2,1.0
ID50,pKi,2,1.0
K,10'6/mol,2,1.0
ID50,mg kg-1 day-1,2,1.0
Rotorod index,,2,1.0
AUMC,ng/mL.hr^2,2,1.0
K,10'9/s,2,1.0
Activity,10^8(p/s/cm^2/sr)/(uW/cm^2),2,1.0
Activity,10^9CFU,2,1.0
DC50,umol/L,2,1.0
C24,ng mL-1,2,1.0
AUMC,mg.hr/L,2,1.0
AUMC,ug.hr/L,2,1.0
SLI,,2,1.0
ID50,10'-8mol/L,2,1.0
AUMC,hr.hr.ng/g,2,1.0
SPB,%,2,1.0
Papp,uM,2,1.0
Log10 cfu,/ml,2,1.0
ID50,mg kg-1 b.i.d.,2,1.0
CL free,nmol/min/mg,2,1.0
deltaS,10^3cal/mol/degree,2,1.0
delta Log Doct-dod 7.4,,2,1.0
ALT/GPT,l,2,1.0
Cavg,ng/dL,2,1.0
Drugexcretion,%molar,2,1.0
Drugexcretion,/hr,2,1.0
deltapH,,2,1.0
Control S/T,,2,1.0
SD,,2,1.0
Ke,M,2,1.0
dpm bound to protein,,2,1.0
Log k,obs,2,1.0
Ke selectivity ratio,,2,1.0
ID90,ng/ml,2,1.0
Cmax,ul ml-1,2,1.0
deltaS,KJ/(mol.K),2,1.0
deltaS,10^2cal/mol/degree,2,1.0
deltaS,,2,1.0
EC50,10^3ug/ml,2,1.0
deltaH,cal/mol.K,2,1.0
SD200,uM kg-1,2,1.0
SD80,mg kg-1,2,1.0
K,10'9/M,2,1.0
AUMC,ug/L.hr,2,1.0
CS50,mA,2,1.0
Absoption,,2,1.0
Cr leakage,,2,1.0
Cmax,mg,2,1.0
Affinity constant,l M-1,2,1.0
Loss of activity,%,2,1.0
delta logPoct-dod,,2,1.0
Kdiss,10^2/M/s,2,1.0
Drugabsorption,mg/hr,2,1.0
Kdiss,nM,2,1.0
Kds,nM,2,1.0
Plasma,mM,2,1.0
Specific radioactivity,,2,1.0
Permeability index,Pi,2,1.0
PA,ml/s/g,2,1.0
K,10^6No_unit,2,1.0
PB,pmol/mg.hr,2,1.0
CA activity,(ml of NaOH) min-1,2,1.0
PB,nmol/mg,2,1.0
PB,nmol,2,1.0
Sni,,2,1.0
IC50L,uM,2,1.0
Clp,M min-1 kg-1,2,1.0
Activity,10^3pg/ml,2,1.0
IC50/EC50,,2,1.0
AUCt,hr.ng/L,2,1.0
K,10^9No_unit,2,1.0
Specific activity,uM min-1mg-1,2,1.0
Specific binding per mg of protein,fM mg-1,2,1.0
AUCt,mg.hr/kg,2,1.0
ED100,MPK,2,1.0
PC50,microg/cm2,2,1.0
PC50,nM,2,1.0
Sleep time,,2,1.0
P50,mM,2,1.0
Stability,mg/dl,2,1.0
Kdiss,10^-7M,2,1.0
Clp,mg min-1 kg-1,2,1.0
ED 50,mg kg-1 day-1,2,1.0
D,10^-10m2/s,2,1.0
K,microM/s,2,1.0
Stability,nM/min/mg,2,1.0
AUClast,uM.min/ml,2,1.0
K,mole fraction,2,1.0
AUClast,pmol.min/mg,2,1.0
D,10'-7cm2/sec,2,1.0
AUClast,pmol.min,2,1.0
D,10^-20No_unit,2,1.0
Saldiuretic activity,pM equiv kg-1 6hr-1,2,1.0
K,L/hr,2,1.0
AUCt/dose,uM.hr.kg/mg,2,1.0
AUEC,,2,1.0
Peff,10^-8cm/s,2,1.0
Activity,10^4CFU,2,1.0
ILS,hr,2,1.0
Plasma [14C] cholesterol,dpm dl-1,2,1.0
C0(unbound),uM,2,1.0
Renal clearance,L.h-1,2,1.0
Plasma Level,uM,2,1.0
K,10'-8/s,2,1.0
Plasma Ca2+,mg dl-1,2,1.0
Report,,2,1.0
Paw swelling,,2,1.0
Ac,,2,1.0
Absorption,ul min-1,2,1.0
Activity,10^3L/mol,2,1.0
Absorption,mg kg-1,2,1.0
Resorption,,2,1.0
K,10'2/M,2,1.0
ID90,M,2,1.0
Activity,10^4L/mol,2,1.0
Peff,10^-5cm/s,2,1.0
DeltaCp,kcal/mol.K,2,1.0
K,10'4/mol,2,1.0
ID50,umol/kg/h,2,1.0
Activity,10^5/mm3,2,1.0
Activity,10^5CFU,2,1.0
Blockage,%,2,1.0
AUMCt,ug/ml.hr^2,2,1.0
AUMCt,ug/L.hr,2,1.0
Ri,nM,2,1.0
Blockade effect,,2,1.0
ID50,uM/ml,2,1.0
Rlung,% delta,2,1.0
AUMCt,mg/L.hr,2,1.0
K,10'6/min,2,1.0
AUMClast,hr2.ug/g,2,1.0
Rotational behavior,,2,1.0
Drugexcretion,hr,2,1.0
AUC,mg ml-1,2,1.0
Kdiss,10^-4M,2,1.0
MFC90,,2,1.0
Kcat/Km,10'6/Ms,2,1.0
BC,,2,1.0
Vmax,pM assay-1 hr-1,2,1.0
GR50,ppb,2,1.0
Drug uptake,nCi/cc,2,1.0
Vmax,pmol/(min.ug),2,1.0
Vmax,mol/min/L,2,1.0
Kcat/Km,10^-6/nM/s,2,1.0
AUC,%.hr,2,1.0
GR50,gAe/L,2,1.0
Vmax,pmol/min/ml,2,1.0
Drug uptake,nM/mg,2,1.0
Cell permeation,,2,1.0
Cp,fmol/uL,2,1.0
Vmax,uM min-1 (ug of protein)-1,2,1.0
Kcat/Km,microM/min,2,1.0
Activity,rat,2,1.0
Activity,ppm/g/hr,2,1.0
Activity,pmolequiv,2,1.0
MI,uM,2,1.0
ED50,nM kg,2,1.0
Ki,/min/M,2,1.0
Alpha Ki,uM,2,1.0
fLOAEL,uM,2,1.0
Drugexcretion,umol,2,1.0
fc max,,2,1.0
fc max,mg/L,2,1.0
Drugexcretion,umol/hr,2,1.0
fm,,2,1.0
fEC90,nmol/L,2,1.0
AUC,(umol/L).min,2,1.0
Kd,10^4/M/s,2,1.0
Ya,,2,1.0
Kcat/Km,10'2 uM/s,2,1.0
AUC,microM.hr'2,2,1.0
Drug uptake,ng.hr/g,2,1.0
AUC,mU min dl-1,2,1.0
Kcat/Km,ug ml-1,2,1.0
Vmax,10'-4 uM/s,2,1.0
Vmax,10'-6mM/min,2,1.0
Vmax,10'-6mol/min/ug,2,1.0
Vmax,10'-7cpm/min,2,1.0
Vmax,10^-5M/min,2,1.0
MIC,ug cm**-3,2,1.0
Vmax,U mg-1,2,1.0
Drug uptake,mg%,2,1.0
BIC,uM,2,1.0
Cp,microg.hr/mL,2,1.0
Kcat/Km,10'-4/M/s,2,1.0
Vmax,10'-3umol/min/U,2,1.0
Vmax,umol.min,2,1.0
Activity,ug g-1,2,1.0
MED99.9,,2,1.0
IC50,ucm/s,2,1.0
Activity,pg/mm2,2,1.0
Vmax,10'-3deltaA/s,2,1.0
Vmax,pmol/min.ug,2,1.0
Kcat/Km,10'-5/s/uM,2,1.0
BBC,uM,2,1.0
Vmax,mol/min,2,1.0
MIC,10'-2nmol,2,1.0
AUC,mmHg.day,2,1.0
Vinact,min-1,2,1.0
Drug uptake,fmol/min,2,1.0
AUC,mmHg,2,1.0
MIC90,%,2,1.0
ED50,gAe/L,2,1.0
Drug uptake,fmol/uL,2,1.0
Vm,10'-5m3/mol,2,1.0
MIC60,uM,2,1.0
Vmax,%/min,2,1.0
Vmax,/abs/min,2,1.0
Kcat,mol/dm3,2,1.0
Log P/Log D,,2,1.0
EC50,10^2 ug/ml,2,1.0
Log Pdod N,,2,1.0
MAD,10'-3microL,2,1.0
Cmin ss,ng/mL,2,1.0
MAC,mg kg-1,2,1.0
Fraction excreted unchanged,%,2,1.0
Affinity,M,2,1.0
Fos,%,2,1.0
Affinity,M-1 s-1,2,1.0
Fu,10'-5No_unit,2,1.0
MBC99.9,mg/ml,2,1.0
Ke(app),,2,1.0
Cmax (Ratio),uM,2,1.0
Ki,10'-3/min,2,1.0
g/30min,,2,1.0
gammaCMC,,2,1.0
grade,,2,1.0
Fabs,/hr,2,1.0
APPTT,uM,2,1.0
MAD,10'-6microL,2,1.0
ionization,%,2,1.0
Cdyn,% delta,2,1.0
Activity_index,mm,2,1.0
Kd,M-1,2,1.0
[3H] thymidine cpm/dish,,2,1.0
Drug uptake,ug.hr/ml,2,1.0
"[A]T,L",/mol.dm'3,2,1.0
"[A]T,L",10'-8 /no of units.cm'3,2,1.0
Fungicidal,%,2,1.0
MBC,ug cm**-3,2,1.0
MBC,ng/ml,2,1.0
MBC,mg kg-1,2,1.0
Kd,umol/dm3,2,1.0
Affinity,uM,2,1.0
alphaKi,,2,1.0
alphat1/2,,2,1.0
alphat1/2(app),hr,2,1.0
inhibition (at 100uM),%,2,1.0
ED50,ng/kg,2,1.0
fEC85,ng/ml,2,1.0
k cat,uM min-1mg-1,2,1.0
fpEC50,,2,1.0
Control,uM kg-1,2,1.0
Kel,10'-3/hr,2,1.0
Log Poct Z,,2,1.0
ED50,nM hr-1 kg-1,2,1.0
Log Poct N,,2,1.0
AHA,,2,1.0
fCmax/dose,nM,2,1.0
Kf,M-1,2,1.0
fCmin,uM,2,1.0
fCmin,ug ml-1,2,1.0
Kgmax,10'-3 log10CFU/ml/hr,2,1.0
fEC50,nmol/L,2,1.0
Allodynia score,,2,1.0
fp,,2,1.0
Ke(app),/M/min,2,1.0
Ki,10^8M,2,1.0
Fa,hr.ng/ml,2,1.0
EC50,10^-4microM,2,1.0
AED,mg kg-1,2,1.0
k cat,1/min,2,1.0
Duration of action,mg kg-1,2,1.0
fpKi,,2,1.0
CL/F,g/hr/kg,2,1.0
Amount,,2,1.0
k cat/Km,1/(M*min),2,1.0
k cat/Km,mM s-1,2,1.0
Ki,10'7nM,2,1.0
Ki,10'8/M/min,2,1.0
Ki,10^-12M,2,1.0
k cat/Kuncat,M-1 s-1,2,1.0
Ki,10^2 nM,2,1.0
Duration of peak action,min,2,1.0
FRP,,2,1.0
Oxytocic activity,,2,1.0
Reduced_circadian_oscillation,,2,1.0
D,kHz,2,1.0
Bmax,fM mg-1 protein,2,1.0
IZ,cm2,2,1.0
K,/min/M,2,1.0
C,,2,1.0
Activity,(pM of product) min-1 (mg of protein)-1,2,1.0
Imax,ug ml-1,2,1.0
Activity,/min/M,2,1.0
Activity,/min/nM,2,1.0
Intake,%,2,1.0
CSF levels,uM,2,1.0
Ratio IC50,10^-3No_unit,2,1.0
Intinsic activity,%,2,1.0
Quench,%,2,1.0
Ratio IC50/EC50,10'6No_unit,2,1.0
Activity,10'-3/s,2,1.0
QH,ml/hr.kg,2,1.0
Brain level,ng ml-1,2,1.0
Reduction in arterial blood pressure,,2,1.0
Brdu positive,%,2,1.0
Brain/Plasma,%,2,1.0
Pro/Min/Enz,M,2,1.0
Survival time,min,2,1.0
OD max,,2,1.0
K ass app,l uM-1,2,1.0
K inact,U s-1,2,1.0
CLr,l/hr,2,1.0
Optimum T/C,%,2,1.0
Days to tumor doubling,,2,1.0
Brain levels,uM,2,1.0
Activity,/M/min,2,1.0
Reduced_Cyp7a1_gene_exp,,2,1.0
Reduced_Serpine1_gene_exp,,2,1.0
Reduced_Srebf1_gene_exp,,2,1.0
MEC,mg kg-1,2,1.0
Production,ng (g of tissue)-1,2,1.0
Activity,10'9CFU,2,1.0
K,/nM.min,2,1.0
Ratio ki,,2,1.0
Inverse agonism,%,2,1.0
DPM,,2,1.0
Acid output,m equiv [H+] l-1,2,1.0
Relative stimulation index,%,2,1.0
Plasma insulin,uU ml-1,2,1.0
Activity,10^3CFU,2,1.0
C0,nmol/L,2,1.0
Accumulation,nM/mg of dry wt,2,1.0
C0,ug.hr/ml,2,1.0
Plasma conc,ng/ml,2,1.0
DOPA accumulation,%,2,1.0
INH,10'-4M,2,1.0
Intact,,2,1.0
INH,ngequiv,2,1.0
Relative cytotoxic activity,,2,1.0
IT50,hr,2,1.0
K,1/sM,2,1.0
INH,mol,2,1.0
Plasma levels,uM,2,1.0
ED200,ug ml-1,2,1.0
Relative peroxidation,,2,1.0
ED200,umol/Kg,2,1.0
Protective dose,uM,2,1.0
Reaction time,,2,1.0
ED25,10'-4M,2,1.0
Protective dose,mg kg-1,2,1.0
Reactivation,,2,1.0
Ratio pIC50,hr,2,1.0
IUP AD50,ug kg-1,2,1.0
Rel brain exposure,,2,1.0
Damage score,0-10,2,1.0
Activation,mU ml-1,2,1.0
K,10'-4M,2,1.0
ED100,mg Kg-1,2,1.0
C0,ng/mg,2,1.0
Activity,10^2pg/ml,2,1.0
Stenosis,%,2,1.0
Dose,mg rat-1,2,1.0
Dose,pM kg-1,2,1.0
IC40,uM,2,1.0
IC50,10^-5 ug/ml,2,1.0
Occulations,,2,1.0
T max,ug ml-1,2,1.0
AUClast,nM/min,2,1.0
T-cell binding,,2,1.0
AUC/dose,uM.hr.kg,2,1.0
K inact,1/minute,2,1.0
Dose,ug/embryo,2,1.0
Occlusion time,min,2,1.0
IC50,10'8nM,2,1.0
AUC_ratio,,2,1.0
Stimulation index,%,2,1.0
Of tumors,%,2,1.0
CPmax,uM,2,1.0
K app x10e6,,2,1.0
K inact,nM,2,1.0
Survivors,day,2,1.0
Change in body weight,,2,1.0
No. resp animals / Total,/ 5,2,1.0
Survivors,ug ml-1,2,1.0
AUClast,nmol.hr/g,2,1.0
Cmax,kg/L,2,1.0
OT,,2,1.0
Activity,U (g of tissue)-1,2,1.0
IC50,10'3pM,2,1.0
K 0.5,,2,1.0
AUClast,hr.mmol,2,1.0
Occ,ng/ml,2,1.0
AUClast,day.ng/ml,2,1.0
OT interval,,2,1.0
K second,M-1 s-1,2,1.0
K inact,mM,2,1.0
K,nM/min,2,1.0
K x10e-5,,2,1.0
Off-rate,min,2,1.0
Activity,abs/uL,2,1.0
Susceptibility,nM hr-1 (mg of protein)-1,2,1.0
Cmax,L/hr,2,1.0
IC50,10^-6nmol,2,1.0
AUC/dose,nmol.hr/g,2,1.0
ED,nM,2,1.0
Survival after 30 days,,2,1.0
Onset time,s,2,1.0
Non-specific binding,,2,1.0
Survivors at day 28,,2,1.0
T/C (tumor vol),%,2,1.0
Survivial / total,,2,1.0
IC50,10^-8nmol,2,1.0
Clp,ng hr ml-1,2,1.0
IC50,10^-3mg/ml,2,1.0
Staining,%,2,1.0
IC50,10'6pM,2,1.0
Dose,nM mouse-1,2,1.0
Stability of BSR,%,2,1.0
ODC activity,,2,1.0
IC35,uM,2,1.0
K ACT,M-1 s-1,2,1.0
Substrate activity,mM,2,1.0
Stroke volume,ml,2,1.0
Cmax,U,2,1.0
IC50,10'6uM,2,1.0
Change in blood glucose,%,2,1.0
IC50,10^4 uM,2,1.0
Sublethal dose,mg kg-1,2,1.0
Cytostatic concentration,ug ml-1,2,1.0
Stroke work,g,2,1.0
Activity,cpm/min,2,1.0
Synergy,%,2,1.0
AUClast,hr.ug/g,2,1.0
Change in density of uterine gland,,2,1.0
Occ90,uM,2,1.0
AUC/dose,nmol/ml.hr,2,1.0
C,ng ml-1,2,1.0
DUR,mg kg-1,2,1.0
Activity,PFU/ml,2,1.0
Remaining rate,,2,1.0
Degree of cross resistance,,2,1.0
Inhibitory zone,,2,1.0
Ratio,10^6/s/M,2,1.0
Ratio,10^6No_unit,2,1.0
Activity,10'5/M,2,1.0
K,ms,2,1.0
Accumulated counts/30,,2,1.0
AUCt,nmol/g.min,2,1.0
K,10'-2/Ms,2,1.0
Serum LH level,mg ml-1,2,1.0
K,10^3/M.s,2,1.0
K,10^3/Ms,2,1.0
ED1/3,M,2,1.0
Activity,Kcal/kg/hr,2,1.0
Clonic,,2,1.0
K,10^5/min/M,2,1.0
Inhibitory ratio,,2,1.0
Ratio,10^-4/uM/s,2,1.0
Ratio,10^-3No_unit,2,1.0
Ratio,10^-3/uM/min,2,1.0
Ratio EC50,10^-6No_unit,2,1.0
Increase in [Ca+2],,2,1.0
RBA,M,2,1.0
Increase in cAMP,fold,2,1.0
Ratio,CC/OC,2,1.0
BmaxH,nmol/mg,2,1.0
Ratio,10'4/M/min,2,1.0
Ratio,10'4/s/M,2,1.0
Cl,ml min-1,2,1.0
Decrease of spontaneous firing rate,M,2,1.0
Ratio,10'7/M/min,2,1.0
Ratio,10'8/M/min,2,1.0
Ratio,10^-2No_unit,2,1.0
Activity,10'5CFU/ml,2,1.0
Activity,10'-5g,2,1.0
ICdATP-50,uM,2,1.0
DA level,pg 5ul-1,2,1.0
ICL50,,2,1.0
PC95,microg/cm2,2,1.0
Sedative dose,mg kg-1,2,1.0
Seizure stage,,2,1.0
ID100,mg kg-1,2,1.0
C5 min,nM,2,1.0
AUCt/dose,microg.hr/mL,2,1.0
Difference,,2,1.0
POE score,,2,1.0
DBP15,ug kg-1,2,1.0
PPB,pmol,2,1.0
PC95,,2,1.0
ED delta5,,2,1.0
ED delta20,,2,1.0
K,L/min.mmol,2,1.0
IC50 ratio,%,2,1.0
Bioavailability Increase,%,2,1.0
PPB,ug ml-1,2,1.0
PR,%,2,1.0
PD 50,mg kg-1,2,1.0
K,10^-5/nM/min,2,1.0
C50g,mg/L,2,1.0
C6h,ng ml-1,2,1.0
C6h,ug ml-1,2,1.0
Activity,L/hr,2,1.0
K,10^6/M.s,2,1.0
AUCt,ug ml-1,2,1.0
DBP,,2,1.0
ID/g femur,,2,1.0
PKb,,2,1.0
PTD50,,2,1.0
K,10^-4No_unit,2,1.0
PT,min,2,1.0
K,10^-5/mM/s,2,1.0
PS,,2,1.0
ID30,10'-5M,2,1.0
Delta BP,,2,1.0
Activity,10'-4M,2,1.0
Ratio CC50/EC50,10'5No_unit,2,1.0
Radiolabel recovery,ugequiv.hr/ml,2,1.0
Rate of recovery,s-1,2,1.0
Radiolabel recovery,hr,2,1.0
Brain conc,ng/g,2,1.0
Inhibition concentration,uM,2,1.0
Activity,10'-7/M/s,2,1.0
Ratio,/mM.s,2,1.0
Radioactivity in urine,% of dose,2,1.0
Radioactivity in urine,%,2,1.0
Induction of catalepsy,,2,1.0
Activity,10'2CFU/ml,2,1.0
Radioactive absorption,%,2,1.0
Ratio,/nM/s,2,1.0
Decrease in life span,day,2,1.0
RVCF,%,2,1.0
Rate of hydrolysis,nM min-1,2,1.0
Inhibition at 1uM,%,2,1.0
Infusion rate,uM min-1 kg-1,2,1.0
Rate of hydride transfer,,2,1.0
Insulin lowering effect,%,2,1.0
Relative Vmax,%,2,1.0
Blood pressure,mM,2,1.0
Pm,mg/ml,2,1.0
Activity,10^-5/s,2,1.0
Polymorphonuclear cells,,2,1.0
Relative antiandrogenic activity,,2,1.0
Activity,10^10/M,2,1.0
DTH,10e-3mm,2,1.0
Poct,,2,1.0
Pmax,,2,1.0
Relative binding affinity,nM,2,1.0
INH,umol/L,2,1.0
IO,,2,1.0
Accumulation,mU ml-1,2,1.0
Ratio EC50,uM,2,1.0
Body weight gain,g,2,1.0
Bound,,2,1.0
Bmax,pM g-1,2,1.0
Rate constant,mM,2,1.0
RTG,,2,1.0
BmaxL,nmol/mg,2,1.0
Ratio,U M-1 s-1,2,1.0
Activity,10'5PFU,2,1.0
Bmax,pmol/ml,2,1.0
Ratio,m M-1 min-1,2,1.0
Ratio,mL/min.umol,2,1.0
Ratio,mg/g,2,1.0
Ratio,microM/s,2,1.0
Ratio,ml/min/nmol,2,1.0
Activity,10'-5/s,2,1.0
Ratio,ng/kg,2,1.0
Activity,10'-5/min,2,1.0
Activity,10'-5 ug/ml,2,1.0
Ratio AUC(inf),,2,1.0
Ratio,10'-4/min.mol%'-4,2,1.0
Activity,10'-9No_unit,2,1.0
Rate,nM min-1 (mg of protein)-1,2,1.0
Range,%,2,1.0
Bone damage score,,2,1.0
Rate,M-1 s-1,2,1.0
Rate,nl min-1,2,1.0
Rate,pM min-1,2,1.0
Rate,pM min-1 (mg of protein)-1,2,1.0
Rate acceleration,,2,1.0
Inhibition (alpha = 0.01),%,2,1.0
RUmax,RLU,2,1.0
Inhibition,min-1,2,1.0
Rate constant,s-1,2,1.0
Choline uptake,,2,1.0
Activity,10'-8No_unit,2,1.0
Rate of [Ca+2] increase,nM min-1,2,1.0
Inhibition,(ul of blood) (2ml BALF)-1,2,1.0
Activity,10'-9/min,2,1.0
Vss,k,2,1.0
Papp,10'-6m/s,2,1.0
Drug uptake,pM,2,1.0
K4,min-1,2,1.0
CI,l min-1,2,1.0
Inhibition,pmol,2,1.0
Max fold increase,,2,1.0
Max plasma level,uM,2,1.0
Kapp,10'-4/M,2,1.0
Time to max. BSR,s,2,1.0
Time spent,s,2,1.0
NcoR1_recruitment,,2,1.0
Activity,mg/hr/dl,2,1.0
Activity,g/cm3,2,1.0
TD10,mg kg-1,2,1.0
K5,hr-1,2,1.0
IC100,10'-4M,2,1.0
AUC/dose,%,2,1.0
NOL,mM,2,1.0
TED,,2,1.0
Triglyceride level,%,2,1.0
Heart rate,mmHg,2,1.0
Max inhibition concentration,uM,2,1.0
Treatment,ng ml-1,2,1.0
Activity,mg/min/dl,2,1.0
Activity,mg/min/kg,2,1.0
Max weight loss,,2,1.0
Max reversing rate,%,2,1.0
Activity,microA,2,1.0
Max rev,,2,1.0
Ka,10^-4/s,2,1.0
Creatinine_CL,min/ml/hr,2,1.0
Activity,microM/g,2,1.0
Ka,10^3/Ms,2,1.0
Ka,10^-5M,2,1.0
Transporter deg rate const (k),day-1,2,1.0
Transporter production rate (r),fM mg-1 day-1,2,1.0
Max mean weight loss,%,2,1.0
Drug metabolism,pmol/mg/min,2,1.0
Drug degradation,10'-3nmol/min,2,1.0
NOAEL,ug/kg/day,2,1.0
NOAEL,ug/kg,2,1.0
Activity,dg/ml,2,1.0
AUC/dose,ng.hr.kg/ml/mg,2,1.0
CC50,10^3 uM,2,1.0
No. of culturesactive/total,,2,1.0
Dose normalized clearance,L/hr,2,1.0
Activity,dyn/mg,2,1.0
K/10e4,M-1,2,1.0
AUC nom,uM*h*kg/mg,2,1.0
CC50,mol,2,1.0
K0.5,10'-4M,2,1.0
K0.5,mM,2,1.0
AUC/dose,nM.hr/ml,2,1.0
Cmax,microM.hr,2,1.0
K1,1/M,2,1.0
No. of active/no. of tested,,2,1.0
IC20,10'-3M,2,1.0
Activity,dpm (mg of protein)-1,2,1.0
T3,,2,1.0
NOAEL,ug ml-1,2,1.0
"K(p,uu,brain)",nM,2,1.0
TF/P,,2,1.0
CCIC50,,2,1.0
IC,nmol/ml,2,1.0
NOAEL,nmol/Kg,2,1.0
Activity,kBq/ml,2,1.0
ED50,10'-11 ug/ml,2,1.0
IC,mg kg-1,2,1.0
Ct,ug/L,2,1.0
ED50,10'-13 ug/ml,2,1.0
Cmax,nM g-1,2,1.0
K3,M-1 min-1,2,1.0
K2,1/M,2,1.0
No change,,2,1.0
TC50,ng/ml,2,1.0
T1/2,l kg-1,2,1.0
Creatinine_CL,ml/min.kg,2,1.0
Central selectivity,,2,1.0
AUC,ug .hr/g,2,1.0
Tissue weight,g,2,1.0
Media area,10e3 um2,2,1.0
Time to righting,min,2,1.0
KSV,10^5L/mol,2,1.0
AUC,ug/g,2,1.0
AUC,ug/L,2,1.0
Css-12w,pg/mL,2,1.0
Mean tumor delay,day,2,1.0
CFU,/uL,2,1.0
Ka,10^3/min,2,1.0
CFU,10'2/ml,2,1.0
Mean tumor atency,day,2,1.0
Critical micelle concentration,uM,2,1.0
Highest nontoxic dose,,2,1.0
AUC,ug.hr/ml/day,2,1.0
Hg,,2,1.0
Drug metabolism,g/mol,2,1.0
CFU,10'7/g,2,1.0
CFU,10'7/ml,2,1.0
Total CL,L/hr,2,1.0
CFU,10'9/g,2,1.0
Activity,mg hr-1 kg-1,2,1.0
Total glomeruli,,2,1.0
AUC,uM.min/ml,2,1.0
Ka,10'1/M,2,1.0
Mean duration,hr,2,1.0
Mean day survival,day,2,1.0
Mean day,,2,1.0
Mean activity,,2,1.0
Mean KD,M,2,1.0
Vi,ml/kg,2,1.0
AUC,uM.h/L,2,1.0
Toxic,mg kg-1,2,1.0
Mean,uM,2,1.0
Ka,10'4mol/L,2,1.0
Bactericidal,ug ml-1,2,1.0
KSV,10^6L/mol,2,1.0
Mean time to death,day,2,1.0
AUC,ug min g-1,2,1.0
Ka,micromol/min,2,1.0
Max fall in MAP,,2,1.0
BSR,uM kg-1,2,1.0
Tumor volume reduction,%,2,1.0
AUC,pmol·min/mg,2,1.0
Max PI,,2,1.0
AUC,pmol.min/mg,2,1.0
HF2,,2,1.0
Turns/1st,,2,1.0
Max BSR,%,2,1.0
Max,nM,2,1.0
CL,%ID,2,1.0
HED,mg kg-1,2,1.0
Activity,ml min-1 kg-1,2,1.0
Ka app,uM,2,1.0
Hk,,2,1.0
EC5x,,2,1.0
Max delta,,2,1.0
Tmax,ng.hr/ml,2,1.0
Tumor inhibition,%,2,1.0
KT4,,2,1.0
Tmax,ug.hr/ml,2,1.0
Tonic,,2,1.0
Tonic seizures,,2,1.0
KSV,10^6/M,2,1.0
AUC,uM kg-1,2,1.0
Bacterial counts,,2,1.0
Ka,10'7/M.s,2,1.0
Tumor area,,2,1.0
Ka,10^4M,2,1.0
ED50,10'-9mol/cm2,2,1.0
Max delta MAP,,2,1.0
Max delta MABP,,2,1.0
Drug metabolism,uM.hr,2,1.0
Max delta FC,,2,1.0
Activity,fmol/ug,2,1.0
No. active,,2,1.0
Dose range,uM kg-1,2,1.0
BQL,,2,1.0
Drug recovery,mg,2,1.0
Utreotropic effect,,2,1.0
Drug recovery,ng/ml,2,1.0
Cells arrested,,2,1.0
Cmax,pg/g,2,1.0
Vc/F,L/hr/kg,2,1.0
AUC,nM l-1 hr-1,2,1.0
Cp(f),mM,2,1.0
No effect dose,,2,1.0
V0,mg/ml/hr,2,1.0
Activity,ng ml-1 hr-1,2,1.0
Uterus to blood ratio,,2,1.0
CPD50,mg kg-1,2,1.0
Vbeta,kg-1,2,1.0
CL,hr/L/kg,2,1.0
MIC=<50,ug ml-1,2,1.0
Kb,10^-4/M,2,1.0
Drug transport,ug/hr,2,1.0
MPO release,,2,1.0
Kapp,10^6/M,2,1.0
Urinary volume,ml min-1,2,1.0
VDR affinity,,2,1.0
Unchanged NDEA,% of dose,2,1.0
KbS,uM,2,1.0
Kc,M,2,1.0
HC>=50,ug ml-1,2,1.0
CL,L.h/kg,2,1.0
Vd,Kg,2,1.0
Gross kill,,2,1.0
Vd/F,ml,2,1.0
Kbapp,uM,2,1.0
Kapp,10^7/M,2,1.0
Vdss,%,2,1.0
CL,/s,2,1.0
Ca2+ excretion,uM day-1,2,1.0
Vd,L/hr,2,1.0
VRT,ha2,2,1.0
MST,g,2,1.0
Vd/F,g/Kg,2,1.0
Drug uptake,Gy/MBq,2,1.0
Activity,nanometer,2,1.0
MST,range,2,1.0
MTD/16,mg kg-1,2,1.0
Cp(f),nmol/ml,2,1.0
Activity,mmol/L.min,2,1.0
MNTD>90,uM,2,1.0
Kapp,nM,2,1.0
MTD,umol,2,1.0
VFT,,2,1.0
Growth zone,,2,1.0
Drug uptake,AU/min,2,1.0
Kb,10^2/M,2,1.0
EC50,ug kg-1,2,1.0
Vz,L/hr/kg,2,1.0
Vagus,,2,1.0
Activity,ng/cm2,2,1.0
MIW,,2,1.0
Kapp,10'4/M/s,2,1.0
VRT(t),hr,2,1.0
EC50,ug.hr/ml,2,1.0
Kb,10^3L/mol,2,1.0
Drug uptake,cps/ml,2,1.0
Growth rate,,2,1.0
Group performance time,s,2,1.0
ED50,KgAi/ha,2,1.0
Drug uptake,dpm/ml,2,1.0
Growth inhibiton,%,2,1.0
Activity,pA2,2,1.0
CL,L (min mg)-1,2,1.0
MMC,,2,1.0
Growth inhibition,uM,2,1.0
Vascular relaxation,,2,1.0
Variation,,2,1.0
AUC,nM hr-1 ml-1,2,1.0
MTD,uM/ml,2,1.0
Vdss,kg/L,2,1.0
AUC,ug/g.min,2,1.0
Metabolic rate,%,2,1.0
Css-4w,pg/mL,2,1.0
Mem Rec,%,2,1.0
Css-48h,pg/mL,2,1.0
Median tumor,day,2,1.0
KSV,10'4M,2,1.0
Activity,mM/min,2,1.0
Drug metabolism,fmol/mg,2,1.0
Time of peak action,min,2,1.0
Time,uM,2,1.0
Time to 30% BSR,min,2,1.0
ED50,10'-3micromol/ml,2,1.0
Molarity,M,2,1.0
TMED,,2,1.0
I50,10'2mol/L,2,1.0
Metabolic rate,nmol/min*mg of protein,2,1.0
Hydrolysis rate constant,s-1,2,1.0
AUC inf,nM l-1 hr-1,2,1.0
Therapeutic index,14 day,2,1.0
AUC/dose,ng h/ mL,2,1.0
AUC nom,uM h kg/mg,2,1.0
Activity,kg/kg,2,1.0
I50,M kg-1,2,1.0
Molar equivalence bound,,2,1.0
Drug level,,2,1.0
Mobilization,,2,1.0
Therm_solubility,ug,2,1.0
KHOX,,2,1.0
Min oral dose,,2,1.0
Min ID,uM kg-1,2,1.0
Cmax,ng.hr/g,2,1.0
Activity,mBq,2,1.0
Activity,mCi animal-1,2,1.0
Tick action,%,2,1.0
Activity,kiloU/hr,2,1.0
Cmax,ng,2,1.0
MLD,10^-8mol,2,1.0
Therapeutic dose,mg kg-1,2,1.0
Rate,nM (mg of protein)-1,2,1.0
CL,L.h-1,2,1.0
H2 activity,,2,1.0
Activity,mmHg s-1,2,1.0
Kbapp,10'-7M,2,1.0
AUC,ng min,2,1.0
Cp,ug/g,2,1.0
MTD,mg kg-1 day-1,2,1.0
CL,(mg/kg)/(ng/ml)/hr,2,1.0
CPA,,2,1.0
Activity,nM min-1,2,1.0
MIC>99,ng/ml,2,1.0
Vd,L/1.73 m2,2,1.0
Vdss,hr,2,1.0
Gross log kill,,2,1.0
Kapp,10'-6M,2,1.0
Drug excretion,uM,2,1.0
KB,10'5/M,2,1.0
Drug excretion,pmol,2,1.0
TPR,,2,1.0
Bile flow,ml hr-1,2,1.0
AUC Npo,uM.h/dose,2,1.0
I14,uM,2,1.0
TTC,min,2,1.0
AUC,umol/l.min,2,1.0
Ct,nmol/mg,2,1.0
Tc,,2,1.0
KD1,nM,2,1.0
KD2,nM,2,1.0
Change in DA synthesis,%,2,1.0
Drug excretion,nmol,2,1.0
CPM,%,2,1.0
Ct,mmol/g,2,1.0
CDOG,,2,1.0
Cmax,ng/hr/ml,2,1.0
AUC N,,2,1.0
Ka,10'-5M,2,1.0
1/Ki,M-1,2,1.0
Kinetic_solubility,ug/ml/min,2,1.0
Kinetic_solubility(app),,2,1.0
Cardiac output,,2,1.0
pInhibition,%,2,1.0
pChange,%,2,1.0
LD10,g/hm2,2,1.0
pEC50,%,2,1.0
CLt/F,uL/min,2,1.0
LC50,gAi/L,2,1.0
CLH,ug/ml/hr,2,1.0
pFe3+,,2,1.0
Efficacy,No. of mice tumor free,2,1.0
Cmax_ratio,(null),2,1.0
Effective molarity,,2,1.0
1-logKi,,2,1.0
Cmax_tumor,nmol/L,2,1.0
Cmax_PTH,pg/ml,2,1.0
ED50,umol/ml,2,1.0
LD33,mg kg-1,2,1.0
pBBB,microL/min/g,2,1.0
pKiL,,2,1.0
Ea,,2,1.0
-Delta G obs,kCal mol-1,2,1.0
(kcat/KM)/kuncat,M-1,2,1.0
EU,g-1,2,1.0
Complete survival dose,mg kg-1,2,1.0
pKb,M,2,1.0
ED75,mg/kg/day,2,1.0
Apoptotic cells,%,2,1.0
Kkmax,10'-3 log10CFU/ml/hr,2,1.0
Elimination,,2,1.0
Average gross pathology scores+/- SE,,2,1.0
pBBB,%,2,1.0
LD40,mmol/Kg,2,1.0
Elevation,%,2,1.0
LC99,ppm,2,1.0
Efflux,,2,1.0
pA2 app,,2,1.0
t0.9,day,2,1.0
t1/2,uM,2,1.0
t1/2,ug ml-1,2,1.0
t1/2_ratio,,2,1.0
tCmax,min,2,1.0
tR,,2,1.0
ED90,%,2,1.0
Kq,10'7No_unit,2,1.0
x fold,100uM,2,1.0
Cmin_ratio,,2,1.0
LC50,10'-2ppm,2,1.0
Kuncat,M-1 min-1,2,1.0
Kp,nm/s,2,1.0
pMIC,ug ml-1,2,1.0
Cmin,ng/dL,2,1.0
LC30,ppm,2,1.0
t1/2,nanoseconds,2,1.0
solubility,ugA/ml,2,1.0
ED75,uM,2,1.0
ED90,KgAi/ha,2,1.0
Kobs,10^-3/s,2,1.0
% bound fraction,%,2,1.0
qKD,nM,2,1.0
CLint,uL/(min.pmol),2,1.0
ED90,mg/L,2,1.0
reduction in CL_renal,%,2,1.0
rel k,,2,1.0
relative signal,relative signal,2,1.0
Kr,min-1,2,1.0
Attacks,%,2,1.0
ED90,g/ha,2,1.0
Kq,10^14L/mol/s,2,1.0
solubility,10'-4mg/ml,2,1.0
Co,ug ml-1,2,1.0
solubility,10^-3mg/ml,2,1.0
pKiH,,2,1.0
Average GI50,,2,1.0
%LBF,%,2,1.0
MEC1.5,uM,2,1.0
Drug uptake,uM/g,2,1.0
AUC,0-tIdc,2,1.0
AUC,0-infinity,2,1.0
XL50,,2,1.0
Kd,10^-8mol/L,2,1.0
MEC1.5,,2,1.0
Volume of urine,,2,1.0
Kd,/uM/s,2,1.0
-Log EC50,,2,1.0
Vmax / Km,uM min-1 (ug of protein)-1,2,1.0
MED90,,2,1.0
MED50,ug/kg,2,1.0
AUC,hr/ng.ml,2,1.0
Vmax(app),10'-4abs/s,2,1.0
Vmax(app),abs/hr,2,1.0
Vmax(app),abs/min,2,1.0
Cmax,ug hr ml-1,2,1.0
Worm reduction,,2,1.0
MBEC,mg/L,2,1.0
Kd,10^3/M,2,1.0
GI,cm/day,2,1.0
Ka,10'-5/RU/s,2,1.0
MEC,10'-6 mol/L,2,1.0
Kd,10^-10mol/L,2,1.0
AUC,hr.ug/g,2,1.0
Cell cycle effect,,2,1.0
Activity,umol/min/g,2,1.0
GH,%,2,1.0
MCC,ucm,2,1.0
MEC,nmol/Kg,2,1.0
Weight change of AP-S,mg,2,1.0
Correct responses,%,2,1.0
Kd,10^2/M,2,1.0
AUC,L/hr/kg,2,1.0
Weight ratio,,2,1.0
MED,ug/Kg/min,2,1.0
Vmax/Km,/M,2,1.0
Dose elevation,,2,1.0
k(on)/k(off),,2,1.0
Cardiac contractile force,g,2,1.0
CLT,,2,1.0
Km,10'-5M/min,2,1.0
Km,Me-3,2,1.0
Km,uM kg-1,2,1.0
LC50,pg,2,1.0
Compound recovery,microg.hr/mL,2,1.0
-Log K B,,2,1.0
pKa_B3,,2,1.0
pKa_decrease,,2,1.0
LC50,microg/dm2,2,1.0
CLH,umol/min/ml,2,1.0
EC25(unbound),ng/ml,2,1.0
Arterial occlusion,%,2,1.0
Compound Recovery,%,2,1.0
Km,10'-3mol/mol,2,1.0
FPT msad,mg kg-1,2,1.0
Vmax/Km,10'-4L/min,2,1.0
Activity,pEC50,2,1.0
Vmax/Km,U/mg,2,1.0
MED,uM/g,2,1.0
MED,pmol/hr,2,1.0
MED,nmol/Kg,2,1.0
Vmax/Km,pmol/microM,2,1.0
MED,mg/kg/hr,2,1.0
Activity,ug/min.kg,2,1.0
CMT,,2,1.0
Activity,ug/min/cm2,2,1.0
Cell death,,2,1.0
VmaxL,pmol/min/mg,2,1.0
Volume,ml min-1 kg-1,2,1.0
Volume,mm**3,2,1.0
Volume distribution,l,2,1.0
k'',,2,1.0
Koff,1/nM.1/min,2,1.0
VmaxH,pmol/min/mg,2,1.0
LC15,mg/L,2,1.0
Carotid flow reduction,%,2,1.0
LD80,mmol/Kg,2,1.0
Antidiuretic activity,%,2,1.0
LD80,mM,2,1.0
LD50 x 1/20,,2,1.0
LD50 x 1/10,,2,1.0
2aPTT,10'-4M,2,1.0
Kinact,10^-1/min,2,1.0
LD50,pmol,2,1.0
CLH,10^3uL/min,2,1.0
LD50,ng/ml,2,1.0
EC50,10'-2 ug/cm2,2,1.0
2T11,,2,1.0
p10 MIC,,2,1.0
LD50,ml,2,1.0
Kinact,10^3/M.s,2,1.0
LD50 x 1/40,,2,1.0
EC1000,,2,1.0
Emesis_ED,,2,1.0
LD90,g/hm2,2,1.0
LD90,mg kg-1,2,1.0
Light transmission,,2,1.0
CLH,L/hr/mg,2,1.0
ka,10^3/M/s,2,1.0
ka,10^6/M/s,2,1.0
FE,%,2,1.0
LambdaZ,/min,2,1.0
EC,ng/ml,2,1.0
AC30,,2,1.0
Kinact,/us,2,1.0
Concentration,ug 100ml-1,2,1.0
Antifertility activity,,2,1.0
logEmax,,2,1.0
ED50,ug/L,2,1.0
Enoyl-CoA hydratase,uM min-1mg-1,2,1.0
EC100,10'-5M,2,1.0
log10EID50/g,,2,1.0
LL,,2,1.0
CLz/F,L.hr/kg,2,1.0
Anticonulsant activity,mg kg-1,2,1.0
log(activity),%,2,1.0
log(activity),/min,2,1.0
Kin x,hr-1,2,1.0
log(activity),CFU/g,2,1.0
log(activity),PFU/ml,2,1.0
A0.5,mM,2,1.0
LOAEL,ng/ml,2,1.0
EC50,10^-2microM,2,1.0
Glucuronidation rate,,2,1.0
Vmax/Km,/nM.min,2,1.0
MIC98,ug ml-1,2,1.0
AUC,ug h ml-1 kg-1,2,1.0
% of kinase activity,%,2,1.0
CFU,10^5/g,2,1.0
Css,mg/L,2,1.0
Kin,uM,2,1.0
Kin,ml/min/g,2,1.0
log(1/C),ug ml-1,2,1.0
Excess MST,%,2,1.0
CLz/F,L/kg/hr,2,1.0
Kin,10'-2/min,2,1.0
ABC,mmHg.hr,2,1.0
Exhalation of 14CO2,% of dose,2,1.0
Exhal+B1718ation of 14CO2,%,2,1.0
LZ,/hr,2,1.0
log(1/K),,2,1.0
Concentration in Brain,uM,2,1.0
CLz/F,L/Kg,2,1.0
LV dP/dt,%,2,1.0
Excretion,,2,1.0
Excreted glucose,mg,2,1.0
LV DRxHR,%,2,1.0
LV,,2,1.0
A50,mg Kg-1,2,1.0
kR,,2,1.0
Total binding,,2,1.0
Animals,,2,1.0
kik0/Ki,uM-1 min**-2,2,1.0
permeability,10^-3cm/min,2,1.0
LD50,gAe/L,2,1.0
pA2,mg kg-1,2,1.0
EC2,,2,1.0
Anogenital distance,mM,2,1.0
keq,,2,1.0
FB,,2,1.0
Level,mg g-1,2,1.0
F,ng/ml,2,1.0
Kiact,min-1,2,1.0
Level,fM mg-1,2,1.0
Kic,10'-7M,2,1.0
Anti-Factor Xa activity,mg,2,1.0
Concentration_plasma,ug ml-1,2,1.0
Kidney VDR,fM (mg of protein)-1,2,1.0
Kieq,pM,2,1.0
permeability,omegacm2,2,1.0
permeability,nmol/cm2/hr,2,1.0
EC30,10'-9M,2,1.0
ED80,mg/kg/day,2,1.0
EIR,,2,1.0
EIC50,uM,2,1.0
EC50,10'5pM,2,1.0
EC30,10'-8M,2,1.0
LC10,mgAi/L,2,1.0
permeability,10'-6cm/s,2,1.0
permeability,ug ml-1,2,1.0
EF90,,2,1.0
LBF,ml/min.kg,2,1.0
EDP,mmHg,2,1.0
% injected dose/cm3,%,2,1.0
permeability,10^4cm2/sec,2,1.0
Colonic weight,mg cm-1,2,1.0
Kp,10^-4cm/hr,2,1.0
permeability,cm/hr,2,1.0
Level,ng dl-1,2,1.0
CLb,ml/hr,2,1.0
kon,1/M1/S,2,1.0
EC50,10'9PFU,2,1.0
Average uterine weight,,2,1.0
Ki slope,,2,1.0
Average tumor weight,g,2,1.0
FIC50,uM,2,1.0
Contractile force,,2,1.0
k2/Ks,M-1 s-1,2,1.0
CLH,/min/uL,2,1.0
Log,1/M MIC,2,1.0
Level,pg ml-1,2,1.0
AD50,ug brain-1,2,1.0
kIAM',,2,1.0
CLH,mL/mg/kg,2,1.0
E50,,2,1.0
FC,10'7No_unit,2,1.0
kDPPH,,2,1.0
Ki,nM-1 min-1,2,1.0
FI50,ppm,2,1.0
EC50,10^-1microM,2,1.0
Anti-emetic,,2,1.0
ACR,,2,1.0
ACAT activity,%,2,1.0
Anti-analgesic,,2,1.0
Concentration of max response,M,2,1.0
Left atrial pressure,mmHg,2,1.0
Exudate,ml,2,1.0
Extraction ratio,,2,1.0
Latency time,min,2,1.0
koff,nM-1 min-1,2,1.0
Last therapy day,%,2,1.0
Level,nmol ofpHB/min/mgof protein,2,1.0
CLz/F,l/hr.kg,2,1.0
kp,min-1,2,1.0
Tm shift degreeC,degrees C,1,1.0
Optimal dosage,,1,1.0
EC90,microM,1,1.0
IC50,nmol/min,1,1.0
AUC,uN h kg/mg,1,1.0
Activity,PbU,1,1.0
Drug metabolism,ng/mg,1,1.0
IC50,uM.hr,1,1.0
Activity,mean,1,1.0
Ka,/nM,1,1.0
Tmin,day,1,1.0
CC,uM,1,1.0
Oral activity,%,1,1.0
CFU,ml,1,1.0
Topical dosage,M,1,1.0
Ka,/nM/min,1,1.0
Oral activity,ml min-1,1,1.0
Basal glucose,mg dl-1,1,1.0
Mean maximumtemp drop,degrees C,1,1.0
K,M-2,1,1.0
Drug metabolism,mg,1,1.0
Stability,pM/mg/hr,1,1.0
Change,uM kg-1,1,1.0
CFU,10^6/g,1,1.0
IC50,uL/ml,1,1.0
AUClast,ngequiv.hr/g,1,1.0
Activity,L/Kg,1,1.0
Median,%,1,1.0
EC50H,nM,1,1.0
Tmax/dose,hr,1,1.0
Activity,ml/cm,1,1.0
Kact,/s,1,1.0
IC50,mg/kg/day,1,1.0
Specific activity,uM Pi/min/mg protein,1,1.0
K,10e4min-1,1,1.0
Ka,10'-7M,1,1.0
AUClast,ug.min/g,1,1.0
Mean effective dose,,1,1.0
ED Arec,,1,1.0
Ka,10'1/M/s,1,1.0
Stability,microg.min/mL,1,1.0
Ka,10'10L/mol/s,1,1.0
Oxidation,%,1,1.0
AUC,uM.hr/mg,1,1.0
AUC,uM.hr.kg,1,1.0
Ka,10'10M,1,1.0
K,fM,1,1.0
Ka,10'2/Ms,1,1.0
Ka,10'2L/mol,1,1.0
Total acid output,,1,1.0
P50C,mmHg,1,1.0
IC50,nM/g,1,1.0
AUC,ug min/mL,1,1.0
Max reduction,mg kg-1,1,1.0
Ka,10^-7M,1,1.0
Creatinine_CL,mg/dl,1,1.0
Ka,10^1 uM,1,1.0
Max APD95,%,1,1.0
Ka,10^1/M,1,1.0
Css min,ng/mL,1,1.0
Ka,10'8M,1,1.0
EC80,mgAi,1,1.0
ED35,ng,1,1.0
K B,nM,1,1.0
AUClast/dose,ug.hr/ml,1,1.0
ED,umol/Kg,1,1.0
Css min,mcg/mL,1,1.0
AUClast,ng/hr,1,1.0
Spontaneous reperfusion,%,1,1.0
IC50,ug/kg,1,1.0
Ka,10'6/Ms,1,1.0
Activity,Osm/kg,1,1.0
Ka,10'7(1/Ms),1,1.0
Hepatic blood flow,L.h.Kg-1,1,1.0
P,pcm s-1,1,1.0
IC50,ug cm**-2,1,1.0
Maximal activation,uM,1,1.0
Heme loss,nM,1,1.0
Ka,10^-7/M,1,1.0
Specific binding,,1,1.0
Displacement,nM,1,1.0
Oral dose,mg kg-1,1,1.0
Tmax,ng/ml,1,1.0
IC50,ng/mg,1,1.0
Change in entry latency,,1,1.0
EC90,nmol/L,1,1.0
Drug metabolism,mM,1,1.0
ED 50,,1,1.0
EC90,mg/ml,1,1.0
Unchanged NDEA,%,1,1.0
Stability,%/min,1,1.0
Ka,10'4 /uL,1,1.0
Clp,l kg-1,1,1.0
Opsin shift activity,,1,1.0
Dissociation,,1,1.0
Tlast,,1,1.0
Specific incorporation,,1,1.0
CI,10'6No_unit,1,1.0
CI,10'7No_unit,1,1.0
CI,10^-5No_unit,1,1.0
IC50,microA,1,1.0
CAC,10^-5M,1,1.0
AUCss(tau) normalised,(nmol.h.L-1)/(mg/kg),1,1.0
Transcriptional activity,,1,1.0
EC50L,nM,1,1.0
MTT,mg/ml,1,1.0
U/P,,1,1.0
K H,%,1,1.0
Max cAMP,,1,1.0
ED50,10^-5 ug/ml,1,1.0
Cp(f)ss,nM,1,1.0
Drug metabolism,fmol/ug,1,1.0
Ka,10^5/M.s,1,1.0
Sleep latency,%,1,1.0
EC70,mg kg-1,1,1.0
CI50,ug ml-1,1,1.0
Ka,10^2/M,1,1.0
Clp,ml hr-1,1,1.0
Max inhibition,uM,1,1.0
IC50H,uM,1,1.0
IC50,mg/cm3,1,1.0
Tissue swelling,uM g-1,1,1.0
Activity,M-1,1,1.0
Stabilty,months,1,1.0
Tissue levels,,1,1.0
PAO activity,pM min-1 mg-1,1,1.0
Activity,micromol/dl,1,1.0
PAP,mM,1,1.0
IC60,10'-2 ug/ml,1,1.0
PActivity,,1,1.0
ED50,10'-8mol,1,1.0
Ka,mM,1,1.0
Max contractile activity,mg,1,1.0
Ka,10^4/M.s,1,1.0
Drug metabolism,uM/g,1,1.0
K,10'-8No_unit,1,1.0
EC50,PuM,1,1.0
P (Ei),Ei,1,1.0
Rescued neurons,,1,1.0
Weight change,T-C,1,1.0
SEC50,10'-10M,1,1.0
SEC50,10'-8M,1,1.0
Vm,rel,1,1.0
Clp,ml mg-1 kg-1,1,1.0
"Onset for sleep, min",,1,1.0
Smax,IU/ml/hr,1,1.0
Ka,10^5/Ms,1,1.0
ED50,10'1 ug/ml,1,1.0
IC75,mg kg-1,1,1.0
HSF release,,1,1.0
Activity,mN,1,1.0
K,10^7No_unit,1,1.0
Max delta BP,mg kg-1 p.o.,1,1.0
Dispacement,%,1,1.0
Change in ovarian follicular atresia,,1,1.0
Ka,10^7/M.s,1,1.0
Ka,10^7/M/s,1,1.0
CA,,1,1.0
EC70,uM,1,1.0
EC70,ng/ml,1,1.0
Kact,mV,1,1.0
Ultrafiltration,,1,1.0
PD50,pmg kg-1,1,1.0
Median toxicity,mg kg-1,1,1.0
K,10^3No_unit,1,1.0
Margin before onset of hypokalemia,mg kg-1,1,1.0
K,10^5/s,1,1.0
Cp(f)/dose,nM/mg/kg,1,1.0
Margin before onset of tachycardia,mg kg-1,1,1.0
EC59,nM,1,1.0
Stimulation,uM,1,1.0
ED50,DIUR,1,1.0
Max MBP,,1,1.0
Of viability,%,1,1.0
D50,nM,1,1.0
Tumour inhibition,,1,1.0
Max IOP reduction,,1,1.0
K,10^5No_unit,1,1.0
CIp,mg kg-1,1,1.0
IC90,%,1,1.0
K,10^9/M/min,1,1.0
Turnover,ug ml-1,1,1.0
IC90,Gy,1,1.0
IC90,PuM,1,1.0
Twitch tension,,1,1.0
PD50,mg/ml,1,1.0
EC91,nM,1,1.0
Halucinogenic activity,,1,1.0
KSV,10'4/mol,1,1.0
PB,equiv,1,1.0
Half duration,,1,1.0
Ka,10^4/s,1,1.0
Histamine release,,1,1.0
AUCt,ml/min.kg,1,1.0
Med tumor area,mg,1,1.0
C90,,1,1.0
Cp(f)max,uM,1,1.0
Stimulatory activity,%,1,1.0
PCaco-2,cm s-1,1,1.0
Stimulatory effect,nM min-1 (mg of protein)-1,1,1.0
AUCt,ng/nL.hr,1,1.0
HDL-C change,,1,1.0
UV,ml kg-1,1,1.0
PD' 2,,1,1.0
Kapp,10'-7M,1,1.0
Ulcer incidence,,1,1.0
MTT,hr,1,1.0
Kapp,10'3L/mol,1,1.0
MTL,,1,1.0
AUClast,nM,1,1.0
Time of dosing before antigen challenge.,hr,1,1.0
K act,M-1 s-1,1,1.0
Toxicity,number of dead animals,1,1.0
Kapp,10'5/M/s,1,1.0
Activity,mg/kg/hr,1,1.0
Uterine activity,,1,1.0
K,10^-6/mM/s,1,1.0
MRT,ng/ml,1,1.0
Activity,mol/g,1,1.0
AUC,ng.h-1.ml-1,1,1.0
Time after dose,,1,1.0
EC50,ug hr ml-1,1,1.0
Selectivity Index,uM,1,1.0
MRC,mg kg-1,1,1.0
Selectivity Index,10^5No_unit,1,1.0
K,10^1/s,1,1.0
AUC,ng/L,1,1.0
K,10^10No_unit,1,1.0
Cp(T),ug ml-1,1,1.0
Occupancy,mg kg-1,1,1.0
Untreated control,,1,1.0
Kapp,10'5L/mol,1,1.0
HD50,umol/Kg,1,1.0
MTD,ng,1,1.0
ID/animal,%,1,1.0
Uptake,% injected dose cm**-3,1,1.0
Cp(f),nmol/L,1,1.0
BSA binding,,1,1.0
MTD,mg/g,1,1.0
MST,MST,1,1.0
Selectivity in binding,,1,1.0
Uptake,nM 3s-1 (mg of protein)-1,1,1.0
PLT,10E3/mm3,1,1.0
ID50,10'-9mol/L,1,1.0
EC50,pnM,1,1.0
Vel rem,%,1,1.0
Velocity,,1,1.0
MIC=<90,uM,1,1.0
Min lytic concentration,,1,1.0
Kcat,10'2/s,1,1.0
K,10^-1(1/Ms),1,1.0
Cp,nmol/Kg,1,1.0
MIC=>90,mg/ml,1,1.0
AUCt/dose,ngequiv.hr/ml/mg,1,1.0
CL,mL.min,1,1.0
CL,lL/min/million,1,1.0
C5 min,ug ml-1,1,1.0
K,10^1/M/s,1,1.0
Selectivity ratio,uM,1,1.0
Activity,mmol.h/L,1,1.0
PIC seizure,,1,1.0
K,10^-8/M/s,1,1.0
MTC,%,1,1.0
AUCt/dose,,1,1.0
K,10^-6No_unit,1,1.0
Selectivity index,Monkey,1,1.0
Drug transport,%ID,1,1.0
CL,(ml/min)/kg,1,1.0
P Increase,,1,1.0
Drug uptake,%ID/mg/ml,1,1.0
VV,,1,1.0
K,10^-5/min,1,1.0
Ti,,1,1.0
Clerance,l hr-1 kg-1,1,1.0
MNTD,mg,1,1.0
Activity,nM/10e6,1,1.0
Occ90,ng/ml,1,1.0
Activity,nM/g,1,1.0
Variation of edema volume,%,1,1.0
KSV,10'-4M,1,1.0
Kb,10^1/M,1,1.0
Kb,10^-5L/mol,1,1.0
Clinical reference,,1,1.0
BP increase,AUD30min,1,1.0
Drug metabolism,10^-2/s,1,1.0
Activity,Ci/mmol,1,1.0
Cp,umol,1,1.0
AUC,ng.Eq/ml,1,1.0
PPB,%ID,1,1.0
Kb,10'6/mol,1,1.0
BP increase,%,1,1.0
ILA,,1,1.0
Cp,ug/hr.ml,1,1.0
Cp,uM/g,1,1.0
VSV,,1,1.0
Kapp,10'7/M/s,1,1.0
Kb,10^3/M,1,1.0
CL,/hr,1,1.0
Diuretic activity,(m equiv [Na+]) 5hr-1 kg-1,1,1.0
K,10^2No_unit,1,1.0
K,10^2/Ms,1,1.0
Cz,ug ml-1,1,1.0
HD40,mg kg-1,1,1.0
K,10^2/M/min,1,1.0
K,10^2/M,1,1.0
IC50,10^5uM,1,1.0
ED10,,1,1.0
MTD,ug/m2/day,1,1.0
Cmax,ng/10^6 cells in 4 h,1,1.0
Selectivity Index,10^3No_unit,1,1.0
Time,10'11min,1,1.0
CFC20,,1,1.0
Second order,M s-1,1,1.0
AUC,ug/mg/day,1,1.0
EC50,ucm/s,1,1.0
AUCt/dose,ng.hr/ml/mg,1,1.0
AUC,ng hr g-1,1,1.0
DC50,mmol/L,1,1.0
CL,kg-1 hr-1,1,1.0
Hydrolysis rate constant,t/2,1,1.0
Vdu,,1,1.0
Papp,10'-9cm/s,1,1.0
Vdss(app),ml/min.kg,1,1.0
ID50,10'-3M,1,1.0
CS50,,1,1.0
KNa,M-1,1,1.0
DCmax,%,1,1.0
ID50,10'-7mol/L,1,1.0
Vdss,L/hr.Kg,1,1.0
Kc,min-1,1,1.0
K,10^-12/min,1,1.0
Papp,10'-3cm/s,1,1.0
K,10^-11/min,1,1.0
SUV,nCi/cc,1,1.0
MLC,mg/ml,1,1.0
BP change,,1,1.0
Activity,mCi/M,1,1.0
Diuretic activity,(m equiv [Na+]) kg-1,1,1.0
K,10^-3No_unit,1,1.0
CL,mg kg-1,1,1.0
MLD50,,1,1.0
Vasopressor activity,mg,1,1.0
MLD,ug/kg,1,1.0
AUC,nM/L.hr,1,1.0
Activity,nanometer2,1,1.0
Saline control,,1,1.0
KSV,10'-4L/M,1,1.0
ID50,10'-3microM,1,1.0
Papp,10'-6/s,1,1.0
Kb,10^7L/mol,1,1.0
ID50,10'-2microM,1,1.0
IC50 reduction,,1,1.0
P-450 loss,nM,1,1.0
CFU/ml,10'3/ml,1,1.0
Toxicity index,,1,1.0
CFU/ml,10'4/ml,1,1.0
CFU/ml,10'7/ml,1,1.0
Ka,10'7/Ms,1,1.0
CAC,mg/ml,1,1.0
deltaA,degrees C,1,1.0
K,10^3L/mol,1,1.0
Kapp,10'4M,1,1.0
Drug metabolism,10'-4/s,1,1.0
KS,uM,1,1.0
Cp,pg/ml,1,1.0
AUMC,,1,1.0
Vd,ml/mg,1,1.0
ID50,10'-1microM,1,1.0
Kbapp,10'4/M,1,1.0
Vd app,L,1,1.0
Vd area,mg kg-1,1,1.0
Vd(app),L,1,1.0
Vd(app),L/hr,1,1.0
BP (ED50),%,1,1.0
Occ50,uM/g,1,1.0
Saldiuretic activity,(m equiv) 6hr-1 kg-1,1,1.0
DC50,uM/L,1,1.0
Diameter of inhibition zone,diameter mm,1,1.0
Kcat,10'7/s,1,1.0
Kcat,10^4/s,1,1.0
MIC75,ug ml-1,1,1.0
Glucose lowering relative to positive control,%,1,1.0
AUMC,ug.hr2/L,1,1.0
Glucose lowering ob/ob dose,mg kg-1,1,1.0
MIC65,ug ml-1,1,1.0
Papp,cm2/sec,1,1.0
IC50,10^-6 ug/ml,1,1.0
Suppression of parasitemia,,1,1.0
Ventricular tachycardia,,1,1.0
Hypnosis duration,,1,1.0
Change in systolic pressure,,1,1.0
Activity,ng/min/dl,1,1.0
Vdss,mg/L,1,1.0
Drug uptake,L/Kg,1,1.0
CL,mg/kg/microM.hrs,1,1.0
Kcat,/hr,1,1.0
Vdss,ml/hr/kg,1,1.0
Vdss,ml/mg,1,1.0
BNa,,1,1.0
KIapp,nM,1,1.0
Vdss(app),l,1,1.0
Therm_solubility,10'-1mol/L,1,1.0
MIC82,uM,1,1.0
Activity,10^7CFU/g,1,1.0
Drug metabolism,10'-2/s,1,1.0
PVCs,,1,1.0
Vc/F,L/hr,1,1.0
MLC,pug ml-1,1,1.0
K act,nM,1,1.0
MLC,ml/min.kg,1,1.0
Bleeding time,uM,1,1.0
CL,mg/hr/kg,1,1.0
SUVmax,kBq/cm3,1,1.0
Min concentration,,1,1.0
KL,M,1,1.0
Papp,10^-6cm2/s,1,1.0
EC98,uM,1,1.0
MIC97,ug ml-1,1,1.0
Activity,10^8CFU/ml,1,1.0
KI50,,1,1.0
Activity,10^7cm/s,1,1.0
Activity,pKa,1,1.0
IC50,10^-5mg/ml,1,1.0
Change in corpora lutea,,1,1.0
Activity,10^7IFU/ml,1,1.0
Virucidal,ng/ml,1,1.0
MIC95,mg/L,1,1.0
CL,ng/min/kg,1,1.0
Gastric emptying,,1,1.0
TT,nM,1,1.0
Vmax,10'-8M/s,1,1.0
Vmax,10'-7mol/s,1,1.0
Vmax,10'-6mol/s,1,1.0
Vm,uM ml-1,1,1.0
Activity,pM/min/ml,1,1.0
Papp,microg/cm2,1,1.0
AUC,min.ng/g,1,1.0
SDS,,1,1.0
Activity,pg.hr/ml,1,1.0
Activity,pg/dl,1,1.0
Papp,microg/cm3,1,1.0
Glucose level,%,1,1.0
Activity,10^7CFU,1,1.0
Papp,nanometer/sec,1,1.0
Vmax,10'-2umol/min/U,1,1.0
SD90,,1,1.0
Activity,log10pfu/g,1,1.0
Activity,10^7.99CFU/g,1,1.0
Activity,10^7.67CFU/g,1,1.0
Glucose,mg dl-1,1,1.0
Hypoglycemic,,1,1.0
MIC,ug.hr/ml,1,1.0
Activity,pg/uL,1,1.0
Vmax,10'-6deltaA/s,1,1.0
EC50,nM g-1,1,1.0
Drug uptake,mg/L.hr,1,1.0
Survival,10'3CFU/ml,1,1.0
Cp,ml/kg,1,1.0
GI50,PuM,1,1.0
Vmax,pM 0.5hr-1,1,1.0
Kcat/Km,10'7M/s,1,1.0
Vmax,10'-8cpm/min,1,1.0
Vmax,10'3mmol/min/mg,1,1.0
Kcat,umol/min/nmol,1,1.0
Papp,uL/min.mg,1,1.0
Vmax,10'7U/min,1,1.0
Molar ratio,,1,1.0
SC50,ng/ml,1,1.0
Generalization,,1,1.0
Activity,pg/ug,1,1.0
MIC,ucm/s,1,1.0
Vmax,L/Kg,1,1.0
MIC,ucm,1,1.0
Gastric lesions,,1,1.0
Clearance,ml min-1,1,1.0
EC50,nM kg-1,1,1.0
ID50,mg kg-1 day-1 b.i.d.,1,1.0
K,10'8Lmol,1,1.0
Kcat/Km,/min.uM,1,1.0
Gastric concentration,,1,1.0
CO,uM,1,1.0
Clearance_blood,Not_given,1,1.0
SCW reduction,%,1,1.0
Drug uptake,microg.hr/mL,1,1.0
Kcat/Km,10'2/Ms,1,1.0
CL,min,1,1.0
K,10'7/mol,1,1.0
MIC,IU/ml,1,1.0
CC50,10'10uM,1,1.0
Activity,10^6IFU/ml,1,1.0
Vmax,deltaOD/hr,1,1.0
Cp,microg.min/mL,1,1.0
DIZ,ug ml-1,1,1.0
MIC,10^-6 uM,1,1.0
MIC,10^-4 ug/ml,1,1.0
MIC,10^-3micromol/ml,1,1.0
Vmax,mM/hr,1,1.0
EC50,mmol/Kg,1,1.0
Mortality,nM,1,1.0
Vmax,mOD/minute,1,1.0
CL,micromol.hr/L/mg/kg,1,1.0
MIC,10'-4nmol,1,1.0
ID50,mg/kg/hr,1,1.0
Activity,10^6CFU/ml,1,1.0
KH,M,1,1.0
K,10'7L/mol,1,1.0
IC50,10^-4mg/ml,1,1.0
"S20,w",s,1,1.0
ID50,microg/cm2,1,1.0
EC98.6,nM,1,1.0
Gain,,1,1.0
Activity,10^6/100microL,1,1.0
MIC,M-1,1,1.0
GTPshift,,1,1.0
Kcat/Km,10'3/M.s,1,1.0
Kcat/Km,10'4/M/min,1,1.0
Vmax,nM/hr,1,1.0
Parasite_Clearance_time,,1,1.0
Monomer,%,1,1.0
KH,%,1,1.0
Parasites,,1,1.0
IC50,10^-3umol/L,1,1.0
Vmax,nanomol/min,1,1.0
Kcat/Km,10'5/Ms,1,1.0
MHC,10'-6M,1,1.0
Vmax,nmol/cm2/s,1,1.0
MHC,10'-5M,1,1.0
MHC,10'-4M,1,1.0
Cp,mg/min/kg,1,1.0
Cp,mg kg-1,1,1.0
EC50,mgAi,1,1.0
Vmax,nmol/min/kg,1,1.0
K,10'6/nM/min,1,1.0
CL,min.ug/ml,1,1.0
Vmax,nmol/min/ml,1,1.0
Vmax(app),nM/min,1,1.0
K,10'3mol/dm3/s,1,1.0
Activity,10^4CFU/mg,1,1.0
BBB Impermeable,,1,1.0
Activity,10^5CFU/ml,1,1.0
Terminal t1/2,hr,1,1.0
Terminal elimination t1/2,hr,1,1.0
Vmax,pM hr-1 mg-1,1,1.0
Activity,uCi/ml,1,1.0
ID50,pM,1,1.0
Kcat/Km,10^-4/M/s,1,1.0
Kcat/Km,10^-4/nM/s,1,1.0
CL,ml,1,1.0
Survival dose,,1,1.0
ID50,pg kg-1,1,1.0
Cp,mM,1,1.0
ID50,pmg kg-1,1,1.0
Activity,uM kg-1 s.c.,1,1.0
AUC,mg.hr,1,1.0
ID50,pug ml-1,1,1.0
Activity,10^5PFU/g,1,1.0
Vmax,pmol/min/U,1,1.0
Vmax,pmol/min/cm2,1,1.0
Kcat/Km,10^1/M/s,1,1.0
Paw volume,ml,1,1.0
Paw weight increase,,1,1.0
Mortality ratio,,1,1.0
Peak GH,ug l-1,1,1.0
Peak concentration,%,1,1.0
Kd,10'-29M,1,1.0
K,10'4/s/M,1,1.0
V0,10^-5/s,1,1.0
Vmax,uM g-1,1,1.0
Vmax,uM hr-1,1,1.0
Cmax,ng.hr,1,1.0
Vmax,uM mg-1,1,1.0
AUMCt,ug.hr2/L,1,1.0
Kcat/Km,10^8/M/s,1,1.0
K,10'5/mol,1,1.0
GR control,%,1,1.0
Binding constant,1/M,1,1.0
OD,M,1,1.0
Kcat/Km,uM,1,1.0
Cp,M,1,1.0
Vmax,uM/L.min,1,1.0
Drug uptake,ng/cm2/h,1,1.0
TdeltaS,10^2kJ/mol,1,1.0
ED50,10'-1umol/L,1,1.0
ID50,ug kg-1 min-1,1,1.0
Peak effect,%,1,1.0
ED50,mg g-1 day-1,1,1.0
Activity,ug cm**-2 hr-1,1,1.0
Vmax (uM),%,1,1.0
Kd,/nM/min,1,1.0
Kcat/Km,10^2/M/s,1,1.0
Temperature change,(degrees C)-1,1,1.0
ID50,ug/hr.kg,1,1.0
Cmax,ng kg-1,1,1.0
Vmax/Km,10'-5L/min,1,1.0
Vmax/Km,10'-4min,1,1.0
IC50,10'7nM,1,1.0
Blood Pressure,,1,1.0
AUC Npo,,1,1.0
AbA/analogue ratio,,1,1.0
MED50,uM,1,1.0
Activity,10^5/Ms,1,1.0
ID60,mg kg-1,1,1.0
Activity,ug.hr/ml,1,1.0
CTD50,mM,1,1.0
Ct,pg/ml,1,1.0
BBB,hr,1,1.0
Kcat/Km,10^-3/M/s,1,1.0
Kd,10'-10L/mol,1,1.0
Kd,10'-11/M,1,1.0
Vmax(app),pmol/mg/min,1,1.0
Cp,L/Kg,1,1.0
Activity,10^4log10CFU/ml,1,1.0
Kd,10'-2(1/s),1,1.0
BBB,10'-3cm/min,1,1.0
Activity,U/min/ml,1,1.0
Performance,,1,1.0
Vmax/Km,10'-5min,1,1.0
Vmax/Km,10'3/M/s,1,1.0
Peroxidase rate,,1,1.0
GI75,nM,1,1.0
Vmax / Km,ml min-1 mg-1,1,1.0
MED,ug min-1 kg-1,1,1.0
BBB,%,1,1.0
DeltaCp,,1,1.0
EC99,mg/ml,1,1.0
Kd,10'-5 cm/s,1,1.0
Permeability,nM/s,1,1.0
KD non ionic,mM,1,1.0
Activity,10^4/M/s,1,1.0
MED,mmol/Kg,1,1.0
ID90,nM,1,1.0
Permeability limited,,1,1.0
Permeability,nm/s,1,1.0
Kd,10'-7/s,1,1.0
GI50/EC50,uM,1,1.0
K,10'3/s/M,1,1.0
KD hydro,,1,1.0
DeltaBP,,1,1.0
CMI,ug ml-1,1,1.0
Cell density,cells ml-1,1,1.0
Activity,l hr-1 kg-1,1,1.0
MED,g/Kg,1,1.0
Parasite_Clearance,,1,1.0
IC50,10^-4 ug/ml,1,1.0
MC100,uM,1,1.0
Kd,10^-1M,1,1.0
DNA single strand breaks,,1,1.0
Photoxic reaction,mg,1,1.0
ED5,umol/Kg,1,1.0
EC50,mM/L,1,1.0
Phototoxicity,mg kg-1,1,1.0
Kd,10'-9/M,1,1.0
Kd,10'-9L/mol,1,1.0
MEC2.0,uM,1,1.0
Pharmacokinetic,%,1,1.0
MEC2.0,nM,1,1.0
Kd,10'1/s,1,1.0
ED100,M,1,1.0
GI50,10'-8cm/s,1,1.0
K,10'2/M/min,1,1.0
I10,M,1,1.0
K,10'1mol/dm3/s,1,1.0
WCC90,ug ml-1,1,1.0
Volume reduction,%,1,1.0
MEC,pM,1,1.0
Vp/F,L/hr,1,1.0
KBp,,1,1.0
MEC,nmol/L,1,1.0
GI tolerance,,1,1.0
K,10'1/s,1,1.0
Kd,10^-17M,1,1.0
C10,,1,1.0
WBC,10E3/mm3,1,1.0
Kdiss,10^-3M,1,1.0
Kdiss,10'-6/s,1,1.0
Kd,10^4/M,1,1.0
Plasma clearance,,1,1.0
Kd,10^4 uM,1,1.0
Vss/F,,1,1.0
Vss/F,L,1,1.0
MEC,g/ml,1,1.0
GI,ng/ml,1,1.0
K,10'11/M,1,1.0
Activity,10^3log10CFU/ml,1,1.0
MEC,10'-8M,1,1.0
MEC,10'-7M,1,1.0
GI,10'-7M,1,1.0
K,10'10/s,1,1.0
K,10'10/M,1,1.0
IFN gamma concentration,pg ml-1,1,1.0
Activity,U/ml/min,1,1.0
GI,10'-6M,1,1.0
Activity,um3.um2/day,1,1.0
ED25,ug ml-1,1,1.0
GI,%/hr,1,1.0
Kd,10^-15M,1,1.0
GI clearence,,1,1.0
Delta non HDL-C,%,1,1.0
MIC,10'4pg/ml,1,1.0
XI50,nM,1,1.0
XL50,nM,1,1.0
GC200 [d],%,1,1.0
I16,uM,1,1.0
MBIC100,ug ml-1,1,1.0
Clearance,l kg-1,1,1.0
Drug uptake,uM/L,1,1.0
MDH Reactivation,,1,1.0
PkB,,1,1.0
Kd,10^-4 mol/L,1,1.0
Kd,10^-4/M,1,1.0
K,10'1/mol/s,1,1.0
Pka2,,1,1.0
Kd,10^-5 mol/L,1,1.0
Kd,10^-52M,1,1.0
Weight (mg/g),%,1,1.0
K,10'1/M/s,1,1.0
I13,uM,1,1.0
AUC,hr.nmol/g,1,1.0
Dmax,%,1,1.0
MCC50,mM,1,1.0
Plasma,ng ml-1,1,1.0
MC100,ug ml-1,1,1.0
CL,nM/min/mg,1,1.0
IC50,10'5uM,1,1.0
ILS (Sur),%,1,1.0
Resistance ratio,,1,1.0
AUC,0-tldc,1,1.0
Kd,10'7/M/s,1,1.0
Vss,L/m2,1,1.0
Kd,10'5/M,1,1.0
Activity,pM/min/mg,1,1.0
WCC99.9,uM,1,1.0
Kd,10^-2M,1,1.0
Weight increase,%,1,1.0
I20,uM,1,1.0
Replacement,%,1,1.0
AUC,L/hr.Kg,1,1.0
KB1,,1,1.0
Kd,10^3 uM,1,1.0
CL,ng/ml/hr,1,1.0
Kd,10^3/M/s,1,1.0
I23,M,1,1.0
N/D,,1,1.0
C0(unbound),ng/ml,1,1.0
ED50,mg/cm2,1,1.0
TR,min,1,1.0
CTD50,ug ml-1,1,1.0
Drug uptake,uM/ml,1,1.0
AUC,10^6nM,1,1.0
Kd,10^3/s,1,1.0
Kdiss,10^-2/Ms,1,1.0
I42,uM,1,1.0
Kdiss,10^-1M,1,1.0
average log GI50,M,1,1.0
INCC50,,1,1.0
Kd,microM/s,1,1.0
Kd,microL/min/mg,1,1.0
Plasma clearance,hkg,1,1.0
Clearance,l hr-1,1,1.0
Remained,%,1,1.0
AUBC,ng.hr/ml,1,1.0
I28,uM,1,1.0
MBC99,ug ml-1,1,1.0
MBC99,mM,1,1.0
Activty,%,1,1.0
Kd,10^6uM,1,1.0
Plasma clearance,mg kg-1,1,1.0
Kd,M-1 s-1,1,1.0
Actvity,,1,1.0
Plasma clearance,mg.ml-1,1,1.0
I30,uM,1,1.0
[3H] thymidinecpm/dish,,1,1.0
Plasma concentration,%,1,1.0
G1,,1,1.0
CMC,umol/dm3,1,1.0
No_cures,,1,1.0
ED100,mg,1,1.0
Full inhibition,uM,1,1.0
Kd2,,1,1.0
Acid output,(equiv of [H+]) 2hr-1,1,1.0
Kd1,,1,1.0
Activity,ul g-1,1,1.0
MED,M,1,1.0
GI50,10^3nM,1,1.0
BBB,,1,1.0
AT1 affinity,,1,1.0
AUC/dose,uM/hr/Kg/mg,1,1.0
Fu,umol/L,1,1.0
ILSmaxOD,,1,1.0
K,10'-7/nM/min,1,1.0
Plasma concentration,ug equiv ml-1,1,1.0
Fu,nmol/Kg,1,1.0
AUC glu reduction(mM x min),%,1,1.0
Fu,microg.hr/mL,1,1.0
ED25,pmg kg-1 day-1,1,1.0
alphaKi,mM,1,1.0
K,10'-7/M,1,1.0
Fu,%ID,1,1.0
Clast,ug.hr/ml,1,1.0
K,10'-6/hr,1,1.0
BAV,,1,1.0
Cmax,ug m-1 min-1,1,1.0
IN,,1,1.0
Adverse effect,,1,1.0
[Ca2+],nM,1,1.0
Drug uptake,ug.min/g,1,1.0
Relative weight loss,%,1,1.0
KB,mg kg-1,1,1.0
ED50,ml/kg,1,1.0
Activity,10^3/M,1,1.0
Activity,10^3/cm2,1,1.0
I5,uM,1,1.0
Change non HDL-C,,1,1.0
MAD,10'-2microL,1,1.0
INCC50,%,1,1.0
KdSPA,mM,1,1.0
Delta beats/min,,1,1.0
KdSPR,uM,1,1.0
APD95,uM,1,1.0
INCC50,ug ml-1,1,1.0
Kdiss,/hr,1,1.0
K,10'-5L/mol,1,1.0
INH,/min,1,1.0
Plasma clearance,Clp,1,1.0
Survivors,mg kg-1,1,1.0
Acid hydrolysis,mol/mol,1,1.0
K,10'-53No_unit,1,1.0
Kdiss,10'-7M,1,1.0
Kdiss,10^-1/s,1,1.0
Kdiss,10^-10M,1,1.0
M.A.D,,1,1.0
INH,10'-8mol/kg,1,1.0
APA,ms,1,1.0
APD,%,1,1.0
K,10'-5/s/nM,1,1.0
behavioral observation,,1,1.0
MAD,10'-4microL,1,1.0
beta t1/2,%,1,1.0
Ka,/min,1,1.0
Ccontrol,%,1,1.0
APD95,,1,1.0
K,10'-51No_unit,1,1.0
Lowering activity,,1,1.0
Kdiss,10^-5M,1,1.0
Kdiss,10^-6M,1,1.0
Delta TM,K,1,1.0
Plasma_NEFA,%,1,1.0
Relative potency,nM,1,1.0
INH,10'-7mol/L,1,1.0
delta T,K,1,1.0
Loss of activity,,1,1.0
Drug uptake(free),umol/L,1,1.0
delta Vmax,%,1,1.0
INH,10'-7mol/kg,1,1.0
Food intake,g 5mice-1 5days-1,1,1.0
Plasma_IL-6,%,1,1.0
Kdiss,10^-8M,1,1.0
V0,10^-3/s,1,1.0
EAUC50,ug.hr/ml,1,1.0
MPE,uM,1,1.0
Average weight gain,,1,1.0
I7,uM,1,1.0
Control at the dose of 50.0microg/mouse,%,1,1.0
Cbrain,ng g-1,1,1.0
CL free,10^4uL/min/mg,1,1.0
Ke,10^-4M,1,1.0
Fmean,%,1,1.0
deltaS,kcal/mol.K,1,1.0
Ke,10^-5M,1,1.0
INH,E^-1%,1,1.0
Activ ity,,1,1.0
Log of inhibitory zone,mM,1,1.0
Agonism inflection point,nM,1,1.0
Fold IC50,,1,1.0
deltaTm,°C,1,1.0
Platelet count,10e3 ul-1,1,1.0
INH,E^1%,1,1.0
INH,L/hr/kg,1,1.0
CMC,mmol/dm3,1,1.0
Drugexcretion,Da,1,1.0
Control at the dose of 5.0microg/mouse,%,1,1.0
K,10'-5/hr,1,1.0
Activ ity,%,1,1.0
Cmax,ug/ml.hr,1,1.0
Activity,10^1/mm2,1,1.0
Relative,uM,1,1.0
IC50,10'20 uM,1,1.0
Log EC50(uM),,1,1.0
k cat,*10e-3,1,1.0
Amine formed,,1,1.0
CCID50,PuM,1,1.0
EC50,10^-6 uM,1,1.0
Activity,10^-11M,1,1.0
k cat,hr-1,1,1.0
AE score,%,1,1.0
Delta IOP,,1,1.0
K cat/Km,1/M.s,1,1.0
Blood volume,HB g ml-1,1,1.0
Ki,10'5/M,1,1.0
Ki,10^-9/min,1,1.0
Drug degradation,10'-5/s,1,1.0
Activity,10'9CFU/ml,1,1.0
Duration of block,,1,1.0
Log IC50(uM),,1,1.0
Ki,10'5/M/s,1,1.0
Relation,%,1,1.0
K,/s/M,1,1.0
TGI,10^5uM,1,1.0
Ki,10^-2/min,1,1.0
Ki,10^-4microM,1,1.0
Potentiation inflection point,uM,1,1.0
Fluoroscence,,1,1.0
ALP_CHANGE_TO,,1,1.0
AUC/dose,uM.hr/ml,1,1.0
deltaS,J/mol,1,1.0
ECmax,ng/ml,1,1.0
Relative inactivation,,1,1.0
ED50,nM animal-1,1,1.0
CL-renal,L/hr,1,1.0
IC50,10'13nM,1,1.0
fCmax,ng/g,1,1.0
IC50,10'-4umol/L,1,1.0
fCmax,nmol/L,1,1.0
Relative contractile potency,,1,1.0
fCmax,nmol/ml,1,1.0
INH,ug/kg,1,1.0
CL-renal,mL/min,1,1.0
Delta SBP,,1,1.0
fCmax,umol/L,1,1.0
INH,pmol,1,1.0
Log Poct A,,1,1.0
Log Pn,cyh,1,1.0
Pm,ucm/s,1,1.0
fCmin,ng/ml,1,1.0
TID20,mg kg-1,1,1.0
ED50,10'-13mol,1,1.0
K cat,1/sM,1,1.0
Fez,%,1,1.0
Control current,,1,1.0
INH,10^-10mol/L,1,1.0
Ct,uM/L,1,1.0
INH,10'6/M/s,1,1.0
INH,AU/sec,1,1.0
INH,10^-8mol/L,1,1.0
deltaG,10^2kJ/mol,1,1.0
Control level,ng ml-1,1,1.0
CL,uM.hr,1,1.0
Relative oncentration,uM,1,1.0
Drugabsorption,microg/cm2,1,1.0
INH,10'-9mol/L,1,1.0
CL,ug.hr/ml,1,1.0
deltaH,10'4cal/mol,1,1.0
deltaH,10^3kJ/mol,1,1.0
Drugabsorption,ml/hr/kg,1,1.0
Plasma_cholesterol,%,1,1.0
CL,umol/min/mg,1,1.0
deltaH,10^6cal/mol,1,1.0
INH,10'4/M/s,1,1.0
Plasma_glucose,%,1,1.0
CL,ug/hr,1,1.0
Plasma_insulin,%,1,1.0
Plasma_leptin,%,1,1.0
CL,ug/ml/hr,1,1.0
Drugabsorption,pmol,1,1.0
Plasma_triglyceride,%,1,1.0
NOAEL,mg,1,1.0
FRP at 10microM,%,1,1.0
Cave,ug ml-1,1,1.0
Change of weight,g mouse-1,1,1.0
KA,uM l-1,1,1.0
Activity,10^-3/s,1,1.0
K,10'-12/min,1,1.0
Log Ke,M-1,1,1.0
hSlo current,,1,1.0
Ki,10'11mM,1,1.0
Control,ng ml-1,1,1.0
K cat/Km,1/M*s,1,1.0
CL/F,(mg/kg)/(microg/ml)/hr,1,1.0
Activity,10^-3/hr,1,1.0
Ki,10'2/M/min,1,1.0
Ki,10'22mM,1,1.0
K,10'-11M,1,1.0
Control,mg kg-1,1,1.0
Drug degradation,10'-6/hr,1,1.0
Log KB,,1,1.0
Activity,%mg,1,1.0
EC50,10^-6nmol,1,1.0
Cmax/Tmax,hr,1,1.0
Potency Ratio,,1,1.0
Log KZ,,1,1.0
"Cave,ss",ng/ml,1,1.0
Control,pfu/ml,1,1.0
g/mouse,,1,1.0
K,10'-18No_unit,1,1.0
Ki,PuM,1,1.0
Activit y,,1,1.0
%Bound_Albumin,%,1,1.0
%AUC,%,1,1.0
Cmin,ng/g,1,1.0
pWeight change,,1,1.0
LC25,ppm,1,1.0
% reduction,%,1,1.0
Activity,10'-6No_unit,1,1.0
CL_biliary,ml/min.kg,1,1.0
Cures@ 80 mg/kg,,1,1.0
Cures@ 40mg/kg,,1,1.0
CL_renal,l/h,1,1.0
IC25,PuM,1,1.0
Activity,10'12L/mol/s,1,1.0
Asorbance,,1,1.0
T/C @ 20mg/kg,%,1,1.0
LC100,mg/L,1,1.0
Ratio,/microsec/nM,1,1.0
LC100,,1,1.0
Kon,10e3* M-1 s-1,1,1.0
% reduction,,1,1.0
Catalase rate,,1,1.0
LDH50,uM,1,1.0
Pressor response,,1,1.0
Activity,kJ/cm2,1,1.0
Ki,/min,1,1.0
Activity,10^-9M,1,1.0
Activity,kT/e,1,1.0
Clast,ng/mL.hr,1,1.0
Reduction of prostate weight,%,1,1.0
Ki,10^2/M/s,1,1.0
Ki,10^4/M/s,1,1.0
Ki,10^6/M/s,1,1.0
IC50,10'-13 ug/ml,1,1.0
No. of survivors,48h,1,1.0
Ki,Kg,1,1.0
LOAEL,ml/kg,1,1.0
ED25,10'-9M,1,1.0
NOAEL,mg Kg-1,1,1.0
Reduction in respiratoryvolume,ml,1,1.0
Pressure response,%,1,1.0
NOAEL,ng/kg,1,1.0
Cav(ss),nmol.L-1,1,1.0
Reduction in movement,,1,1.0
Anabolic activity,,1,1.0
Contractility,mg kg-1,1,1.0
Reduction in heart rate,%,1,1.0
Reduction in blood pressure,%,1,1.0
k1,,1,1.0
Ki,ml/min/g,1,1.0
Reduction in arterial blood pressure,%,1,1.0
Pressor activity,%,1,1.0
K,10'-10No_unit,1,1.0
Log K4,,1,1.0
C(24h),mcg/mL,1,1.0
fIC80,nM,1,1.0
Drugexcretion,ug ml-1,1,1.0
Alpha Ki,,1,1.0
Activity,10^-7/hr,1,1.0
K,10'-2/s/M,1,1.0
fKi,uM,1,1.0
Activity,10^-6M,1,1.0
fMEC,nM,1,1.0
K,10'-2/nM/min,1,1.0
fMEC,ng/ml,1,1.0
AFLCl,ms,1,1.0
K,10'-2M,1,1.0
Drugexcretion,umol/L,1,1.0
Log Kill,,1,1.0
fc max,mg L-1,1,1.0
IP,nm/s,1,1.0
Log Ki,uM.hr/L,1,1.0
CD50,mg/ml,1,1.0
Activity,10^-3No_unit,1,1.0
Relative Vmax/Km,rel,1,1.0
food intake,g mouse-1 day-1,1,1.0
Activity,10^-5No_unit,1,1.0
Kgmax,nM,1,1.0
Cytotoxic endpoint,,1,1.0
Body weight,kg,1,1.0
Activity,/10^3mm3,1,1.0
"Ki,app",nM,1,1.0
k3/K1,uM,1,1.0
Progressed tumors,,1,1.0
Ki' uncomp,mM,1,1.0
IC100,mg/kg/day,1,1.0
A0.5,,1,1.0
IC50,10'-11uM,1,1.0
k3/ki,,1,1.0
Anesthesia duration,,1,1.0
CLH,10^-4L/hr/kg,1,1.0
Activity,10'6log10CFU/ml,1,1.0
Antibody titer,log-2,1,1.0
IC5,ng/ml,1,1.0
IC50,/uM/s,1,1.0
Prolactin release,ng mg-1 hr-1,1,1.0
EC50,10'6pM,1,1.0
IZ/AAR / AAR/LV,,1,1.0
Analgesicactivity,,1,1.0
TG 2X lag,,1,1.0
TG,mg kg-1 diet,1,1.0
Ki comp,mM,1,1.0
Ki inact,min-1,1,1.0
AD50,umol/Kg,1,1.0
Log,(degrees C)-1,1,1.0
ED50,uM ear-1,1,1.0
Ctau,nM,1,1.0
Bmax,fM,1,1.0
Anti-arhythmic,,1,1.0
Incorporated,,1,1.0
KA,10^-3/M,1,1.0
Activity,10'-10s,1,1.0
Activity,10'-1microM,1,1.0
QH,L/Kg,1,1.0
AC50,g,1,1.0
CLH,mg/kg/min,1,1.0
Ratio of distribution,,1,1.0
ED14.5,ug/kg,1,1.0
EC50,10'-6microg/cm2,1,1.0
KA,10'8/M,1,1.0
AC50,mg,1,1.0
Ratio Ki,10'-7No_unit,1,1.0
AC50,hr.nmol/L,1,1.0
log Kp,10'-6 cm/s,1,1.0
AC50,g/dl,1,1.0
Kin,10^-3/s,1,1.0
Increase,ml min-1,1,1.0
Brain levels,nM,1,1.0
Locomotor,Counts,1,1.0
IZ/AAR / AAR/LV,%,1,1.0
k21,/hr,1,1.0
Ki obs / [I],M-1 s-1,1,1.0
A ctivity,,1,1.0
K,10'-3/M/s,1,1.0
Bmax,fM bound (mg of protein)-1,1,1.0
Anticoagulant activity,mg kg-1 hr-1,1,1.0
EC50,10'10PFU,1,1.0
Imax,ng/ml,1,1.0
Concentration in Brain,,1,1.0
Anticancer activity,,1,1.0
Activity,10'-3nmol,1,1.0
Liphophilicity,sigma pi,1,1.0
Delta F75,,1,1.0
Activity,10'9/ml,1,1.0
Prolongation,,1,1.0
Jmax,pmol/min/mg,1,1.0
Liver catalase,mg of protein,1,1.0
Activity,/10^6mm3,1,1.0
Ki0,nM,1,1.0
FC,10'-4No_unit,1,1.0
kOH-,,1,1.0
Reduced food intake,%,1,1.0
Imax,min,1,1.0
IC100,mM,1,1.0
Activity,10'7/M,1,1.0
Qmax,10^10L/mol/s,1,1.0
AD50,ng,1,1.0
K inact,M-1 min-1,1,1.0
Chemosensitizing activity,mg l-1,1,1.0
ka,10^5L/mol,1,1.0
EC50,10'8PFU,1,1.0
Ratio IC50,nM,1,1.0
k2/Ki,,1,1.0
Bmax,10'-6pmol,1,1.0
Synergistic effect,,1,1.0
Ratio ED50/MIC50,,1,1.0
Ctau,ug ml-1,1,1.0
E2,,1,1.0
Activity,10'6PFU,1,1.0
EC99.6,uM,1,1.0
CL/F,ug.hr/ml,1,1.0
Activity,10'-3umol/min,1,1.0
ED100,pmol,1,1.0
Concentration,ug of B/ml,1,1.0
Ki/Km,nM,1,1.0
Kin,10'-3ml/s/g,1,1.0
Ki/ki,uM,1,1.0
Life span,%,1,1.0
Prolonged QT,,1,1.0
EAUC50,ng.hr/ml,1,1.0
AD50,day,1,1.0
Level in serum,mg dl-1,1,1.0
Ratio IC50,10^7No_unit,1,1.0
Level in serum,mM l-1,1,1.0
Recovery rate,,1,1.0
Activity,10'-1/M/s,1,1.0
QA,,1,1.0
Activity,10'-1 ug/ml,1,1.0
Drugexcretion,ml/min.kg,1,1.0
Pm,10^-6 cm/s,1,1.0
Pm,/ml,1,1.0
k12,/hr,1,1.0
Tmin,min,1,1.0
CC50,10'5uM,1,1.0
kinact/KIapp,M-1s-1,1,1.0
Lethal dose,ng ml-1,1,1.0
Cytocidal effect,%,1,1.0
kmax,s-1,1,1.0
Kin,min-1,1,1.0
kmax/KS,M-1 s-1,1,1.0
Average score,%,1,1.0
AD90,ug/kg,1,1.0
Protein,,1,1.0
kinact,uM,1,1.0
kobs,,1,1.0
ED25,10'-11M,1,1.0
Protein bound,%,1,1.0
ED100,ug day-1 kg-1,1,1.0
F,ml/min.kg,1,1.0
KA,10^8/M,1,1.0
Activity,g/hr,1,1.0
Ratio Ki,10'-5No_unit,1,1.0
CL(app),L/min,1,1.0
Kel,min,1,1.0
Killed,%,1,1.0
Drugexcretion,ml/hr/kg,1,1.0
Relative bioavailability,nM ml-1,1,1.0
duration of action,hr,1,1.0
fAUClast,uM.hr,1,1.0
Drugexcretion,ng,1,1.0
eduction,%,1,1.0
I50,10'5mol/L,1,1.0
Log geometric mean,ppfu mg-1,1,1.0
IC50,10'16 uM,1,1.0
f %t > MIC,%,1,1.0
Activation,uM,1,1.0
C0,ng.hr,1,1.0
Fluorescence,,1,1.0
fAUC,mg/L,1,1.0
fAUC,nM,1,1.0
Activity,10^2CFU/ml,1,1.0
AlDH activity,nM min-1,1,1.0
NBT reduction,%,1,1.0
C0,ng ml-1,1,1.0
Drugexcretion,mg/day,1,1.0
K,10'-3No_unit,1,1.0
fAUC/dose,hr.Kg/L,1,1.0
Kel,L/Kg,1,1.0
Change of body weight,,1,1.0
Ratio_Cmax_brain/plasma,,1,1.0
KA,10^4/M,1,1.0
Anti-HIV activity,,1,1.0
LV dp/dt,%,1,1.0
Decreace in BP,mM,1,1.0
log Pe,10^-6 cm/s,1,1.0
Kin,/min,1,1.0
Cataleptic effect,,1,1.0
QH,L/min,1,1.0
AC30,%,1,1.0
Activity,10'-2M,1,1.0
AC200,,1,1.0
Concentration of Cl-,m equiv 6hr-1 kg-1,1,1.0
Kin,10'-5ml/s/g,1,1.0
T,degree,1,1.0
QH,ml/min,1,1.0
Activity,10'-3 ug/ml,1,1.0
Ratio Ki,10^-6No_unit,1,1.0
Bmax,fmol/ug,1,1.0
Concentration in serum,,1,1.0
log(1/ID50),uM,1,1.0
ED15,%,1,1.0
Ratio Ki,10'7No_unit,1,1.0
log(1/IC50),mM,1,1.0
Ratio Ki,10'4No_unit,1,1.0
RatioGI50,10'4No_unit,1,1.0
LambdaZ,L/min,1,1.0
Cholesterol,,1,1.0
KA,10^-4/M,1,1.0
EBD20,,1,1.0
AUC(0-24) normalised,(nmol.h.L-1)/(mg/kg),1,1.0
Intrinsic,,1,1.0
Brain level,nM,1,1.0
Recovered in bile,%,1,1.0
Level,nmol of pHB/min/mg of protein,1,1.0
ED50,ug animal-1,1,1.0
Activity,10'8/ml,1,1.0
Protection,mg kg-1,1,1.0
Systolic blood pressure,SBP,1,1.0
Level,mg/gof liver,1,1.0
AD100,mg kg-1,1,1.0
Lethal toxicity,mg kg-1,1,1.0
Ratio IC50/EC50,10'3No_unit,1,1.0
Activity,10'7PFU/ml,1,1.0
Intraperitoneal score,,1,1.0
NOL,mg kg-1,1,1.0
NOL,ug kg-1,1,1.0
EC99,ng/ml,1,1.0
IC05,,1,1.0
AD,,1,1.0
CC50,10'7uM,1,1.0
Antagonist efficacy,%,1,1.0
Ratio IC50/EC50,10'7No_unit,1,1.0
%Cleared,%,1,1.0
pRatio,,1,1.0
MPC,ng/ml,1,1.0
3.3,uM,1,1.0
2xAPTT,,1,1.0
Kinact,10'-8/s,1,1.0
Kinact,10'-9M,1,1.0
Kinact,10'2/M/s,1,1.0
Kinact,10'2/s,1,1.0
logP,10'-2No_unit,1,1.0
logP,c.p.m.,1,1.0
Emesis_ED,mg kg-1,1,1.0
Injected dose (g),%,1,1.0
Activity,10'-4g,1,1.0
Bmax,pg/mm2,1,1.0
Activity,10'-5 mol/L,1,1.0
2x PT,,1,1.0
RBC,10e-6ul-1,1,1.0
Kinact,10'-5/s,1,1.0
EC50,10'-2mol%,1,1.0
logD7.5,,1,1.0
Anticonvulsant activityAnticonvulsant activity,,1,1.0
KinX,hr-1,1,1.0
CC90,nM,1,1.0
EC10,,1,1.0
log10CFU/ml,mg/L,1,1.0
CLH,ml/mg,1,1.0
Antihypertensive activity,mg kg-1,1,1.0
30 day survival/total,,1,1.0
Equieffective dose,,1,1.0
LD95,,1,1.0
LD50,10'-8M,1,1.0
CLH,umol/min/g,1,1.0
ED58,,1,1.0
1/2Kcat/Km,M-1 s-1,1,1.0
Curative Index,%,1,1.0
Effective dose,ug kg-1,1,1.0
Ratio,10^3/mM/s,1,1.0
Cmax_triphosphate,uM,1,1.0
Increased,%,1,1.0
Degree of activation,,1,1.0
Bmax1,fM (mg of protein)-1,1,1.0
CLH,umol/min/kg,1,1.0
LC95,ug/g,1,1.0
pH50,,1,1.0
LD50,10'2umol/kg,1,1.0
Emax,10'-1/hr,1,1.0
LD50,g,1,1.0
5-HT Level,%,1,1.0
RBC,10e3 ul-1,1,1.0
CLH,ml/min/10^6cells,1,1.0
Kinact,10'-7/s,1,1.0
Ratio CC50/EC50,10^10No_unit,1,1.0
Enoyl-CoA hydratase,uM min-1 (mg of protein)-1,1,1.0
No. of rats died,,1,1.0
Ratio EC50,10^-5No_unit,1,1.0
max activation,pmol/mg/min,1,1.0
EC16,M,1,1.0
Net body weight delta,g,1,1.0
Kinact,10^3/M/s,1,1.0
2PT,nM,1,1.0
EC16,uM,1,1.0
LD50,mg-1 kg-1,1,1.0
Ratio,microL/min/mg,1,1.0
ED50,umol/g,1,1.0
Ratio,mg/mm,1,1.0
Net cell kill,,1,1.0
Kinact,10^4/s,1,1.0
Increase in blood pressure,,1,1.0
Ratio,mg kg-1,1,1.0
Antipsychotic,,1,1.0
Kinact,10^4nM,1,1.0
Ratio,ml/min/umol,1,1.0
Cmax/dose,ngequiv/ml/mg,1,1.0
nKa,mM-1,1,1.0
Ratio,mole fraction,1,1.0
Kinact,10'4nM,1,1.0
CLH,uL/hr,1,1.0
Bmax,pmol/g,1,1.0
Ratio,umolequiv/umol,1,1.0
LD70,ug ml-1,1,1.0
LD50,microM/g,1,1.0
ED19.5,ug/kg,1,1.0
Average peak Concn,ug ml-1,1,1.0
Ratio,ml g-1,1,1.0
Ratio EC50,10^-4No_unit,1,1.0
EmaxL,%,1,1.0
Ratio EC50,10^-2No_unit,1,1.0
EC50,10'-3 ug/cm2,1,1.0
LDLO,mg kg-1,1,1.0
Brain level,,1,1.0
T max,mg kg-1,1,1.0
KB,10'3/M,1,1.0
Drug,nM (mg of protein)-1,1,1.0
Antidiuretic activity,IU mg-1,1,1.0
LDH,U g-1,1,1.0
logD,,1,1.0
RBC,10E6/mm3,1,1.0
Antihypertensive,,1,1.0
Brain level,%,1,1.0
pKa BZ,,1,1.0
EmaxH,%,1,1.0
Emax,ug/kg,1,1.0
LD50,ng/kg,1,1.0
Cmax/dose,nmol,1,1.0
RC50,10'-5mg/ml,1,1.0
K3,s-1,1,1.0
Cholesterol,mg kg-1 diet,1,1.0
LCC99,uM,1,1.0
pH,ml 4hr-1,1,1.0
Cmax_triphosphate,pmol/10^6cells,1,1.0
Effllux,min-1,1,1.0
Dose/g,,1,1.0
Kiuc,10'3nM,1,1.0
Brain concentration,uM,1,1.0
ED2,Na2,1,1.0
Ratio,10^5No_unit,1,1.0
pEC50,10^-6No_unit,1,1.0
EC200,,1,1.0
pEC50,uM,1,1.0
ED20,ug/kg,1,1.0
1/Km,10'2/M,1,1.0
LD,g,1,1.0
LD10,umol/L,1,1.0
Increase in heart rate,,1,1.0
10E2 K1,min-1,1,1.0
Cl-,,1,1.0
Initial inhibition,ug ml-1,1,1.0
Kinact,mV,1,1.0
Initial heart rate,,1,1.0
K2,mM,1,1.0
RD500,ug kg-1,1,1.0
pBBB,10'-3cm/s,1,1.0
T-cell,,1,1.0
pBBB,cm/s,1,1.0
Anxiolytic affect,,1,1.0
Cmax,hr.ng/ml,1,1.0
pGI50,uM,1,1.0
Concentration,mequiv/L,1,1.0
CFR,mg kg-1,1,1.0
AUC,ng ml kg-1,1,1.0
CL,hr,1,1.0
PPB,L/hr/kg,1,1.0
V1,ml,1,1.0
PPB,mM,1,1.0
V2,ml,1,1.0
ID100,M,1,1.0
KSV,10'-5M,1,1.0
PPB,mg/ml,1,1.0
Cmax,ng/10^6 cells,1,1.0
MPA,,1,1.0
Relative peroxidation,%,1,1.0
ED50,mmol,1,1.0
Kdiss,microM/s,1,1.0
LD10,ug/uL,1,1.0
LD10,ug ml-1,1,1.0
EC50,10'-1ppm,1,1.0
Average bile flow,ml hr-1,1,1.0
Anxiolytic activity,,1,1.0
IC40,nm,1,1.0
pDelta IOP,mmHg,1,1.0
Ratio,10^8/M/s,1,1.0
K inact/I,M-1 s-1,1,1.0
AUC/dose,min.g/L,1,1.0
LD30,mg kg-1,1,1.0
IC15,10'-7M,1,1.0
IC40,mM,1,1.0
CC50,ucm,1,1.0
Ratio,10'7/s/M,1,1.0
Km,mg/min/microL,1,1.0
Edema inhibition,,1,1.0
Km,min-1,1,1.0
pKP,,1,1.0
Bmax2,,1,1.0
-Log LC50,,1,1.0
pKa AN,,1,1.0
pKa AZ,,1,1.0
pKa BN,,1,1.0
Conc_brain,,1,1.0
EC24,uM,1,1.0
Km,/min,1,1.0
Ratio,10^-6No_unit,1,1.0
No effective/ no. tested,,1,1.0
LCC99.9,uM,1,1.0
Increase in heart rate,%,1,1.0
Increase in heart rate,beats min-1,1,1.0
Efficacy,mg/dl,1,1.0
Ratio,10^3No_unit,1,1.0
Bmax1,,1,1.0
K1,s-1,1,1.0
pK3',,1,1.0
ED60,mM,1,1.0
ED50 / ED50 (taxol),nM,1,1.0
LD100,ug/kg,1,1.0
Bmax,sites cell-1,1,1.0
REM latency,,1,1.0
Activity,10'5L/mol,1,1.0
LD100,ng,1,1.0
Ratio,M,1,1.0
Eggs,,1,1.0
pCB,,1,1.0
135,nM,1,1.0
Ratio,KB 7d-1,1,1.0
Ratio,CPP/GLY,1,1.0
Km,10'-4M/min,1,1.0
Ratio,10^4No_unit,1,1.0
pED50,mg kg-1,1,1.0
Concentration,PuM,1,1.0
Effective dose,M,1,1.0
Ratio,10^-4No_unit,1,1.0
ECmax,mg kg-1,1,1.0
-TdeltaS,J/mol.K,1,1.0
Inhibitory dose,mg kg-1,1,1.0
IC15,nM,1,1.0
AUC/dose,ngequiv.hr/ml/mg,1,1.0
max activation,pmol,1,1.0
LD60,mg kg-1,1,1.0
Activity,10'2pg/ml,1,1.0
LC50,10^5uM,1,1.0
Ratio,10'-5/M/s,1,1.0
ED2,uM,1,1.0
Increases,%,1,1.0
Activity,fM,1,1.0
LC50,10'-4ppm,1,1.0
Body temperature,,1,1.0
ET-1 level,pg ml-1,1,1.0
Ratio,10'-2/s,1,1.0
Cl,ml hr-1,1,1.0
Ratio,1/M1/s,1,1.0
%max,ng/ml,1,1.0
LC50,10'-13 ug/ml,1,1.0
pMEC,,1,1.0
ERH,nM,1,1.0
No. of axonal branchpoints/cell,,1,1.0
ECMax,uM,1,1.0
ER/PR,,1,1.0
K inact/Ki,10e4 M-1 s-1,1,1.0
Inhibition_index,10'27No_unit,1,1.0
Dose per organ,,1,1.0
Ea,kcal/mol,1,1.0
pKa(1),,1,1.0
Ratio,10'6/s/M,1,1.0
LC50,10'5uM,1,1.0
Ratio,10'-5/min.mol%'-4,1,1.0
Km app,rel,1,1.0
Ratio,10'-6/nM/s,1,1.0
Cminss,ng/ml,1,1.0
T1/2 iv,,1,1.0
solubility,10'-7mol,1,1.0
solubility,10'-8mol,1,1.0
permeability,microg/cm2,1,1.0
solubility,10'3ug/ml,1,1.0
Kq,10'13/mol/s,1,1.0
Boron incorporation,ug,1,1.0
Range of MIC,ug ml-1,1,1.0
Cmin(ss),nmol.L-1,1,1.0
Kq,10^13L/mol,1,1.0
Kq,10^13/M,1,1.0
Kq,10'14/M/s,1,1.0
solubility,mmol/ml,1,1.0
solubility,ppb,1,1.0
Cmin(80hr),pg/mL,1,1.0
% Inhibition of Control Agonist Response,%,1,1.0
Decrease in arterial blood pressure,,1,1.0
LBF,L/hr/kg,1,1.0
Activity,10'10L/mol/s,1,1.0
% inhibition in liver,%,1,1.0
ED75,,1,1.0
Ratio,10'-6cm/min,1,1.0
Edema,uM,1,1.0
-Log Kb,,1,1.0
Cumulative dose,mM kg-1,1,1.0
% of Control Agonist Response,%,1,1.0
CLt/F,L/hr,1,1.0
EFF+/-SD,%,1,1.0
Activity,10'-7 cm/s,1,1.0
Body weight change,,1,1.0
Ratio,%ID,1,1.0
LBF,ml/min.Kg,1,1.0
T>IC50,uM,1,1.0
Dose non renally cleared,%,1,1.0
permeability,10^-6cm/min,1,1.0
permeability,10^-6m/s,1,1.0
% inhibition in spleen,%,1,1.0
permeability,10^-8cm/s,1,1.0
K-1,1/min,1,1.0
Infection score mean,,1,1.0
LBF,ml/hr,1,1.0
Radioactivity remained,%,1,1.0
Cl,l hr-1,1,1.0
permeability,cm/min,1,1.0
permeability,10'-6/s,1,1.0
T/C @ 30mg/kg,%,1,1.0
LC10,ppm,1,1.0
CL_renal,mL/min/1.73 m2,1,1.0
Kobs,uM,1,1.0
LC1,uM,1,1.0
permeability,10'-6cm2/s,1,1.0
LC50,ug.cm'-2,1,1.0
Cures,day,1,1.0
Compound recovery,ug ml-1,1,1.0
T/C,log10,1,1.0
LC50,p.p.m.,1,1.0
Compound recovery,ml/hr,1,1.0
Decrease of spontaneous firing rate,,1,1.0
CL_biliary,%,1,1.0
Kmax,/hr,1,1.0
Ratio,10'5/min/M,1,1.0
AUC/dose,ng/hr.ml,1,1.0
EC25(unbound),nM,1,1.0
Cmedia,ug of B g-1,1,1.0
Activity,10'-5nmol,1,1.0
Binding,mg kg-1,1,1.0
Ratio,10'3/s/M,1,1.0
Activity,10'4/M,1,1.0
pKb(app),,1,1.0
Compound in urine,%,1,1.0
IC33,uM,1,1.0
Bmax2,fM (mg of protein)-1,1,1.0
Km,ng/ml,1,1.0
pMax,%,1,1.0
%Remaining,%,1,1.0
Decrease in RFU,uM,1,1.0
solubility,10'-2g,1,1.0
solubility,10'-1mol/L,1,1.0
solubility,10'-1mg/ml,1,1.0
Inhibition at 10nM,%,1,1.0
Activity,dyn.s.cm'-5.10'4,1,1.0
K obs,mM,1,1.0
Kq,10'10L/mol/s,1,1.0
EC37,%,1,1.0
T4,,1,1.0
ED90,kg/ha,1,1.0
Cures@ 40 mg/kg,,1,1.0
K+2/Ki,,1,1.0
Rate of formation,,1,1.0
K obs / s,,1,1.0
Cures@ 20mg/kg,,1,1.0
Kr,nM,1,1.0
Kq,10'11L/mol.s,1,1.0
Range,ug ul-1,1,1.0
Co,ng ml-1,1,1.0
Brain,ng g-1,1,1.0
Activity,deltalog10/ml,1,1.0
Rate of metabolism,pM/mg/minute,1,1.0
IC25,ug ml-1,1,1.0
CLt/F,,1,1.0
LBF,L/hr,1,1.0
ED97,,1,1.0
Rate of rotation,turns 5min-1,1,1.0
Ks,10'4/M,1,1.0
CPmax,ng ml-1,1,1.0
Kq,10^14/M/s,1,1.0
Radiolabel recovery,ugequiv/ml,1,1.0
CPmax,,1,1.0
Increase in MAP,%,1,1.0
EC50,10'-2mg/ml,1,1.0
TCID50,log10/ml,1,1.0
Injected,,1,1.0
mequiv of Na+/kg,,1,1.0
LD50,ug/uL,1,1.0
Cmax/dose,ng/ml/mg,1,1.0
Ratio,ms,1,1.0
EC14,M,1,1.0
Kinact,10^-2microM,1,1.0
n/N,/ 7,1,1.0
Kinact,10^-4/min,1,1.0
2X PT,,1,1.0
LD50,po,1,1.0
EC10x,,1,1.0
Concentration,ug min-1 kg-1,1,1.0
pKa E2,,1,1.0
T/C,g,1,1.0
pka,M-1,1,1.0
IC30,10'-8M,1,1.0
ppKb,,1,1.0
Ks,10^6/M,1,1.0
% inhibition in bone-marrow,%,1,1.0
T/C @ 40mg/kg,%,1,1.0
Kp,10^-5cm/hr,1,1.0
Kp,ml/min/g,1,1.0
t1/2,ug.hr/ml,1,1.0
t1/2(app),,1,1.0
t1/2/dose,hr,1,1.0
Inhibition (500 µM),%,1,1.0
t1/2eff,,1,1.0
ED90,1/mg.1/kg.1/day,1,1.0
T1/2,uM,1,1.0
tCmax,hr,1,1.0
"K(p,uu,brain)",%,1,1.0
T1/2,mg kg-1,1,1.0
Cmin(1),nmol.L-1,1,1.0
Inhibition,umol,1,1.0
Cures@ 10mg/kg,,1,1.0
CLr,L/hr,1,1.0
washout,%,1,1.0
Kq,10'6No_unit,1,1.0
Rate constant,M s-1,1,1.0
T1/2 h/s,,1,1.0
solubility,ug/kg,1,1.0
solubility,ug,1,1.0
Inhibition,cm,1,1.0
Cmin,ug/g,1,1.0
K+2,,1,1.0
T1/2 beta,,1,1.0
Rate,ul min-1,1,1.0
Kq,10'4No_unit,1,1.0
Kuncat,min-1,1,1.0
% dose,%,1,1.0
Brain,weight,1,1.0
permeability,nmol/sec,1,1.0
Rate of reduction,,1,1.0
permeability,pmol/min,1,1.0
LA,,1,1.0
T/C @ 50mg/kg,%,1,1.0
Cmin,nmol/L,1,1.0
L,%,1,1.0
Kup,ml/min,1,1.0
Activity,10'-8 ug/ml,1,1.0
t1/2,microsec,1,1.0
permeability,ug/cm2.hr,1,1.0
Kuncat,M-1 s-1,1,1.0
T50,ug,1,1.0
pinhibition,%,1,1.0
T/C value,,1,1.0
Kq,10'12L/mol.s,1,1.0
Inhibition,c.p.m. 50ul-1,1,1.0
Decrease in arterial blood pressure,%,1,1.0
T1/2 h/min,,1,1.0
Kq,10'4L/mol,1,1.0
ECG,,1,1.0
